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Abstract	  	  
	  
Coeliac	  disease	  is	  a	  common	  (1%	  prevalence)	  inflammatory	  disease	  of	  the	  small	  
intestine,	   involving	   the	   role	   of	   tissue	   transglutaminase	   and	   HLA-­‐DQ	   binding	  
immuno-­‐dominant	  wheat	  peptides.	  The	  disease	  is	  highly	  heritable,	  however,	  at	  
most	  only	  40%	  of	  this	  heritability	  is	  explained	  by	  HLA-­‐DQ	  and	  risk	  variants	  from	  
genome	   wide	   association	   and	   fine	   mapping	   studies.	   The	   hypothesis	   of	   the	  
research	   in	  this	  thesis	   is	  that	  rare	  (minor	  allele	  frequency	  <0.5%)	  mutations	  of	  
large	   effect	   size	   (odds	   ratios	   ~2	   –	   5)	   exist,	   especially	   in	   multiply	   affected	  
pedigrees,	  which	  account	  for	  the	  missing	  heritability	  of	  disease.	  	  	  
NimbleGen	  exome	  capture	  and	  Illumina	  GAIIx	  high	  throughput	  sequencing	  was	  
performed	   in	  75	  coeliac	  disease	   individuals	   from	  55	  multiply	  affected	  families.	  
Candidate	  genes	  were	  chosen	  from	  various	  analytical	  strategies:	  linkage,	  shared	  
variants	  between	  multiple	  related	  subjects	  and	  gene	  burden	  tests	   for	  multiple	  
potentially	   causal	   variants.	   Highly	   multiplexed	   amplicon	   sequencing,	   using	  
Fluidigm	   technology,	   of	   all	   RefSeq	   exons	   from	   24	   candidate	   genes	   in	   2,304	  
coeliac	  cases	  and	  2,304	  controls	  was	  performed	  to	  locate	  further	  rare	  variation.	  
Gene	  burden	  tests	  on	  a	  highly	  stringent	  post	  quality	  control	  dataset	   identified	  
no	  significant	  associations	  (P<1x10-­‐3)	  at	  the	  resequenced	  candidate	  genes.	  	  
The	   strategy	   of	   sequencing	  multiply	   affected	   families,	   and	   deep	   follow	   up	   of	  
candidate	   genes,	   has	   not	   identified	   new	   disease	   risk	   mutations.	   Common	  
variants	  (and	  other	  factors,	  e.g.	  environmental)	  may	  instead	  account	  for	  familial	  








	   3	  
Contents	  
	  
Abstract	  	   	   	   	   	   	   	   	   	   	  2	  
Tables	  list	  	   	   	   	   	   	   	   	   	   	  8	  
Figures	  list	  	   	   	   	   	   	   	   	   	   	  10	  
Acknowledgements	  	   	   	   	   	   	   	   	  12	  
Statement	  of	  Originality	  	   	   	   	   	   	   	   	  13	  
Abbreviations	  	   	   	   	   	   	   	   	   	  15	  
Bioinformatic	  resources	  and	  software	  	   	   	   	   	   	  17	  
	  
Chapter	  1:	  Introduction	   	   	   	   	   	   	   	  19	  
1.1 Coeliac	  disease:	  a	  complex	  autoimmune	  disorder	  	   	   	   	  20	  
1.2	  Clinical	  manifestations	  and	  pathophysiology	  	   	   	   	   	  20	  	  	  
1.3	  Disease	  epidemiology	  	   	   	   	   	   	   	   	  24	  
1.4	  The	  major	  histocompatibility	  complex	  and	  coeliac	  disease	  	   	   	  26	  
1.4.1	  The	  major	  histocompatibility	  complex	  
1.4.2	  HLA	  association	  with	  coeliac	  disease	  	  
1.5	  Identifying	  susceptibility	  genes	  in	  complex	  disease	  	   	   	   	  31	  
1.5.1	  Single	  nucleotide	  polymorphisms	  and	  linkage	  disequilibrium	  	  
1.5.2	  International	  HapMap	  Project,	  1000	  Genomes	  Project	  and	  Encode	  
1.5.3	  Family	  based	  studies	  	  
1.5.4	  Heritability	  	  
1.5.5	  Genome	  wide	  association	  studies	  	  
1.6	  Known	  genetic	  structure	  of	  coeliac	  disease	  	   	   	   	   	  	  40	  
1.6.1	  Regions	  identified	  through	  linkage	  analysis	  	  
1.6.2	  Susceptibility	  gene	  loci	  identified	  by	  GWAS	  and	  further	  dense	  genotyping	  
with	  Immunochip	  	  
1.6.3	  Overlap	  with	  other	  autoimmune	  diseases	  
1.7	  Finding	  further	  genetic	  causal	  variants	  in	  complex	  disease	  	   	   	  51	  	  	  
1.7.1	  Targeted	  gene	  resequencing	  	  
1.7.2	  Exome	  sequencing	  
	   4	  
1.7.3	  Whole	  genome	  sequencing	  
1.8	  Summary	  and	  outline	  of	  research	  hypothesis	  and	  aims	  	   	   	  58	  
Chapter	  2:	  General	  Methods	  	   	   	   	   	   	   	  59	  
2.1	  DNA	  sample	  collection	  	   	   	   	   	   	   	   	  60	  
2.2	  Genomic	  DNA	  extraction	  	   	   	   	   	   	   	  60	  
2.3	  Genomic	  DNA	  quantification	  	   	   	   	   	   	   	  61	  
2.4	  PCR	  and	  gel	  electrophoresis	  	  	   	   	   	   	   	   	  62	  
2.5	  Exome	  target	  capture	  	   	   	   	   	   	   	   	  63	  
2.5.1	  NimbleGen	  Human	  Exome	  2.1M	  Array	  (Phase	  One)	  
2.5.1.2	  Library	  preparation	  and	  index	  PCR	  	  
2.5.1.3	  Array	  capture	  and	  PCR	  	  
2.5.1.4	  Enrichment	  qPCR	  
2.5.1.5	  Pooled	  DNA	  library	  quantification	  
2.5.2	  NimbleGen	  SeqCap	  EZ	  Human	  Exome	  In-­‐Solution	  (Phase	  Two)	  
2.5.2.1	  Single	  library	  quantification	  with	  qPCR	  	  
2.6	  Illumina	  Immunobeadchip	  genotyping	  	   	   	   	   	   	  68	  
2.7	  Fluidigm	  48.48	  Access	  Array	  Integrated	  Fluidic	  Circuit	  Technology	  	   	  68	  
2.7.1	  Assay	  design	  and	  pooling	  	  	  
2.7.2	  Multiplex	  PCR	  on	  the	  Access	  Array	  IFC	  
2.7.3	  Barcode	  PCR	  
2.7.4	  Post	  PCR	  purification,	  quantification	  and	  library	  pooling	  	  
2.8	  High	  throughput	  sequencing	  on	  Illumina	  Genome	  Analyzer	  IIx,	  MiSeq	  and	  
HiSeq	  2000	  	   	   	   	   	   	   	   	   	   	  71	  
2.8.1	  Cluster	  generation	  for	  Illumina	  GAIIx	  
2.8.2	  Paired-­‐end	  and	  multiplex	  sequencing	  on	  Illumina	  GAIIx	  
2.8.3	  Illumina	  MiSeq	  and	  HiSeq	  2000	  
2.9	  DNA	  sequence	  alignment	  and	  variant	  annotation	  	   	   	   	  74	  
2.9.1	  Phase	  one	  and	  two	  exome	  sequencing	  study	  	  	   	   	   	  74	  
2.9.2	  Fluidigm	  pilot	  and	  candidate	  gene	  resequencing	  study	  	   	   	  74	  
	  
	  
	   5	  
Chapter	  3:	  Exome	  sequencing	  in	  75	  coeliac	  disease	  individuals	  	   	  76	  
3.1	  Introduction	  	   	   	   	   	   	   	   	   	  77	  
3.2	  Aim	  and	  hypothesis	  	   	   	   	   	   	   	   	  80	  
3.3	  Experimental	  design	  and	  sample	  selection	  	   	   	   	   	  81	  
3.4	  Phase	  One:	  multiplex	  exome	  sequencing	  with	  microarray	  capture	  	   	  82	  
3.4.1	  Phase	  One:	  Laboratory	  and	  in	  silico	  methods	  
3.4.2	  Phase	  One:	  Results	  
3.4.2.1	  Indexing,	  enrichment	  and	  clonal	  reads	  assessment	  
3.4.2.2	  Sequence-­‐based	  calls	  versus	  genotype-­‐based	  calls	  concordance	  rate	  	  
3.4.3	  Phase	  One:	  Conclusions	  
3.5	  Phase	  Two:	  single-­‐sample	  exome	  sequencing	  with	  in-­‐solution	  capture	  
	   	   	   	   	   	   	   	   	   	   	  87	  	  	  	  	  	  	  
3.5.1	  Selecting	  related	  samples	  for	  exome	  sequencing	  	  
3.5.2	  Phase	  Two:	  Laboratory	  and	  in	  silico	  methods	  
3.5.2.1	  Sanger	  Capillary	  Sequencing	  
3.5.3	  Phase	  Two:	  Results	  
3.5.3.1	  Shared	  variants	  between	  related	  exomes	  and	  segregation	  analysis	  
3.5.3.2	  Single-­‐SNP	  and	  aggregate	  tests	  for	  rare	  variants	  	  
3.6	  Chapter	  Discussion	  	   	   	   	   	   	   	   	  111	  
3.7	  Chapter	  Conclusions	  	   	   	   	   	   	   	   	  116	  
Chapter	  4:	  Illumina	  Immunochip:	  Linkage	  analysis,	  exome	  SNP	  case-­‐
control	  association	  and	  current	  coeliac	  loci	  contribution	  in	  disease	  cases	  
	   	   	   	   	   	   	   	   	   	   	  118	  
4.1	  Introduction	  	  	   	   	   	   	   	   	   	   	  119	  
4.1.1	  Principles	  of	  genetic	  linkage	  	  
4.1.2	  Linkage	  models	  in	  complex	  disease	  	  	  
4.2	  Aims	  and	  hypotheses	  	   	   	   	   	   	   	   	  123	  
4.3	  Sample	  Selection	  	  	   	   	   	   	   	   	   	  124	  
4.4	  Experimental	  design	  and	  laboratory	  method	  	   	   	   	   	  125	  
4.5	  Results:	  Linkage	  analysis	  with	  Immunochip	  SNP	  markers	  	   	   	  126	  
4.5.1	  Sample	  and	  data	  quality	  control	  
	   6	  
4.5.2	  Non-­‐parametric	  linkage	  analysis	  
4.5.3	  Analysis	  of	  exome	  variants	  in	  linkage	  peaks	  	  
4.6	  Results:	  Exome	  SNP	  case	  control	  association	  	   	   	   	   	  136	  
4.6.1	  Conditional	  logistic	  regression	  
4.7	  Results:	  Current	  coeliac	  associated	  loci	  contribution	  in	  coeliac	  individuals	  
	   	   	   	   	   	   	   	   	   	   	  140	  
4.8	  Chapter	  Discussion	  	   	   	   	   	   	   	   	  144	  
4.9	  Chapter	  Conclusions	  	   	   	   	   	   	   	   	  148	  
Chapter	  5:	  Exome	  study	  candidate	  gene	  resequencing	  in	  2,304	  coeliac	  
cases	  and	  2,304	  controls	  	   	   	   	   	   	   	   	  149	  
5.1	  Introduction	  	   	   	   	   	   	   	   	   	  150	  
5.2	  Aim	  and	  hypothesis	  	   	   	   	   	   	   	   	  152	  
5.3	  Pilot	  study	  	   	   	   	   	   	   	   	   	  153	  
5.3.1	  Fluidigm	  48.48	  Access	  Array	  Intergrated	  Fluidic	  Circuit	  technology	  	  
5.3.2	  Pilot	  study	  Method	  
5.3.3	  Pilot	  study	  Results	  
5.3.3.1	  Read	  depth	  analysis	  	  	  
5.3.3.2	  Clonality	  	  
5.3.4	  Pilot	  Study	  Conclusions	  
5.4	  Power	  Considerations	  	   	   	   	   	   	   	   	  161	  
5.5	  Experimental	  design	  and	  sample	  set	  	   	   	   	   	   	  162	  
5.5.1	  Laboratory	  method	  
5.5.2	  In	  silico	  methods	  and	  quality	  control	  steps	  
5.6	  Results	  	   	   	   	   	   	   	   	   	   	  166	  
5.6.1	  Association	  and	  gene-­‐burden	  tests	  
5.7	  Chapter	  Discussion	  	   	   	   	   	   	   	   	  171	  
5.8	  Chapter	  Conclusions	  	   	   	   	   	   	   	   	  175	  
Chapter	  6:	  Research	  discussion	  	   	   	   	   	   	   	  176	  
6.1	  Research	  background	  and	  summary	  of	  findings	  	  
6.2	  Effects	  of	  sample	  and	  experimental	  design	  	  
6.3	  Progression	  in	  exome	  studies	  	  
	   7	  
6.4	  Where	  does	  ‘missing	  heritability’	  of	  disease	  lie?	  
6.5	  Research	  update	  and	  concluding	  remarks	  
Chapter	  7:	  Future	  work	  and	  directions	  	   	   	   	   	   	  189	  
7.1	  Further	  research	  in	  the	  field	  of	  coeliac	  disease	  genetics	  	  
	  
References	  	   	   	   	   	   	   	   	   	   	  196	  
Appendix	  I	  Sample	  information,	  exome	  capture	  protocol	  and	  summary	  
statistics	  	   	   	   	   	   	   	   	   	   	  218	  
Appendix	  I-­‐A	  Samples	  and	  pedigree	  information	  
Appendix	  I-­‐B	  Preparation	  of	  Illumina	  library	  prior	  to	  solution	  capture	  (EZ	  Exome	  
System)	  with	  no	  pre	  hybridisation	  PCR	  
Appendix	  II	  Linkage	  graphs	  for	  12	  coeliac	  pedigrees	  	   	   	   	  246	  
Appendix	  III	  Fluidigm	  pilot	  study	  and	  candidate	  gene	  resequencing	  
results	  	   	   	   	   	   	   	   	   	   	  269	  




















Table	  1.1:	  39	  non-­‐HLA	  coeliac	  loci	  from	  Immunochip	  study	  (2011)	  showing	  
association	  with	  other	  autoimmune	  diseases	  	   	   	   	   	  48	  
Chapter	  2	  
Table	  2.1:	  Standard	  PCR	  reagents,	  concentrations	  and	  volumes	  for	  genomic	  DNA	  
	   	   	   	   	   	   	   	   	   	   	  63	  
Table	  2.2:	  Fluidigm	  oligonucleotide	  sequences	  for	  Illumina	  MiSeq	  and	  HiSeq	  
2000	  sequencing	  	   	   	   	   	   	   	   	   	  73	  
Chapter	  3	  
Table	  3.1:	  PCR	  conditions,	  number	  of	  clonal	  reads	  and	  enrichment	  statistics	  for	  
five	  multiplex	  pools	  	   	   	   	   	   	   	   	   	  84	  
Table	  3.2:	  Total	  number	  of	  SNV	  calls	  in	  75	  exomes	  	   	   	   	   	  91	  
Table	  3.3:	  Rare	  nonsynonymous	  nonsense	  and	  missense	  mutations	  shared	  by	  
related	  coeliac	  individuals	  	   	   	   	   	   	   	   	  95	  
Table	  3.4:	  Rare	  non-­‐synonymous	  single	  nucleotide	  variants	  located	  in	  immune	  
genes	  and	  shared	  by	  related	  coeliac	  individuals	  with	  Annovar	  annotation	  	  	  104	  
Table	  3.5:	  Top	  5	  most	  significant	  genes	  for	  the	  aggregate	  test	  rare	  variants	  (LoF,	  
non-­‐synonymous	  and	  splice	  site)	  between	  cases	  and	  controls	  	   	   	  108	  
Table	  3.6:	  Top	  3	  most	  significant	  genes	  for	  the	  aggregate	  test	  for	  rare	  LoF	  
variants	  only	  between	  cases	  and	  controls	  	   	   	   	   	   	  109	  
Table	  3.7:	  Top	  15	  most	  significant	  genes	  for	  the	  aggregate	  test	  for	  rare	  LoF	  
variants	  in	  immune	  genes	  between	  cases	  and	  controls	  	   	   	   	  109	  
Table	  3.8:	  Candidate	  genes	  from	  exome	  sequencing	  analyses	  selected	  for	  
targeted	  gene	  resequencing	  	   	   	   	   	   	   	   	  116	  
Chapter	  4	  
Table	  4.1:	  Linkage	  pedigrees	  	  	   	   	   	   	   	   	  125	  
Table	  4.2:	  Summary	  of	  non-­‐parametric	  linkage	  results	  	   	   	   	  128	  
Table	  4.3:	  Nonsynonymous	  SNPs	  located	  in	  linkage	  regions	  (p	  <	  0.01)	  	   	  134	  
	   9	  
Table	  4.4:	  Fisher	  Exact	  test	  results	  for	  rare	  exome	  SNPs	  in	  coeliac	  UK	  dataset	  at	  
p	  <	  0.01	  	   	   	   	   	   	   	   	   	   	  137	  
Table	  4.5:	  Results	  for	  conditional	  logistic	  regression	  for	  two	  associated	  SNPs,	  
vh_6_24672519	  and	  vh_6_24684610	  	   	   	   	   	   	  140	  
Table	  4.6:	  Candidate	  genes	  from	  linkage	  analysis	  selected	  for	  targeted	  gene	  
resequencing	  	   	   	   	   	   	   	   	   	   	  148	  
Chapter	  5	  
Table	  5.1:	  Candidate	  genes	  for	  targeted	  amplicon	  resequencing	  	   	   	  163	  
Table	  5.2:	  Number	  of	  coding,	  rare	  and	  loss	  of	  function	  variants	  across	  24	  
candidate	  genes	  	   	   	   	   	   	   	   	   	  168	  
Table	  5.3:	  Top	  five	  P	  values	  for	  multiple	  rare	  variant	  gene-­‐based	  tests	  across	  all	  































Figure	  1.1:	  Model	  of	  deamidated	  gluten	  peptide	  presentation	  by	  APC	  to	  T	  cells	  
for	  subsequent	  loading	  onto	  HLA-­‐DQ2	  or	  HLA-­‐DQ8	  heterodimers	  	   	   	  23	  
Figure	  1.2:	  Stages	  of	  villous	  atrophy	  in	  coeliac	  disease	  	   	   	   	  24	  
Figure	  1.3:	  HLA	  haplotype	  combinations	  in	  coeliac	  disease	  	   	   	   	  30	  
Figure	  1.4:	  Total	  genetic	  variance	  contributed	  to	  CD	  by	  significant	  and	  
suggestive	  39	  2010	  non-­‐HLA	  loci	  	   	   	   	   	   	   	  43	  
Figure	  1.5:	  Manhattan	  plot	  showing	  previously	  associated	  and	  new	  CD	  risk	  loci	  
with	  significant	  threshold	  set	  at	  P≤	  5x10-­‐8	  	   	   	   	   	   	  46	  
Chapter	  3	  
Figure	  3.1:	  Bar	  plot	  of	  the	  number	  of	  reads	  per	  index	  	   	   	   	  84	  
Figure	  3.2:	  Graph	  of	  the	  number	  of	  clonal	  reads	  in	  each	  uniquely	  aligned	  pool	  
	   	   	   	   	   	   	   	   	   	   	  85	  
Figure	  3.3:	  Number	  of	  non-­‐reference	  SNP	  calls	  per	  exome	  (n	  =	  75)	  and	  
corresponding	  average	  read	  depth	  	   	   	   	   	   	   	  90	  
Figure	  3.4:	  Total	  number	  of	  reference	  and	  non-­‐reference	  variants	  	  	   	  91	  
Figure	  3.5:	  Exon	  library	  comparison	  between	  coeliac	  SAL-­‐12583-­‐9	  and	  control	  
NA12878	  samples	  with	  two	  different	  calling	  algorithms	  	   	   	   	  92	  
Figure	  3.6:	  Pedigrees	  from	  Table	  3.4	  	  	   	   	   	   	   	  97	  
Figure	  3.7:	  Segregation	  result	  for	  novel	  c.184C>T	  SNV	  in	  TNFRSF21	  in	  BRK	  family	  
	   	   	   	   	   	   	   	   	   	   	  101	  
Figure	  3.8:	  Segregation	  result	  for	  novel	  c.70G>A	  SNV	  in	  IL21R	  in	  entire	  Neu4801	  
family	  	  	   	   	   	   	   	   	   	   	   	  102	  
Figure	  3.9:	  Pedigrees	  from	  Table	  3.5	  	  	   	   	   	   	   	  105	  
Figure	  3.10:	  Manhattan	  plot	  of	  single-­‐SNP	  tests	  comparing	  the	  case	  data	  (n	  =	  
41)	  with	  the	  control	  samples	  (n	  =	  222)	  	   	   	   	   	   	  106	  
Figure	  3.11:	  Q-­‐Q	  plot	  of	  single-­‐SNP	  tests	  comparing	  case	  data	  (n=41)	  with	  
control	  samples	  (n=222)	  	   	   	   	   	   	   	   	  107	  
	  
	   11	  
Chapter	  4	  
Figure	  4.1:	  Linkage	  and	  disease	  genes	  	   	   	   	   	   	  121	  
Figure	  4.2:	  Graph	  of	  number	  of	  different	  HLA	  genotypes	  in	  affected	  and	  
unaffected	  individuals	  from	  12	  linkage	  families	  	   	   	   	   	  130	  
Figure	  4.3:	  Alleles	  shared	  IBD	  and	  IBS	  in	  sibling	  pairs	  when	  allele	  sharing	  differs	  
in	  second	  sibling,	  assuming	  the	  marker	  is	  unlinked	  to	  the	  disease	  	   	   	  131	  
Figure	  4.4:	  HLA	  genotypes	  IBD	  and	  IBS	  for	  SDY	  family	  	   	   	   	  132	  
Figure	  4.5:	  Q-­‐Q	  plot	  of	  Fisher	  Exact	  test	  P	  values	  	   	   	   	   	  139	  
Figure	  4.6:	  SNP	  score	  for	  57	  coeliac	  risk	  loci,	  with	  and	  without	  HLA	  SNP	  
rs2187668	  	   	   	   	   	   	   	   	   	   	  142	  
Figure	  4.7:	  SNP	  score	  for	  57	  (58	  with	  HLA	  SNP	  rs2187668)	  coeliac	  risk	  loci	  
stratified	  against	  number	  of	  affected	  individuals	  per	  family	  	   	   	  143	  
Figure	  4.8:	  SNP	  score	  for	  HLA	  DQ2.5	  rs2187668	  alone	  vs.	  number	  of	  affected	  
individuals	  per	  family	  	  	   	   	   	   	   	   	   	  144	  
Chapter	  5	  
Figure	  5.1:	  Primer	  set	  up	  for	  Fluidigm	  multiplex	  amplicon	  tagging	  for	  Illumina	  
high	  throughput	  sequencing	  	   	   	   	   	   	   	   	  154	  
Figure	  5.2:	  Total	  reads	  for	  384	  sample	  barcodes	  	   	   	   	   	  156	  
Figure	  5.3:	  Total	  aligned	  trimmed	  reads	  	   	   	   	   	   	  156	  
Figure	  5.4:	  Depth	  of	  coverage	  per	  sample	  for	  CUBN	  196bp	  amplicon	  	   	  158	  
Figure	  5.5:	  Number	  of	  reads	  for	  position	  2526658	  for	  one	  sample	  	   	   	  160	  
Figure	  5.6:	  Power	  calculation	  with	  increasing	  odds	  ratios	  and	  0.5%	  risk	  allele	  
frequency	  	   	   	   	   	   	   	   	   	   	  162	  
Chapter	  7	  
Figure	  7.1:	  MALBAC	  single-­‐cell	  WGA	  to	  decrease	  amplification	  bias	  	   	  193	  






	   12	  
Acknowledgments	  
	  
The	   completion	   of	   the	  work	   in	   this	   PhD	   thesis	  would	   not	   have	   been	   possible	  
without	   the	   following	   individuals	   whom	   I	   wish	   to	   extend	   thanks.	   Foremost	   I	  
would	   like	   to	   express	  my	   sincere	   gratitude	   to	  my	   supervisor,	   Professor	   David	  
van	   Heel,	   for	   continuous	   support	   of	   my	   PhD	   study,	   especially	   during	   my	  
bioinformatic	   angst	   –	   your	   patience	   was	   highly	   appreciated.	   I	   also	   thank	   Dr	  
Vincent	  Plagnol	  for	  his	  statistical	  input	  in	  my	  research.	  I	  would	  like	  to	  thank	  past	  
and	   present	  members	   of	   the	   DvH	   group:	   to	   Dr	   Karen	   Hunt	   for	   your	   ongoing	  
supportive	   words	   and	   research	   input,	   I	   am	   extremely	   lucky	   to	   have	   worked	  
alongside	   you,	   to	   Nick	   Bockett	   for	   help	   with	   laboratory	   and	   sequencing	  
techniques,	   and	   to	   Dr	   Graham	   Heap	   and	   Dr	   Patrick	   Dubois	   for	   setting	   great	  
examples.	   I	   would	   also	   like	   to	   thank	   my	   fellow	   department	   and	   institute	  
members,	  Professor	  David	  Kelsell,	  Dr	  Tania	  Marchbank,	  Nicola	  Kingston,	  Anna	  
Alongi	  and	  Abdul	  Monaf,	  for	  always	  being	  there	  for	  guidance	  and	  advice	  when	  
needed.	  	  
My	  family	  deserves	  my	  heartfelt	  thanks;	  I	  would	  not	  have	  made	  it	  here	  if	  not	  for	  
your	  continuous	  backing,	   loving	  support	  and	  ambition	  for	  my	  scientific	  career,	  
for	   this	   I	   am	   continually	   thankful	   and	   deeply	   appreciative.	   Finally,	   to	   my	  
boyfriend	  Mel	  –	  your	  calmness	  has	  got	  me	  through	  a	  busy	  and	  stressful	  career	  












	   13	  
Statement	  of	  Originality	  
	  
	  
This	  statement	  outlines	   individuals	  contributing	  to	  the	  work	  carried	  out	   in	  this	  
thesis	  project.	  Unless	  stated	  otherwise,	  all	  individuals	  have	  been	  acknowledged	  
here	  and	  in	  publications.	  	  
	  	  
DNA	  samples	  and	  preparation	  
DNA	  samples	  from	  multigenerational	  European	  and	  American	  families	  used	  for	  
exome	   sequencing,	   genotyping	   and	   linkage	   analysis	   were	   provided	   by	   the	  
following	  individuals:	  
• Paul	  Ciclitira	  at	  St	  Thomas’	  Hospital,	  London.	  	  
• Susan	   Neuhausen	   at	   Beckman	   Research	   Institute	   at	   the	   City	   of	   Hope,	  
California.	  	  
• Åsa	  Naluai	  at	  Gothenburg	  University,	  Sweden.	  	  
David	   van	   Heel	   and	   I	   collected	   additional	   UK	   family	   samples	   via	   email/letter	  
contact.	  Saliva	  DNA	  extractions	  and	  quantifications	  were	  performed	  by	  Dr	  Karen	  
Hunt,	  Dr	   Patrick	  Dubois,	  Nick	   Bockett,	  Dr	  Graham	  Heap	   and	  myself.	   Dr	   Karen	  
Hunt,	   Dr	   Patrick	   Dubois	   and	   Dr	   Graham	   Heap	   extracted	   DNA	   from	   blood	  
samples	  (cases	  and	  controls)	  prior	  to	  my	  joining	  the	  group	  in	  2008,	  which	  were	  
also	   used	   for	   exome	   sequencing	   and	   genotyping.	   Exome	   control	   DNAs	   (222)	  
from	  neurological	  disease	  samples	  were	  made	  available	  by	  Dr	  Vincent	  Plagnol	  at	  
University	  College	  London	  Genetics	  Institute.	  	  
	  
Exome	  capture,	  sequencing	  and	  data	  analysis	  
I	  performed	  all	  library	  preparations	  for	  NimbleGen	  exome	  array	  (60	  individuals)	  
and	   in-­‐solution	   captures	   (75	   individuals).	   Nick	   Bockett,	   Kerith	   Rae-­‐Dias	   and	   I	  
carried	  out	  Illumina	  GAIIx	  high	  throughput	  sequencing	  at	  Barts	  and	  the	  London	  
Genome	   Centre.	   David	   van	   Heel	   generated	   all	   fastq	   files	   and	   Vincent	   Plagnol	  
performed	   subsequent	   alignments	   and	   variant	   annotation	   for	   all	   exomes	   at	  
University	   College	   London	  Genetics	   Institute.	   Vincent	   Plagnol,	   David	   van	  Heel	  
	   14	  
and	   I	   performed	   exome	   variant	   analysis.	   I	   performed	   all	   Sanger	   sequencing	  
validation	  experiments.	  	  
	  
Immunochip	  genotyping	  and	  linkage	  analysis	  
I	   ran	  all	   Immunochip	  genotyping	  chips	  for	  coeliax	  exome	  samples	  at	  Barts	  and	  
the	   London	   Genome	   Centre	   and	   performed	   genotype	   data	   analysis.	   Vincent	  
Plagnol	   performed	   linkage	   analysis	   at	   University	   College	   London	   Genetics	  
Institute.	  	  
	  
Candidate	  gene	  resequencing	  library	  preparation	  and	  data	  analysis	  
I	   performed	   all	   Fluidigm	   Access	   Array	   library	   preparations	   for	   2,304	   coeliac	  
cases	   and	   2,304	   controls.	   I	   performed	   sequencing	   on	   the	   Illumina	   MiSeq	   at	  
Barts	  and	  the	  London	  Genome	  Centre	  for	  all	  libraries.	  Muddassar	  Murza	  carried	  
out	  high	  throughput	  sequencing	  for	  all	  libraries	  on	  the	  HiSeq	  2000	  at	  the	  NIHR	  
GSTFT/KCL	   Biomedical	   Research	   Centre	   at	   Guy’s	   Hospital.	   Michael	   Simpson	  
generated	   fastq	   files	   for	   4,608	   samples.	   I	   performed	   sequence	   alignments,	  



















	   15	  
Abbreviations	  
	  
λ s	   	   Sibling	  recurrence	  ratio	  
1000G	  	  	   1000	  Genomes	  Project	  
ATI	   	   	  Amylase/trypsin	  inhibitors	  	  
CD	  	   	   Coeliac	  disease	  	  
CDCV	  	   	   Common	  disease	  common	  variant	  	  
CDRV	  	   	   Common	  disease	  rare	  variant	  	  
CNV	  	   	   Copy	  number	  variant	  
Encode	   Encylopedia	  of	  DNA	  Elements	  
eQTL	   	   Expression	  quantitative	  trait	  loci	  
GA	  	   	   Genome	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GFD	  	   	   Gluten	  free	  diet	  	  
GWAS	  	  	   Genome	  wide	  association	  studies	  	  
HLA	  	   	   Human	  leukocyte	  antigen	  
HWE	  	   	   Hardy	  Weinberg	  equilibrium	  	  
IBD	  	   	   Identical	  by	  descent	  	  
IBS	  	   	   Identical	  by	  state	  
IEL	  	   	   Intestinal	  intraepithelial	  lymphocytes	  	  
IFC	  	   	   Integrated	  Fluidic	  Circuit	  
InBD	  	   	   Inflammatory	  bowel	  disease	  
Indel	  	   	   Insertion-­‐deletion	  
LD	  	   	   Linkage	  disequilibrium	  
LOD	  	   	   Logarithm	  of	  odds	  score	  	  
LoF	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  of	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MAF	  	   	   Minor	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MHC	  	   	   Major	  histocompatibility	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NGS	  	   	   Next	  generation	  sequencing	  	  
NHLBI	   	   National	  Heart,	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  and	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NPL	  	   	   Non-­‐parametric	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OR	   	   Odds	  ratio	  
	   16	  
PCR	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  reaction	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   Rheumatoid	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  fragment	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SNV	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T1D	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  1	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TDT	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  test	  
TG2	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  transglutaminase	  
WGA	   	   Whole	  genome	  amplification	  	  
WGS	  	   	   Whole	  genome	  sequencing	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   Wellcome	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1.1	  Coeliac	  disease:	  a	  complex	  autoimmune	  disorder	  
	  
Gluten	   sensitive	   enteropathy,	   commonly	   known	   as	   coeliac	   disease	   (CD),	   is	   a	  
complex	   autoimmune	   disorder	   of	   the	   small	   intestine	   that	   carries	   a	   strong	  
genetic	   component	   and	   an	   equally	   strong	   environmental	   trigger	   of	   gluten.	  
When	  a	  genetically	   susceptible	   individual	   ingests	  gluten,	  an	   immune	   response	  
triggers	   gut	   inflammation	   resulting	   in	   acute	   morphological	   changes.	   The	  
identification	  of	  the	  human	  leukocyte	  antigen	  (HLA)	  DQ	  gene	  variants	  and	  their	  
role	   in	   CD	   has	   greatly	   contributed	   to	   our	   understanding	   of	   disease.	   A	   strong	  
genetic	   component	   comes	   from	   an	   individual’s	   HLA-­‐DQ	   genotype	   for	   the	   risk	  
allele	   coupled	   with	   the	   intake	   of	   gluten	   that	   is	   key	   in	   initiating	   an	   abnormal	  
immune	   response	   in	   genetically	   at	   risk	   individuals	   (Abadie,	   Sollid	   et	   al.	   2011).	  
Symptoms	  are	  only	  reversed	  whilst	  maintaining	  a	  gluten	  free	  diet	  (GFD).	  Despite	  
the	  causative	  trigger	  being	  non-­‐self,	  CD	  is	  described	  as	  an	  autoimmune	  disease	  
due	  to	  it	  possessing	  autoimmune	  components	  during	  disease	  manifestation	  i.e.	  
the	  role	  of	  HLA-­‐DQ2.5/8	  in	  binding	  negatively	  charged	  gluten	  peptides	  eliciting	  
a	  CD4+	  T	  cell	  response	  (Djilali-­‐Saiah,	  Schmitz	  et	  al.	  1998),	  activation	  of	  intestinal	  
intraepithelial	  lymphocytes	  (IELs)	  driving	  tissue	  damage	  (Chang,	  Mahadeva	  et	  al.	  
2005)	   and	   recent	   non-­‐HLA	   associations	   that	   include	   an	   enrichment	   of	   genes	  
predicted	   to	   control	   chemokine	   receptor	   activity,	   cytokine	   binding	   and	  
production,	  and	  T	  and	  NK	  cell	  activation	  (Hunt,	  Zhernakova	  et	  al.	  2008;	  Dubois,	  
Trynka	   et	   al.	   2010).	   Its	   genetic	   molecular	   basis	   can	   be	   described	   as	   a	  
quantitative	   polygenic	   trait	   as	   the	   outcome	   phenotype	   is	   consequential	   of	  
combinations	  of	  genes	  on	  multiple	  loci	  having	  an	  effect	  on	  each	  other.	  	  
	  
1.2	  Clinical	  manifestations	  and	  pathophysiology	  
	  
Pathways	  for	  CD	  pathogenesis	  have	  been	  elucidated	  for	  many	  years;	  an	  atypical	  
response	  to	  gluten	  produces	  an	  antigen-­‐specific	  immunologic	  hypersensitivity	  in	  
the	  mucosa	  of	  the	  small	  intestine	  leading	  to	  presentation	  of	  symptoms	  such	  as	  
malabsorption,	   malnutrition,	   steatorrhea	   (diarrhoea	   caused	   by	   excess	   fat),	  
weight	  loss,	  abdominal	  pain	  and	  anaemia.	  Samuel	  Gee	  was	  the	  first	  physician	  to	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describe	   the	   disease	   in	   1988,	   largely	   focusing	   on	   fat	   malabsorption.	  
Consequentially,	   this	   led	   to	   the	   suggestion	   of	   removing	   fat	   from	   the	   diet	   to	  
combat	   steatorrhea	   but	   this	   did	   not	   lead	   to	   any	   promising	   cure	   and	   other	  
contributions	  in	  the	  field	  correctly	  implicated	  the	  effects	  of	  wheat	  flour	  (Dicke,	  
HA	  et	  al.	   1953;	  Losowsky	  2008).	   Later,	   an	   increase	   in	   intestinal	  enzyme	   tissue	  
transglutaminase	   (TG2)	   activity	   in	   coeliac	   patients	   was	   reported	   (Bruce	   at	   al.	  
1985)	  and	  its	  upregulation	   in	  the	  subepithelial	   lamina	  propria	  has	  been	  widely	  
studied	  (Hansson,	  Ulfgren	  et	  al.	  2002;	  Skovbjerg,	  Hansen	  et	  al.	  2004).	  In	  1997,	  it	  
was	  discovered	  that	  TG2	  is	  the	  antigen	  of	  the	  biomarker	  endomysial	  antibodies	  
(EMA)	   (Dieterich,	   Ehnis	   et	   al.	   1997).	   It	   is	   now	   understood	   that	   intestinal	  
inflammation	   is	   triggered	  by	  an	  adaptive	  T-­‐cell	  mediated	   immune	  response	   to	  
gluten	   proteins	   found	   in	   dietary	   prolamins	   –	   plant	   storage	   proteins	   in	   grains	  
such	  as	  wheat	  (gliadin),	  barley	  and	  rye.	  The	  TG2	  enzyme	  catalyzes	  an	  aberrant	  
deamidation	  	  (removal	  of	  the	  amide	  group)	  of	  specific	  glutamine	  residues	  from	  
dietary	  wheat	  gliadins.	  	  
The	  process	  of	   the	  well-­‐characterized	  adaptive	   response	   to	  gluten	   ingestion	   is	  
illustrated	   in	   figure	   1.1.	   The	  mucosa	   of	   the	   small	   intestine	   is	   covered	   by	   villi:	  
finger-­‐like	  projections	   that	  have	  a	   large	   surface	  area	   for	  absorption.	   Intestinal	  
villous	   atrophy	   is	   when	   villi	   become	   truncated,	   inhibiting	   nutrient	   absorption	  
(Figure	   1.2).	   Other	   morphological	   changes	   characterizing	   CD	   enteropathy	  
include	   hyperplastic	   crypts,	   epithelial	   cell	   damage	   and	   lymphoid	   infiltrates	  
(Ferguson,	   Arranz	   et	   al.	   1993).	   These	   changes	   occur	   as	   proline-­‐rich	   areas	   of	  
gliadin	  peptides	  are	  catalyzed	  to	  glutamic	  acids	  by	  TG2	  (Sjostrom,	  Lundin	  et	  al.	  
1998);	  they	  pass	  through	  the	  epithelial	  barrier	  of	  the	   intestine	   into	  the	   lamina	  
propria,	   instigating	   deamidation	   (Molberg,	   Mcadam	   et	   al.	   1998).	   There	   is	  
increased	   peptide	   affinity	   to	   HLA	   class	   II	   molecules	   (HLA-­‐DQ2	   or	   HLA-­‐DQ8)	  
generating	   CD4+	   T-­‐helper	   1	   cell	   (Th1)	   activation,	   including	   up-­‐regulation	   of	  
interferon	  (IFN)-­‐γ	  production	  and	  T-­‐bet	  levels	  in	  gut	  infiltrating	  cells	  (Holtmann	  
and	  Neurath	  2004).	  	  
Roles	   in	   the	   innate	   immune	   response	  have	  also	  come	   to	   light	   in	   recent	  years.	  
The	  MHC	  class	  I	  receptor,	  MICA,	  is	  associated	  with	  the	  IEL	  (the	  majority	  of	  which	  
are	   CD8+	   T	   cells)	   response	   to	   gluten	   (Hue,	  Mention	   et	   al.	   2004).	   IELs	   interact	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with	   secretory	   enterocytes,	   which	   secrete	   IL15	   inducing	   stimulation	   and	  
activation	   through	   NKG2D	   receptors	   producing	   a	   cytotoxic	   inflammatory	  
response.	  Armed	  effector	  IELs	  are	  activated	  to	  lymphokine-­‐activated	  killing	  cells	  
under	   high	   doses	   of	   IL2,	   producing	   epithelial	   cell	   death	   in	   a	   T	   cell	   receptor	   –	  
independent	  manner	  (Meresse,	  Chen	  et	  al.	  2004).	  Additionally,	  a	  role	  for	  Th17	  
cells	  has	  also	  been	  suggested;	  these	  cells	  differ	  in	  their	  role	  in	  terms	  of	  cytokine	  
production	   and	   a	   high	   expression	   of	   interferon	   regulatory	   factor-­‐4	   has	   been	  
shown	  as	  a	  feature	  of	  gliadin-­‐specific	  cells	  from	  CD	  patients	  (Castellanos-­‐Rubio,	  
Santin	  et	  al.	  2009;	  Fernandez,	  Molina	  et	  al.	  2011).	  	  
Other	   strong	   activators	   of	   the	   innate	   immune	   responses	   are	   monocytes,	  
macrophages	  and	  dendritic	  cells.	  A	  recent	  study	  showed	  that	  gliadin	  fragments	  
induce	  Th1	  cytokine	  production	  by	  dendritic	  cells	  (Palova-­‐Ielinkova	  et	  al.	  2011)	  
and	  amylase/trypsin	   inhibitors	   (ATI),	  which	  engage	   the	   toll-­‐like	   receptor-­‐MD2-­‐
CD14	  complex,	  have	  been	  shown	  to	  release	  pro-­‐inflammatory	  cytokines	  in	  cells.	  
The	  activation	  of	  the	  TLR4	  signaling	  through	  ATI’s	  may	  be	  a	  novel	  contributor	  to	  
disease	   as	   mice	   deficient	   in	   TLR4	   are	   protected	   from	   intestinal	   immune	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Figure	  1.1:	  Model	  of	  deamidated	  gluten	  peptide	  presentation	  by	  APC	  to	  T	  cells	  
for	  subsequent	  loading	  onto	  HLA-­‐DQ2	  or	  HLA-­‐DQ8	  heterodimers	  
	  
	  
Adapted	   from	   Meresse,	   Ripoche	   et	   al.	   2009	   (Meresse,	   Ripoche	   et	   al.	   2009).	   The	  
removal	   of	   the	   amide	   functional	   group	   from	   an	   organic	   compound	   is	   described	   as	  
deamidation.	  In	  CD,	  this	  chemical	  reaction	  degrades	  proteins	  as	  it	  damages	  the	  amide-­‐
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Haematoxylin	  and	  eosin	  stain	  images	  of	  varying	  stages	  of	  instestinal	  villous	  atrophy:	  A	  -­‐	  
infiltrative	  non-­‐atrophic	  lesions,	  B	  –	  atrophic	  lesions	  with	  shortened	  but	  detectable	  villi,	  
C	  –	  complete	  villous	  atrophy.	  Taken	  from	  Di	  Sabatino	  and	  Corazza	  2009	  (Di	  Sabatino	  
and	  Corazza	  2009).	  	  
	  
1.3	  Disease	  epidemiology	  	  
	  
While	   gluten	   is	   the	   only	   known	   environmental	   factor	   for	   CD	   occurrence,	  
multiple	   inherited	   genetic	   factors	   affecting	   disease	   susceptibility	   have	   been	  
postulated.	  Early	  evidence	  was	  highlighted	  by	  a	  dizygotic	  twin	  concordance	  rate	  
of	  20%	  when	  sharing	  two	  HLA	  haplotypes	   identical	  by	  descent,	  compared	  to	  a	  
monozygotic	  pairwise	  concordance	  rate	  of	  75%-­‐80%	  (Greco,	  Romino	  et	  al.	  2002;	  
Di	  Sabatino	  and	  Corazza	  2009).	  The	  sibling	  recurrence	  risk	  ratio	  (λs)	   is	  10%	  for	  
disease	  development	  (Greco,	  Romino	  et	  al.	  2002;	  Polanco	  2008).	  Approximately	  
1	  in	  100	  individuals	  of	  white	  European	  descent	  (Lohi,	  Mustalahti	  et	  al.	  2007)	  and	  
0.4	  -­‐	  0.95%	  of	  individuals	  in	  the	  USA	  (Dube,	  Rostom	  et	  al.	  2005)	  have	  CD,	  but	  it	  
is	   less	   common	   in	   Asia	   and	   South	   America	   (Cummins	   and	   Roberts-­‐Thomson	  
2009;	  Kotze	  2009).	  	  
The	   dispersion	   of	   HLA-­‐DQ	   variants	   in	   Europeans	   coincides	   with	   high	   disease	  
prevalence	   in	   this	   population;	   HLA-­‐DQ8	   is	  most	   common	   in	   Northern	   Europe	  
and	   Latin	   America,	  whereas	  HLA-­‐DQ2	   is	  most	   common	   in	  Western	   Europe	   as	  
well	   as	   North	   and	   West	   Africa,	   the	   Middle	   East	   and	   Central	   Asia.	   High	  
frequencies	  of	  HLA-­‐DQ2	  are	  also	  present	  in	  the	  Saharawi	  population	  of	  Algeria,	  
where	  the	  prevalence	  of	  disease	  is	  5.6%	  (Catassi,	  Ratsch	  et	  al.	  1999),	  contrasting	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to	  almost	  negligible	  prevalence	   in	   the	  Chinese-­‐Japanese	  population	   (Cummins	  
and	  Roberts-­‐Thomson	  2009).	  CD	  is	  notably	  more	  common	  in	  woman	  (between	  
2-­‐3:1	  men	  to	  woman	  ratio)	  however	  there	  are	  no	  gender	  differences	  at	  age	  of	  
onset	  (Bai,	  Brar	  et	  al.	  2005).	  	  
Disease	  diagnosis	  for	  CD	  has	  proven	  to	  be	  ambiguous,	  largely	  due	  to	  symptoms	  
presenting	  similarly	  to	  other	  gut	  diseases,	  such	  as	  inflammatory	  bowel	  disease	  
(InBD),	   and	   the	   distinction	   between	   gluten	   sensitivity	   and	   coeliac	   requires	  
clarification	  prior	  to	  any	  disease	  diagnosis.	  At	  present,	  the	  ratio	  of	  diagnosed	  to	  
undiagnosed	  is	  1:7	  (Heap	  and	  van	  Heel	  2009),	  but	  testing	  for	  disease	  presence	  
has	   improved	  with	  more	   sensitive	   and	   specific	   serological	   screenings.	   Prior	   to	  
biopsy,	   testing	   for	   the	   presence	   of	   immunoglobulin	   A	   auto-­‐antibodies	   to	  
endomysium	  is	  a	  specific	  marker	  for	  the	  presence	  of	  CD	  (Ferguson,	  Arranz	  et	  al.	  
1993;	   Dieterich,	   Ehnis	   et	   al.	   1997).	   If	   positive,	   confirmation	   is	   necessary	   by	  
biopsy	  of	   the	  duodenal	  mucosa	  where	   the	  Marsh	  classification	  system	   is	  used	  
for	   diagnosis	   according	   to	   small	   bowel	   pathology.	   If	   villous	   atrophy	   is	   not	  
observed	   an	   IEL	   count	   is	   taken	   for	   early	   signs	   of	   disease	   manifestation	  
(Ferguson,	  Arranz	  et	  al.	  1993;	  Chang,	  Mahadeva	  et	  al.	  2005).	  A	  high	  number	  if	  
IEL’s	   with	   normal	   villous	   morphology	   is	   the	   earliest	   pathological	   change	  
following	  gluten	  challenge,	  however	  this	  may	  only	  be	  a	  sign	  of	  gluten	  sensitivity.	  
Furthermore,	  HLA	  typing	  can	  be	  useful	  for	  exclusion	  in	  patients	  with	  equivocal	  
histological	  finding	  but	  carries	  low	  specificity	  (Kaukinen,	  Partanen	  et	  al.	  2002).	  	  
Currently,	   adhering	   to	   a	   GFD	   prevents	   disease	   relapse	   and	   symptoms	   often	  
reduce	  within	  a	  few	  weeks.	  There	  are	  subsets	  of	  patients	  who	  do	  not	  respond	  
to	  GFD	  (between	  2-­‐5%),	  mainly	  those	  diagnosed	  at	  the	  age	  of	  50	  or	  above	  (Tack,	  
Verbeek	  et	  al.	  2010).	  This	  is	  known	  as	  refractory	  CD.	  The	  leading	  cause	  of	  death	  
for	  these	  patients	  is	  enteropathy-­‐associated	  T	  cell	  lymphoma	  (Al-­‐toma,	  Visser	  et	  
al.	  2007).	  	  
Although	   disease	   remission	   is	   maintained	   through	   a	   GFD	   in	   the	   majority	   of	  
patients,	   this	   fails	   to	   completely	   reverse	   the	   histological	   changes	   in	   the	  
intestinal	  mucosa	  (Lanzini,	  Lanzarotto	  et	  al.	  2009).	  An	  alternative	  treatment	   in	  
the	  form	  of	  a	  dietary	  supplement	  of	  peptidases	  (peptidases	  destroy	  proline	  and	  
glutamine	   rich	   peptides)	   was	   taken	   to	   clinical	   trials	   in	   2009	   and	   provided	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evidence	   of	   reduced	   immunological	   activity	   following	   a	   gluten	  meal,	   however	  
no	   reduction	  of	   symptoms	  were	   noted	   (Tye-­‐Din,	   Anderson	   et	   al.	   2010).	  More	  
recently,	   the	   use	   of	   human	   hookworm	   for	   the	   suppression	   of	   immune	  
responses	  to	  gluten	  has	  been	  described	  in	  coeliac	  patients,	  showing	  a	  decrease	  
of	   circulating	  T-­‐reg	  cells,	   IFN-­‐γ	   and	   IL17A	  post	   infection	   (McSorley,	  Gaze	  et	  al.	  
2011;	  Croese,	  Gaze	  et	  al.	  2013).	  	  
	  
1.4	  The	  major	  histocompatibility	  complex	  and	  coeliac	  disease	  
	  
The	  major	  histocompatibility	  complex	  (MHC)	  associated	  genes	  play	  a	  major	  role	  
in	   the	   immune	   system.	   Its	   primary	   function	   is	   to	   bind	   pathogenic	   peptide	  
fragments	  and	  display	   them	  on	   the	  cell	   surface	   for	  T-­‐cell	   recognition.	  There	   is	  
significant	   association	  with	   CD	   and	   a	   number	   of	   other	   autoimmune	   diseases,	  
such	   as	   type	   1	   diabetes	   (T1D)	   (HLA-­‐B	   and	   HLA-­‐A	   class	   I	   genes)	   (Nejentsev,	  
Howson	  et	  al.	  2007),	  ulcerative	  colitis	  (HLA-­‐DR2,	  HLA-­‐DR9	  and	  HLA-­‐DRB1*0103	  
class	   II	   genes)	   (Stokkers	   et	   al.	   1999)	   and	   ankylosing	   spondylitis,	   where	  
polymorphisms	   in	  ERAP1	   affect	   risk	   of	   disease	   in	  HLA-­‐B27	  positive	   individuals	  
(Evans	  et	  al.	  2011).	  The	  MHC	  gene	  molecules	  are	  encoded	  on	  the	  short	  arm	  of	  
chromosome	  6p21.	   Coeliac	   associated	  MHC	   class	   II	  molecules	   are	   encoded	   at	  
gene	  loci	  HLA-­‐DQ,	  HLA-­‐DP	  and	  HLA-­‐DR	  (Sollid	  2000).	  
	  
1.4.1	  The	  major	  histocompatibility	  complex	  
	  
The	  MHC	  is	  one	  of	  the	  most	  hugely	  studied	  regions	  in	  the	  human	  genome	  due	  
to	  its	  crucial	  role	  in	  immunity.	  The	  first	  MHC-­‐encoded	  proteins	  were	  discovered	  
on	  white	  blood	  cells	  and	  hence	  termed	  leukocyte	  antigens	  (commonly	  known	  as	  
the	  HLA	  region).	  The	  MHC	  consists	  of	  421	  loci	  -­‐	  252	  are	  expressed	  as	  genes,	  30	  
are	   classified	   as	   transcripts	   and	   139	   are	   pseudogenes	   (Horton,	  Wilming	   et	   al.	  
2004).	   Early	   research	   in	   the	  MHC	   region	  confirmed	  presence	  of	  MHC-­‐relevant	  
genes	   extending	   beyond	   the	   defining	   boundaries	   of	   the	   region	   at	   that	   time,	  
known	  as	  the	  classical	  MHC.	  The	  extended	  MHC	  was	  subsequently	  sequenced	  in	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2003	  and	  spans	  a	  7.6Mb	  region	  on	   the	  short	  arm	  of	  chromosome	  6	   (Mungall,	  
Palmer	  et	  al.	  2003).	  	  
The	  MHC	  class	  I	  super	  cluster	  (a	  super	  cluster	  is	  defined	  as	  clusters	  with	  related	  
genes	   outside	   the	   core	   cluster	   but	  within	   the	   extended	  MHC)	   are	   present	   on	  
nearly	  all	  nucleated	  cells	  and	  include	  three	  classical	  class	  I	  genes	  (HLA-­‐A,	  -­‐B,	  -­‐C).	  	  
The	   genes	   encode	   a	   transmembrane	   heavy	   chain,	   which	   possess	   two	  
polymorphic	  domains,	  α1	  and	  α2,	  responsible	  for	  binding	  peptides.	  The	  bound	  
peptides	  are	  presented	  to	  CD8+	  cytotoxic	  T	  cells	  via	  the	  endogenous	  pathway.	  
Apart	  from	  four	  non-­‐classical	  genes	  and	  12	  pseudogenes,	  there	  are	  also	  class-­‐I	  
like	   genes	   such	   as	   the	   stress	   response	   genes	  MICA	   and	  MICB.	   The	   latter	   is	  
located	   47kb	   centromeric	   to	   HLA-­‐B.	   Promoter	   polymorphisms	   in	   this	   gene	  
highlighted	   an	   association	   with	   CD,	   with	   one	   out	   of	   the	   four	   promoter	  
polymorphism	   haplotypes	   being	   overrepresented	   in	   CD	   patients	   (Rodriguez-­‐
Rodero,	  Rodrigo	  et	  al.	  2006).	  Additionally,	  the	  expression	  profile	  of	  these	  class	  I-­‐
like	  MIC	  genes	  indicate	  a	  possible	  role	  in	  the	  mucosal	  immune	  system	  of	  the	  gut	  
(Bahram	  2000).	  The	  class	  II	  cluster	  includes	  HLA-­‐DP,	  -­‐DQ	  and	  –DR	  that	  encode	  α	  
and	  β	  chains	  expressed	  as	  heterodimers	  on	  the	  cell	  surface	  and	  are	  responsible	  
for	   antigen	   presentation	   to	   CD4+	   T	   cells	   via	   the	   exogenous	   pathway	   (Watts	  
2004).	  Both	  class	  I	  and	  II	  cover	  a	  3.6Mb	  region	  and	  in	  between	  both	  clusters	  is	  
class	   III	   -­‐	  this	  supercluster	   is	  the	  most	  gene	  dense	  of	  anywhere	  in	  the	  genome	  
with	  61	  expressed	  genes	  (Xie	  et	  al.	  2003).	  	  
Almost	   all	   autoimmune	   diseases	   show	   significant	   association	   with	   genes	  
encoded	   in	   the	   MHC.	   For	   example,	   the	   tumor	   necrosis	   factor	   superfamily,	   a	  
cluster	  of	  genes	  in	  the	  class	  III	  region,	  encodes	  proteins	  which	  play	  key	  roles	  in	  
inflammation	   and	   immunity,	   and	   has	   been	   associated	   with	   susceptibility	   to	  
autoimmune	   diseases	   such	   as	   T1D	   (Kumar,	   Goswami	   et	   al.	   2007;	   Stayoussef,	  
Benmansour	   et	   al.	   2010)	   and	   neonatal	   lupus	   (Clancy,	  Marion	   et	   al.	   2010).	   In	  
spite	  of	  these	  associations,	  it’s	  difficult	  to	  elucidate	  susceptibility	  genes	  in	  some	  
diseases	   due	   to	   the	   complexity	   of	   linkage	   disequilibrium	   (LD)	   patterns	   and	  
coinheritance	   between	   genetic	   polymorphisms	   in	   the	   region.	   The	   MHC	  
sequencing	   consortium	  published	   an	  extensive	  map	  of	   LD	  patterns	   across	   the	  
MHC	   (de	   Bakker,	   McVean	   et	   al.	   2006)	   highlighting	   increased	   LD	   between	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haplotype	   blocks	   resulting	   in	   ancestral	   haplotypes	   that	   were	   found	   to	   be	  
common	   in	   Northern	   Europeans.	   LD	   was	   lower	   in	   Africans	   with	   shorter	  
haplotypes.	  Also,	  high	  density	  gene	  clusters	  makes	  variant	  mapping	  complex	   -­‐	  
the	   two	   largest	   gene	   clusters	   in	   the	   extended	   MHC	   are	   of	   the	   histone	   and	  
transfer	  RNA	  genes	  and	  it	  is	  thought	  these	  might	  be	  under	  selective	  pressure	  to	  
cluster	  in	  order	  to	  maximize	  transcription	  levels	  in	  chromosomal	  regions	  such	  as	  
the	  MHC,	  which	  is	  a	  transcriptional	  hotspot	  as	  well	  as	  a	  recombination	  hotspot	  
(Mungall,	  Palmer	  et	  al.	  2003).	  	  
	  
1.4.2	  HLA	  association	  with	  coeliac	  disease	  	  
	  
The	  most	  common	  genetic	  background	  coeliac	  individuals	  share	  is	  the	  presence	  
of	   HLA	   class	   II	   genes	   HLA-­‐DQ2	   or	   HLA-­‐DQ8	   (Figure	   1.3).	   HLA	   class	   II	   DQ2	  
molecules	  have	  a	  unique	  peptide-­‐binding	  motif,	  which	  is	  necessary	  for	  CD,	  and	  
encode	   for	   cell	   surface	   proteins	   on	   CD4+	   lymphocytes	   that	   recognize	   gliadin	  
peptides.	   These	  molecules	   are	   expressed	   on	  APCs	   (B	   cells,	   dendritic	   cells	   and	  
macrophages).	  When	  the	  HLA-­‐DQ2	  serotype	  was	  identified	  as	  a	  true	  association	  
it	  was	  found	  to	  be	  mediated	  through	  the	  DQ2.5	  haplotype	  (Tosi,	  Vismara	  et	  al.	  
1983).	   The	  DQ2.2	  haplotype	  does	  not	  appear	   to	  predispose	   to	  disease	   (Sollid,	  
Markussen	   et	   al.	   1989).	   HLA-­‐DQ2	   is	   encoded	   by	   HLA-­‐DQA1*05	   allele	   (alpha	  
chain)	  and	  HLA-­‐DQB1*02	  allele	   (beta	  chain).	  The	  two	  alleles	  are	  present	   in	  cis	  
conformation	  on	  the	  DR3	  haplotype.	  90%	  of	  European	  patients	  carry	  the	  HLA-­‐
DQ2	  heterodimer	  and	  the	  remaining	  carries	  either	  one	  DQ2	  allele	  or	  HLA-­‐DQ8	  
(Karell,	  Louka	  et	  al.	  2003).	  HLA-­‐DQ8	  is	  encoded	  by	  HLA-­‐DQA1*03	  (alpha	  chain)	  
and	  HLA-­‐DQB1*0302	  alleles	  (beta	  chain).	  	  
It	   is	   possible	   to	   generate	   a	   combination	   of	   DQ2.2	   and	   DQ2.5	   haplotypes	  
depending	  on	  parental	  genotypes,	  since	  each	  haplotype	  is	  only	  present	  on	  one	  
chromosome.	  If	  in	  cis	  conformation,	  both	  alpha	  and	  beta	  chain	  are	  encoded	  on	  
the	   same	   chromosome	   rather	   than	   each	   parent	   supplying	   one	   chain	   (trans	  
conformation).	  One	  or	  two	  copies	  of	  HLA-­‐DQ2	  give	  an	  a	  priori	   intermediate	  or	  
high	   risk	   for	   disease.	   Monsuur	   et	   al.	   (2008)	   used	   tagging	   single	   nucleotide	  
polymorphisms	   (SNP)	   to	  predict	  HLA	  associated	   risk	   factors	   in	  CD.	  They	   found	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that	  individuals	  with	  an	  increased	  disease	  risk	  were	  homozygous	  for	  the	  DQ2.5	  
haplotype	  or	  possessed	  a	  single	  copy	  of	  DQ2.5	  and	  one	  copy	  of	  DQ2.2,	  DQ2.7	  or	  
DQ2.8	  (Monsuur,	  de	  Bakker	  et	  al.	  2008).	  This	  coincides	  with	  previous	  findings	  by	  
van	   Belzen	   et	   al.	  who	   reported	   that	   being	   homozygote	   for	   DQ2.5	   gives	   a	   4-­‐6	  
times	   increased	  risk	  of	  disease	  (van	  Belzen,	  Koeleman	  et	  al.	  2004).	   	  Additional	  
susceptibility	  coeliac	  alleles	  may	  be	  present	  in	  the	  MHC,	  however	  it	  is	  difficult	  to	  
account	   for	   the	   high	   LD	   present	   in	   the	   region	   in	   a	   statistical	   test;	   any	   test	  
outcome	  misses	   low	   frequency	   risk	   alleles	   due	   to	   the	   effect	   of	   common	  HLA-­‐
DQA1	  and	  HLA-­‐DQB1	  high	  risk	  genotypes	  (Ahn,	  Ding	  et	  al.	  2012).	  	  
The	   presence	   of	   HLA	   class	   II	   genes	   is	   not	   the	   sole	   genetic	   component	   for	  
disease.	   HLA-­‐DQ2	   is	   expressed	   in	   30%	   of	   the	   European	   population	   (Sollid,	  
Markussen	   et	   al.	   1989),	  with	   2-­‐5%	  of	   gene	   carriers	   developing	   disease.	   These	  
early	   findings	   suggest	  other	  genetic	   factors	  contribute	   to	   the	  manifestation	  of	  
CD.	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White	   boxes	   denote	   ‘other’	   haplotype.	   DQ2.5	   cis	   is	   shown	   as	   a	   heterozygote;	   a	   DQ2.5	   cis	   homozygote	   will	   carry	   same	   alleles	   on	   both	  
chromosomes.	  Majority	  of	  CD	  patients	  express	  HLA-­‐DQ2.5	  encoded	  either	  in	  cis	  on	  the	  DR3-­‐DQ2	  haplotype,	  or	  in	  trans	  on	  the	  DR5-­‐DQ7/DR7-­‐DQ2	  
haplotype	   for	  heterozygous	   individuals.	  HLA-­‐DQ2.2	   confers	   low	   risk	   for	  CD	   if	   expressed	   solely.	  HLA-­‐DQ8	   is	   expressed	   in	  DQ2-­‐negative	  patients	  
(Abadie,	  Sollid	  et	  al.	  2011).	  Adapted	  from	  Dubois	  and	  van	  Heel	  2008	  (Dubois	  and	  van	  Heel	  2008).	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1.5	  Identifying	  susceptibility	  genes	  in	  complex	  disease	  	  
	  
The	  past	   decade	  has	   been	   subject	   to	   a	   series	   of	   successful	   genetic	   studies	   all	  
with	  the	  aim	  of	  finding	  risk	  variants	  susceptible	  to	  rare	  and	  common	  diseases.	  
The	   identification	   of	   genetic	   factors	   for	   complex	   traits	   can	   be	   explained	   by	  
efforts	   in	   Mendelian	   disease	   mapping.	   For	   these	   rare,	   monogenic	   traits,	  
positional	   cloning	  was	   the	   traditional	  method	   to	  map	  a	  gene	  of	   interest	  using	  
family	  based	  designs.	  Principal	  steps	  of	  this	  method	  are	  to	  identify	  and	  localize	  
linkage	   to	   a	   small	   interval	   by	   performing	   successive	   rounds	   of	   mapping	   in	  
families	   and	   then	   searching	   the	   area	   for	  mutations	   and	   relevance	   to	   disease.	  
The	   idea	   is	   to	   find	   the	   gene	   and	   then	   assess	   its	   function	   in	   relevance	   to	   the	  
phenotype	  and	  many	  Mendelian	  traits	  were	  mapped	  in	  this	  fashion.	  Difficulties	  
in	   this	   approach	   in	   multifactorial	   traits	   (where	   phenotype	   is	   controlled	   by	  
multiple	  genes)	  due	   to	   the	  weak	   relationship	  between	  genotype,	  at	  any	  given	  
locus,	   and	   phenotype,	   led	   to	   the	   candidate	   gene	   approach.	   This	   strategy	  
focused	   on	   identifying	   susceptibility	   variants	   through	   direct	   examination	   of	  
biological	  candidates;	  for	  example,	  the	  TNF	  gene	  was	  shown	  to	  be	  important	  in	  
the	  pathogenesis	  of	  a	  number	  of	  autoimmune	  and	  infectious	  diseases,	  such	  as	  
malaria	   (Kwiatkowski,	   Hill	   et	   al.	   1990)	   and	   an	   early	   candidate	   gene	   approach	  
study	   found	  strong	  association	  with	  severe	  malaria	  of	  homozygosity	   for	  a	  TNF	  
promoter	  SNP	  (Kwiatkowski,	  Hill	  et	  al.	  1990).	  One	  gene	  belonging	  to	  the	  tumor	  
necrosis	  factor	  family,	  TNFAIP3I,	  has	  been	  implicated	  in	  CD.	  This	  association	  was	  
first	   found	   in	   2010	   by	   a	   more	   modern	   strategy,	   a	   genome	   wide	   association	  
study	   (GWAS)	   (Dubois,	   Trynka	   et	   al.	   2010).	   The	   application	   of	   GWAS	   was	  
developed	   on	   the	   background	   of	   several	   years	   of	   linkage	   and	   candidate	   gene	  
studies	   and	   largely	   commenced	   after	   extensive	  mapping	   of	   common	   and	   low	  
frequency	   variation	   by	   the	   International	   HapMap	   Consortium.	   The	   following	  
sections	   explain	   how	   SNPs	   have	  been	  mapped	   and	   exploited	   in	  GWA	   studies,	  
the	   use	   of	   family-­‐based	   association	   designs	   and	   linkage	   analysis	   to	   map	  
chromosomal	   regions	   in	   related	   cases,	   and	   the	   strategy	   of	   GWA	   studies	   in	  
complex	  disease	  using	  unrelated	  cases.	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1.5.1	  Single	  nucleotide	  polymorphisms	  and	  linkage	  disequilibrium	  	  
	  
SNPs	  are	  the	  most	  common	  type	  of	  variation	   in	  the	  human	  genome	  and	  were	  
the	  single	  most	  important	  finding	  from	  the	  Human	  Genome	  Project	  (HGP).	  Since	  
then	   studies	   have	   assessed	   common	   and	   rare	   SNP	   frequencies	   in	   the	   human	  
genome.	   A	   study	   in	   2001	   identified	   3,899	   SNPs	   in	   82	   unrelated	   individuals	   of	  
varied	  ancestry,	  resulting	  in	  ~	  1	  SNP	  every	  185	  bases	  present	  at	  a	  frequency	  of	  
at	   least	  5%	   in	  each	  population,	  and	  more	  polymorphic	   sites	  were	  observed	   in	  
the	  3’	  UTR	  regions	  (Stephens,	  Schneider	  et	  al.	  2001).	  A	  recent	  study	  sequenced	  
202	  genes	  in	  a	  larger	  sample	  set	  of	  14,002	  individuals	  and	  reported	  on	  average	  
1	  SNP	  every	  17	  bases	  with	  a	  minor	  allele	  frequency	  (MAF)	  <0.5%,	  revealing	  an	  
abundance	  of	  rare	  SNPs	  in	  coding	  regions	  (Nelson,	  Wegmann	  et	  al.	  2012).	  	  
The	   differences	   in	   single	   nucleotides	   between	   two	   individuals	   contribute	   to	  
phenotypic	   variability	   in	   human	   populations.	   For	   this	   reason	   they	   have	   been	  
targeted	  for	  disease	  susceptibility	  in	  common	  traits.	  Almost	  all	  SNPs	  are	  biallelic	  
and	   it’s	   the	   differences	   in	   one	   of	   two	   alleles	   that	   are	   observed	   between	  
individuals.	  Most	   SNPs	   are	   non-­‐coding	   but	   two	   types	   of	   SNPs	   occur	   in	   coding	  
regions	   of	   the	   genome:	   synonymous,	   which	   do	   not	   modify	   the	   amino	   acid	  
sequence,	   and	   nonsynonymous,	   which	   change	   the	   amino	   acid	   sequence	  
resulting	  in	  a	  deleterious	  effect	  on	  protein	  function.	  Nonsynonymous	  SNPs	  are	  
further	  categorized	  into	  missense	  (substitution	  of	  an	  amino	  acid)	  and	  nonsense	  
mutations	   (substitution	   to	   a	   premature	   stop	   codon	   in	   the	   mRNA	   transcribed	  
sequence	  resulting	   in	  a	  truncated	  protein).	  Some	  missense	  mutations	  can	  also	  
be	  deleterious	  and	  the	  most	  commonly	  known	  disease	  caused	  by	  such	  mutation	  
is	  sickle	  cell	  anemia;	  an	  A→T	  mutation	   in	   the	  HBB	  gene	  causes	  an	  amino	  acid	  
change	   in	   the	   β–globin	   protein.	   The	   mutation	   is	   pathogenic	   because	   a	   polar	  
amino	   acid,	   glutamic	   acid,	   is	   replaced	   with	   a	   non-­‐polar	   one,	   valine,	   causing	  
adhesive	  interactions	  between	  heamoglobin	  molecules	  (Ingram	  1957).	  	  
SNPs	   that	  are	   statistically	   associated	  are	   said	   to	  be	  on	   the	   same	  haplotype.	  A	  
haplotype	   is	   a	   combination	   of	   DNA	   sequences	   at	   adjacent	   loci	   that	   are	  
transmitted	  together.	  Nearly	  all	  variants	  result	  from	  a	  single	  historical	  mutation	  
so	   that	   combinations	   of	   alleles	   at	   very	   close	   markers	   reflect	   ancestral	  
	   33	  
haplotypes.	   Therefore	   each	   new	   allele	   is	   initially	   associated	   with	   the	   other	  
alleles	  that	  were	  present	  on	  the	  particular	  chromosomal	  background	  on	  which	  
it	  arose,	  and	  this	  association	  is	  measured	  by	  the	  amount	  of	  LD	  i.e.	  alleles	  within	  
a	  haplotype	  show	  LD	  and	  reside	  in	  recombination	  hotspots.	  	  
The	   concept	   of	   LD	   is	   centralized	   on	   the	   non-­‐random	   association	   of	   alleles	   at	  
different	   loci.	  Natural	  selection,	  or	  chance,	  caused	  the	  spread	  of	  common	  SNP	  
mutations	   that	   arose	   thousands	   of	   generations	   ago.	   A	   second	   mutation	  
occurring	   later	   but	   close	   to	   an	   earlier	   one	   results	   in	   both	   alleles	   being	  
transmitted	   to	   the	   same	  offspring	   in	   subsequent	   generations.	   It	   is	   this	  model	  
that	  is	  exploited	  in	  a	  GWAS	  (Xiong	  and	  Guo	  1997).	  An	  increased	  risk	  of	  disease	  
caused	  by	  one	  SNP	  denotes	  direct	  association	  between	  that	  SNP	  and	  disease	  in	  
the	  population	  and	  indirect	  association	  between	  several	  nearby	  SNPs	  due	  to	  LD.	  
Therefore	   it	   is	   possible	   to	   identify	   association	   in	   the	   chromosomal	   region	  
without	  genotyping	  every	  SNP	  in	  a	  GWAS	  i.e.	  by	  using	  tagging	  SNPs.	  LD	  is	  prone	  
to	   decay	   by	   recombination	   (since	   the	   probability	   of	   recombination	   increases	  
with	   distance,	   the	   strength	   of	   LD	   between	   loci	   declines	   with	   distance)	  
recurrence	  of	  the	  same	  mutation	  and	  gene	  conversion.	  	  
	  
1.5.2	  International	  HapMap	  Project,	  1000	  Genomes	  Project	  and	  Encode	  	  
	  
The	  International	  HapMap	  Project	  commenced	  in	  2002	  with	  a	  focus	  to	  map	  all	  
common	  genetic	  variation	  (greater	  than	  5%	  MAF)	  across	  11	  populations	  (1,400	  
individuals),	  equating	  to	  3.5	  million	  SNPs.	  There	  have	  been	  26	  data	  releases	  so	  
far	   capturing	   approximately	   90%	   of	   genetic	   variation	   in	   the	   Caucasian	  
population	   by	   using	   high	   throughput	   genotyping	   chips	   (Consortium	   2003;	  
Thorisson,	  Smith	  et	  al.	  2005).	  This	  dataset	  was	  the	  first	  to	  describe	  the	  different	  
types	  of	  variants,	  where	  they	  occur	  in	  our	  DNA	  and	  their	  distribution	  within	  and	  
amongst	   populations.	   By	   comparing	   1,400	   individual	   DNA	   sequences,	  
haplotypes	   could	   be	   deciphered	   by	   mapping	   chromosomal	   regions	   of	   shared	  
genetic	  variants.	  This	  preceded	  the	  initiation	  and	  rise	  of	  many	  GWA	  studies	  as	  
the	   HapMap	   provided	   a	   detailed	   measurement	   of	   genetic	   variation	   and	   LD	  
patterns	  across	  major	  populations,	  as	  well	  as	  the	  identification	  of	  tag	  SNPs	  that	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act	  as	  haplotype	  markers	   (Smith,	  Wang	  et	  al.	  2006).	  Over	   the	   last	  decade	   the	  
quantity	  of	  know	  variation	  has	  increased	  from	  20%	  discovery	  by	  the	  HGP	  to	  90%	  
of	  mapped	  human	  variation	  with	  the	  help	  of	  HapMap	  and	  other	  similar	  projects.	  	  
The	  1000	  Genomes	  Project	  (1000G)	  was	  set	  up	  in	  2007	  with	  a	  goal	  of	  identifying	  
95%	   of	   SNPs	   present	   at	   least	   1%	   frequency	   in	   a	   range	   of	   populations	  
(www.1000genomes.org).	  In	  the	  pilot	  phase,	  which	  commenced	  in	  2008,	  three	  
different	   strategies	   were	   used:	   high	   coverage	   sequencing	   of	   family	   trios	   to	  
obtain	  true	  phasing	  of	  the	  variants	  detected,	  low	  coverage	  sequencing	  of	  many	  
individuals	  (179)	  to	  allow	  broader	  detection	  of	  variants	  but	  requiring	  statistical	  
phasing	   and	   sequencing	   of	   specific	   exon	   targets	   in	   a	   larger	   number	   of	  
individuals	   (700)	   to	   allow	   detection	   of	   rare	   variants	   but	   would	   remain	   un-­‐
phased	   (Durbin,	   Abecasis	   et	   al.	   2010).	   	   A	   main	   goal	   here	   was	   to	   reconstruct	  
haplotypes	   using	   all	   variants	   typed	   from	   all	   datasets.	   The	   more	   recently	  
published	  phase	  one	  dataset	  includes	  the	  genomes	  of	  1,092	  individuals	  from	  14	  
populations	  (Abecasis,	  Auton	  et	  al.	  2012).	  In	  this	  paper,	  functional	  variation	  was	  
mapped	  by	  a	  combination	  of	  low	  coverage	  whole	  genome	  sequence	  data	  (2-­‐6x	  
read	   depth),	   targeted	   deep	   exome	   sequence	   data	   (50-­‐100x),	   and	   dense	   SNP	  
genotype	   data.	   The	   phase	   two	   dataset	   compiled	   in	   2011	   includes	   1,715	  
individuals	   from	   19	   populations.	   The	   final	   phase	   three	   includes	   an	   additional	  
2,500	   African	   and	   South	   Asian	   samples.	   This	   public	   reference	   catalogue	   of	  
human	   genetic	   variation	   is	   already	   being	   used	   for	   imputation	   and	   will	   aid	   in	  
identifying	   previously	   missed	   associations	   and	   provide	   a	   filter	   in	   Mendelian	  
disease	  for	  exclusionary	  purposes.	  	  
Another	   project	   named	   Encylopedia	   of	   DNA	   Elements	   (Encode)	   published	   a	  
myriad	  of	   papers	   in	   2012	  based	  on	   the	   identification	  of	   transcription	   regions,	  
transcription	  factor	  association,	  chromatin	  structure	  and	  histone	  modifications	  
in	  the	  human	  genome.	  This	  project	  differs	  completely	  from	  the	  genotype-­‐based	  
HapMap	   and	   1000G	   projects	   and	   focuses	   on	   functional	   elements	   of	   gene	  
products	   giving	   previously	   unknown	   insights	   into	   gene	   regulation	   and	   how	  
statistical	   associations	   with	   disease	   correspond	   to	   these	   functional	   elements	  
(Dunham,	  Kundaje	  et	  al.	  2012).	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1.5.3	  Family	  based	  studies	  
	  
Family	  based	  designs	  for	  the	  investigation	  of	  inherited	  disease	  have	  been	  used	  
since	   Mendel’s	   laws	   of	   inheritance	   dominated	   the	   fundamental	   concepts	   of	  
genetics.	   Studies	   of	   extended	   pedigrees	   have	   several	   favourable	   features	   for	  
novel	   gene	   discovery:	   causative	   gene	   pathways	   are	   more	   homogenous	   and	  
there	   is	   a	   certain	   level	   of	   phenotypic	   control	   against	   genetic	   background	   and	  
environmental	  exposures	  (Borecki	  and	  Province	  2008).	  Gene	  mapping	  strategies	  
utilize	   linkage	   and	   association	   studies,	   both	   of	   which	   use	   family	   data,	   but	  
association	   studies	   can	   also	   be	   performed	   with	   unrelated	   individuals.	   A	  
commonly	  used	  family	  based	  association	  test	  is	  the	  transmission	  disequilibrium	  
test	  (TDT),	  first	  introduced	  in	  1993	  (Spielman,	  McGinnis	  et	  al.	  1993).	  A	  TDT	  uses	  
parents	   as	   controls	   for	   the	   cases,	   who	   are	   the	   affected	   offspring,	   so	   any	  
confounding	   effects	   of	   population	   stratification	   are	   removed.	   The	   purpose	   of	  
the	   test	   is	   to	   confer	  whether	   the	   disease	   allele	   is	   transmitted	   from	  parent	   to	  
offspring	  more	  often	   in	  a	  disease	  population	  using	  genetic	  markers	   in	  nuclear	  
families	   (trios)	   by	   mapping	   disequilibrium	   between	   the	   marker	   allele	   and	  
disease	  locus.	  If	  the	  disease	  allele	  is	  transmitted	  to	  unrelated	  cases	  more	  often	  
than	  expected	  by	  chance,	  this	   implicates	  a	   linked	  allele	  that	   is	  associated	  with	  
the	  disease	  mutation.	  	  If	  the	  allele	  is	  only	  seen	  in	  related	  cases,	  then	  it	  becomes	  
a	   test	   of	   linkage,	   not	   association.	   	   In	   essence,	   the	   TDT	   combines	   linkage	   and	  
association	  approaches	  in	  cases	  where	  either	  performed	  separately	  have	  failed	  
to	  provide	  a	  positive	  result.	  This	   test	  has	  been	  developed	  to	   include	  all	   family	  
members	  and	  genotypic	  information	  (Abecasis,	  Cookson	  et	  al.	  2000).	  	  
Where	  association	  analysis	  is	  powerful	  for	  the	  detection	  of	  common	  alleles	  that	  
confer	   modest	   disease	   risk,	   linkage	   analysis	   is	   more	   powerful	   for	   identifying	  
high-­‐risk	   disease	   alleles.	   The	   independence	   of	   segregation,	   as	   inferred	   by	  
Mendel’s	  law	  of	  segregation,	  is	  not	  always	  true:	  there	  are	  group	  of	  traits	  which	  
are	  linked	  and	  the	  genes	  controlling	  them	  tend	  to	  be	  inherited	  together	  by	  the	  
offspring	   as	   a	   group,	   not	   independently.	   This	   is	   the	   underlying	   principle	   of	   a	  
linkage	   study:	   if	   two	   individuals	   are	   phenotypically	   similar	   i.e.	   carry	   disease,	  
then	  a	  genetic	  marker	   located	  near	  a	  disease	  susceptibility	  gene	  must	  also	  be	  
	   36	  
similar	  i.e.	  shared	  by	  both	  carriers.	  Linkage	  analysis	  searches	  for	  a	  high	  number	  
of	   shared	   alleles	   than	   expected	   by	   chance	   amongst	   affected	   family	  members	  
across	   regions	   of	   the	   genome.	   This	   indicates	   that	   there	   is	   a	   disease	   causing	  
allele	  shared	  by	  affected	  individuals	  within	  the	  ‘linked’	  region.	  Large	  regions	  of	  
the	  genome	  are	  shared	  between	  closely	  related	   individuals	   inherited	  from	  the	  
same	   common	   ancestor,	   so	   less	   than	   500	   polymorphic	   markers	   are	   usually	  
sufficient	  to	  detect	  a	  linked	  region	  in	  an	  initial	  scan	  (Carlson,	  Eberle	  et	  al.	  2004).	  
The	   region	  of	   interest	   can	  only	   be	  narrowed	  down	  by	   further	   candidate-­‐gene	  
analysis	  because	  of	  the	  small	  number	  of	  recombination	  events	  within	  families.	  
In	   the	   past,	   linkage	  maps	  were	   constructed	   using	   restriction	   fragment	   length	  
polymorphisms	   (RFLP)	   as	   genetic	   markers	   and	   recombinant	   DNA	   technology	  
(Botstein,	  White	  et	  al.	  1980).	  	  On	  the	  back	  of	  that	  knowledge,	  the	  development	  
of	   an	   RFLP	   linkage	   map	   was	   proposed	   to	   allow	   more	   powerful	   analytical	  
strategies	  for	  the	  study	  of	  human	  diseases	  (Lander	  and	  Botstein	  1986).	  Now,	  in	  
silico	   approaches	   are	   used	   to	   map	   linkage	   in	   large	   multiplex	   families	   using	  
several	  polymorphic	  markers	  for	  Mendelian	  and	  complex	  traits,	  such	  as	  autism	  
spectrum	  disorders	  where	  great	  heterogeneity	   is	  observed	  (Szatmari,	  Paterson	  
et	   al.	   2007).	   The	   factors	   contributing	   to	   a	   linkage	  model,	  which	  will	   prove	   or	  
disprove	  the	  null	  of	  no	  linkage,	  are	  the	  overall	  contribution	  of	  the	  trait	  loci	  and	  
the	  genetic	  distance	  between	  the	  disease	  gene	  and	  marker	  being	  tested.	  Since	  
this	   research	  project	  has	   a	   linkage	   component,	   this	   section	   is	   expanded	  on	   in	  
the	   introduction	   of	   ‘Chapter	   4.2:	   Linkage	   Analysis	   with	   all	   Immunochip	   SNP	  
variants’.	  	  
	   	   	  
1.5.4	  Heritability	  
	  
Recent	   genetic	   studies	   have	   been	   attempting	   to	   close	   the	   gap	   on	   heritability	  
estimates	   in	   common	   diseases	   and	   ‘missing	   heritability’	   is	   a	   common	   phrase	  
seen	   in	   most	   reviews	   surrounding	   this	   topic	   (Manolio,	   Collins	   et	   al.	   2009;	  
Eichler,	   Flint	   et	   al.	   2010).	   Heritability	   is	   defined	   as	   the	   ratio	   of	   the	   genetic	  
component	   to	   the	   total	   phenotypic	   variance.	   Main	   approaches	   to	   estimate	  
heritability	   is	   based	   on	   the	   correlation	   of	   disease	   status	   in	   relative-­‐pairs,	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comparing	   disease	   concordances	   in	   twins,	   and	   using	   Bayesian	   methods	   to	  
estimate	   genetic	   variance	   components	   in	   families	   of	   pedigrees	   (Tenesa	   and	  
Haley	   2013).	   Accurately	   testing	   heritability	   is	   important	   as	   knowledge	   of	   all	  
genetic	   variants	   that	   account	   for	   disease	   can	   provide	   better	   insight	   into	  
biological	   mechanisms.	   Estimating	   heritability	   has	   associated	   caveats,	   for	  
example,	   assumptions	   of	   shared	   environment	   between	   twin	   pairs.	   However,	  
this	   variation	   can	   be	   overlooked	   by	   ascertaining	   shared	   alleles	   identical	   by	  
descent	   (IBD)	   by	   using	   genetic	   markers,	   making	   the	   estimate	   free	   from	  
confounding	  non-­‐genetic	  factors	  (Visscher,	  Medland	  et	  al.	  2006).	  	  
GWAS	   attempt	   to	   explain	   heritability	   estimates	   by	   interpreting	   results	   in	   a	  
population-­‐specific	   manner,	   where	   a	   shared	   environment	   is	   assumed.	   In	  
Manolio	   et	   al,	   evidence	   is	   stated	   that,	   for	   a	   GWAS,	   the	   premise	   is	   that	   a	  
proportion	   of	   common	   diseases,	   most	   likely	   due	   to	   genetic	   variants,	   are	  
heritable	   (Manolio,	   Collins	   et	   al.	   2009).	   Visscher	   has	   published	   an	   array	   of	  
papers	  describing	  software	  for	  the	  estimation	  of	  heritability	  from	  GWAS	  data;	  it	  
estimates	  relatedness	  among	  samples,	  which	  is	  directly	  linked	  to	  the	  amount	  of	  
phenotypic	   sharing.	   This	  multivariate	   approach	  was	   applied	   to	   seven	  diseases	  
from	  the	  Wellcome	  Trust	  Case	  Control	  Consortium	  (WTCCC)	  study	  (Lee,	  Wray	  et	  
al.	  2011)	  and	  human	  height	   (Yang,	  Benyamin	  et	  al.	  2010),	  where	  the	  estimate	  
increased	   to	   80%.	   However,	   this	   method	   used	   a	   set	   of	   all	   genotyped	   SNPs,	  
including	   non-­‐causal	   ones	   that	   mask	   correlation	   of	   causal	   SNPs,	   to	   estimate	  
genetic	  correlation.	  Further	  optimization	  of	   this	  method	  based	  on	  a	  maximum	  
likelihood	   estimation	   on	   causal	   SNPs	   increased	   accuracy	   (Golan	   and	   Rosset	  
2011).	  	  
GWA	  studies	  often	   report	  a	   large	  gap	  between	  population	  variance	   in	  disease	  
and	   heritability	   estimates.	   Where	   a	   GWAS	   focuses	   on	   SNP	   frequencies,	  
completely	   evaluating	   the	   overall	   genetic	   architecture	   of	   the	   genome	   for	  
different	  traits	  can	  help	   in	  finding	  the	  missing	  genetic	  variance	  contributing	  to	  
the	   total	   phenotypic	   variance	   in	   disease.	   Some	   examples	   of	   where	   missing	  
heritability	   may	   lie	   are:	   epigenetic	   changes	   (Slatkin	   2009),	   rare	   variants	   of	  
relatively	   large	  effect,	  disease	  associated	   structural	   variants	  and	   copy	  number	  
polymorphic	  duplications	  (Alkan,	  Kidd	  et	  al.	  2009),	  epistasis	  (Zuk,	  Hechter	  et	  al.	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2012),	   hundreds	   of	   more	   common	   variants	   and	   GWAS	   region	   tag	   variants	  
underestimating	   the	   effect	   of	   correlated	   true	   causal	   variants.	   Furthermore,	  
hidden	   gene-­‐environment	   interactions	   and	   complex	   inheritance	   could	   also	  
account	  for	  a	  substantial	  fraction	  of	  heritability.	  	  
	  
1.5.5	  Genome	  wide	  association	  studies	  	  
	  
A	  GWAS	  using	  SNP	  markers	  is	  a	  more	  powerful	  approach	  for	  elucidating	  genetic	  
determinants	  than	  family	  based	  linkage	  studies	  for	  a	  complex	  disease,	  due	  to	  its	  
heterogenic	   nature	   and	   combined	   environmental	   effects.	   It	  was	   developed	   in	  
tandem	   with	   the	   ‘common	   disease	   common	   variant	   (CDCV)’	   hypothesis,	  
recognizing	  that	  multiple	  genomic	  loci	  were	  likely	  to	  be	  involved	  in	  susceptibility	  
to	  common	  multifactorial	  traits	  due	  to	  variants	  being	  present	  at	  relatively	  high	  
frequency	   with	   an	   individually	   small	   magnitude	   of	   effect	   (Lander	   1996;	   Risch	  
and	  Merikangas	  1996).	  With	   increasing	  sample	  size	  and	  wider	  coverage	  of	  the	  
genome,	  more	  and	  more	  susceptibility	  loci	  for	  a	  wide	  range	  of	  complex	  diseases	  
have	  been	  found.	  	  
The	   first	  GWA	   study	  was	   in	   2005	   and	   compared	   96	   subjects	  with	   age-­‐related	  
macular	  degeneration	  against	  50	  healthy	  controls	  (Haines,	  Hauser	  et	  al.	  2005).	  
Two	  years	  later,	  the	  WTCCC	  published	  the	  largest	  GWAS	  at	  the	  time,	  collecting	  
subjects	   across	   seven	   common	   diseases,	   totaling	   14,000	   cases	   and	   3,000	  
controls	   (Burton,	  Clayton	  et	  al.	  2007).	   In	  2009,	  over	  500	  GWAS	  studies	   in	  300	  
diseases	   were	   published,	   of	   which	   more	   than	   30	   have	   been	   published	   in	  
autoimmune	  disease	  (Baranzini	  2009),	  and	  this	  number	  has	  risen	  sharply	  since	  
then.	  Some	  studies	  have	  been	  follow-­‐ups	  from	  linkage	  signals	  or	  candidate	  gene	  
studies	   to	   narrow	  down	   association	   to	   a	   single	   haplotype,	   such	   as	   the	   region	  
near	  the	  CTLA4	  gene	  in	  CD	  (Hunt,	  McGovern	  et	  al.	  2005).	  	  
A	   GWAS	   uses	   SNP	   markers	   across	   the	   whole	   genome,	   which	   are	   tested	   for	  
association	  with	  a	  disease	   in	  a	   large	  cohort	  of	  disease	  cases	   compared	  with	  a	  
similar	   or	   higher	   number	   of	   controls.	   After	   performing	   correctional	   tests,	  
common	   variants	   in	   correlation	  with	   disease	   are	   identified	   depending	   on	   the	  
risk	  allele	  frequency,	  its	  association	  between	  marker	  genotyped	  and	  relative	  risk	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conferred	  by	  genotype.	  For	  a	  successful	  GWAS	  large	  sample	  sizes,	  strict	  quality	  
control,	   accurate	   genotyping	   to	   confer	   accurate	   phenotypes	   and	   careful	  
adjustment	   for	   confounding	   factors	   are	   essential	   (de	   Bakker,	   Ferreira	   et	   al.	  
2008).	   Up	   to	   now	   associated	   variants	   have	   been	   found	  mostly	   in	   non-­‐coding	  
regions	   through	  GWAS,	   so	   it	   is	  accepted	   that	   common	  variant	   contribution	   to	  
disease	  is	  more	  likely	  to	  be	  of	  regulatory	  function	  rather	  than	  protein	  coding.	  	  
Whilst	  GWAS	  has	   increased	  the	  number	  of	   identifiable	  disease-­‐associated	   loci,	  
the	  odds	  ratio	  (OR;	  disease	  risk	  if	  in	  possession	  of	  disease	  associated	  SNPs)	  for	  
these	   risk	   variants	   have	   been	   fairly	  modest	   (commonly	   between	   1.05-­‐1.5),	   so	  
the	  proportion	  of	   the	   risk	   attributable	   to	   genetic	   variants	   remains	   small.	   That	  
said,	  there	  are	  other	  aims	  in	  a	  GWAS,	  which	  is	  to	  use	  the	  information	  in	  order	  to	  
understand	  downstream	  processes	  leading	  to	  the	  observed	  disease	  phenotype.	  
Linking	   the	  measured	  genotype	   to	  phenotype	   is	  often	  a	  painstaking	   task	  as	   in	  
some	  cases	   the	  outcome	  genotypic	  association	  may	  have	  no	   reflection	  on	   the	  
hypothesized	  disease	  pathway.	  Combining	  transcriptional	  network	  analysis	  and	  
gene	   expression	   is	   required	   to	   discover	   regulatory	   gene	   networks	   (Keller,	  
Martini	  et	  al.	  2012).	  	  
When	   a	   GWAS	   has	   failed	   to	   find	   a	   significant	   finding,	   or	   the	   finding	   has	   not	  
reached	  a	  significant	  statistical	  association,	  a	  meta-­‐analysis	   is	  an	  excellent	  tool	  
in	   combining	   GWAS	   results	   for	   the	   same	   phenotype	   in	   order	   to	   gain	   a	  more	  
meaningful	   association.	   A	  meta-­‐analysis	   automatically	   increases	   the	   statistical	  
power	  due	  to	  a	  larger	  sample	  size,	  and	  may	  provide	  further	  support	  for	  known	  
risk	   signals,	   as	   in	   T1D	   for	   the	   IL2-­‐IL21	   region	   (Cooper,	   Smyth	   et	   al.	   2008)	   or	  
highlight	   previously	   unknown	   associations,	   as	   in	   rheumatoid	   arthritis	   (RA)	  
where	   seven	   new	   risk	   alleles	   were	   identified	   in	   a	   sample	   size	   of	   ~42,	   000	  
(Plenge,	   Stahl	   et	   al.	   2010).	   Additional	   power	   can	   be	   achieved	   by	   combining	  
phenotypes	  where	  there	  is	  a	  clear	  shared	  genetic	  foundation	  to	  identify	  shared	  
risk	   alleles.	   A	   meta-­‐analysis	   combining	   CD	   and	   RA	   published	   GWAS	   results	  
identified	   four	  additional	  gene	   loci	  not	  previously	  confirmed	   in	  either	  disease,	  
and	   also	   implicated	   four	   gene	   loci	   previously	   established	   in	   CD	   and	   RA	   to	   be	  
significant	   in	  other	  autoimmune	  diseases	  (SH2B3,	  8q24,	  STAT4,	  and	  TRAF1-­‐C5)	  
(Zhernakova,	  Stahl	  et	  al.	  2011).	  Other	  successful	  studies	  have	  demonstrated	  the	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power	  of	  meta-­‐analyses	   and	   the	   advantages	  of	   collaborating	  with	  other	  GWA	  
study	  cohorts	  in	  order	  to	  gain	  valuable	  insights	  into	  disease	  pathways	  (Barrett,	  
Hansoul	   et	   al.	   2008;	   Zeggini,	   Scott	   et	   al.	   2008).	   Furthermore,	   genome	   wide	  
imputation	   from	   a	   reference	   panel,	   such	   as	   HapMap	   or	   1000G,	   can	   locate	  
stronger	  associations.	  This	  has	  been	  highlighted	  for	  the	  TAGAP	  risk	  locus	  in	  RA	  
(Plenge,	  Stahl	  et	  al.	  2010;	  Chen,	  Stahl	  et	  al.	  2011).	  Imputation	  was	  designed	  to	  
allow	  testing	  of	  un-­‐typed	  variants	  by	  combining	  SNP	  correlation	  patterns	  from	  a	  
reference	   panel	   with	   genotype	   data	   on	   tagged	   SNPs	   (Servin	   and	   Stephens	  
2007).	   The	   genotype	   estimation	   is	   then	   tested	   for	   phenotype	   association	   and	  
further	   assessed	   in	   a	   replication	   cohort.	   This	  method	   increases	   the	   statistical	  
power	   to	   detect	   novel	   associations	   as	   well	   as	   identifying	   missed	   associated	  
variants,	  for	  example,	   imputation	  from	  the	  1000	  genomes	  panel	  observed	  two	  
variants	   (IL2RA	   associated	   with	   T1D	   and	   CDKN2B	   associated	   with	   type	   2	  
diabetes)	   that	   were	   previously	   undetected	   in	   the	   WTCCC	   case	   control	   study	  
(Burton,	   Clayton	   et	   al.	   2007;	   Huang,	   Ellinghaus	   et	   al.	   2012).	   1000G-­‐based	  
imputation	   has	   proven	   to	   be	   an	   excellent	   tool	   in	   increasing	   genome-­‐wide	  
coverage	  in	  different	  populations	  because	  of	  a	  higher	  number	  of	  common	  and	  
low	  frequency	  SNPs	  resulting	  in	  more	  accurate	  genotyping	  (Gao,	  Haritunians	  et	  
al.	  2012;	  Sung,	  Gu	  et	  al.	  2012).	  	  
	  
1.6	  Known	  genetic	  structure	  of	  coeliac	  disease	  
	  
As	   noted,	   the	   most	   significant	   association	   to	   CD	   so	   far	   is	   with	   HLA-­‐DQ2.	  
Possession	  of	  HLA-­‐DQ2	  serotypes	  is	  necessary	  for	  affinity	  to	  deamidated	  gliadin,	  
yet	   30%	   of	   the	   Caucasian	   population	   also	   carry	   HLA-­‐DQ2	  without	   developing	  
disease	  (Heap	  and	  van	  Heel	  2009).	  The	  following	  sections	  explain	  methods	  used	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   1.6.1	  Regions	  identified	  through	  linkage	  analysis	  
	  
To	  determine	  absolute	  risk	  of	  disease,	  non-­‐HLA	  risk	  alleles	  in	  CD	  must	  be	  taken	  
into	  account.	  Unlike	  Mendelian	  disease,	  complex	  disease	  has	  had	  less	  success	  in	  
finding	   causal	   variants	   through	   linkage.	   In	   CD,	   linkage	   was	   found	   to	   various	  
regions	  in	  early	  studies	  including	  5q	  (Greco,	  Corazza	  et	  al.	  1998;	  Greco,	  Babron	  
et	   al.	   2001;	   Percopo,	   Babron	   et	   al.	   2003),	   which	   was	   replicated	   in	   a	   meta	  
analysis	   of	   multiple	   populations	   (Babron,	   Nilsson	   et	   al.	   2003),	   and	   19p	   (Van	  
Belzen,	  Meijer	  et	  al.	  2003).	  Linkage	  to	  2q33,	  containing	  CTLA4,	   ICOS	  and	  CD28	  
which	   is	   involved	   in	   immune	   suppression,	   suggested	   several	   independent	   loci	  
contributing	   to	   disease	   (Amundsen,	   Naluai	   et	   al.	   2004).	   Haplotype	   analysis	   in	  
this	   region	  showed	  strong	  association	   in	   the	   Irish	  population	   (Brophy,	  Ryan	  et	  
al.	  2006)	  as	  well	  as	  linkage	  in	  several	  other	  populations	  (Djilali-­‐Saiah,	  Schmitz	  et	  
al.	  1998;	  Naluai,	  Nilsson	  et	  al.	  2000;	  King,	  Moodie	  et	  al.	  2002)	  and	  variants	   in	  
the	   3’	   region	   of	   CTLA4	   were	   thought	   to	   influence	   responses	   in	   T1D	   (King,	  
Yiannakou	   et	   al.	   2000).	   In	   spite	   of	   promising	   initial	   analysis,	   replication	   in	  
genome	  wide	  scans	  was	  inconsistent	  for	  this	  region	  (King,	  Moodie	  et	  al.	  2003).	  	  
A	  whole	  genome	  linkage	  approach	  followed	  by	  Immunochip	  genotyping	  in	  two	  
multiply	   affected	   Finnish	   and	   Hungarian	   coeliac	   families	   found	   linkage	  
(logarithm	  of	  odds	   score	   (LOD)	  >1.3)	  at	  4q,	  6p,	  6q,	  7p,	  17p,	  17q	  and	  22p,	  but	  
only	  variants	  at	  4q,	  harbouring	  the	  IL2-­‐IL21-­‐TENR	  locus,	  segregated	  with	  disease	  
in	   both	   families.	   This	   risk	   haplotype	   was	   estimated	   to	   have	   a	   2%	   frequency	  
estimation	  in	  the	  CEU	  population	  indicating	  that	  the	  observed	  linkage	  was	  due	  
to	   a	   rare	   risk	   haplotype	   in	   this	   region	   not	   tagged	   by	   previously	   described	  
common	   variants	   (Einarsdottir	   et	   al.	   2012).	   This	   illustrates	   the	   need	   for	  
genotyping	  chips	  with	  less	  than	  5%	  frequency	  SNPs	  to	  search	  for	  those	  rare	  risk	  
alleles	  with	  large	  effect	  size,	  which	  is	  discussed	  in	  more	  detail	  in	  section	  1.7.	  	  
It	   is	   known	   that	   the	   power	   of	   family	   studies	   is	   decreased	   due	   to	   small	   effect	  
sizes	  attributable	  to	  genetic	  variants	  present	  at	  high	  frequency	  (Kruglyak	  2008).	  
An	  exception	  is	  NOD2	  in	  Crohn’s	  disease	  (Hugot,	  Chamaillard	  et	  al.	  2001;	  Ogura,	  
Bonen	  et	  al.	  2001),	  and	  HLA	  replication	  in	  CD,	  due	  to	  common	  encoding	  variants	  
being	  of	  large	  effect	  size	  hence	  having	  sufficient	  statistical	  power.	  	  This	  explains	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that	  predisposition	  to	  complex	  disease	  is	  not	  caused	  by	  just	  a	  handful	  of	  highly	  
penetrant	  mutations	  but	  a	  mixture	  of	  multiple	  risk	  variants	  with	  varying	  effect	  
size.	  
	  
1.6.2	  Susceptibility	  gene	  loci	  identified	  by	  GWAS	  and	  further	  dense	  
genotyping	  with	  Immunochip	  
	  
To	   date	   two	   GWA	   studies	   using	   samples	   of	   European	   ancestry	   have	   been	  
carried	   out	   in	   CD	   identifying	   non-­‐HLA	   variants.	   In	   the	   first	  GWAS,	   778	   coeliac	  
cases	  and	  1,422	  matched	  population	  controls	  using	  310,605	   tag	  SNPs	   showed	  
the	  highest	  association	  on	  chromosome	  4q27	  harbouring	   the	  KIAA1109-­‐TENR-­‐
IL2-­‐IL21	   LD	   block	   (van	   Heel,	   Franke	   et	   al.	   2007).	   Follow	   up	   studies	   found	  
associations	  in	  REL,	  TNFAIP3	  and	  a	  region	  encompassing	  CTLA4,	  ICOS	  and	  CD28	  
(Smyth,	  Plagnol	  et	  al.	  2008;	  Trynka,	  Zhernakova	  et	  al.	  2009).	  The	  UK	  follow	  up	  
replication	   study	   by	   Hunt	   et	   al.	   identified	   a	   further	   seven	   regions	   reaching	  
genome-­‐wide	  combined	  significance	  (P≤5	  x	  10-­‐7)	  (Hunt,	  Zhernakova	  et	  al.	  2008).	  
An	   additional	   association	   was	   found	   in	   ITGA4	   in	   a	   US	   case	   control	   collection	  
(Garner,	  Murray	  et	  al.	  2009).	  Six	  out	  of	   the	  eight	  coeliac	   regions	   found	   in	  van	  
Heel	   et	   al.	   (2007)	   and	   Hunt	   et	   al.	   (2008)	  were	   replicated	   in	   an	   Italian	   cohort	  
(Romanos,	  Barisani	  et	  al.	  2009).	  	  
The	   second	   generation	   GWAS	   by	   Dubois	   et	   al.	   used	   a	   larger	   sample	   size	  
(discovery	  dataset	  included	  4,533	  European	  cases	  and	  10,750	  matched	  controls)	  
and	   identified	  a	   further	  13	  genome	  wide	  significant	  regions,	  with	  evidence	  for	  
an	  additional	  13	  suggestive	   loci	  upon	  replication,	  28	  of	  which	  contained	  genes	  
controlling	  immune	  responses	  (Figure	  1.4)	  (Dubois,	  Trynka	  et	  al.	  2010).	  A	  study	  
by	  Amundsen	  et	  al.	  used	  family	  TDT	  (to	  remove	  any	  sources	  of	  false	  positives)	  
and	  found	  significant	  associations	  in	  four	  out	  of	  the	  nine	  CD	  regions	  tested	  in	  a	  
Swedish-­‐Norwegian	   family	   cohort	   (Amundsen,	  Rundberg	  et	   al.	   2010).	  A	  meta-­‐
analysis	  combining	  both	  CD	  published	  GWAS	  datasets	  (Zhernakova,	  Stahl	  et	  al.	  
2011)	  with	  an	  RA	  sample	  cohort	  including	  5,539	  cases	  identified	  four	  novel	  SNPs	  
for	   both	   diseases	   in	  DDX6,	   CD247,	  UBE2L3	   and	  UBASH3A.	   The	   SNP	   in	   CD247	  
(rs864537)	   was	   previously	   identified	   in	   CD	   (Dubois,	   Trynka	   et	   al.	   2010),	   but	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reached	  a	  higher	  statistical	  significance	  in	  this	  larger	  meta-­‐analysis	  dataset	  (P=2	  
x	  10-­‐11).	  The	  other	  three	  new	  overlapping	  associations	  for	  CD	  and	  RA	  were	  later	  
statistically	  significant	  in	  a	  CD	  fine	  mapping	  study	  carried	  out	  in	  2011	  (discussed	  
below).	  	  
	  
Figure	  1.4:	  Total	  genetic	  variance	  contributed	  to	  CD	  by	  significant	  and	  




HLA-­‐DQ2/DQ8	  is	  present	  in	  45.3%	  of	  the	  population	  and	  97.4%	  of	  coeliac	  individuals.	  
Boxes	  surround	  immune	  genes.	  Adapted	  from	  Dubois	  et	  al.	  2010	  (Dubois,	  Trynka	  et	  al.	  
2010).	  
	  
Fine	   mapping	   is	   a	   necessary	   step	   after	   genotyping	   in	   an	   attempt	   to	   refine	  
associated	  region(s)	  to	  a	  causal	  variant(s)	  by	  analyzing	  a	  high	  density	  of	  genetic	  
markers	   across	   the	   associated	   LD	   region.	  Using	   T1D	   as	   an	   example,	   extensive	  
mapping	   across	   the	   MHC	   region	   for	   discovery	   of	   HLA-­‐linked	   loci	   to	   T1D	  
established	   HLA-­‐B	   and	   HLA-­‐A	   to	   be	   associated	   independently	   of	   HLA	   class	   II	  
genes	  (Brown,	  Pierce	  et	  al.	  2009;	  He,	  Hamon	  et	  al.	  2009;	  Howson,	  Walker	  et	  al.	  
2009).	  Results	  from	  this	  study	  illustrated	  the	  multilocus	  effects	  due	  to	  classical	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HLA	  genes	  and	  extensive	  LD	  spanning	  the	  entire	  region.	  Additionally,	  the	  major	  
susceptibility	   gene	   to	   T1D	   was	   refined	   to	   two	   independent	   groups	   of	   SNPs	  
encompassing	   IL2RA	   intron	   1	   and	   5’	   regions	   of	   IL2RA	   and	  RBM17	   after	   large	  
scale	   fine	   mapping	   (Lowe,	   Cooper	   et	   al.	   2007).	   IL2RA	   is	   involved	   in	   the	  
regulation	   of	   T	   cells	   correlating	  with	   functional	   work	   in	   a	   non-­‐diabetic	   obese	  
mouse	  model	   showing	  reduced	  expression	  of	   IL2	   relating	   to	   increased	  disease	  
risk	  and	  reduced	  T-­‐reg	  cell	  activity	  (Yamanouchi,	  Rainbow	  et	  al.	  2007).	  A	  coeliac-­‐
associated	   locus,	   IL2/IL21,	   is	   also	   implicated	   in	   SLE	   and	   present	   research	   has	  
localized	  the	  effect	  of	  this	  locus	  to	  two	  SNPs	  in	  high	  LD	  through	  fine	  mapping	  of	  
45	  tag	  SNPs	  in	  the	  region	  (Hughes,	  Kim-­‐Howard	  et	  al.	  2011).	  Again,	  it	  is	  easy	  to	  
identify	  multiple	  associated	  loci	  across	  autoimmune	  diseases	  by	  looking	  deeper	  
into	  GWAS	  associated	  regions.	  Recently,	  this	  has	  been	  greatly	  expanded	  by	  the	  
development	  of	  the	  Immunochip	  genotyping	  array.	  	  
In	  2010	  a	  deep	  replication	  effort	  to	  fine	  map	  autoimmune	  diseases	  was	  created	  
by	   the	   Immunochip	   Consortium,	   providing	   an	   opportunity	   to	   refine	   GWAS	  
signals	   and	   to	   identify	   new	   disease	   associations	   with	   loci	   implicated	   in	   other	  
autoimmune	   diseases.	   In	   collaboration	   with	   Illumina,	   this	   Infinium	   chip	  
contained	   186	   non-­‐HLA	   risk	   loci	   including	   many	   more	   markers	   in	   both	  
regulatory	   and	   exonic	   gene	   regions	   and	   all	   1000G	   pilot	   CEU	   low	   frequency	  
variants	  for	  dense	  SNP	  mapping	  analysis.	  The	  first	  paper	  to	  be	  published	  was	  in	  
CD:	   a	   scan	   was	   performed	   in	   12,041	   coeliac	   cases	   and	   12,228	   controls	   of	  
European	   and	   Indian	   origin.	   This	   study	   replicated	   previously	   described	  
associations	   (Hunt,	   Zhernakova	   et	   al.	   2008;	   Dubois,	   Trynka	   et	   al.	   2010)	   and	  
identified	   13	   new	   disease	   risk	   loci	   reaching	   genome	  wide	   significance	   (Figure	  
1.5)	   (Trynka,	   Hunt	   et	   al.	   2011).	   In	   addition,	   over	   a	   third	   of	   loci	   containing	  
multiple	   independent	   associations	   were	   a	   combination	   of	   common,	   low	  
frequency	  and	  rare	  variants.	  	  
This	  study	  illustrates	  the	  effectiveness	  of	  the	  Immunochip	  array	  in	  refining	  risk	  
associations,	   as	   53%	   of	   signals	   were	   localized	   to	   a	   single	   gene.	   Despite	   this	  
major	  advance,	  only	  13.7%	  of	  genetic	  variance	  was	  found	  to	  be	  explained	  by	  39	  
non-­‐HLA	  associated	  risk	   loci	   in	   individuals	  of	  European	  ancestry	  (this	   increases	  
to	   40%	   with	   the	   HLA).	   Similar	   statistics	   are	   observed	   for	   other	   autoimmune	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diseases:	   Eyre	   et	   al.	   identified	  14	  new	  RA	   loci	   at	   P	  <	  5x10-­‐8	  with	   Immunochip	  
genotypes	  and	  seven	  additional	   loci	  when	  combined	  with	  GWAS	  meta-­‐analysis	  
data,	  totaling	  51%	  of	  the	  heritability	  estimate,	  of	  which	  36%	  is	  explained	  by	  the	  
HLA	  (Eyre	  et	  al.	  2012);	  39	  independent	  signals	  in	  psoriasis	  at	  P	  <	  5x10-­‐8	  account	  
for	  14.3%	  total	  variance	  or	  ~22%	  heritability	  (Tsoi	  et	  al.	  2012);	  26	  independent	  
SNPs	   and	   four	   HLA	   types	   account	   for	   4.9%	   and	   1.4%	   variance	   in	   liability,	  
respectively,	   with	   the	   total	   heritability	   estimate	   at	   16.2%	   in	   primary	   biliary	  
cirrhosis	   (Liu,	   Almarri	   et	   al.	   2012).	   Although	   heritability	   estimates	   have	   not	  
entirely	  been	  explained,	   the	   Immunochip	   consortium	  has	  allowed	  progression	  
in	  many	   immune-­‐mediated	   disease	   types	   using	   different	   analytical	   strategies.	  
For	   example,	   a	   massive	   InBD	   meta-­‐analysis	   combining	   imputation-­‐based	  
association	   analysis	   using	   15	   GWAS	   datasets	   from	   Crohn’s	   disease	   and	  
ulcerative	   colitis	   and	   validation	   using	   Immunochip	   genotypes	   identified	   193	  
independent	  association	  signals	   in	  163	   regions,	  of	  which	  71	  were	  new.	  Out	  of	  
163	   loci,	   110	   were	   associated	   with	   both	   Crohn’s	   and	   ulcerative	   colitis	  
phenotypes,	   and	   113	   of	   these	   InBD	   loci	   were	   shared	   with	   other	   complex	  
diseases	   (Jostins,	   Ripke	   et	   al.	   2012).	   This	   study	   also	   highlighted	   shared	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Figure	  1.5:	  Manhattan	  plot	  showing	  previously	  associated	  and	  new	  CD	  risk	  loci	  
with	  significant	  threshold	  set	  at	  P≤	  5x10-­‐8	  
	  
	  
Novel	  loci	  are	  in	  blue	  and	  multiple	  signal	  loci	  are	  highlighted	  in	  grey.	  Taken	  from	  Trynka	  
et	  al.	  2011.	  	  
	  
1.6.3	  Overlap	  with	  other	  autoimmune	  diseases	  	  
	  
The	  numbers	  of	  autoimmune	  disease	  loci	  that	  overlap	  with	  CD	  highlight	  shared	  
immunological	  pathways	  e.g.	  CTLA4	  (T	  cell	  co-­‐stimulation),	  IL2-­‐IL21	  (B	  cell	  and	  T	  
CD8	  differentation),	   ICOSLG	   (B	  cell	  help),	  PTPN2	   (IFNy	  and	   IL76	   signaling),	  and	  
IL18RAP	   (signal	   transduction)	   (Meresse,	  Malamut	   et	   al.	   2012).	   Approximately	  
64%	   of	   39	   known	   CD	   loci	   are	   shared	   with	   at	   least	   one	   other	   autoimmune	  
disease	   (Gutierrez-­‐Achury,	  de	  Almeida	  et	  al.	  2011).	  Table	  1.1	  outlines	  39	  non-­‐
HLA	  coeliac	  risk	  loci	  and	  the	  GWAS	  associated	  overlapping	  autoimmune	  disease	  
at	   P	   <	   5	   x	   10-­‐5.	   The	   reported	   gene	   function	   is	   also	   noted	   in	   this	   table,	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highlighting	  processes	   involving	  T-­‐lymphocyte	  proliferation,	  cytokine	  processes	  
and	  signaling.	  The	  SNP	  with	  the	  largest	  significant	  association	  in	  CD	  is	  rs2030519	  
in	  LPP	   (p=3.0	   x	  10-­‐49);	   this	   association	   is	  not	   shared	   in	  any	  of	   the	  obvious	  gut	  
related	   immune-­‐mediated	  diseases	   but	   is	   reported	   in	   vitiligo	   (Jin,	   Birlea	   et	   al.	  
2010),	  an	  autoimmune	  disease	  characterized	  by	  loss	  of	  pigmentation	  in	  skin	  and	  
hair.	  This	  is	  unsurprising	  since	  the	  ubiquitous	  nature	  of	  the	  immune	  system	  can	  
lead	   to	   alterations	  manifesting	   in	   other	   etiologically	   related	   diseases.	   Crohn’s	  
disease	  shares	  most	  loci	  with	  CD,	  but	  out	  of	  all	  of	  them	  TAGAP	  and	  PUS10	  have	  
been	   firmly	   identified	   as	   shared	   risk	   loci	   after	   replication	   with	   combined	   p	  
values	  of	  1.55	  x	  10-­‐10	  and	  1.38	  x	  10-­‐11	  respectively	  (Festen,	  Goyette	  et	  al.	  2011).	  	  
From	  previous	  meta-­‐analysis	  and	  Immunochip	  studies	  in	  autoimmune	  diseases	  
it	   is	   clear	   that	  one	  dataset	  combining	  different	  diseases	  yields	  more	  power	   to	  
finding	  shared	  loci,	  however	  this	  can	  be	  further	  improved	  by	  proper	  phenotypic	  
characterization	   as	   CD	   and	   other	   autoimmune	   diseases	   can	   manifest	   into	   a	  
broad	   range	   of	   overlapping	   symptoms.	   Apart	   from	   clinical	   perspectives,	   the	  
advantages	   of	   being	   able	   to	   deduce	   a	   shared	   immunological	   profile	   from	  
information	  on	   loci	   effects	   in	   different	   diseases	   can	   allow	   investigation	   into	   a	  
shared	   host	   microbiome,	   as	   observed	   between	   InBD	   loci	   and	   responses	   to	  
mycobacteria	   (Jostins,	   Ripke	   et	   al.	   2012)	   and	   interpretation	   of	   any	   protective	  
associations.	  A	   study	  has	   shown	   that	   three	  out	  of	   the	   five	   risk	  markers	   in	   the	  
IL2/IL21	   region	  showing	  strong	  association	  with	  CD	  have	  a	  protective	  effect	   in	  
ulcerative	  colitis	  (Glas,	  Stallhofer	  et	  al.	  2009)	  supporting	  the	  notion	  that	  alleles	  
are	   in	  balancing	  selection	  if	  they	   increase	  risk	  of	  one	  disease	  but	  decrease	  the	  
risk	  of	  another	  (Blekhman,	  Man	  et	  al.	  2008).	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Table	  1.1:	  39	  non-­‐HLA	  coeliac	  loci	  from	  Immunochip	  study	  (2011)	  showing	  association	  with	  other	  autoimmune	  diseases	  
	  
Associated	  coeliac	  loci	   Reported	  genes	   Overlapping	  autoimmune	  diseases	  
1q24.3	   FASLG,	  TNFSF18	   Crohn's	  disease	  
1q32.1	   C1orf106	   Ulcerative	  colitis,	  Type	  1	  diabetes,	  Crohn's	  disease,	  Multiple	  
sclerosis,	  Ankylosing	  spondylitis	  
1q31.2	   RGS1	   Multiple	  sclerosis,	  Type	  1	  diabetes	  
1p36.11	   RUNX3	   Psoriasis	  
1p36.32	   TNFRSF14,	  MMEL1	   Rheumatoid	  arthritis,	  Ulcerative	  colitis,	  Multiple	  sclerosis,	  Graves’	  
disease	  
2q12.1	   IL18RAP,	  IL18R1	   Crohn's	  disease,	  Type	  1	  diabetes	  
2p14	   PLEK,	  FBX048	   Rheumatoid	  arthritis,	  Crohn's	  disease,	  
2p16.1	   PUS10	   Ulcerative	  colitis,	  Crohn's	  disease,	  Psoriasis,	  Rheumatoid	  arthritis	  
2q31.3	   ITGA4,	  UBE2E3	   Ankylosing	  spondylitis	  
2q32.3	   STAT4	   Crohn's	  disease	  
2q33.2	   CTLA4,	  ICOS,	  CD28	   Type	  1	  diabetes,	  Rheumatoid	  arthritis,	  Graves’	  disease	  
3q13.33	   ARHGAP31	   Vitiligo,	  Multiple	  Sclerosis	  
3p21.31	   CCR1-­‐3,	  LTF	   Ulcerative	  colitis,	  Crohn's	  disease	  
3p22.3	   CCR4,	  GBL1	   None	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3q25.33	   IL12A,	  SCHIP1	   Multiple	  Sclerosis	  
3q28	   LPP	   Vitiligo	  
4q27	   IL2,	  IL21,	  KIAA1109,	  TENR,	  ADAD1	   Ulcerative	  colitis,	  Type	  1	  diabetes,	  Rheumatoid	  arthritis,	  Crohn's	  
disease,	  Psoriasis	  
6q15	   BACH2	   Type	  1	  diabetes,	  Crohn's	  disease,	  Multiple	  Sclerosis,	  Graves’	  disease	  
6q22.33	   PTPRK	   Crohn's	  disease,	  Multiple	  Sclerosis	  
6q23.3	   TNFAIP3,	  OLIG3	   Psoriasis,	  Rheumatoid	  arthritis,	  Systemic	  lupus	  erythematosus,	  
Ulcerative	  colitis,	  Multiple	  Sclerosis,	  Type	  1	  diabetes	  
6q25.3	   TAGAP	   Crohn's	  disease,	  Multiple	  Sclerosis,	  Type	  1	  diabetes,	  Psoriasis	  
6p25.3	   IRF4	   None	  
7p14.1	   ELMO1	   Rheumatoid	  arthritis	  
8q24.21	   PVT1	   Multiple	  Sclerosis,	  Crohn's	  disease,	  Rheumatoid	  arthritis	  
11q23.1	   POU2AF1	   None	  
11q23.3	   TREH,	  DDX6	   Crohn’s	  disease,	  Vitiligo,	  Multiple	  Sclerosis,	  Systemic	  lupus	  
erythematosus,	  Rheumatoid	  arthritis	  
11q24.3	   ETS1	   Crohn's	  disease,	  Psoriasis	  
10p15.1	   PFKFB3,	  PRKCQ	   Multiple	  Sclerosis,	  Crohn's	  disease,	  Type	  1	  diabetes,	  Rheumatoid	  
arthritis,	  Vitiligo	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10q22.3	   ZMIZ1	   Multiple	  Sclerosis,	  Crohn's	  disease	  
12q24.12	   SH2B3,	  ATXN2	   Rheumatoid	  arthritis,	  Type	  1	  diabetes,	  Vitiligo	  
14q24.1	   ZFP36L1	   Type	  1	  diabetes,	  Crohn's	  disease,	  Multiple	  Sclerosis	  
15q24.1	   CLK3	   None	  
16p13.13	   CIITA,	  SOCS1,	  PRM1,	  PRM2	   Multiple	  Sclerosis,	  Type	  1	  diabetes,	  Ulcerative	  colitis,	  Crohn's	  
disease,	  Psoriasis	  
18p11.21	   PTPN2	   Type	  1	  diabetes,	  Crohn's	  disease	  
21q22.3	   UBASH3A	  
ICOSLG	  
Type	  1	  diabetes,	  Crohn's	  disease,	  Rheumatoid	  arthritis,	  Ulcerative	  
colitis	  
22q11.21	   UBE2L3,	  YDJC	   Crohn's	  disease,	  Psoriasis	  
Xq28	   HCFC1,	  TMEM187,	  IRAK1	   Type	  1	  diabetes	  
	  
Coeliac	  loci	  with	  genome	  wide	  significance	  at	  P	  <	  5	  x	  10-­‐8	  ;	  autoimmune	  disease	  overlapping	  loci	  with	  genome	  wide	  significance	  P	  <	  5	  x	  10-­‐5	  
Autoimmune	  diseases	  with	  overlapping	  loci	  according	  to	  the	  Catalogue	  of	  Published	  Genome-­‐Wide	  Association	  Studies	  
(http://www.genome.gov/26525384,	  refer	  to	  website	  for	  references.	  -­‐	  Accessed	  on	  17th	  February	  2013)	  and	  published	  papers.	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1.7	  Finding	  further	  genetic	  causal	  variants	  in	  complex	  disease	  	  
	  
GWA	   studies	   in	   CD	   and	   other	   complex	   diseases	   have	   been	   useful	   tools	   for	  
expanding	   the	   genetic	   understanding	   of	   disease	   by	   identifying	   new	   loci	   and	  
replicating	   previously	   associated	   loci	   through	   further	   fine	   mapping	   (Trynka,	  
Hunt	  et	  al.	  2011;	  Eyre,	  Bowes	  et	  al.	  2012;	  Tsoi,	  Spain	  et	  al.	  2012).	  Overall,	  GWAS	  
findings	   have	   implicated	   numerous	   associated	   variants	   that	   are	   mostly	  
common,	  have	  modest	  to	  weak	  effect	  sizes,	  and	  are	  credible	  disease	  markers,	  
however	  only	  explain	  a	  small	  fraction	  of	  heritability.	  By	  design,	  GWAS	  focus	  on	  
common	   variants	   (MAF	   >5%)	   to	   tag	   large	   haplotype	   blocks	   and	   overlook	  
potentially	  functionally	  detrimental	  variation	  contributed	  by	  low	  frequency	  and	  
rare/novel	  mutation.	  In	  order	  to	  expand	  the	  genetic	  architecture	  of	  disease	  and	  
close	   the	   heritability	   gap,	   searching	   away	   from	   common	   ancestral	   haplotypes	  
and	   looking	   at	   variation	   arising	   from	   recent,	   more	   rare	   genomic	   events	   is	  
necessary.	  	  
Next	   generation	   sequencing	   (NGS)	   allows	   deeper	   visualization	   of	   types	   of	  
variants	  not	   typically	  seen	   in	  genome	  wide	  scans	  of	  non-­‐coding	  regions	  of	   the	  
genome.	  In	  the	  past,	  sequencing	  studies	  have	  commonly	  been	  dismissed	  due	  to	  
the	   associated	   high	   costs,	   but	   vast	   improvements	   since	   2008	   (the	   year	  
sequencing	   transitioned	   from	   Sanger	   and	   capillary	   based	   to	   next,	   or	   second,	  
generation	  sequencing)	  has	  reduced	  the	  cost	  from	  $10m	  per	  genome	  to	  $7,500	  
per	  genome	  in	  2012	  (Wetterstrand).	  Sequencing	  studies	  are	  now	  commonplace	  
in	  genetic	  research	  (Metzker	  2010)	  and	  are	  being	  used	  as	  a	  diagnostic	  tool	  for	  
disorders	   observed	   in	   clinic,	   such	   as	   rare	   pediatric	   disorders	   (Kingsmore,	  
Dinwiddie	  et	  al.	  2011).	  Diagnosing	  rare	  conditions	  at	  birth	  often	  involves	  lengthy	  
and	   costly	   investigations	   to	   establish	   disease	   etiology,	   so	  NGS	   combined	  with	  
the	   advanced	   bioinformatic	   expertise	   has	   offered	   a	   breakthrough	   in	   prenatal	  
diagnosis,	  allowing	  more	  targeted	  and	  systematic	  individual	  therapy	  from	  birth	  
(Talkowski,	  Ordulu	  et	  al.	  2012).	  	  
All	  commercially	  available	  NGS	  protocols	  have	  shared	  attributes:	  fragmentation	  
of	  genomic	  DNA,	  ligation	  with	  custom	  adapters	  to	  create	  a	  DNA	  library	  and	  then	  
library	  amplification	  on	  a	   solid	   surface	   (either	  a	  bead	  or	  glass).	  There	   is	  direct	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step-­‐by-­‐step	   detection	   of	   each	   nucleotide	   base	   incorporated	   during	   the	  
sequencing	  reaction	  and	  thousands	  of	  reactions	  are	  imaged	  per	  instrument	  per	  
run,	   giving	   it	   the	   term	   ‘massively	   parallel	   sequencing’.	   The	   read	   lengths	   are	  
short	   compared	   to	  capillary	   sequencers	  and	   reads	  can	  be	   run	   single	  or	  paired	  
end,	   meaning	   the	   linear	   DNA	   fragment	   is	   sequenced	   at	   both	   ends	   in	   two	  
separate	   reactions	   i.e.	   two	  sequences	   from	  a	  single	  DNA	   fragment.	  Once	  DNA	  
has	  been	  sequenced,	  it	  is	  aligned	  to	  a	  reference	  sequence	  panel.	  This	  is	  where	  
paired	   end	   sequencing	   provides	  more	   accuracy	  when	  mapping	   reads	   in	   large	  
and	  complex	  genomes	  but	  it	  has	  a	  higher	  cost	  and	  can	  be	  time	  consuming.	  The	  
main	   companies	  providing	  NGS	  worldwide	   are	   Illumina,	   Life	   Technologies	   and	  
Roche	  and	  all	  have	  their	  own	  associated	  benefits	  and	  drawbacks,	  the	  main	  ones	  
being	  errors	  in	  calling	  the	  alternate	  allele,	  errors	  in	  variant	  calling	  and	  coverage	  
differences	  due	  to	  G-­‐C	  content	  (Shendure	  and	  Ji	  2008;	  Ratan,	  Miller	  et	  al.	  2013).	  	  
The	  question	  now	  is	  how	  to	  apply	  NGS	  in	  a	  research	  study	  to	  find	  novel	  genes	  in	  
complex	   traits	   in	  which	  genetic	  heritability	   still	   remains	   largely	  unknown?	  The	  
large-­‐scale	  GWAS	  design	  has	  established	  many	  common	  associated	  disease	  risk	  
variants	   with	   consistently	   low	   to	   modest	   effect	   sizes	   and	   an	   overall	   modest	  
combined	   genetic	   variance,	   and	   further	   genotyping	   in	   larger	   sample	   sizes	  
(>10,000)	   may	   achieve	   the	   power	   needed	   to	   increase	   the	   genetic	   variance	  
attributed	   to	   common	   regulatory	   variants.	   Conversely,	   a	   spectrum	   of	   low	  
frequency	   rare	  variants	  with	   functional	  effects	  on	   the	   transcribed	  protein	  and	  
an	  intermediate	  to	  large	  effect	  size	  (OR	  of	  2.5	  and	  above)	  may	  possibly	  be	  the	  
key	  to	  establishing	  more	  disease	  causing	  loci	  (Manolio,	  Collins	  et	  al.	  2009).	  Low	  
frequency	   (0.5%	   to	  5%	  MAF)	   and	   rare	   variant	   (below	  0.5%)	   analysis	   has	  been	  
shown	   to	   contribute	   significantly	   to	   genetic	   architecture	  of	  disease	   (Coventry,	  
Bull-­‐Otterson	  et	  al.	  2010;	  Durbin,	  Abecasis	  et	  al.	  2010).	  Evidence	  suggests	  that	  
an	   excess	   of	   rare	   variants	   are	   to	   be	   found	   in	   disease-­‐associated	   genes	   and	   a	  
recent	   study	   analyzing	   6,515	   exomes	   (protein-­‐coding	   regions)	   predicted	   that	  
most	  deleterious	  single	  nucleotide	  variants	  (SNV)	  only	  arose	  in	  the	  last	  5,000	  -­‐	  
10,000	   years	   and	   that	   disease	   genes	   contained	   more	   of	   these	   variants	   than	  
other	   genes,	   highlighting	   implications	   for	   the	   prioritization	   of	   these	   genes	   in	  
complex	   disease	   research	   studies	   (Fu,	   O'Connor	   et	   al.	   2013).	   It	   has	   been	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frequently	   proposed	   that	   rare	   mutations	   of	   large	   effect	   size	   account	   for	   a	  
substantial	   proportion	   of	   the	   missing	   heritability	   in	   disease	   (Pritchard	   2001;	  
Eichler,	   Flint	   et	   al.	   2010),	   coinciding	   with	   the	   ‘common	   disease	   rare	   variant	  
(CDRV)’	   hypothesis.	   This	   hypothesis	   is	   founded	  upon	   the	   fact	   that	   genes	  with	  
loss	   of	   function	   (LoF)	   variants	   are	   sparsely	   observed	   in	   healthy	   individuals	   –	  
those	  that	  are	   found	  are	  common	  at	  minor	  allele	   frequencies	  of	  >5%	  and	   in	  a	  
very	   small	   number	  of	  nonessential	   genes,	   such	  as	  olfactory	   receptors,	   and	  do	  
not	  result	  in	  any	  severe	  phenotype	  (Carlson,	  Eberle	  et	  al.	  2004).	  Studies	  suggest	  
that	  while	  genes	  with	  common	  LoF	  variants	  are	  likely	  to	  be	  benign,	  genes	  with	  
low	   frequency	   LoF	   variants	   are	  more	   likely	   to	   be	   deleterious,	   simply	   because	  
selection	   prevents	   these	   deleterious	   variants	   from	   reaching	  moderate	   to	   high	  
allele	   frequencies	   (MacArthur,	   Balasubramanian	   et	   al.	   2012).	   The	   following	  
sections	   explain	   how	   targeted	   gene	   resequencing,	   exome	   and	  whole	   genome	  
sequencing	  can	  be	  used	   in	   the	   search	   for	   these	   types	  of	  disease	   susceptibility	  
variants	  in	  complex	  disease.	  	  
	  
1.7.1	  Targeted	  gene	  resequencing	  
	  
Targeted	  or	  candidate	  gene	  resequencing	  studies	  are	  useful	  when	  there	  is	  clear	  
evidence	  of	   variants	  presiding	   close	   to	  or	   in	   genes	  and	   these	   risk	   variants	  are	  
more	   prevalent	   in	   persons	   with	   disease	   than	   in	   the	   overall	   population.	  
Furthermore,	  the	  combination	  of	  variants	  observed	  in	  previous	  studies,	  such	  as	  
GWAS,	   may	   not	   explain	   the	   entire	   genetic	   variance	   contributing	   to	   disease	  
therefore	   further	   analysis	   into	   key	   risk	   genes	   can	   provide	   a	   more	  
comprehensive	  architecture	  of	  genetic	  structure.	  Concentrating	  on	  coding	  SNPs	  
has	   excellent	   potential	   for	   candidate	   gene	   analysis,	   as	   the	   number	   of	   coding	  
SNPs	   is	   several	   magnitudes	   smaller	   than	   the	   overall	   number	   of	   SNPs	   in	   the	  
genome	  (Cargill,	  Altshuler	  et	  al.	  1999).	  This	  cost-­‐effective	  approach	  maximizes	  
the	   number	   of	   samples	   one	   can	   sequence	   compared	   to	   whole	   genome	  
sequencing	   (WGS)	  by	   focusing	  on	  a	   limited	  number	  of	   candidate	  genes	  but	   in	  
turn	   increasing	   the	   statistical	   power	   of	   finding	   a	   causal	   risk	   variant.	   This	   said,	  
the	   cost	   of	   multiplex	   amplicon	   sequencing	   will	   effect	   the	   prioritization	   of	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candidate	   genes,	   but	   successful	   strategies	   can	   be	   developed,	   such	   as	   ranking	  
top	  those	  genes	  with	  the	  highest	  number	  of	  mutations	  (Fieuw,	  De	  Wilde	  et	  al.	  
2012).	   As	  well	   as	   saving	   on	   cost,	   the	   sequencing	   efficiency	   and	  high	   depth	  of	  
coverage	   achieved	   (owing	   to	   sequencing	   the	   same	   gene	  or	   amplicon	   in	  many	  
samples)	  allows	  much	  deeper	  examination	  of	  candidate	  genes	  for	  detection	  of	  
both	   common	   and	   rare	   variants.	   Positive	   evidence	   for	   gene	   resequencing	   has	  
implicated	   rare	   variation	   contributing	   to	   protective	   and	   causal	   phenotypic	  
effects,	  for	  example	  individuals	  with	  low	  plasma	  levels	  of	  HDL	  cholesterol	  have	  
been	  shown	  to	  inherit	  rare	  alleles	  in	  three	  candidate	  genes	  contributing	  to	  the	  
Mendelian	   form	  of	   disease	   (Cohen,	   Kiss	   et	   al.	   2004),	  whereas	   rare	   variants	   in	  
the	  IFIH1	  gene	  were	  found	  to	  confer	  protection	  against	  T1D	  by	  altering	  protein	  
expression	  and	  structure	  (Nejentsev,	  Walker	  et	  al.	  2009).	  Similarly,	  Momozawa	  
et	   al.	   identified	   low	   frequency	   coding	   variants	   from	   63	   GWAS-­‐identified	  
positional	   candidate	   genes	   showing	   protection	   against	   InBD	   in	   IL32R,	   but	   no	  
rare	  variants	  were	   found	  predisposing	   to	  Crohn’s	  disease	   (Momozawa,	  Mni	  et	  
al.	  2011).	  These	  studies,	  along	  with	  plenty	  others	  showing	  rare	  variation	  burden	  
in	  disease	  provide	  compelling	  evidence	  of	  specific	  gene	  pathways	  predisposing	  
to	  genetic	  disease	  (Johansen,	  Wang	  et	  al.	  2010;	  O'Roak,	  Vives	  et	  al.	  2012).	  	  
This	   research	   project	   involves	   a	   targeted	   resequencing	   component	   and	   this	  
section	   is	   expanded	   on	   in	   the	   introduction	   of	   ‘Chapter	   Five:	   Exome	   study	  
candidate	  gene	  resequencing	  in	  2,304	  cases	  and	  2,304	  controls’.	  	  
	  
1.7.2	  Exome	  sequencing	  	  
	  
The	   last	   five	   years	   has	   produced	   many	   successful	   genetic	   studies	   applying	  
exome	   sequencing	   to	   explore	   coding	   variants	   that	   are	  not	  detected	  by	  GWAS	  
arrays.	  Success	  in	  candidate	  gene	  and	  Mendelian	  disease	  studies	  have	  allowed	  
the	   development	   of	   exome	   arrays	   for	   an	   entire	   search	   of	   the	   protein-­‐coding	  
region	  (~30	  Mb)	  of	  the	  genome	  where	  a	  candidate	  gene	  is	  not	  known,	  making	  it	  
more	  cost	  effective	  than	  WGS	  as	  only	  1%	  of	  the	  genome	  is	  captured.	  As	  noted	  
earlier,	   the	   concept	   surrounding	   exome	   sequencing	   is	   founded	   in	   population	  
genetics	   theory	  which	  states	   that	   there	   is	   selection	  driving	  against	  amino	  acid	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replacements	   in	   the	   protein-­‐coding	   regions	   of	   the	   genome	  and	   so	   are	   rare	   in	  
the	  population	   (Williamson,	  Hernandez	  et	  al.	  2005;	  Yampolsky,	  Kondrashov	  et	  
al.	   2005;	   Kryukov,	   Pennacchio	   et	   al.	   2007).	   Every	   gene	   is	   expected	   to	   contain	  
functionally	   important	   variants	   that	   can	   be	   found	   and	   tested	   through	   exome	  
sequencing,	  even	   if	   they	  are	   relatively	   rare	  because	  mutations	  are	   continually	  
occurring	   in	   each	   protein-­‐coding	   gene	   (for	   nonsynonymous	   variants	   the	  
mutation	   rate	   per	   gene	   per	   generation	   is	   ~1	   x	   10-­‐5)	   (Nachman	   and	   Crowell	  
2000).	  	  
The	   interest	   in	   exome	   sequencing	   comes	   from	   the	   potential	   to	   identify	  many	  
genes	   underlying	   complex	   traits	   and	   straightforward	   functional	   annotation	   of	  
the	   coding	   variation.	   The	   method	   has	   proven	   extremely	   powerful	   for	   rare	  
monogenic	   disorders	   (Byun,	   Abhyankar	   et	   al.	   2010)	   giving	   much	   insight	   into	  
disease	  etiology,	  for	  example	  in	  rare	  congenital	  diseases	  (Lin,	  Chen	  et	  al.	  2012),	  
and	   has	   progressed	   into	   the	   development	   of	   programs	   dedicated	   to	   the	  
diagnosis	   of	   rare	   disease	   types	   (Maxmen	   2011),	   coupled	   by	   ongoing	  
developments	  in	  software	  for	  exome	  sequencing-­‐based	  discovery	  (Li,	  Gui	  et	  al.	  
2012).	  	  
The	   first	   study	   to	   use	   exome	   sequencing	   was	   carried	   out	   by	   Ng	   et	   al.	   and	  
highlighted	  the	  high	  number	  of	  coding	  variants	   in	  an	   individual	  exome:	  12,500	  
variants	   of	  which	   15-­‐20%	   are	   rare	   in	   the	   population	   (Ng,	   Levy	   et	   al.	   2008).	   A	  
proof	  of	  principle	  study	  by	   the	  same	  authors	  captured	  12	  human	  exomes	  and	  
developed	   a	   strategy	   with	   data	   from	   a	   small	   number	   of	   individuals	   to	   find	   a	  
candidate	  gene	  for	  Freeman-­‐Sheldon	  syndrome	  (Ng,	  Turner	  et	  al.	  2009).	  A	  year	  
later,	   exome	   sequencing	   was	   applied	   to	   ten	   unrelated	   probands	   with	  
transmitting	   Kabuki	   syndrome	   and	   only	   found	   a	   suggestive	   candidate	   gene,	  
MLL2,	   after	   less	   stringent	   filtering	   suggesting	   that	   diseases	   which	   are	  
hetergenous	  may	  not	  necessary	  harbour	  the	  same	  mutations	  in	  the	  same	  genes	  
across	   individuals	   or	   that	   not	   all	   the	   targeted	   exome	   was	   captured	   and	  
sequenced	   (Ng,	   Bigham	   et	   al.	   2010).	   The	   former	   point	   is	   a	   major	   caveat	   for	  
complex	  disease.	  	  
Combining	   linkage	   with	   whole	   exome	   sequencing	   has	   become	   common	  
practice;	  individuals	  contributing	  to	  a	  known	  linkage	  peak	  can	  either	  be	  exome	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sequenced	  to	  find	  the	  causal	  variant,	  like	  in	  the	  analysis	  of	  ADIPOQ	  (Bowden,	  An	  
et	  al.	  2010),	  or	  exome	  variants	  can	  be	  filtered	  based	  on	  the	  linkage	  logarithm	  of	  
odds	   (LOD)	   score	   from	   SNP	   based	   genome-­‐wide	   linkage	   analysis	   and	   then	   on	  
allele	  frequency	  depending	  on	  the	  inheritance	  model	  (Yamaguchi,	  Hosomichi	  et	  
al.	   2011).	   In	   terms	   of	   applying	   this	   method	   to	   a	   complex	   trait,	   evidence	   has	  
shown	   that	   significent	   associations	   for	   complex	   disease,	   such	   as	   Crohn’s	   and	  
T1D,	   reside	   in	   the	   exons	   (Lehne,	   Lewis	   et	   al.	   2011;	   Albrechtsen,	  Grarup	   et	   al.	  
2013).	   A	   myriad	   of	   success	   stories	   have	   been	   observed	   in	   autism	   spectrum	  
disorders	  which	  have	  located	  de	  novo	  mutations	  subsiding	  in	  neurological	  gene	  
pathways	  (O'Roak,	  Deriziotis	  et	  al.	  2011;	  Sanders,	  Murtha	  et	  al.	  2012).	  	  
Another	  main	  goal	  for	  overall	  understanding	  of	  genetic	  disease	  is	  to	  construct	  a	  
mutation	  profile	  to	  deduce	  the	  mechanisms	  underlying	  disease	  progression,	  and	  
such	  profiles	   can	  be	   started	   from	  birth	   (Christodoulou,	  Wiskin	   et	   al.	   2012).	   In	  
spite	  of	  this	  important	  issues	  must	  be	  considered	  when	  carrying	  out	  an	  exome	  
sequencing	  study	  on	  a	  complex	  trait,	  such	  as	  the	  choice	  of	  samples	  to	  sequence,	  
generation	   of	   sequence	   data	   to	   achieve	   a	   decent	   coverage	   over	   all	   protein-­‐
coding	  variants,	  and	  variant	  calling	  strategies	  (Do,	  Kathiresan	  et	  al.	  2012).	  Data	  
from	  the	  1000G	  project	  phase	  one	  identified	  that	  the	  power	  to	  detect	  alleles	  at	  
frequencies	  of	  >1%	  is	  equivalent	  between	  exome	  and	  low	  coverage	  sequencing	  
but	  for	  rare	  alleles	  exome	  sequencing	  has	  much	  more	  power	  (Abecasis,	  Auton	  
et	   al.	   2012),	   so	   this	   is	   a	   suitable	   method	   to	   search	   for	   rare	   disease-­‐causing	  
mutations.	  	  
One	   major	   component	   of	   this	   research	   project	   is	   exome	   sequencing	   so	   this	  
section	  is	  expanded	  in	  the	  introduction	  of	  ‘Chapter	  3:	  Exome	  Sequencing	  in	  75	  
coeliac	  disease	  individuals’.	  
	  
1.7.3	  Whole	  genome	  sequencing	  	  
	  
To	   truly	   elucidate	   the	   relationship	   between	   disease	   phenotype	   and	   their	  
corresponding	   genetic	   basis,	   attention	   ought	   to	   be	   focused	   on	   the	   entire	  
genome,	  where	  the	  entire	  spectrum	  of	  variants	  can	  be	  analysed.	  Many	  methods	  
have	   been	   postulated	   on	   the	   best	   way	   to	   identify	   SNVs,	   insertion-­‐deletions	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(indels)	   and	   copy	   number	   variants	   (CNVs)	   in	   whole	   genomes	   sequences,	   but	  
before	  variant	  calling,	  short	  reads	  can	  be	  assembled	   in	  two	  different	  ways:	  de	  
novo	   assembly	   or	   reference	   panel	   assembly	   (Ng	   and	   Kirkness	   2010).	   	   Once	  
bionformatic	   methods	   are	   refined,	   WGS	   can	   be	   a	   powerful	   tool	   in	   disease	  
research.	   Lupski	   et	   al.	   (2010)	   showed	   the	   power	   to	   diagnose	   a	   Mendelian	  
disease	  using	  whole	  genome	  sequencing	   is	  much	  stronger	  than	  using	  targeted	  
approaches	  (Lupski,	  Reid	  et	  al.	  2010).	  WGS	  applications	   in	   inherited	  disease	   in	  
families	   have	   narrowed	   candidate	   genes	   down	   to	   four	   in	   two	   Mendelian	  
disorders	  (Roach,	  Glusman	  et	  al.	  2010).	  This	  family	  based	  approach	  is	   low	  cost	  
and	  the	  results	  can	  be	  extrapolated	  during	   investigation	   in	  other	   families	  with	  
the	   same	  diseases.	  Other	   family	  based	  designs	  have	  shown	  de	  novo	  mutation	  
hotspots	   that	  underlie	  autism	   (Michaelson,	   Shi	  et	  al.	   2012).	   	   Furthermore	   low	  
coverage	  WGS	   sequencing	   has	   been	   shown	   to	   give	   similar	  P	   values	   at	   known	  
associated	   variants	   from	   genotype	   data	   (Pasaniuc,	   Rohland	   et	   al.	   2012)	  
indicating	  that	   low	  coverage	  WGS	  can	  yield	  several	   times	  the	  effective	  sample	  
size	  of	   SNP	  array	  data	  with	   an	   increase	   in	   statistical	   power.	  A	   combination	  of	  
GWAS	   imputation	   and	   WGS	   established	   robust	   disease	   associations	   in	   an	  
isolated	  Icelandic	  population	  for	  sick	  sinus	  syndrome	  (Holm,	  Gudbjartsson	  et	  al.	  
2011).	   This	   study	   found	   a	   signal	   on	   chromosome	   14	   through	   GWAS	   and	  
imputation	  of	  1000G	  variants	  and	  then	  aimed	  to	  refine	  that	  signal	  by	  imputing	  
11	   million	   WGS	   variants	   from	   seven	   cases	   and	   80	   controls	   into	   the	   GWAS	  
dataset.	  The	  study	  showed	  that	  low	  population	  frequency	  (0.1-­‐1%)	  variants	  can	  
be	   found	   through	   this	   sequence-­‐based	   association	  method	   and	   is	   a	   powerful	  
approach	   for	   complex	   traits	   as	   only	   a	   subset	   of	   cases	   with	   well	   defined	  
phenotypes	   were	   sequenced	   making	   it	   cost-­‐effective	   (Zeggini	   2011).	   With	  
ongoing	  decrease	   in	  sequencing	  cost,	  WGS	  alone	  may	  be	  affordable	   in	  a	   large	  
cohort	  of	  patients	  required	  for	  complex	  disease	  genetics.	  WGS	  has	  recently	  had	  
a	  major	  push	  into	  clinical	  practice,	  especially	  in	  the	  UK.	  Government	  funding	  has	  
propelled	  a	  £100	  million	  cash	  injection	  into	  sequencing	  up	  to	  100,000	  patients	  
with	   cancers	   and	   rare	   diseases.	   This	   massive	   sequencing	   effort	   will	   integrate	  
cutting	   edge	  medical	   science	   into	   the	   current	   healthcare	   system	   and	   has	   the	  
potential	  to	  create	  better-­‐tailored	  treatments	  and	  therapy.	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1.8	  Summary	  and	  outline	  of	  research	  hypothesis	  and	  aims	  
	  
This	   introduction	   chapter	   has	   summarized	   CD	   symptoms,	   epidemiology,	  
physiology	  and	   immune	  characteristics,	   incorporating	  the	  role	  of	  how	  genetics	  
had	  aided	   in	   finding	  up	   to	  39	  non-­‐HLA	  disease	  associations.	  Common	  and	   low	  
frequency	   (5-­‐0.5%)	   variation	   in	   CD	   has	   been	   found	   through	   case	   control	  
association	  studies,	  but	   there	   is	  a	   tail	  of	  weaker	  associations	   that	  are	   likely	   to	  
explain	  some	  but	  not	  all	  disease	  heritability.	  Rare	  variant	  contribution	  of	   large	  
effect	   is	  hypothesized	  to	  have	  an	  impact	  on	  disease	  onset.	  From	  the	  results	  of	  
Mendelian	   studies	   and	   other	   complex	   traits,	   it	   is	   hypothesized	   that	   rare	  
variation	  of	   large	  effect	  size	  contribute	  to	  the	  missing	  heritability	  of	  CD.	  These	  
variants	  can	  be	  found	  through	  a	  combination	  of	  exome	  sequencing,	  rare	  variant	  
genotyping	   and	   targeted	   gene	   resequencing	  methods.	   The	   next	   chapters	   will	  
discuss	   exome	   sequencing	   in	   75	   CD	   individuals	   (Chapter	   3),	   association	   based	  
analysis	   with	   Illumina	   Immunobeadchip	   genotyping	   with	   protein	   coding	   SNPs	  
generated	   from	   exome	   sequencing	   and	   linkage	   analysis	   in	   multigenerational	  
multiply	  affected	  coeliac	  families	  (Chapter	  4).	  Finally,	  from	  a	  combination	  of	  the	  
outlined	   methods	   above,	   the	   resulting	   candidate	   genes	   have	   been	   taken	  
forward	   in	   a	   targeted	   resequencing	   study	   of	   2,304	   cases	   and	   2,304	   controls	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2.1	  DNA	  sample	  collection	  	  	  
	  
The	  DNA	  sample	  collection	  for	  the	  exome	  sequencing	  study	  (Chapter	  3),	  entire	  
Immunochip	   case	   control	   study	   and	   linkage	   analysis	   (Chapter	   4)	   and	   the	  
candidate	  gene	  resequencing	  study	  (Chapter	  5)	  is	  described	  here.	  	  
An	   advertisement	   was	   placed	   in	   Coeliac	   UK	   magazine	   (England,	   Wales	   and	  
Scotland	   registered	   charity)	   for	   coeliac	   sample	   collection.	   Upon	   receipt	   of	  
interest,	   an	   Oragene	   DNA	   saliva	   kit	   (with	   a	   unique	   identification	   number)	  
supplied	  by	  DNA	  Genotek,	  Inc	  (Oragene	  cat#	  OG-­‐250)	  was	  delivered	  together	  
with	   a	   consent	   form,	   questionnaire	   and	   research	   information	   sheet	   to	   each	  
subject.	   Control	   DNA	   was	   obtained	   from	   relatives/friends	   of	   coeliac	   subjects	  
without	  disease.	  Written	  informed	  consent	  was	  obtained	  from	  all	  subjects,	  with	  
Ethics	   Committee/Institutional	   Review	   Board	   approval.	   All	   individuals	   are	   of	  
European	  ancestry.	  Samples	  from	  ten	  multigenerational	  families	  used	  for	  exome	  
sequencing	   and	   linkage	   analysis	   were	   collected	   from	   Paul	   Ciclitiria’s	   coeliac	  
family	  sample	  collection	  at	  St	  Thomas’	  Hospital,	   five	   families	  were	   from	  Susan	  
Neuhausen	   at	   Beckman	  Research	   Institute	   at	   the	   City	   of	  Hope,	   California	   and	  
one	  family	  was	  from	  Åsa	  Naluai	  at	  Gothenburg	  University,	  Sweden.	  In	  addition,	  
DNA	   from	  blood	   samples	  were	  previously	   collected	  and	  extracted	  prior	   to	  my	  
joining	  the	  research	  laboratory	  and	  this	  repository	  was	  available	  for	  use	  in	  this	  
thesis	  project.	  	  
	  
2.2	  Genomic	  DNA	  extraction	  
	  
For	   saliva	   DNA	   extraction,	   a	   protocol	   provided	   by	   DNA	   Genotek,	  
(www.dnagenotek.com/DNA_Genotek_Product_Oragene_DNA_A_Lit.html)	  was	  
followed.	  Briefly,	  Oragene	  saliva	  pots	  were	  defrosted	  at	  room	  temperature	  for	  
at	   least	   one	  hour	   and	   then	  placed	   in	   a	   50°C	   incubator	   for	   a	  minimum	  of	   two	  
hours.	  After	  incubation,	  500µl	  of	  saliva	  was	  transferred	  into	  a	  labeled	  0.5ml	  safe	  
lock	   test	   tube	   (Eppendorf	   cat#	   0030.121.023).	   The	   remainder	  was	   transferred	  
into	  a	  5ml	  cyrotube	  (Sigma	  Aldrich	  cat#	  CLS430663-­‐500EA)	  and	  frozen	  at	  -­‐80°C	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for	   future	  use.	  20µl	   of	  DNA	  purifier	   (Oragene	  OG-­‐L2P)	  was	  added	   to	  500µl	   of	  
saliva,	   vortexed	   and	   incubated	  on	   ice	   for	   10	  minutes.	   The	   entire	  mixture	  was	  
centrifuged	   at	   13,000	   rpm	   (15,000g)	   (Eppendorf	   Centrifuge	   5415-­‐D)	   for	   five	  
minutes.	  The	  clear	  supernatant	  was	  transferred	  to	  500µl	  of	  100%	  ethanol	  and	  
the	  remaining	  white	  pellet	  discarded.	  The	  tube	  was	   inverted	  ten	  times	  to	  mix,	  
allowed	   to	   stand	   for	   ten	   minutes	   to	   allow	   DNA	   precipitation,	   followed	   by	  
centrifugation	   at	   13,000	   rpm	   (15,000g)	   for	   two	  minutes.	   A	   visible	   DNA	   pellet	  
was	  then	  washed	  with	  200µl	  70%	  ethanol	  after	  removal	  of	  the	  supernatant.	  The	  
pellet	   was	   left	   to	   air	   dry	   for	   five	   minutes,	   and	   then	   re-­‐suspended	   in	   20µl	   of	  
molecular	  biology	  grade	  water	  (Sigma	  Aldrich	  cat#	  W4502)	  and	  placed	  in	  a	  rack	  
on	   an	   orbital	   shaker	   overnight.	   After	   overnight	   re-­‐suspension,	   the	   extracted	  
DNA	  was	  frozen	  at	  -­‐80°C.	  	  
	  
2.3	  Genomic	  DNA	  quantification	  	  
	  
All	   saliva	   extracted	   DNA	   and	   DNA	   received	   by	   St	   Thomas’	   Hospital	   was	  
quantified	   using	   the	   Quant-­‐iT™	   picogreen	   DNA	   assay	   kit	   (Invitrogen	   cat#	  
P11496).	   Quantification	   was	   carried	   out	   on	   40	   samples	   at	   any	   one	   time,	  
arranged	   in	   5	   columns	   of	   8	   samples	   on	   a	   96-­‐well	   plate.	   100x	   TE	   buffer	   was	  
diluted	  to	  1x	  and	  999µl	  transferred	  to	  columns	  A1-­‐H10	  of	  a	  deep	  96-­‐well	  plate	  
(VWR	  cat#	  736-­‐0344).	  A	  1µl	  aliquot	  of	  DNA	  was	  added	  to	  the	  wells	  containing	  
1x	  TE	  buffer	  in	  duplicate	  (A1	  and	  A2	  for	  sample	  1,	  B1	  and	  B2	  for	  sample	  2,	  etc).	  
The	   deep	   well	   plate	   was	   sealed	   and	   left	   on	   an	   orbital	   shaker	   to	   mix.	   DNA	  
standards	  were	  prepared	  with	   lambda	  DNA	  and	  1x	   TE	   buffer	   at	   the	   following	  
concentrations:	   2000ng/ml,	   500ng/ml,	   125ng/ml,	   3125ng/ml,	   7.81ng/ml,	  
1.95ng/ml,	  0.488ng/ml,	  0ng/ml	  (no	  lambda	  DNA).	  100µl	  of	  DNA	  was	  transferred	  
from	  the	  deep	  well	  plate	   into	  a	  96-­‐well	   fluorescence	  plate	  (Sigma	  Aldrich	  cat#	  
CLS3610-­‐48EA)	   and	   100µl	   of	   each	   lambda	   DNA	   standard	   transferred	   in	  
duplicate,	   starting	   from	  blank	  1	  x	  TE	  buffer.	  The	  supplied	   fluorescent	  dye	  was	  
thawed	  and	  50µl	  diluted	  in	  11	  ml	  of	  1x	  TE	  buffer.	  100µl	  of	  dye	  was	  transferred	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to	  each	  well	  in	  the	  96-­‐well	  fluorescence	  plate,	  covered	  with	  foil	  and	  left	  for	  four	  
minutes.	  	  
Fluorescence	   was	   measured	   on	   a	   fluorometer	   (POLARstar	   OPTIMA,	   BMG	  
LabTech)	  with	  excitation	   filter	  set	  at	  485P	  and	  emission	   filter	  set	  at	  520P,	  and	  
measurement	  set	  at	  ‘FI	  top’.	  Results	  were	  collected	  on	  an	  excel	  spreadsheet;	  a	  
standard	   curve	   was	   drawn	   with	   ng/ml	   of	   standard	   DNA	   on	   the	   y-­‐axis	   and	  
average	   fluorescence	   on	   x-­‐axis.	   The	   best	   possible	   fit	   was	   ensured	   by	   only	  
plotting	   values	   covering	   the	   range	   of	   fluorescence	   of	   the	   DNA	   samples	   being	  
quantified.	  A	  polynomial	   trend	   line	  was	   fitted	  so	   r=1	  or	  very	  close	   to	  1,	  and	  a	  
line	   equation	   was	   displayed	   and	   used	   to	   back-­‐fit	   the	   standard	   curve	  
fluorescenceas	   a	   quality	   check.	   The	   same	   equation	  was	   used	   to	   calculate	   the	  
DNA	  concentration	  in	  each	  well;	  the	  average	  of	  duplicate	  samples	  was	  taken.	  	  
	  
2.4	  PCR	  and	  gel	  electrophoresis	  	  
	  
Reagents,	   concentrations	   and	   volumes	   for	   a	   standard	   PCR	   experiment	   on	  
human	  genomic	  DNA	  are	  outlined	  in	  table	  2.1.	  Primers	  were	  received	  at	  100mM	  
concentration	   in	   water.	   Each	   primer	   pair	   was	   diluted	   to	   10mM;	   50µl	   of	   the	  
forward	  stock	  primer	  and	  50µl	  of	  the	  reverse	  stock	  primer	  was	  added	  to	  400µl	  
of	   molecular	   grade	   deionised	   water	   in	   an	   eppendorf	   tube.	   Stock	   human	  
genomic	  DNA	  was	   diluted	   to	   5ng/µl	   in	  molecular	   grade	  water	   and	   5µl	   of	   this	  
dilution	  was	  added	  to	  a	  PCR	  plate	  well.	  The	  PCR	  mix	  was	  prepared	  for	  x	  number	  
of	  DNA	  samples,	  briefly	  vortexed,	  and	  13µl	  added	  to	  each	  well	  containing	  DNA,	  
plus	  a	  negative	  control.	  If	  PCR	  reactions	  with	  many	  different	  primers	  pairs	  were	  
being	  performed,	  2µl	  of	  each	  10mM	  primer	  pair	  was	  added	   to	   the	  associated	  
DNA	  sample.	   If	  not,	   the	  primer	  pair	  was	  added	  directly	   into	   the	  PCR	  mix.	  The	  
final	   volume	   of	   each	   PCR	   reaction	   was	   20µl	   and	   run	   at	   the	   following	   cycling	  
times	  on	  a	  thermocycler:	  96°C	  for	  10	  min,	  35	  cycles	  of	  95°C	  for	  15	  sec,	  72°C	  for	  
15	  sec,	  60°C	  for	  15	  sec,	  extension	  at	  72°C	  for	  5	  min	  and	  final	  hold	  at	  4°C	  for	  10	  
min.	  	  
PCR	  products	  were	  viewed	  on	  a	  2%	  agarose	  gel:	  3g	  of	  agarose	  (Sigma	  Aldrich	  cat	  
#	  A9539)	  was	  diluted	   in	  150ml	  of	  100x	  TAE	  buffer	   (Sigma	  Aldrich	  cat	  #	  T6025)	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and	   heated	   in	   the	  microwave	   until	   fully	   dissolved	   (approximately	   3	  minutes).	  
10µl	  of	  GelRed	  nucleic	  acid	  stain	  gel	  (VWR	  cat	  #	  89139-­‐140)	  was	  added	  to	  the	  
heated	   agarose,	   and	   the	   entire	   solution	   was	   poured	   into	   an	   electrophoresis	  
tank	  and	   left	  to	  cool	  for	  10	  minutes.	  DNA	  samples	  mixed	  with	  5µl	   loading	  dye	  
were	   loaded	  onto	   the	   set	   gel	   along	  with	  5µl	   of	  HyperLadder	   100bp	   (Bioline	  
cat	  #	  33056);	  the	  gel	  was	  run	  at	  100V	  for	  up	  to	  20	  minutes.	  
	  







Volume	  for	  one	  
reaction	  
Primers	  	  
(Sigma	  Aldrich,	  100µM)	  
10uM	   2µl	  forward	  and	  
reverse	  
AmpliTaq	  Gold®	  PCR	  Master	  Mix	  
includes:	  
AmpliTaq	  Gold®	  DNA	  polymerase	  
Gold	  Buffer	  
MgCl2	  




















Stock	  genomic	  DNA	   25ng	   5µl	  
Molecular	  Grade	  Water	  
(Sigma	  Aldrich	  cat	  #	  W4502)	  
-­‐	   6.8µl	  
	  
	  
2.5	  Exome	  target	  capture	  	  
	  
Two	   target	   capture	   methods	   are	   outlined	   in	   this	   section:	   the	   first	   method	  
describes	   array	   capture	   with	   12-­‐sample	   pooling	   and	   multiplex	   sequencing	  
(Phase	   One,	   intended	   as	   a	   pilot	   study);	   the	   second	   describes	   single	   sample	  
capture	   with	   exome	   probes	   in-­‐solution	   (Phase	   Two).	   The	   same	   library	  
preparation	  reagents	  were	  used	  for	  both	  methods.	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2.5.1	  NimbleGen	  human	  exome	  2.1M	  array	  (Phase	  one)	  
	  
A	  pilot	   experiment	  was	   carried	   out	  with	   60	   samples	   on	  NimbleGen	   Sequence	  
Capture	  Human	   Exome	  2.1M	  Array,	   v1	   (NimbleGen,	  USA),	   containing	   180,000	  
coding	  exons	   (CCDS	   transcripts)	   and	  551	  miRNA	  exons	   totaling	  26.7Mb	  of	   the	  
human	   exome.	   Samples	   were	   multiplexed	   (12	   samples	   per	   pool)	   and	   each	  
sample	   in	   the	   pool	   had	   a	   unique	   6bp	   barcode.	   A	   PCR	   was	   performed	   to	  
incorporate	  the	  barcodes	  before	  capture	  to	  the	  array.	  	  
	  
2.5.1.2	  Library	  preparation	  and	  index	  PCR	  
	  
Genomic	  DNA	  was	  prepared	   for	   high	   throughput	   sequencing	  by	   following	   the	  
Illumina	   ‘Preparing	   Samples	   for	   Multiplexed	   Paired-­‐End	   Sequencing’	   Protocol	  
(part	   #1005361	   Revision	   B	   December	   2008	   available	   at	   www.illumina.com).	  
Multiplex	   reagents	  were	   supplied	  by	   Illumina	   as	   part	   of	   the	  Multiplex	   Sample	  
Preparation	  Oligonucleotide	  Kit	  (cat#	  PE-­‐400-­‐1001).	  	  
The	   Illumina	   1005631	   protocol	   outlines	   nebulization	   as	   a	   method	   for	   DNA	  
fragmentation,	  however	  this	  application	  was	  modified	  to	  use	  sonication	  instead.	  
5µg	   of	   genomic	   DNA	  was	   diluted	   in	   a	   total	   volume	   of	   50µl	   1x	   TE	   buffer	   and	  
150µl	  of	  nebulization	  buffer.	  The	  BioRupter	  sonicator	  apparatus	  was	  assembled	  
and	  filled	  with	  water	  and	  ice.	  Samples	  were	  loaded	  (6	  per	   load)	  and	  sonicated	  
for	  30	  minutes.	  Fragmented	  DNA	  was	  cleaned	  with	  QIAquick	  PCR	  purification	  kit	  
(Qiagen	   cat	   #	   28106)	   and	   1µl	  was	   run	   on	  DNA	  7500	   bioanalyzer	   chip	   for	   size	  
confirmation.	  The	   library	  preparation	  steps	  following	  DNA	  fragmentation	  were	  
a)	   repairing	   the	  ends	  of	  double	  stranded	  DNA	  fragments;	  b)	  adding	  an	  A	  base	  
overhang	   to	   the	   3’	   ends	   of	   DNA	   fragments;	   c)	   ligation	   of	   DNA	   to	   double	  
stranded	  DNA	  adapters.	  A	  purification	  step	  was	  performed	  with	  the	  QIAquick	  kit	  
subsequent	   to	   steps	   a,	   b	   and	   c.	   Ligated	   DNA	   templates	   were	   size	   selected	  
(between	  250-­‐300bp)	  and	  then	  a	  6bp	   index	   (or	  barcode)	  was	  added	  via	  an	  18	  
cycle	  PCR.	  After	  quantification	  on	  a	   spectrophotometer	   (Nanodrop,	  Nanodrop	  
Technologies,	  USA),	   12	   indexed	   libraries	  were	  pooled	   together	  with	   the	   same	  
concentration	  of	  each	  library	  in	  the	  pool.	  	  
	   65	  
2.5.1.3	  Array	  capture	  and	  PCR	  
	  
Array	   capture	   and	   post	   capture	   PCR	   was	   performed	   according	   to	  
manufacturer’s	   instructions	   (Nimblegen	   Sequence	   Capture	   User	   Guide:	  
Sequence	  Capture	  Array	  Deliver	  v3.1,	  available	  at	  www.nimblegen.com)	  
Prior	  to	  microarray	  hybridization,	  a	  solution	  of	  Cot-­‐1	  DNA	  and	  1ug	  of	  the	  pooled	  
DNA	   library	  was	  dried	  down,	   resuspended	   in	  molecular	  grade	  water	  and	   then	  
incubated	   at	   70°C.	   Hybridization	   enhancing	   oligonucleotides	   (forward	   and	  
reverse	  primers	  used	   in	  post	   capture	  PCR,	  added	   in	  excess,	   to	  prevent	  duplex	  
formation	   between	   adapter	   regions	   of	   the	   genomic	   fragments)	   and	  
hybridization	   buffers	   were	   added	   to	   the	   re-­‐suspended	   pooled	   DNA	   and	   then	  
denatured	  at	  95°C.	  Samples	  were	  loaded	  onto	  a	  2.1M	  sequence	  capture	  exome	  
array	   and	   hybridized	   at	   42°C	   for	   66-­‐72	   hours	   on	   the	  Nimblegen	   hybridization	  
system.	  	  
After	   hybridization,	   washing	   and	   elution	   of	   the	   post-­‐captured	   library	   was	  
performed;	   elution	   at	   95°C	   with	   water	   was	   later	   replaced	   with	   elution	   with	  
sodium	   hydroxide	   at	   room	   temperature	   (Nimblegen	   Sequence	   Capture	   User	  
Guide:	  Sequence	  Capture	  Array	  Deliver	  v3.2,	  available	  at	  www.nimblegen.com);	  
both	  methods	  were	  used	  in	  this	  experiment.	  A	  final	  PCR	  step	  on	  the	  eluate	  was	  
carried	  out,	  where	   a	   reaction	  mix	  was	  prepared	   for	   10	   reactions	  per	   capture.	  
For	   clean	   up	   after	   PCR,	   5	   reactions	  were	   pooled	   and	   added	   to	   1250µl	   of	   PBI	  
buffer	  (QIAquick	  PCR	  purification	  kit),	  and	  eluted	  in	  a	  total	  of	  100µl	  EB	  buffer.	  	  
	  
2.5.1.4	  Enrichment	  qPCR	  
	  
Enrichment	   qPCR	   was	   performed	   according	   to	   manufacturer’s	   instructions	  
(Nimblegen	   Sequence	   Capture	   User	   Guide:	   Sequence	   Capture	   Array	   Deliver	  
v3.1,	  available	  at	  www.nimblegen.com).	  This	  assay	  determined	  whether	  capture	  
was	   successful	   and	   used	   a	   standardized	   set	   of	   qPCR	   SYBR	   Green	   assays	   as	  
internal	  quality	  controls	  for	  Nimblegen	  sequence	  capture	  experiments	  (referred	  
to	  as	  NSC	  assays).	  The	  genomic	  loci	  recognized	  by	  the	  assays	  were	  included	  as	  
capture	  targets	  on	  every	  human	  NimbleGen	  array	  and	  comparison	  by	  qPCR	  of	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the	   relative	   DNA	   concentrations	   of	   the	   control	   loci	   in	   non-­‐captured	   and	  
captured	  samples	  allowed	  estimation	  of	  enrichment	  of	  a	  capture	  target.	  There	  
were	   four	   NSC	   assays	   (NSC-­‐0237,	   NSC-­‐0247,	   NSC-­‐0268,	   NSC-­‐0207,	   refer	   to	  
manufacturer’s	   guide	   for	   primer	   sequences)	   and	   primers	   for	   each	   assay	  were	  
diluted	  to	  2um.	  Each	  non-­‐capture	  and	  capture	  (post	  PCR)	  product	  was	  diluted	  to	  
5ng/µl	  in	  PCR	  grade	  water	  to	  use	  as	  qPCR	  templates.	  The	  following	  volumes	  of	  
each	   component	   were	   added	   together	   to	   make	   a	   qPCR	  mix	   for	   one	   sample:	  
5.9µl	  PCR-­‐grade	  water,	  0.3µl	  NSC	  2µm	  forward	  primer,	  0.3µl	  NSC	  2µm	  reverse	  
primer,	   7.5µl	   SYBR	   Green	  Master	   (2X),	   1µl	   of	   5ng/µl	   template	   (non-­‐captured	  
product,	   captured	   product	   or	   positive	   control	   genomic	   DNA	   templates).	   The	  
following	   program	   was	   created	   on	   the	   Corbett	   Rotor-­‐gene	   RT-­‐PCR	   machine:	  
pre-­‐incubation	  1	  cycle	  95°C	  5	  min;	  amplification	  40	  cycles	  95°C	  10	  sec;	  melting	  
curve	  1	  cycle	  of	  60°C	  1	  min,	  95°C	  10	  sec	  and	  65°C	  1	  min;	  cooling	  cycle	  40°C	  10	  
sec.	   CT	   values	   for	   all	   reactions	   were	   collected	   and	   calculated	   for	   replicate	  
reactions.	   For	   each	   different	   sample	   and	   NSC	   assay,	   the	   average	   CT	   value	   of	  
captured	  template	  was	  subtracted	  from	  the	  non-­‐captured	  template.	  This	  value	  
was	   defined	   as	   the	   delta-­‐CT.	   The	   fold	   enrichment	  was	   calculated	   for	   the	  NSC	  
control	  locus	  by	  raising	  the	  PCR	  efficiency	  (or	  E:	  1.84	  for	  NSC-­‐0237,	  1.8	  for	  NSC-­‐
0247,	   1.78	   for	   NSC-­‐0268,	   1.93	   for	   NSC-­‐0207)	   for	   that	   assay	   to	   the	   power	   of	  
delta-­‐CT	   measured	   for	   the	   corresponding	   control	   locus.	   This	   enrichment	  
analysis	  was	  performed	  for	  every	  pool.	  	  
	  
2.5.1.5	  Pooled	  DNA	  library	  quantification	  	  
	  
Prior	  to	  clustering	  and	  sequencing	  a	  sample	  on	  the	  high-­‐throughput	  sequencing	  
machine,	   the	   library	   was	   quantified	   by	   Nanodrop	   and	   assayed	   for	   size	   by	  
running	  1ul	  on	  Agilent	  2100	  Bioanalyzer	  with	  the	  DNA	  7500	  chip.	  The	  size	  of	  the	  
DNA	   peak	   was	   determined	   by	   manual	   inspection	   of	   the	   resulting	  
electropherogram.	   The	  molar	   concentration	   of	   the	   DNA	  was	   calculated	   using	  
the	  formula	  below	  and	  the	  library	  diluted	  to	  10nm	  for	  clustering:	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where	   y	   =	   the	  molar	   concentration	   of	   the	   library	   (nM);	   c	   	   =	   concentration	   of	  
DNA	  library	  in	  ng/µl;	  x	  =	  average	  molecular	  weight	  of	  a	  DNA	  base	  at	  324.5;	  s	  =	  
the	  resultant	  size	  of	  the	  DNA	  library.	  Samples	  were	  diluted	  to	  10nM	  using	  the	  
formula	  described.	  	  
	  
2.5.2	  Nimblegen	  EZ	  SeqCap	  human	  exome	  in-­‐solution	  (Phase	  two)	  
	  
A	  total	  of	  75	  single	  samples	  from	  coeliac	  individuals	  (DNA	  extracted	  from	  either	  
blood	   or	   saliva)	  were	   prepared	   for	   high	   throughput	   sequencing	   and	   captured	  
with	   2.1	   million	   Nimblegen	   EZ	   SeqCap	   human	   exome	   in-­‐solution	   probes,	  
covering	   26.7Mb	   and	   44.1Mb	   of	   the	   exome	   for	   the	   v1.0	   kit	   and	   v2.0	   kit	  
respectively.	  Modifications	   to	   the	  protocol	   include	  the	  removal	  of	  pre	  capture	  
PCR	  and	  replacing	  post	  capture	  LM-­‐PCR	  with	  real	   time	  qPCR	  using	  SYBR	  green	  
fluorescent	   dye.	   This	   required	   monitoring	   cycle-­‐to-­‐cycle	   amplification	   and	  
executing	   PCR	   before	   it	   reached	   the	   amplification	   plateau.	   This	   modified	  
protocol	  is	  in	  Appendix	  I-­‐B	  where	  instructions	  for	  library	  preparation,	  in-­‐solution	  
captures	  and	  post	  capture	  PCR	  are	  outlined.	  	  
	  
2.5.2.1	  Single	  library	  quantification	  with	  qPCR	  	  
	  
Single	   in-­‐solution	  exome	  capture	   libraries	  were	  quantified	  with	  TaqMan	  qPCR,	  
developed	   by	   Barts	   and	   the	   London	   Genome	   Centre.	   Previous	   libraries	   that	  
generated	   optimum	   cluster	   numbers	   were	   used	   as	   controls.	   Target	   cluster	  
numbers	  per	  sample	  were	  between	  350-­‐400K	  per	  tile	  with	  version	  3	  sequencing	  
chemistry	   on	   the	   Illumina	  GAIIx.	   Serial	   dilutions	   of	   1ul	   per	   library	   and	   chosen	  
controls	   were	   prepared	   with	   molecular	   grade	   water	   to	   give	   the	   following	  
concentrations:	   20x,	   200x,	   2000x,	   20000x	   and	   200000x.	   5.5µl	   of	   TaqMan	  
Universal	   PCR	   master	   mix	   (Applied	   Biosystems	   cat	   #4304437)	   and	   TaqMan	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Tamra	  Probes	  (FAM	  reporter	  dye)	  (Applied	  Biosystems	  cat	  #450025)	  and	  5ul	  of	  
each	   triplicate	   of	   2000x,	   20000x	   and	   200000x	   dilutions,	   plus	   a	  water	   control,	  
were	  loaded	  onto	  a	  384	  well	  plate	  on	  an	  automated	  Biomex	  FX	  pre	  PCR	  robot,	  
to	  give	  a	   final	   reaction	  mix	  of	  10.5µl.	  The	  prepared	  384	  well	  plate	  was	   loaded	  
onto	   the	   ABI	   7900	   HT	   Fast	   Real	   Time	   PCR	   system	   and	   run	   at	   the	   following	  
cycling	  times:	  50°C	  for	  2	  min,	  95°C	  for	  10	  min,	  60	  cycles	  of	  95°C	  for	  15	  min	  ad	  
60°C	   for	   1	   min.	   SDS	   2.3	   software	   was	   used	   to	   analyse	   results	   at	   absolute	  
quantification	  by	  a	  ∆CT	  method.	  	  
	  
2.6	  Illumina	  Immunobeadchip	  genotyping	  
	  
The	   entire	   exome	   sequencing	   cohort	   of	   75	   samples	   from	   phase	   two	   of	   the	  
exome	  sequencing	  experiment	  plus	  7728	  UK	  coeliac	  cases	  and	  8274	  UK	  controls	  
were	   genotyped	   on	   the	   Immunochip	   custom	   chip	   designed	   by	   Illumina.	   DNA	  
was	   diluted	   to	   200ng	   total	   with	   molecular	   grade	   water	   in	   a	   96-­‐well	   plate	  
(Thermo	   Scientific	   cat	   #AB-­‐0564).	   Genotyping	   was	   performed	   following	   the	  
Illumina	   Infinium	   HD	   Ultra	   User	   Guide	   11328087	   Revision	   B	   (available	   at	  
www.illumina.com)	  at	  Barts	  and	  the	  London	  Genome	  Centre.	  Genomic	  DNA	  was	  
whole	   genome	   amplified	   without	   PCR,	   by	   overnight	   incubation.	   After	  
fragmention,	  precipitation	  and	  resuspension,	  each	  DNA	  sample	  was	  hybridized	  
to	  the	  custom	  beadchip	  in	  a	  capillary	  flow-­‐through	  chamber.	  Non-­‐specific	  DNA	  
was	   washed	   away	   and	   then	   stained	   for	   single	   base	   extension	   of	   the	  
oligonucleotides	   present	   on	   the	   beadchip.	   As	   the	   captured	   DNA	   is	   used	   as	   a	  
template,	   the	   detected	   label	   is	   incorporated	   onto	   the	   beadchip,	   and	   thereby	  
determining	   the	   genotype	  of	   the	   sample.	  All	   beadchips	  were	   analysed	  on	   the	  
Illumina	  iScan	  housed	  at	  the	  Institute	  of	  Health,	  University	  College	  London.	  	  
	  
2.7	  Fluidigm	  48.48	  Access	  Array	  Integrated	  Fluidic	  Circuit	  technology	  
	  
Fluidigm	  Access	  Array	   Integrated	  Fluidic	  Circuit	  (IFC)	  technology	  was	  used	  to	  
for	   target	   specific	   amplification	   of	   26	   exome	   sequencing	   candidate	   genes	   in	  
2,304	  cases	  and	  2,304	  controls,	  equating	  to	  three	  1,536-­‐multipex	  libraries.	  DNA	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was	  collected,	  extracted	  and	  quantified	  as	  stated	  in	  sections	  2.1-­‐2.3	  and	  diluted	  
to	  50ng/µl;	  1µl	  of	   this	  dilution	  was	  transferred	  to	  a	  96-­‐well	  plate.	   Instructions	  
for	   sample	   amplification	   and	   barcode	   PCR	   were	   followed	   according	   to	   the	  
manufacturer’s	   user	   guide	   (Access	   Array	   System	   for	   Illumina	   Sequencing	  
Platform,	  P/N	  100-­‐3770,	  Revision	  C1).	  	  
There	   are	   three	   sets	   of	   Fluidigm	   machines:	   a	   Pre-­‐PCR	   IFC	   Controller	   to	   load	  
samples	  and	  primers	  into	  the	  IFC	  array,	  an	  FC1	  cycler	  for	  PCR	  amplification	  and	  
Post-­‐PCR	   IFC	   Controller	   to	   harvest	   all	   PCR	   products.	   All	   three	   machines	   are	  
housed	  at	  Barts	  and	  the	  London	  Genome	  Centre.	  
	  
2.7.1	  Assay	  design	  and	  pooling	  
	  
The	   NCBI	   gene	   symbol	   for	   24	   target	   genes	   were	   sent	   to	   the	   Fluidigm	   assay	  
design	   team	  who	  designed	  primers	  around	  each	   target	  exon	   (excluding	  5’UTR	  
and	   3’UTR).	   The	   team	   was	   instructed	   to	   design	   amplicons	   with	   an	   optimal	  
length	  of	  200bp	  (minimum	  150bp,	  maximum	  200bp).	  506	  assays	  were	  designed	  
and	   each	   assay	   was	   tagged	   with	   CS1/CS2	   (common	   sequence)	   sequences	   for	  
use	  with	  the	  1,536	  barcodes.	  Six	  separate	  96-­‐well	  plates	  containing	  the	  assays	  
and	  excel	  sheets	  detailing	  the	  plate	  layouts	  were	  received	  with	  the	  Fluidigm	  ID	  
number	  1488AAP1201.	  	  
A	   stock	   multiplex	   primer	   mix	   was	   prepared	   according	   to	   manufacturer’s	  
instructions	   (Fluidigm	  Access	   Array	  Multiplex	   20x	   Primer	   Solution	   Preparation	  
Quick	  Reference,	  PN	  100-­‐3895,	  Revision	  B1).	  Briefly,	  90µl	   from	  each	  of	   the	  12	  
columns	  across	  plates	  1-­‐6	  was	  transferred	  to	  a	  designated	  single	  column	  on	  the	  
stock	  plate	  i.e.	  columns	  A1-­‐H12	  from	  primer	  plate	  1	  were	  pooled	  into	  column	  1	  
in	   the	   stock	   plate,	   columns	   A1-­‐H12	   from	   primer	   plate	   2	   were	   pooled	   into	  
column	   2	   in	   the	   stock	   plate,	   and	   so	   forth.	   All	   primer	   pairs	   were	   provided	   at	  
60µM	  and	  after	  combining	  all	  12	  wells	  for	  each	  plate	  into	  the	  stock	  plate,	  each	  
primer	  was	   at	   a	   final	   concentration	   of	   5µM.	   From	   this	   stock	   plate,	   20µl	   from	  
each	  column	   (A1	  –	  H6)	  was	   transferred	   into	  a	  working	  stock	  plate,	  along	  with	  
5µl	   of	   20x	   Access	   Array	   loading	   reagent	   and	   75µl	   of	   1x	   TE	   buffer.	   This	   was	  
labeled	  as	  the	  20X	  primer	  solution	  plate.	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   2.7.2	  Multiplex	  PCR	  on	  the	  Access	  Array	  	  
	  
DNA	  was	  prepared	  for	  multiplex	  PCR	  on	  the	  Fluidigm	  F1	  cycler	  according	  to	  the	  
manufacturer’s	   instructions	   (Access	   Array	   System	   for	   Illumina	   Sequencing	  
Platform,	  P/N	  100-­‐3770,	  Revision	  C1).	  In	  brief,	  an	  Access	  Array	  IFC	  was	  injected	  
with	  control	  line	  fluid	  and	  500µl	  of	  harvest	  solution	  was	  added	  into	  H1-­‐H4	  wells	  
on	  the	  IFC.	  The	  array	  was	  loaded	  onto	  the	  Pre-­‐PCR	  IFC	  Controller	  and	  primed	  for	  
10	  minutes.	  A	  PCR	  mix	  combining	  components	  from	  the	  FastStart	  High	  Fidelity	  
PCR	   system	  kit	   (Roche	   cat	   #	   04738292001),	   20X	  Access	  Array	   loading	   reagent	  
and	  water	  was	  prepared	   for	  96	   samples	   (two	   IFC	  arrays	  was	   required	   for	  one	  
96-­‐well	  DNA	  plate).	  4µl	  of	  PCR	  mix	  was	  added	  each	  DNA	  sample	  (50ng)	   in	  the	  
96-­‐well	   plate;	   the	   sample	   mix	   plate	   was	   vortexed	   and	   spun	   down	   for	   30	  
seconds.	  The	   IFC	  was	   loaded	  with	  4µl	  of	   the	  sample	  mix	  solution	   into	  each	  of	  
the	   sample	  wells	   and	   4µl	   of	   the	   20x	   primer	   solution	   into	   each	   of	   the	   primer	  
wells.	  The	   IFC	  array	  was	   loaded	  onto	  the	  Pre-­‐PCR	   IFC	  controller	  and	  the	   ‘Load	  
Mix;	  script	  was	  run	  for	  1	  hour	  and	  6	  minutes.	  After	  the	  IFC	  was	   loaded,	   it	  was	  
transferred	  to	  the	  FC1	  cycler	  in	  the	  post	  PCR	  laboratory;	  the	  AA	  48x48	  Standard	  
v1	  protocol	  was	   selected	   for	  PCR	  amplification.	  After	   the	  PCR	  had	  completed,	  
the	   IFC	  was	  harvested	  on	   the	  Post-­‐PCR	   IFC	  Controller	   and	  PCR	  products	  were	  
transferred	  into	  a	  labeled	  96-­‐well	  plate.	  Six	  samples	  from	  each	  harvest	  plate	  (3	  
samples	  per	  array)	  were	  checked	  on	  the	  Agilent	  2100	  Bioanalyzer	  with	  the	  DNA	  
1000	  DNA	  chip.	  	  
	  
	   2.7.3	  Barcode	  PCR	  
	  
A	  barcode	  PCR	  was	  performed	  to	  attach	  1,536	  barcodes	  to	  each	  sample	  and	  the	  
protocol	  was	   followed	   according	   to	  manufacturer’s	   instructions	   (Access	   Array	  
System	  for	  Illumina	  Sequencing	  Platform,	  P/N	  100-­‐3770,	  Revision	  C1).	  Fluidigm	  
supplied	  all	  barcodes	  and	  4µl	  of	  each	  barcode	  was	  aliquoted	   into	  16	  separate	  
96-­‐well	  plates	  previously.	   In	  brief,	  a	  PCR	  mix	  combining	  components	   from	  the	  
FastStart	  High	  Fidelity	  PCR	  system	  kit	  was	  prepared	  for	  96	  samples.	  A	  100-­‐fold	  
dilution	  of	  the	  harvested	  PCR	  products	  was	  prepared	  by	  aliquoting	  1µl	  into	  99µl	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of	  water.	  1µl	  of	  this	  dilution	  was	  added	  to	  15µl	  of	  PCR	  mix	  and	  4µl	  of	  barcode,	  
giving	  a	  20µl	  PCR	  reaction.	  The	  PCR	  plate	  was	  placed	  on	  a	  PCR	  thermal	  cycler	  
and	  the	   following	  protocol	  was	   run:	  95°C	   for	  10	  min,	  15	  cycles	  of	  95°C	   for	  15	  
sec,	   60°C	   for	   30	   sec,	   72°C	   for	   1	   min,	   final	   extension	   at	   72°C	   for	   3	   min.	   Six	  
samples	   from	  each	  barcode	  PCR	  plate	   (3	   samples	  per	  array)	  were	  checked	  on	  
the	  Agilent	  2100	  Bioanalyzer	  with	  the	  DNA	  1000	  chip.	  	  
	  
2.7.4	  Post	  PCR	  purification,	  quantification	  and	  library	  pooling	  
	  
All	  1,536-­‐multiplexed	  barcode	  samples	  were	  pooled	  into	  one	  library	  containing	  
1µl	   of	   each	   sample.	   The	   entire	   library	   was	   purified	   following	   manufacturer’s	  
instructions	   (Access	   Array	   System	   for	   Illumina	   Sequencing	   Platform,	   P/N	   100-­‐
3770,	  Revision	  C1).	  In	  brief,	  12µl	  of	  sample	  pool	  was	  added	  to	  24µl	  of	  TE	  buffer	  
and	  36µl	   of	  Ampure	  XP	  beads	   (Agencourt	  AMPure	  XP,	  Beckman	  Coulter	   cat	  #	  
A63880)	   in	   an	   eppendorf	   tube.	   After	   a	   10-­‐minute	   incubation	   at	   room	  
temperature,	   the	   tube	   was	   placed	   on	   a	   magnetic	   separator	   and	   beads	   were	  
allowed	  to	  separate	   from	  the	  supernatant.	  Once	   the	  supernatant	  was	  clear,	   it	  
was	  removed	  and	  discarded.	  The	  beads	  were	  washed	  with	  180µl	  of	  70%	  ethanol	  
twice	   and	   then	   air	   dried	   for	   10	  minutes.	   40µl	   of	   DNA	   suspension	   buffer	   was	  
added	  to	  the	  beads	  and	  the	  tube	  was	  placed	  on	  the	  magnet.	  The	  supernatant	  
was	  transferred	  to	  a	  new-­‐labeled	  tube	  and	  1µl	  was	  run	  on	  the	  Agilent	  1000	  DNA	  
chip	  to	  check	  the	  size	  and	  concentration	  of	  the	  library.	  The	  library	  was	  diluted	  
to	  10nM	  and	  stored	  at	  -­‐20°C.	  	  
	  
2.8	  High	  throughput	  sequencing	  on	  Illumina	  Genome	  Analyzer	  IIx,	  MiSeq	  and	  
HiSeq	  2000	  
	  
All	  pooled	  and	  single	  sample	  exome	   libraries	  were	  sequenced	  on	  the	  Genome	  
Analyzer	   IIx	   at	   Barts	   and	   the	   London	   Genome	   Centre.	   All	   1,536-­‐multiplex	  
Fluidigm	   libraries	   were	   sequenced	   on	   the	   Illumina	   MiSeq	   at	   Barts	   and	   the	  
London	   Genome	   Centre	   for	   quality	   control	   purposes	   and	   then	   on	   the	   HiSeq	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2000	  at	  the	  NIHR	  GSTFT/KCL	  Biomedical	  Research	  Centre	  at	  Guy’s	  Hospital.	  The	  
sections	   below	   outline	   cluster	   generation	   and	   paired	   end	   sequencing	   for	   the	  
Illumina	  GAIIx,	   sample	   preparation	   for	  MiSeq	   sequencing	   and	  HiSeq	   2000	   run	  
settings.	  	  
	  
2.8.1	  Cluster	  generation	  for	  Illumina	  GAIIx	  
	  
All	  cluster	  generation	  was	  performed	  on	  the	  Illumina	  Cluster	  Generation	  System	  
using	   the	   paired-­‐end	   flow-­‐cell	   v4	   and	   paired-­‐end	   cluster	   generation	   kits	   for	  
genomic	  DNA	   sequencing	   v4	   (Illumina,	  USA).	   The	   appropriate	   amount	  of	  DNA	  
was	   loaded	   onto	   each	   flow	   cell	   lane	   according	   to	   quantification	   results;	  
normally	   4pM	   is	   the	   required	   amount.	   A	   single	   control	   lane	   of	   bacteriophage	  
φX-­‐174	  DNA	  (PhiX	  DNA,	  PhiX	  control	  kit,	  Illumina	  USA,	  CT-­‐901-­‐2001)	  was	  run	  on	  
each	  flowcell.	  	  
	  
2.8.2	  Paired	  end	  and	  multiplex	  sequencing	  on	  Illumina	  GAIIx	  
	  
Subsequent	   to	   cluster	   generation,	   multiplex	   sequencing	   (for	   array	   capture,	  
phase	  one)	   and	   single	   sample	   sequencing	   (for	   in-­‐solution	   capture,	  phase	   two)	  
was	   performed	   on	   the	   Illumina	   Genome	   Analyzer	   IIx.	   The	   paired-­‐end	  module	  
was	   used	   for	   paired-­‐end	   sequencing.	   A	   76bp	   paired-­‐end	   sequencing	   run	   was	  
performed	   for	   phase	   one	   single	   samples	   using	   a	   combination	   of	   36bp	   cycle	  
sequencing	   kits	   v3	   and	   v4.	   Phase	   two	   multiplex-­‐pooled	   samples	   were	   also	  
sequenced	  76bp	  paired-­‐end,	  with	  an	  additional	  6bp	  index	  step.	  	  
	   	  
	   2.8.3	  Illumina	  MiSeq	  and	  HiSeq2000	  
	  
A	   50bp	   paired-­‐end	   11bp	   index	   MiSeq	   run	   was	   performed	   for	   each	   1,536-­‐	  
multiplex	   library	  with	  version	  1	  and	  2	  sequencing	  kits.	  The	  sample	   library	  was	  
prepared	  according	  to	  manufacturer’s	  instructions	  (Illumina	  Sample	  Preparation	  
for	  MiSeq,	  p/n	  15028881	  Revision	  A).	   In	  brief,	   the	  10nM	  library	  was	  diluted	   in	  
elution	   buffer	   to	   2nM.	   A	   stock	   of	   sodium	   hydroxide	  was	   diluted	   to	   0.1N	   and	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10µl	  was	  added	  to	  10µl	  of	  2nM	  DNA.	  The	  mix	  was	   incubated	  for	  5	  minutes	  to	  
allow	  the	  double	  stranded	  DNA	  templates	   to	  denature.	  800µl	  of	   supplied	  HT1	  
buffer	   was	   added	   to	   the	   denatured	   DNA	   to	  make	   a	   20pM	   solution.	   This	   was	  
further	  diluted	  to	  4pM.	  600µl	  of	  4pM	  DNA	  library	  was	   loaded	   into	  the	  sample	  
well	  on	  the	  reagent	  cartridge.	  	  
CS1	   and	   CS2	   custom	   LNA	   sequencing	   primers	   and	   CS1rc	   and	   CS2rc	   index	  
custom	  LNA	  sequencing	  primers	  were	  supplied	  by	  Exiqon	  (www.exiqon.com)	  
and	  resuspended	  in	  low	  EDTA	  TE	  buffer	  (10	  mM	  Tris	  pH	  8.	  0.1mM	  EDTA)	  for	  a	  
final	  concentration	  of	  100µM	  each.	  CS1/CS2	  and	  CS1rc/CS2rc	  were	  combined	  to	  
make	   stock	  FL1	  and	  FL2	  primers,	  with	  a	   final	   concentration	  of	  50µM	  for	  each	  
primer.	  The	  primers	  were	  spiked	   into	  the	  MiSeq	  reagent	  cartridge:	  7	  µl	  of	  FL1	  
into	  well	  12	  for	  read	  one,	  7	  µl	  of	  FL2	  into	  well	  13	  for	  the	  index	  read	  and	  7	  µl	  of	  
FL1	  into	  well	  14	  for	  read	  two	  (see	  Table	  2.2	  for	  primer	  sequences).	  The	  run	  was	  
started	  after	  all	  software	  checks	  were	  complete.	  	  
All	  three	  1,536-­‐multiplex	   libraries	  were	  run	  on	  one	  HiSeq	  flow	  cell	  (one	  library	  
per	  lane)	  using	  a	  TruSeq	  v3	  sequencing	  kit	  (Illumina	  cat	  #	  FC-­‐401-­‐3002).	  The	  run	  
length	   was	   101bp	   paired-­‐end	   with	   an	   11bp	   index	   read.	   Primers	   FL1	   and	   FL2	  
were	  also	  spiked	  into	  the	  libraries	  for	  the	  forward	  and	  index	  reads.	  	  
	  
	  
Table	   2.2:	   Fluidigm	   oligonucleotide	   sequences	   for	   Illumina	   MiSeq	   and	   HiSeq	  
2000	  sequencing	  
	  
Primer	  Name	   Oligonucleotide	  
Name	  
Sequence	  (5’	  -­‐3’)	  
FL1	   CS1	   A+CA+CTG+ACGACA	  TGGTTCT	  ACA	  
	   CS2	   T+AC+GGT+AGCAGAGACTTGGTCT	  
FL2	   CS1rc	   T+GT+AG+AACCATGTCGTCAGTGT	  
	   CS2rc	   A+GAC+CA+AGTCTCTGCTACCGTA	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2.9	  DNA	  sequence	  alignment	  and	  variant	  annotation	  
	  
2.9.1	  Phase	  one	  and	  two	  exome	  sequencing	  study	  	  
	  
A	  custom	  script	  was	  used	  to	  trim	  primer	  sequences	  from	  150	  fastq	  files	  (read	  1	  
and	   read	   2	   data	   for	   75	   samples).	   The	   trimmed	   files	   were	   aligned	   to	  
hg18/build37	   of	   an	   indexed	   human	   genome	   using	   the	   short	   read	   mapper,	  
Novoalign	  with	  settings	  "-­‐H	  -­‐k	  -­‐a	  -­‐o	  Soft	  -­‐t	  250”.	  Novoalign	  allows	  lane	  specific	  
alignment-­‐based	   base	   call	   quality	   calibration	   and	   uses	   base	   call	   qualities	   in	  
alignments,	   and	   permits	   alignment	   of	   small	   indels	   (15bp)	   in	   both	   reads.	   The	  
Needleman-­‐Wunsch	  algorithm	  was	  used	  for	  paired	  end	  data.	  Samtools	  v0.1.16,	  
VCFTools	  v0.1.5	  and	  PicardTools	  v1.55	  were	  used	  for	  data	  processing.	  SNP	  and	  
indel	  annotation	  was	  performed	  with	  both	  SeattleSeq	  and	  Annovar	  annotation	  
software.	  	  
	  
	   2.9.2	  Fluidigm	  pilot	  and	  candidate	  gene	  resequencing	  study	  
	  
All	   PCR	  amplicon	   sequencing	  oligonucleotides	  were	   trimmed	   from	  9,216	   fastq	  
files	  (read	  1	  and	  read	  2	  data	  for	  4608	  samples)	  using	  a	  modified	  version	  of	  Btrim	  
software	  (Kong	  2011)	  with	  the	  following	  settings:	  “-­‐k	  -­‐S	  -­‐u	  2	  -­‐a	  -­‐100”.	  Trimmed	  
fastq	   files	   were	   aligned	   to	   hg19/build37	   of	   an	   indexed	   human	   genome	   using	  
Novoalign	  with	  the	  following	  settings:	  “-­‐t	  100	  -­‐H	  -­‐F	  ILM1.8	  -­‐g	  65	  -­‐x	  7	  -­‐o	  FullNW	  -­‐
c	   1”.	   Sorted	   and	   indexed	  bam	   files	  were	   created	  using	   Samtools	   v0.1.18.	   SNP	  
and	   indel	   annotation	  was	  performed	  with	   the	   genome	  analysis	   toolkit	   (GATK)	  
v2.3-­‐9.	   Firstly,	   interval	   files	   containing	   all	   the	   exon	   coordinates	   for	   the	   target	  
specific	   amplicons	   were	   generated	   and	   used	   for	   realignment	   around	   known	  
indels	  (1000	  genomes	  and	  Mills-­‐Devine	  2-­‐hit)	  and	  sample	  level	  novel	  indels.	  This	  
step	   was	   done	   to	   eliminate	   potential	   false	   positive	   SNPs	   caused	   by	   hidden	  
indels.	   The	  base	   quality	   scores	   of	   all	   realigned	   files	  were	   then	   recalibrated	   to	  
reduce	  bias.	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SNPs	  and	  indels	  were	  called	  with	  the	  following	  GATK	  settings	  using	  the	  ‘Unified	  
Genotyper’	  option:	  
For	  SNPs:	  
‘-­‐-­‐min_base_quality_score	  15	  -­‐stand_call_conf	  30	  -­‐-­‐baq	  
CALCULATE_AS_NECESSARY	  -­‐glm	  SNP	  	  	  -­‐-­‐baqGapOpenPenalty	  65	  -­‐-­‐
downsampling_type	  BY_SAMPLE	  -­‐-­‐downsample_to_coverage	  250’	  and	  then	  
hard	  filtered	  using	  GATK	  settings	  ‘QUAL<80.0	  DP<20	  MQ<40.0	  QD<2.0	  
MQRankSum<-­‐12.5	  HRun>5’	  
For	  indels:	  
‘-­‐-­‐min_base_quality_score	  15	  -­‐stand_call_conf	  30	  -­‐-­‐baq	  
CALCULATE_AS_NECESSARY	  -­‐glm	  INDEL	  -­‐-­‐baqGapOpenPenalty	  65	  -­‐-­‐
downsampling_type	  BY_SAMPLE	  -­‐-­‐downsample_to_coverage	  250’	  and	  then	  
hard	  filtered	  using	  GATK	  settings	  ‘QUAL<80.0	  DP<20	  QD<2.0’	  
	  
Depth	  of	  coverage	  analysis	  was	  performed	  using	  GATK	  v2.3-­‐9.	  Annotation	  of	  all	  
variants	   was	   performed	   using	   the	   GENCODE	   V14	   dataset,	   an	   ENCODE	   sub-­‐
project	   with	   annotated	   variants	   from	   all	   protein	   coding	   loci,	   non-­‐coding	   loci	  
(with	   alternatively	   transcribed	   variants	   and	   transcripts)	   and	   pseudogenes	  
(Howald,	  Tanzer	  et	  al.	  2012).	  Coding	  and	  functional	  variants	  were	  identified.	  All	  
statistical	   analysis,	   including	   variant	   summary	   statistics	   and	   rare	   variant	  
association	   and	   gene	   burden	   tests	   was	   performed	   using	   PLINK/SEQ	   v0.09.
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3.1	  Introduction	  
	  
This	  chapter	  details	  a	  study	  of	  exome	  sequencing	  in	  75	  coeliac	  individuals	  from	  
large	   and	   small	   CD	  pedigrees.	   So	   far,	   39	  non-­‐HLA	   loci	   associated	  with	  CD	   risk	  
have	  been	  located	  through	  GWAS,	  but	  collectively	  only	  explain	  13.7%	  of	  disease	  
heritability	   (Trynka,	   Hunt	   et	   al.	   2011).	   This	   is	   because,	   other	   than	   the	   CDCV	  
model,	   standard	   GWAS	   are	   not	   powered	   or	   designed	   to	   detect	   all	   variation	  
based	   on	   other	   models	   attributed	   to	   disease	   risk	   across	   the	   allele	   frequency	  
spectrum:	  infinitesimal	  model	  (common	  variants	  of	  relatively	  small	  effect),	  rare	  
allele	  model	   (rare	   variants	  of	   large	  effect),	   the	  broad	   sense	  heritability	  model	  
(combination	   of	   environment	   and	   epigenetic	   interactions)	   (Gibson	   2011).	   The	  
largest	   meta-­‐GWA	   studies	   in	   body	   mass	   index	   and	   height	   have	   shown	   it	   is	  
unlikely	   that	   more	   than	   a	   few	   hundred	   loci	   containing	   variants	   with	   allele	  
frequencies	  of	  >5%	  will	  ever	  be	  confirmed	  for	  most	  diseases,	  and	  these	  may	  not	  
explain	   even	   half	   of	   the	   genetic	   variance	   (Lango	   Allen,	   Estrada	   et	   al.	   2010;	  
Speliotes,	  Willer	  et	  al.	  2010).	  As	  there	  are	  several	  causal	  variants	  on	  a	  common	  
haplotype,	  of	  which	  can	  be	  in	  imperfect	  LD	  with	  the	  genotyped	  markers,	  GWAS	  
SNP	  markers	  still	  underestimate	  disease-­‐associated	  risk	   (Manolio,	  Collins	  et	  al.	  
2009).	  Hence,	  moving	  away	  from	  GWAS-­‐based	  designs	  and	  targeting	  variants	  of	  
lower	  frequency	  are	  required	  to	  locate	  the	  remaining	  genetic	  variance	  required	  
to	  calculate	  missing	  disease	  heritability,	  and	  for	  this	  exome	  sequencing	  can	  be	  
an	  effective	  method.	  	  
Exome	   target	   capture	   coupled	   with	   NGS	   are	   able	   find	   unknown	   functional	  
genetic	  variants	  that	  occur	  infrequently	  in	  the	  population	  or	  are	  private	  to	  the	  
affected	  individual.	  Firstly,	  it	  is	  largely	  acknowledged	  that	  coding	  mutations	  are	  
indeed	  present	  at	  low	  frequencies	  in	  the	  population;	  mutations	  in	  these	  regions	  
effect	   the	   expression	   of	   proteins,	   sustaining	   a	   deleterious	   effect	   on	   their	  
function,	   and	   so	   are	   prevented	   from	   attaining	   a	   high	   frequency	   by	   selection	  
(Fay,	   Wyckoff	   et	   al.	   2001;	   Bustamante,	   Fledel-­‐Alon	   et	   al.	   2005).	   Present	  
discoveries	   have	   substantiated	   this	   by	   highlighting	   that	   rare	   SNVs	   are	   more	  
likely	   to	  be	   functional	   than	  common	  ones,	  and	  these	  rare	   functional	  SNVs	  are	  
found	  at	  lower	  population	  allele	  frequencies	  (Zhu,	  Ge	  et	  al.	  2011).	  Furthermore,	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slightly	  deleterious	  alleles	  have	  been	  found	  to	  be	  younger,	  higher	  in	  abundance	  
and	   population-­‐specific	   compared	   to	   neutral	   alleles	   at	   the	   same	   frequency	  
(Kiezun,	   Pulit	   et	   al.	   2013).	   	   Secondly,	   exome	   sequencing	   is	   better	   designed	   to	  
test	  the	  rare	  (typically	  MAF	  <0.5%)	  variant-­‐common	  (typically	  MAF	  >5%)	  disease	  
model,	  which	  states	  that	  many	  rare	  alleles	  of	  large	  effect	  are	  largely	  responsible	  
for	   disease;	   this	   hypothesis	   has	   been	   proven	   in	   complex	   quantitative	   traits	  
showing	   evidence	   of	   involvement	   of	   a	   few	   rare	   (1-­‐5%	   allele	   frequency)	   and	  
many	   ultra-­‐rare/near-­‐private	   mutations	   in	   disease	   genes	   (Cohen,	   Kiss	   et	   al.	  
2004;	  Romeo,	  Pennacchio	  et	  al.	  2007;	  Ji,	  Foo	  et	  al.	  2008).	  Finally,	  the	  effects	  of	  
deleted	   exons	   and	   premature	   stop	   codons	   on	   protein	   function	   can	   be	   easily	  
translated,	   not	   only	   in	   rare	   disease	   but	   also	   for	   complex	   common	   disease	  
without	  a	   clear	  mode	  of	   inheritance.	   For	  example,	   rare	   (MAF	  <3%)	   protective	  
IFIH1	  mutations	  against	  T1D	  suggest	   the	  causative	   factor	   to	  be	  an	  enterovirus	  
(Nejentsev,	  Walker	  et	  al.	  2009),	  whereas	  autophagy	  has	  been	   recognized	  as	  a	  
new	  mechanism	  for	  Crohn’s	  disease	  resulting	  from	  mutations	  in	  NOD2/CARD15	  
and	  ATG16L1	  (Homer,	  Richmond	  et	  al.	  2010).	  	  
These	   advantages	   offer	   great	   potential	   for	   complex	   studies	   but	   only	   if	  
performed	   on	   a	   sample	   set	   powerful	   enough	   to	   detect	   rare	   variants.	   For	  
quantitative	  traits,	  selecting	  samples	  from	  extreme	  ends	  of	  trait	  distribution	  can	  
help	  enrich	  for	  disease	  causing	  variants,	  but	  as	  CD	  is	  a	  binary	  trait	  exhibiting	  a	  
dichotomous	  phenotypic	  expression,	  it	  is	  difficult	  to	  stratify	  extreme	  cases	  and	  
controls.	   In	   this	   case,	   making	   use	   of	   multiply	   affected	   families	   can	   offer	   an	  
opportunity	   for	   the	   pursuit	   of	   novel	   variant	   discovery	   since	   extreme	   familial	  
clustering	  might	   imply	  disease	  risk	  variants	  of	  higher	  penetrance	  (Bodmer	  and	  
Bonilla	   2008).	   Recent	   suggestions	   have	   focused	   on	   family-­‐based	   analyses	   for	  
increasing	  power,	   as	   truly	  private	  mutations	   are	  more	   likely	   to	  be	  pathogenic	  
and	  more	  likely	  to	  cluster	  in	  families	  with	  disease	  (Kazma	  and	  Bailey	  2011;	  Do,	  
Kathiresan	  et	  al.	  2012).	  A	  family-­‐based	  design	  can	  potentially	  enrich	  the	  sample	  
for	  very	  rare	  variants	  for	  which	  the	  effect	  would	  be	  concealed	  at	  the	  population	  
level.	   This	   design	   can	   also	   filter	   hundreds	   of	   mutations	   to	   a	   few	   potential	  
candidate	  mutations	  shared	  by	  affected	  related	  individuals.	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Although	  there	  is	  no	  current	  example	  of	  a	  high	  risk	  rare	  mutation	  in	  CD,	  Crohn’s	  
disease	  which	  has	  similar	  heritability	  provides	  an	  example:	   three	  major	  causal	  
NOD2	   mutations	   of	   population	   allele	   frequency	   ~1-­‐3%	   and	   homozygous	  
genotypes	   conferring	   odds	   ratios	   of	   ~15	   for	   disease	   susceptibility	   under	   an	  
additive	  model	   (Lesage,	   Zouali	   et	   al.	   2002;	   Economou,	   Trikalinos	   et	   al.	   2004).	  
Other	   examples	   of	   rare	   coding	   variants	   in	   common	   disease	   are	   TREX1	   in	  
systemic	  lupus	  erythematosus,	  IFIHI	  in	  T1D,	  CARD14	  in	  psoriasis	  and	  ANGPTL4	  in	  
HDL	  cholesterol	   levels	   (Lee-­‐Kirsch,	  Gong	  et	  al.	  2007;	  Romeo,	  Pennacchio	  et	  al.	  
2007;	  Nejentsev,	  Walker	  et	  al.	  2009;	  Jordan,	  Cao	  et	  al.	  2012).	  Locating	  such	  rare	  
variant(s)	  in	  a	  novel	  gene(s)	  or	  in	  one	  where	  previous	  common	  intronic	  GWAS-­‐
risk	   variants	   have	   been	   located,	  will	   allow	   insight	   into	   genetic	   variation	   in	   CD	  
that	  is	  not	  yet	  accounted	  for.	  Additionally,	  focusing	  on	  immune	  genes	  is	  a	  logical	  
strategy	   based	   on	   known	   coeliac	   and	   other	   overlapping	   autoimmune	   disease	  
associations	  that	  have	  been	  discovered	  in	  immune	  mediated	  pathways.	  	  
To	   further	   understand	   where	   the	   missing	   genetic	   variation	   (and	   hence	  
heritability)	  in	  CD	  lies,	  an	  exome	  target	  capture	  and	  high	  throughput	  sequencing	  
experimental	  design	  with	  a	  family-­‐based	  sample	  set	  was	  chosen	  for	  this	  study.	  
Many	  target	  capture	  kits	  are	  commercially	  available	  for	  targeted	  resequencing	  
large	   portions	   of	   the	   genome	  with	  NGS	   technology,	   proven	   to	   be	   a	   powerful	  
approach	  for	  identifying	  genomic	  variation	  associated	  with	  disease	  (Ng,	  Turner	  
et	  al.	  2009;	  Ng,	  Bigham	  et	  al.	  2010;	  Ng,	  Buckingham	  et	  al.	  2010).	  The	  ultimate	  
goal	  of	   resequencing	   is	   to	  accurately	   identify	   these	  variants	   in	  a	  cost-­‐effective	  
manner,	  whilst	  obtaining	  uniform	  and	  adequate	  sequencing	  read	  depth	  across	  
the	  target	  region	  to	  sufficiently	  call	  variants.	  Roche	  NimbleGen	  was	  the	  first	  
commercial	   company	   to	   release	   target	   capture	   reagents	   for	   27.6Mb	   of	   the	  
human	  exome	  using	  a	  microarray,	  used	   in	  phase	  one	  of	   this	   study.	  They	   later	  
released	  a	  solution	  capture	  kit	  used	  for	  the	  majority	  of	  data	  generation	  in	  phase	  
two	  of	  this	  study.	  Subsequently,	  Agilent	  is	  now	  the	  favoured	  capture	  choice	  but	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3.2	  Aims	  and	  hypothesis	  
	  
The	  hypothesis	  for	  this	  study	  is	  that	  moderately	  highly	  penetrant	  rare	  (defined	  
here	   as	   MAF	   <5%)	   variants	   of	   large	   effect	   size	   (allelic	   odds	   ratios	   ~	   2	   -­‐	   5),	  
possibly	   missed	   by	   family	   linkage	   studies	   using	   a	   small	   number	   of	   markers	  
and/or	   families	   and	   common	   variant	   GWAS,	   predispose	   to	   CD	   risk	   and	   these	  
variants	  account	  for	  a	  proportion	  of	  the	  missing	  heritability	  of	  disease.	  	  	  
A	  summary	  of	  the	  project	  aims	  are	  outlined	  here:	  
a) To	   identify,	   across	   the	   entire	   protein	   coding	   genome,	   rare	   coding	  
variants	   that	  might	   directly	   affect	   gene/protein	   function	   in	   individuals	  
with	  disease.	  
b) To	  target	  capture	  and	  sequence	  the	  exomes	  of	  distantly	  related	  affected	  
individuals	   from	   large	  multiply	   affected	   families	   for	   the	   enrichment	   of	  
private	   segregating	   disease	   causing	   mutations	   pointing	   toward	   a	  
potential	   monogenic	   form	   of	   disease.	   Some	  multiply	   affected	   families	  
will	   be	   sufficiently	   powered	   to	   perform	   segregation	   analysis	   to	   detect	  
novel,	  potentially	  causal,	  variants.	  	  
c) To	   target	   capture	   and	   sequence	   the	   exomes	   of	   individuals	   with	   an	  
extreme	   disease	   phenotype.	   An	   extreme	   phenotype	   individual	   can	   be	  
described	  as	  having	  early	  disease	  onset,	  severe	  symptoms	  or	  belonging	  
to	   a	   family	   with	   a	   high	   incidence	   disease	   rate.	   The	   latter	   has	   been	  
chosen	   here	   in	   the	   hope	   that	   more	   disease	   causing	   mutations	   are	  
prevalent	  in	  an	  individual	  from	  a	  coeliac	  family.	  	  	  
d) To	   perform	   shared	   variant-­‐based	   analysis	   in	   related	   exomes	   and	   case-­‐
control	   rare	   variant	   analysis	   across	   the	   entire	   dataset	   (b	   and	   c	  
combined)	   to	   increase	   the	   likelihood	  of	   finding	  more	  high-­‐risk	   rare	  LoF	  
variants.	  
e) To	  create	  a	  list	  of	  candidate	  genes	  for	  further	  targeted	  resequencing	  in	  a	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3.3	  Experimental	  design	  and	  sample	  selection	  	  
	  
The	  experimental	  design	  is	  split	   into	  phase	  one,	   intended	  as	  a	  pilot	  study,	  and	  
phase	   two	   where	   all	   data	   generated	   was	   used	   for	   downstream	   analysis	   and	  
novel	  variant	  detection.	  Affected	  coeliac	   individuals	  were	  diagnosed	  according	  
to	   standard	   clinical,	   serological	   and	   histopathological	   criteria,	   including	   small	  
intestinal	  biopsy.	  	  
Phase	  one:	  multiplex	  exome	  sequencing	  with	  microarray	  capture	  
The	  phase	  one	  pilot	  study	  consisted	  of	  Roche	  NimbleGen	  exome	  microarray	  
target	   capture	  and	   lllumina	  GAIIx	  multiplex	  high	   throughput	   sequencing	  of	  60	  
unrelated	  coeliac	  individuals	  with	  young	  age	  at	  disease	  onset	  (between	  1	  and	  34	  
years	   of	   age).	   The	   main	   focus	   here	   was	   to	   assess	   data	   quality	   from	   a	   newly	  
released	  commercial	  microarray	  target	  capture	  product	  by	  Roche	  NimbleGen	  
based	  on:	  i)	  the	  number	  of	  usable	  reads	  per	  multiplex	  pool	  by	  determining	  the	  
number	   of	   unique	   non-­‐duplicate	   (or	   non-­‐clonal)	   reads;	   ii)	   concordance	   rates	  
with	   array-­‐based	   genotyped	   SNPs;	   iii)	   whether	  multiplexing	   would	   effectively	  
increase	  sample	  throughput	  without	  compromising	  read	  depth	  for	  each	  sample.	  	  
Phase	  two:	  single-­‐sample	  exome	  sequencing	  with	  in-­‐solution	  capture	  	  
The	  Roche	  NimbleGen	  in-­‐solution	  target	  capture	  kit	  was	  used	  in	  phase	  two	  of	  
the	   study	  on	  a	   sample	   set	  of	  75	  coeliac	   individuals	   followed	  by	   Illumina	  GAIIx	  
single-­‐plex	  high	  throughput	  sequencing.	  The	  75-­‐case	  sample	  set	  included:	  
• 35	   individuals	   from	   large	   (>2	   generations)	   multiply	   affected	   coeliac	  
families:	  two	  or	  more	  exomes	  were	  sequenced	  per	  family.	  
• 40	   unrelated	   individuals	   from	   smaller	   affected	   coeliac	   families:	   one	  
exome	  was	  sequenced	  per	  family.	  
All	   samples	  were	   from	   the	  UK,	  USA	   and	   Sweden	   (Appendix	   I-­‐A	   details	   overall	  
sample	  populations).	  The	  primary	  focus	  for	  phase	  two	  was	  to	  selectively	  enrich	  
for	   disease	   causing	   mutations	   by	   sequencing	   relatives	   from	   large	   coeliac	  
affected	  families,	  with	  the	  assumption	  that	  closely	  related	  affected	   individuals	  
are	   more	   likely	   to	   share	   rare	   highly	   penetrant	   mutations.	   Additionally,	  
sequencing	  individuals	  from	  smaller	  disease	  families	  will	  provide	  an	  enrichment	  
of	  potentially	  causal	  rare	  variants	  in	  the	  dataset.	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3.4	  Phase	  One:	  multiplex	  exome	  sequencing	  with	  microarray	  capture	  
	  
3.4.1	  Phase	  One:	  Laboratory	  and	  in	  silico	  methods	  
	  
DNA	   extraction,	   quantification,	  microarray	   exome	   target	   capture,	   sequencing,	  
data	  alignments	  and	  variant	  annotation	  methods	  for	  phase	  one	  are	  specified	  in	  
Chapter	  2:	  General	  Methods.	   In	  brief,	  5µg	  of	  genomic	  DNA	   from	  each	  sample	  
was	  processed	  to	  create	  a	  DNA	  library,	  which	  consisted	  of	  DNA	  fragmentation,	  
end	   polishing,	   adapter-­‐ligation	   and	   pre-­‐microarray	   capture	   index	   PCR.	   Twelve	  
indexed	  samples	  were	  pooled	  together	  and	  then	  hybridized	  to	  exon	  probes	  on	  a	  
microarray,	  consisting	  of	  26.7Mb	  of	  the	  human	  exome	  (NimbleGen	  Sequence	  
Capture	   Human	   Exome	   2.1M	   Array	   version	   1.0).	   A	   second	   PCR	   to	   enrich	   the	  
eluted	   sample	   pool	   was	   performed	   and	   then	   a	   quantitative	   PCR	   (qPCR)	   was	  
performed	  on	  the	  captured	  and	  non-­‐captured	  samples	  to	  estimate	  relative	  fold-­‐
enrichment.	   All	   five	   pools	   (one	   flow	   cell	   lane	   per	   multiplex	   pool)	   were	  
sequenced	  76bp	  paired	  end,	  6bp	   index,	  on	  the	   Illumina	  GAIIx	  at	  Barts	  and	  the	  
London	  Genome	  Centre.	  Samples	  were	  aligned	   to	  hg18/build36	  of	  an	   indexed	  
human	  genome	  using	  the	  short	  read	  mapper,	  Novoalign	  	  (www.novocraft.com).	  
Variants	  were	  called	  with	  a	  custom	  Bayesian	  SNP	  caller.	  The	  general	  premise	  in	  
detecting	   variants	   using	   a	   Bayesian	  method	   includes	   assigning	   quality	   (Phred)	  
scores	  to	  mapped	  reads	  and	  then	  if	  there	  is	  a	  sufficient	  number	  of	  high-­‐quality	  
allele	   differences	   between	   the	   reference	   and	   sample	   genomes,	   the	   SNP	   is	  
called.	  The	  Bayes’	  theorem	  is	  then	  applied,	  
	  
where	  P(Ei|D)	  is	  the	  posterior	  probability	  of	  event	  Ei	  	  given	  the	  observed	  data	  D,	  
the	   prior	   probabilities	   P(Ei)	   and	   the	   conditional	   probabilities	   P(D|Ei)	   (You,	  
Murillo	   et	   al.	   2012).	   Using	   the	   Bayes	   theorem	   one	   can	   determine	   the	   SNP	  
genotype	  with	  the	  highest	  posterior	  probability	  at	  each	  site.	  	  	  
At	  this	  stage,	  annotation	  was	  performed	  using	  SeattleSeq	  annotation	  software	  
(www.gvs.gs.washington.edu/SeattleSeqAnnotation).	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   3.4.2	  Phase	  One:	  Results	  	  
	  
Data	   for	   the	   microarray	   capture	   experiment	   on	   five	   pools	   containing	   twelve	  
individuals	  per	  pool	  was	  assessed	   for	  high	  quality	   sequencing	   reads.	  Table	  3.1	  
shows	  the	  PCR	  cycling	  conditions	  pre	  and	  post-­‐capture,	  the	  number	  of	  total	  and	  
uniquely	   aligned	   reads,	   the	   number	   of	   clonal	   reads	   and	   the	   enrichment	  
percentages	  per	  pool.	  	  
	  
	   	   3.4.2.1	  Indexing,	  enrichment	  and	  clonal	  reads	  assessment	  	  
	  
It	  was	  important	  to	  assess	  whether	  there	  was	  even	  coverage	  of	  index	  (barcode)	  
reads	   across	   each	   sample	   in	   the	   multiplex	   pool	   -­‐	   a	   range	   of	   variable	   reads	  
causes	   difficulty	   in	   downstream	  analysis	   especially	  when	   calling	   variants.	   Pool	  
four	  was	   tested	   for	  how	  well	   the	  multiplexing	  worked.	   The	   range	  of	  perfectly	  
tagged	   read-­‐pairs	  passing	   filter	  was	  89.3%	   -­‐	  95.7%,	  however	   the	   index	   counts	  
for	  each	  sample	  were	  somewhat	  variable	  (Figure	  3.1).	  	  
Successful	  enrichment	  of	  target	  exons	  from	  human	  genomic	  DNA	  was	  evaluated	  
by	   four	   real-­‐time	  qPCR	  control	   targets,	   ranging	   from	  39.5%	   -­‐	  50%	  of	   captured	  
reads	  mapping	  to	  within	  500bp	  of	  the	  target	  exon	  (Table	  3.1).	  Using	  pool	  four	  as	  
an	   example,	   2,215,692	   of	   4,431,385	   reads	   map	   within	   500bp	   of	   array	   target	  
regions	  (50%).	  However,	  17.9%	  of	  reads	  are	  clonal	  duplicates,	  and	  this	  number	  
was	  higher	  for	  other	  pools	  (Figure	  3.2).	  Clonal	  reads	  are	  multiple	  reads	  with	  the	  
same	   orientation,	   start	   position	   and	   read	   length,	   and	   arise	   from	   PCR	  
amplification.	   Although	   PCR	   amplification	   increases	   the	   number	   of	   available	  
molecules	  for	  sequencing,	  random	  errors	  can	  be	  introduced	  due	  to	  changes	  in	  
the	   number	   and	   representation	   of	   template	   molecules.	   For	   pool	   one,	  
13,791,191	   out	   of	   a	   total	   of	   19,942147	   uniquely	   aligned	   reads	   were	   clonal	  
resulting	   in	   only	   30.8%	   usable	   reads.	   This	   pool	   had	   18	   cycles	   of	   pre-­‐capture	  
index	  PCR	  and	  20	  cycles	  post-­‐capture	  PCR.	  In	  contrast,	  pool	  four	  had	  less	  cycles	  
of	   post-­‐capture	   PCR	   (15	   cycles)	   and	   a	  much	   higher	   number	   of	   non-­‐duplicates	  
(82%).	   From	   these	   results,	   it	   was	   clear	   that	   less	   clonality	   correlated	   with	   a	  
reduction	  in	  post-­‐capture	  PCR	  cycles.	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Table	  3.1:	  PCR	  conditions,	  number	  of	  clonal	  reads	  and	  enrichment	  statistics	  for	  
five	  multiplex	  pools	  
	  
POOL	   One	   Two	   Three	   Four	   Seven	  
PCR	  conditions	  
and	  DNA	  input	  
for	  array	  
hybridization	  
18	  cycle	  index	  
PCR	  
1µg	  pool	  hyb	  
20	  cycle	  post	  
PCR	  
18	  cycle	  index	  
PCR	  
1µg	  pool	  hyb	  




1µg	  pool	  hyb	  




1µg	  pool	  hyb	  
15	  cycle	  post	  
PCR	  
18	  cycle	  index	  
PCR	  
3µg	  pool	  hyb	  
















%	  clonal	  reads	  
	  
%	  enrichment	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3.4.2.2	   Sequence-­‐based	   calls	   versus	   genotype-­‐based	   calls	  
concordance	  rate	  	  
	  
Most	   sequencing	   data	   was	   obtained	   for	   sample	   CAP152639	   from	   pool	   two	  
(index	   CAGATC).	   For	   this	   sample,	   1.6m	   reads	  were	   uniquely	   aligned	   and	   non-­‐
clonal,	  equating	  to	  90Mb	  of	  total	  sequence.	  21.4Mb	  of	  this	  was	  quality	  filtered	  
sequence	  data	  at	  exome	  bases	  (base	  call	  quality	  higher	  than	  phred	  score	  of	  10,	  
a	  maximum	  of	   5	  mismatches	   per	   read	   and	   ~1	   x	  mean	   read	   depth	   across	   the	  
exome).	   SNP	   calls	   for	   sample	   CAP152639	   were	   compared	   to	   array	   based	  
genotype	   calls	   from	   Hap300	   bead	   chips	   (containing	   5,869	   coding	   SNPs).	   169	  
exome	   sequenced	   SNPs	   out	   of	   172	   array	   genotyped	   SNPs	   had	   identical	   calls,	  
giving	  a	  1.7%	  error	  rate	  at	  ≥	  4x	  read	  depth.	  There	  were	  two	  sampling	  errors	  that	  
contributed	  to	  this	  error	  rate:	  one	  was	  no	  observation	  of	  the	  second	  allele	  at	  a	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   3.4.3	  Phase	  One:	  Conclusions	  
	  
This	  experiment	  was	  performed	  to	  assess	  data	  quality	  using	  a	  new	  commercial	  
target	  capture	  kit	  developed	  by	  Roche	  NimbleGen	   for	  27.6Mb	  of	  the	  human	  
exome.	   The	   protocol	   outlined	   a	   two-­‐step	   PCR	   scheme,	   one	   to	   introduce	   6bp	  
indexes	  and	  a	  second	  to	  amplify	  the	  eluted	  pooled	  product.	  It	  was	  evident	  that	  
duplicate	   template	   molecules	   were	   prevalent	   in	   the	   sequencing	   data	   due	   to	  
excess	  PCR;	  this	  observation	  has	  been	  previously	  highlighted	  (Kozarewa,	  Ning	  et	  
al.	  2009;	  Kozarewa	  and	  Turner	  2011).	  Although	  the	  number	  of	  reads	  for	  variant	  
calling	   was	   reduced,	   a	   high	   concordance	   rate	   with	   genotype-­‐based	   calls	  
indicated	   that	   the	   capture	   method	   worked	   well.	   One	   disadvantage	   of	  
multiplexing	   was	   the	   variability	   of	   read-­‐pairs	   per	   sample	   per	   pool,	   and	   a	  
consequence	  of	  this	  was	  less	  specificity	  of	  variant	  calls	  across	  the	  dataset.	  Based	  
on	  these	  results	  a	  number	  of	  changes	  were	  made	  to	  the	  methodology	  for	  phase	  
two	  of	  the	  study:	  
1. No	   multiplexing:	   this	   is	   an	   attractive	   option	   to	   sequence	   multiple	  
individuals	   in	   one	   run,	   reducing	   cost	   and	   time,	   but	   numbers	   of	   reads	  
were	   not	   equimolar	   for	   all	   twelve	   individuals	   per	   pool	   and	   limited	   the	  
number	  of	  sequence	  reads	  for	  certain	  samples,	  thus	  limited	  the	  number	  
of	  SNP	  calls.	  	  Single-­‐plex	  sequencing	  was	  chosen	  for	  phase	  two.	  
2. Minimizing	   PCR	   cycles:	   all	   NGS	   applications	   use	   PCR	   in	   library	  
preparation	  methods,	  but	   the	  amount	  of	  PCR	  can	  be	  altered	  to	  reduce	  
sequencing	  error	  and	  duplicate	  reads.	  The	  number	  of	  cycles	  used	  in	  the	  
post-­‐capture	   PCR	   step	   to	   enrich	   the	   eluted	   sample	   was	   minimized	   by	  
qPCR	   in	   phase	   two.	   PCR	   allows	   exponential	   amplification	   of	   a	   DNA	  
template,	   but	   once	   PCR	   components	   become	   limiting	   (such	   as	   DNA	  
template)	   a	   plateau	   effect	   occurs	   in	   late	   PCR	   cycles	   meaning	   that	  
amplification	  no	  longer	  proceeds	  in	  an	  exponential	  manner.	  This	  reduces	  
amplification	   efficiency	   and	   can	   produce	   duplicate	   reads	   because	   the	  
extra	   number	   of	   cycles	   amplifies	   the	   same	   sequence	   multiple	   times.	  
qPCR	   uses	   fewer	   amplification	   cycles	   than	   a	   basic	   PCR	   because	   the	  
measurement	  is	  taken	  prior	  to	  the	  reaction	  plateau.	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3. Improving	   DNA	   fragmentation:	   the	   machine	   used	   to	   perform	   DNA	  
fragmentation	   method	   was	   changed	   from	   the	   BioRupter	   to	   a	   Covaris	  
LE220,	   a	   focused-­‐ultrasonicator	   machine.	   The	   Covaris	   fragmentation	  
process	   produces	   a	   much	   tighter	   range	   of	   DNA	   fragments,	   crucial	   for	  
library	  preparation,	  in	  a	  faster	  processing	  time	  (200bp	  in	  3	  minutes	  and	  
300bp	  in	  80	  seconds).	  	  
4. Increasing	   on	   target	   reads:	   flow-­‐cell	   cluster	   density	   was	   optimized	   by	  
measuring	  DNA	  library	  concentration	  by	  qPCR	  instead	  of	  Nanodrop.	  	  
5. Improve	   target	   capture:	   an	   improved	   capture	   method	   was	   released	  
towards	   the	  end	  of	   the	  phase	  one	  experiment,	  which	  promised	  better	  
capture	  success	  and	  better	  automation.	  Roche	  Nimblegen	  SeqCap	  EZ	  
Human	  Exome	  In-­‐Solution	  capture	  eliminated	  the	  use	  of	  a	  hybridization	  
station	   (used	   for	   array	   hybridization).	   Single	   in-­‐solution	   captures	  were	  
performed	  in	  a	  standard	  thermocycler	  allowing	  higher	  throughput.	  This	  
method	   was	   also	   easily	   scalable	   using	   a	   multiple	   sample	   magnet	   for	  
capturing	   the	   biotinylated	   DNA	   oligonucleotidess	   with	   streptavidin	  
beads,	  unlike	  array	  captures	  where	  only	  one	  array	  could	  be	  processed	  at	  
once.	  	  
	  
3.5	  Phase	  Two:	  single-­‐sample	  exome	  sequencing	  with	  in-­‐solution	  capture	  
	  
3.5.1	  Selecting	  related	  samples	  for	  exome	  sequencing	  	  
	  	  
Relatives	  from	  the	  same	  family	  were	  selected	  for	  exome	  sequencing	  based	  on	  
the	   amount	   of	   genetic	   sharing	   with	   the	   related	   individual	   and	   if	   the	   shared	  
segments	  were	   likely	   to	   contain	   any	   disease	   risk	  mutations.	   Plink	   analysis	   on	  
genotype	  data	  for	  two	  first	  cousins	  once	  removed	  (SAL-­‐12757-­‐0	  and	  SAL-­‐13281-­‐
5)	  was	  performed	  to	   identify	  shared	  chromosomal	  regions	  and	  confirmed	  that	  
6.25%	  (the	  expected	  number	  for	  this	  relationship	  type)	  of	  19	  long	  segments	  of	  
DNA	   (366.588Mb)	  was	   shared.	  Further	  analysis	  highlighted	   that	  99	  out	  of	  180	  
rare	  calls	   in	  the	  shared	  interval	   in	  SAL-­‐12757-­‐0	  were	  also	  seen	  in	  SAL-­‐13281-­‐5,	  
and	  99	  out	  of	  199	  rare	  calls	  in	  SAL-­‐13281-­‐5	  were	  also	  seen	  in	  SAL-­‐12757-­‐0.	  This	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supports	   the	   assumption	   that	   closely	   related	   affected	   individuals	   share	   rare	  
mutations.	   The	   analysis	   also	   answered	   the	   question	   of	   whether	   having	   to	  
sequence	   the	   second	   individual	   would	   be	   beneficial:	   at	   6.25%	   sharing	   there	  
were	  ~200	   rare	  mutations	   (<5%	  MAF	  based	  on	  1000G)	   in	   shared	   intervals	   (as	  
defined	  by	  GWAS),	   and	  100	  of	   them	  were	   shared	  with	   the	  other	   individual	   in	  
the	   pair,	   so	   exome	   sequencing	   the	   second	   individual	   is	   beneficial.	   Going	   less	  
than	  6.25%	   sharing	   i.e.	   sequencing	   second	   (3.125%	   sharing)	   and	   third	   cousins	  
(0.781%	   sharing)	   decreases	   the	   size	   of	   shared	   intervals	   and	   the	   number	   of	  
mutations	   to	   screen	  but	   a	   higher	  degree	  of	   sharing	   i.e.	   siblings,	   increases	   the	  
chances	   of	   sharing	   high-­‐risk	   variants	   but	   the	   number	   of	   shared	   mutations	  
becomes	   too	   large.	  One	   individual	   in	  each	  affected	  pair	  with	  sharing	   in	   the	  3-­‐
10%	  range	  was	  targeted	  to	  obtain	  a	  manageable	  number	  of	  mutations	  to	  assess	  
for	   high	  disease	   risk.	   In	   conjunction	  with	   the	   increased	   likelihood	  of	   finding	   a	  
novel	  risk	  mutation,	  this	  approach	  subsequently	  relaxes	  potential	  consequences	  
of	   genetic	   heterogeneity	   by	   only	   considering	   novel	   variants	   in	   a	   given	   gene	  
shared	  by	  related	  exomes	  as	  candidates.	  	  
	  
3.5.2	  Phase	  Two:	  Laboratory	  and	  in	  silico	  methods	  
	  
DNA	   extraction,	   quantification,	   exome	   capture,	   sequencing,	   data	   alignments	  
and	   variant	   annotation	   methods	   for	   phase	   two	   are	   specified	   in	   Chapter	   2:	  
General	  Methods.	  The	  full	  protocol	  for	  this	  method	  is	  outlined	  in	  Appendix	  I-­‐B.	  
In	  brief,	  the	  same	  library	  preparation	  process	  used	  in	  phase	  one	  was	  carried	  out	  
on	  75	  single	  sample	  exome	  captures,	  with	  some	  protocol	  alterations.	  Samples	  
were	  not	  multiplexed	  so	  the	  pre-­‐capture	  index-­‐PCR	  step	  (to	  add	  on	  a	  barcode)	  
was	   removed.	  A	   standard	  post-­‐capture	  PCR	  was	   replaced	  with	   real	   time	  qPCR	  
using	   SYBR	   green;	   cycle-­‐to-­‐cycle	   amplification	  was	  monitored	   and	   stopped	   at	  
13-­‐15	  cycles	  (before	  it	  reached	  the	  amplification	  plateau).	  71	  single	  sample	  DNA	  
libraries	  were	  hybridized	  to	  version	  1	   in-­‐solution	  exon	  probes	   (27.6Mb	  human	  
exome)	  and	  four	  samples	  were	  hybridized	  to	  version	  2	  (44.1Mb	  human	  exome)	  
exon	   probes	   (Nimblegen	   SeqCap	   EZ	   Human	   Exome	   In-­‐Solution).	   Each	   sample	  
was	   sequenced	   76bp	   paired-­‐end	   on	   one	   lane	   of	   a	   Illumina	   GAIIx	   flow	   cell	   at	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Barts	   and	   the	   London	   Genome	   Centre.	   The	   same	   alignment	   and	   SNP	   calling	  
methods	   used	   in	   phase	   one	   was	   applied	   to	   75	   exomes,	   with	   SeattleSeq	   and	  
Annovar	  variant	  annotation.	  Quality	  control	  steps	  applied	  were	  a	  phred	  quality	  
score	  of	  >20	  and	  >8x	  coverage	  for	  each	  variant	  position.	  	  
	  
3.5.2.1	  Sanger	  Capillary	  Sequencing	  
	  
For	  follow-­‐up	  confirmation	  of	  identified	  novel	  variants	  and	  segregation	  analysis,	  
capillary	  sequencing	  was	  applied	  to	  all	   familial	  cases	  and	  controls,	  where	  DNA	  
was	  available.	  Sanger	  sequencing	  was	  performed	  on	  PCR	  products.	  PCR	  primers	  
were	  designed	  flanking	  approximately	  200bp	  of	  a	  given	  variant	  and	  outsourced	  
to	   Source	   Bioscience	   for	   dideoxy	   sequencing	   in	   forward	   and	   reverse.	  
Sequencing	   reads	   were	   analyzed	   using	   the	   Sequencher	   software	   package	  
(GeneCodes	  Inc.).	  	  
Some	  exome	  sequenced	  individuals	  had	  rare	  novel	  exome	  SNP	  genotypes	  from	  
the	  Illumina	  Immunochip	  array	  that	  allowed	  allele	  frequencies	  to	  be	  established	  
in	  the	  absence	  of	  DNA	  for	  Sanger	  sequencing.	  	  
	  
3.5.3	  Phase	  Two:	  Results	  	  
	  
One	   Illlumina	  GAIIx	   76bp	  PE	   lane	  provided	   an	  optimal	   ~50x	  mean	   read-­‐depth	  
(on-­‐target,	  non-­‐duplicate	   reads)	   (Figure	  3.3).	  This	   read	  depth	  was	  sufficient	   to	  
call	   15-­‐16,000	   variants	   in	   each	   sample,	   and	   no	   difference	   in	   the	   number	   of	  
variant	   calls	   was	   observed	   at	   a	   higher	   read	   depth.	   A	   high	   number	   of	   SNVs	  
(54,939)	   were	   present	   in	   1000G	   (2011	   release)	   and	   dbSNP130,	   but	   37.8%	  
(33,323)	  of	  these	  variant	  calls	  were	  novel	   in	  75	  exomes,	  and	  5,839	  were	  novel	  
and	   LoF	   (Figure	   3.4	   and	   Table	   3.2).	   Here,	   LoF	   is	   defined	   as	   a	   mutation	   that	  
causes	   reduced	   or	   complete	   loss	   of	   protein	   function	   such	   as:	   frameshift	  
(insertion	  or	  deletion	  of	  a	  number	  of	  bases	  that	   is	  not	  a	  multiple	  of	  3,	  usually	  
introducing	   a	  premature	   stop	   codon	  and	   lots	   of	   amino	  acid	   changes),	   splicing	  
(variant	  is	  within	  2bp	  of	  splice	  junction),	  stop	  loss	  (SNV	  that	  leads	  to	  creation	  of	  
stop	   codon	  which	   can	   be	   nonsynonymous	   or	   frameshift/nonframeshift	   indel),	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stop	   gain	   (SNV	   that	   leads	   to	   elimination	   of	   stop	   codon)	   and	   nonsynonymous	  
nonsense.	  	  
	  
Figure	   3.3:	   Number	   of	   non-­‐reference	   SNP	   calls	   per	   exome	   (n	   =	   75)	   and	  












































	   91	  






Table	  3.2:	  Total	  number	  of	  SNV	  calls	  in	  75	  exomes	  	  
	  
	   75	  exomes	  
Total	  number	  of	  unique	  
SNVs	  
88,262	  
Novel	  unique	  SNVs	   33,323	  
LoF	  unique	  SNVs	   8114	  
Novel	  LoF	  unique	  SNVs	   5839	  
	  
Novel	  defined	  as	  not	  observed	  in	  dbSNP130	  or	  1000G	  2011-­‐release	  reference	  dataset	  	  
	  
	  
Cross	  validation	  for	  SNP	  calling	  methods	  showed	  high	  consistency	  between	  two	  
samples	   sequenced	   at	   two	   different	   sites	   (Figure	   3.5,	   completed	   by	   Ian	  
Stanaway	  at	  University	  of	  Washington):	  SAL-­‐12583-­‐9	  coeliac	  sample	  sequenced	  
here	   and	   NA12878	   HapMap	   control	   sample	   sequenced	   at	   the	   University	   of	  
Washington.	  Comparison	  of	  Novoalign	  read	  mapper	  and	  a	  custom	  Bayesian	  SNP	  
1 5 9 14 19 24 29 34 39 44 49 54 59 64 69 74
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caller	   with	   BWA	   alignments	   and	   Samtools/picard/GATK	   annotation	   methods	  
showed	  near	  identical	  outcomes	  at	  high	  read	  depth,	  but	  the	  former	  was	  more	  
sensitive	  at	  finding	  SNPs	  at	  a	  lower	  coverage.	  On	  average,	  80%	  of	  reads	  were	  on	  
target	  with	  Novoalign	  mapped	  reads.	  Hap300	  GWAS	  data	  was	  available	   for	  26	  
high	   quality	   exomes	   and	   99.96%	   of	   exome	   SNP	   calls	   were	   concordant	   with	  
Hap300	  genotype	  SNP	  calls	  (total	  of	  49,551	  heterozygote	  calls	  in	  both	  datasets	  
and	  21	  heterozygous	  calls	  in	  sequence	  but	  homozygous	  in	  GWAS	  data).	  Within	  
this	   set	   of	   call	   positions,	   the	   high	   concordance	   with	   array-­‐based	   genotypes	  
provides	   an	   estimate	   of	   sensitivity	   for	   rare	   variant	   detection,	   as	   rare	   variants	  
are	  largely	  expected	  to	  be	  heterozygous.	  	  
	  
Figure	   3.5:	   Exon	   library	   comparison	  between	   coeliac	   SAL-­‐12583-­‐9	   and	   control	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   3.5.3.1	   Shared	   variants	   between	   related	   exomes	   and	  
segregation	  analysis	  
	  
David	   van	   Heel	   performed	   early	   ‘shared	   variant’	   analysis	   with	   SeattleSeq	  
annotation	  software	  that	  annotated	  variants	  using	  RefSeq	  NCBI	  (build	  36),	  CCDS	  
and	   1000G	   (2010	   release)	   genes	   and	   dbSNP130	   identifiers.	   SeattleSeq	   uses	  
missense	   and	   nonsense	   for	   nonsynonymous	   substitution	   definitions.	   Variant	  
calls	   were	   further	   annotated	   based	   on	   PolyPhen	   score,	   which	   predicts	   SNP	  
impact	   on	   protein	   function	   (Ramensky,	   Bork	   et	   al.	   2002)	   and	   PhastCons	  
conservation	  score,	  a	  program	  that	  detects	  highly	  conserved	  sequences	  across	  
species	  and	  produces	  a	  conservation	  score	  for	  candidates	  that	  are	  functionally	  
important	   (Margulies,	   Blanchette	   et	   al.	   2003).	   To	   identify	   rare	   and	   low	  
frequency	  novel	  SNVs	  restricted	  to	  immune	  and	  related	  disease-­‐pathway	  genes,	  
in	   line	   with	   expectations	   from	   previous	   coeliac	   studies,	   the	   following	   filters	  
were	   applied	   to	   heterozygous	   variant	   calls	   and	   indels:	   not	   in	   dbSNP130,	   <5%	  
MAF	   in	   1000G	   2010	   release	   reference	   dataset,	   <10%	  MAF	   in	   coeliac	   exomes,	  
not	   in	   101	   control	   exomes	   (54	   ultra	   rare	   diseases	   from	   Kings	   College	   London	  
and	  47	  EGP	  project	  samples	  from	  Prof.	  Debbie	  Nickerson).	  	  
Table	  3.3	  outlines	  shared	  mutations	  in	  sequenced	  exomes	  from	  the	  same	  family	  
and	   subsequent	   validation	   and	   segregation	   results.	   For	   FAM002,	   missense	  
mutations	   in	   LGR5,	  SPIC	   and	  CD180	  were	   confirmed	  by	   Sanger	   sequencing	   as	  
true	  positives,	  however	  the	  only	  informative	  affected	  individuals	  for	  segregation	  
tests	   were	   two	   children	   of	   SAL-­‐12706-­‐6,	   and	   this	   was	   considered	   too	  weakly	  
powered.	  For	  SDY,	  the	  c.1879G>T	  nonsense	  substitution	  in	  IFIHI	  was	  validated	  in	  
two	   out	   of	   three	   exomes	   tested.	   The	   entire	   SDY	   family	   had	   Immunochip	  
genotypes	   for	   this	   SNP	   so	   direct	   segregation	   was	   performed	   on	   genotypes	  
rather	   than	   Sanger	   sequence	   data;	   the	   substitution	   was	   observed	   in	   three	  
unaffected	  and	   three	  affected	   individuals	   and	   two	  affected	   individuals	   carried	  
the	  wild	   type	   AA	   alleles,	   resulting	   in	   no	   segregation	   of	   this	   variant	   in	   familial	  
cases.	  The	  missense	  SNP	  c.1278G>C	   in	   IL12RB2	  and	  nonsense	  SNP	  c.2296C>T	   in	  
MADD	   shared	   in	   FAM006	   were	   validated	   in	   all	   exomes	   but	   DNA	   was	   not	  
available	  for	  any	  other	  cases	  for	  segregation	  tests.	  Additionally,	  genotype	  data	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was	  only	  available	  for	  two	  exome	  sequenced	  individuals	  (SAL-­‐13281-­‐5	  and	  SAL-­‐
12575-­‐0)	  so	  genotype	  segregation	  could	  not	  be	  performed,	  however,	  SNP	  allele	  
frequencies	  and	  corresponding	  p	  values	  were	  identified	  from	  Immunochip	  data.	  
For	  SNPs	  in	  IL12RB2	  and	  MADD	  the	  association	  results	  highlighted	  no	  significant	  
p	   values:	   P=0.9015	   (OR	   1.006,	   chi-­‐square	   (1df)	   0.01266,	   MAF	   0.046)	   and	  
P=0.452	   (OR	  1.053,	   chi-­‐square	  0.5655,	  MAF	  0.064),	   respectively.	   For	   FAM007,	  
high	  throughput	  sequencing	  calls	  for	  SNPs	  in	  PTGS2	  and	  NFIL3	  were	  observed	  in	  
one	  direction	  only,	  which	  suggested	  a	   false	  positive	  call.	  All	  SNPs	  were	  Sanger	  
sequenced	  and	  confirmed	  false	  positive.	  DNA	  was	  unavailable	  for	  all	  samples	  in	  
the	   DA	   family	   so	   segregation	   could	   not	   be	   confirmed.	   From	   table	   3.4,	   two	  
families	  were	  taken	  forward	  for	  segregation	  analysis.	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Table	  3.3:	  Rare	  nonsynonymous	  nonsense	  and	  missense	  mutations	  shared	  by	  related	  coeliac	  individuals	  	  
	  
Family	  ID	   Samples	  
sequenced	  
Relationship	   Selected	  SNPs	  
of	  interest	  	  












c.1270C>G	   LGR5	   Missense	   Benign	   No	   0.999	   2/2	  
c.982C>G	   CD180	   Missense	   Benign	   No	   1	   2/2	  
FAM002	   SAL-­‐12592-­‐9	  
SAL-­‐12706-­‐6	  
1st	  cousins	  	  
c.109A>G	   SPIC	   Missense	   Benign	   Yes	   1	   2/2	  






Uncle	  to	  SDY20	  
and	  SDY101	  
1st	  cousin	  to	  
SDY101	  
	  
c.1879G>T	   IFIH1	   Nonsense	   Missing	  domain	   dbSNP	  
only	  
0.988	   2/2	  
c.1278G>C	   IL12RB2	   Missense	  
	  
Possibly	  damaging	   Yes	   0.913	   2/2	  FAM006	   SAL-­‐13281-­‐5	  
SAL-­‐12575-­‐0	  
1st	  cousins	  once	  
removed	  
c.2296C>T	   MADD	   Nonsense	   Possibly	  damaging	   Yes	   0.941	   2/2	  
	  
c.122G>T	   PTGS2	   Nonsense	   Probably	  damaging	   No	   1	   2/0	  FAM007	   CAP152916	  
CAP200010	  
1st	  cousins	  
c.510G>A	   NFIL3	   Nonsense	   Probably	  damaging	   No	   0.26	   2/0	  
BRK	   BRK4	   Grand-­‐uncle	  to	   c.1153G>A	   IL22RA1	   Missense	   Benign	   No	   0	   2/1	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c.1153G>A	   IL22RA1	   Missense	   Benign	   No	   0	   2/1	  BRK	   BRK11	   BRK11	  
c.184C>T	   TNFRSF21	   Missense	   Benign	   No	   0.998	   2/2	  
	  
DA	   DA269	  
DA194	  
1st	  cousins	   c.1421A>T	   PXK	   Missense	   Benign	   No	   0.984	   2/2	  















c.358T>A	   CEACAM7	   Nonsense	   Probably	  damaging	   No	   0	   3/0	  













1st	  cousin	  to	  
33210	  
c.70G>A	   IL21R	   Missense	   Probably	  damaging	   No	   0.155	   3/3	  
2010	  release	  1000G	  dataset	  and	  dbSNP130	  used	  for	  filtering.	  SNPs	  in	  bold	  were	  taken	  forward	  for	  segregation	  analysis.	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Figure	  3.6:	  Pedigrees	  from	  Table	  3.4	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Black	   =	   coeliac	   cases.	   Pedigrees	   show	   relationships	   of	   those	   individuals	   chosen	   for	  
exome	  sequencing.	  The	  further	  apart	  the	  relationship,	  the	  more	  likely	  they	  are	  to	  share	  
a	   rare	   disease	   causing	   variant	   in	   a	   smaller	   recombinant	   region.	   Sample	   names	   for	  
exome	   sequenced	   individuals	   shown	  only.	   Family	   tree	   for	   FAM007	  was	   not	   available	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TNFRSF21	  
	  
TNFRSF21,	   also	   known	   as	   DR6,	   is	   down-­‐regulated	   in	   active	   T	   cells	   and	   DR6-­‐
deficient	  mice	  display	  reduced	  CTLA4	  expression,	  CD4+	  T	  cell	  proliferation	  and	  
T-­‐helper	   cell	   differentiation	   (Liu,	   Na	   et	   al.	   2001;	   Zhao,	   Yan	   et	   al.	   2001),	  
implicating	   a	   possible	   role	   in	   inflammation.	   Sanger	   sequencing	   confirmed	   the	  
presence	   of	   the	   nonsynonymous	  missense	   substitution,	   c.184C>T	   (p.G62S),	   in	  
five	  of	  the	  five	  coeliac	  cases	  and	  two	  of	  the	  13	  unaffected	  relatives	  in	  the	  BRK	  
family	   (Figure	   3.7).	   Two	   heterozygous	   genotypes	   in	   unaffected	   individuals	  
suggest	  a)	  TNFRSF21	  is	  necessary	  but	  not	  sufficient	  for	  disease	  development	  i.e.	  
dominant	  with	  reduced	  penetrance	  or	  b)	  undiagnosed	  coeliac	  cases.	  
	  





SNP	  c.184C>T	  was	  sequenced	  in	  20	  individuals;	  DNA	  for	  5	  members	  was	  not	  available.	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IL21R	  
IL21R,	   a	   cytokine	   receptor	   for	   interleukin	   21,	   is	   selectively	   expressed	   in	  
lymphoid	  tissues	  and	  is	  important	  for	  proliferation	  and	  differentiation	  of	  B	  cells,	  
T	  cells	  and	  NK	  cell	  expansion	  (Parrish-­‐Novak,	  Dillon	  et	  al.	  2000).	  RA	  patients	  also	  
express	   IL21R	   in	   macrophages	   and	   fibroblasts	   from	   synovial	   joint	   biopsies	  
(Jungel,	  Distler	   et	   al.	   2004).	   Sanger	   sequencing	   identified	   the	  nonsynonymous	  
missense	  substitution,	  c.70G>A	  (p.V24I),	   in	  six	  out	  of	  the	  ten	  coeliac	  cases	  and	  
four	  out	  of	  37	  unaffected	  relatives	  (Figure	  3.9).	  The	  wild	  type	  alleles,	  GG,	  were	  
observed	  in	  rest	  of	  the	  family	  (genotypes	  not	  shown	  in	  Figure	  3.8).	  	  	  
	  





All	  other	  individuals	  carry	  homozygous	  GG	  wild	  type	  alleles	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As	  of	  June	  2010,	  a	  new	  method	  became	  available	  for	  SNP	  annotation	  (Wang,	  Li	  
et	   al.	   2010),	   and	   a	   second	   more	   comprehensive	   analysis	   was	   performed	   on	  
familial	   exomes	   with	   Annovar	   annotated	   SNPs	   (RefSeq	   NCBI	   build	   37,	   1000G	  
2011	  data	  release,	  and	  dbSNP132	  identifiers)	  to	  locate	  more	  shared	  variants	  in	  
immune	  genes	  by	  Vincent	  Plagnol	  (Table	  3.4).	  In	  place	  of	  PhastCons,	  SIFT	  scores	  
were	   assigned	   to	   heterozygous	   calls	   to	   predict	   whether	   an	   amino	   acid	  
substitution	  had	  any	  phenotypic	  effect	  (Ng	  and	  Henikoff	  2003).	  The	  results	  were	  
then	   passed	   onto	   myself	   for	   validation.	   Tests	   for	   segregation	   could	   not	   be	  
performed	   in	   families	   shown	   in	   table	   3.5	  because	  DNA	  on	  other	   affected	   and	  
unaffected	  members	  was	  not	  available.	  	  
In	  addition	  to	  TNFRSF21,	  identified	  from	  family	  segregation,	  a	  further	  two	  genes	  
in	   the	   same	   gene	   superfamily	   were	   observed	   in	   FAM002	   and	   FAM007.	  
TNFRSF10A	   is	   involved	   in	  cell	  death	  and	  apoptosis	  and	  a	  SNP	   in	   this	  gene	  was	  
associated	   in	  cases	  with	  age-­‐related	  macular	  degeneration	  with	  a	  significant	  p	  
value	  of	  1	  x	  10-­‐12	  (Arakawa,	  Takahashi	  et	  al.	  2011).	  More	  interestingly,	  TNFRSF13	  
is	   involved	   in	   T-­‐cell	   independent	   B	   cell	   antibody	   responses	   and	   B-­‐cell	  
homeostasis	   and	   has	   been	   associated	   with	   serum	   IgG	   levels	   in	   the	   Chinese	  
population,	   which	   has	   a	   role	   in	   humoral	   immunity	   (Liao,	   Ye	   et	   al.	   2012).	   All	  
nonsynonymous	  substitutions,	  except	  those	   in	  CFTR	  and	  C4PBA	   (in	  one	  of	  two	  
individuals),	  were	  true	  positives	  and	  possible	  candidates	  for	  resequencing.	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Table	  3.4:	  Rare	  non-­‐synonymous	  single	  nucleotide	  variants	   located	   in	   immune	  genes	  and	  shared	  by	  related	  coeliac	   individuals	  with	  
Annovar	  annotation	  
	  
Family	  ID	   Samples	  
sequenced	  
Relationship	   Selected	  SNPs	  
of	  interest	  	  













c.617G>A	   C4PBA	   Nonsyn	   Benign	   No	   0.24	   2/1	  
c.58C>T	   TNFRSF13B	   Nonsyn	   Probably	  
damaging	  
No	   0	   2/2	  
FAM002	   SAL-­‐12592-­‐9	  
SAL-­‐12706-­‐6	  
1st	  cousins	  	  
c.517G>A	   TRAF4	   Nonsyn	   Benign	   Yes	   0.02	   2/2	  
c.66T>G	   RAF1	   Nonsyn	   Possibly	  
damaging	  




removed	   c.223G>A	   MAP4K2	   Nonsyn	   Possibly	  
damaging	  
No	   0	   2/2	  
c.1251C>A	   CFTR	   Nonsyn	   Benign	   dbSNP130	   0.57	   2/1	  
c.1232T>C	   TNFRSF10A	   Nonsyn	   Probably	  
damaging	  
1000G	   0	   2/2	  
FAM007	   CAP152916	  
CAP200010	  
1st	  cousins	  
c.961C>T	   HAS1	   Nonsyn	   Possibly	  
damaging	  
No	   0.01	   2/2	  
c.588A>C	   C1QBP	   Nonsyn	   Possibly	  
damaging	  




removed	   c.222C>G	   IL12RB1	   Nonsyn	   Possibly	  
damaging	  
dbSNP130	   0	   2/2	  
	  
SIFT	  scores	  range	  from	  0	  to	  1,	  where	  <=	  0.05	  is	  predicted	  damaging	  and	  >0.05	  is	  predicted	  tolerant
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Pedigrees	  for	  FAM002	  and	  FAM006	  are	  illustrated	  in	  Figure	  3.6.	  Pedigree	  for	  FAM007	  
was	  not	  available.	  
	  
	  
3.5.3.2	  Single-­‐SNP	  and	  aggregate	  tests	  for	  rare	  variants	  
	  
Analysis	   in	   the	   study	   so	   far	   has	   based	   criteria	   for	   variant	   searching	   by	   the	  
filtering	  approach	  and	  largely	  focused	  on	  loss	  of	  function	  variants	  only.	  A	  second	  
more	  practical	  approach	  taking	  into	  account	  all	  sequenced	  variants	  was	  used	  to	  
perform	  single	  SNP	  and	  gene-­‐level	  burden	  tests.	  The	  single	  SNP	  test	  compared	  
calls	  from	  222	  neurological	  disorder	  control	  exomes	  (captured	  with	  Agilent	  Sure	  
Select	   version	   1)	   to	   coeliac	   exomes,	   similar	   to	   the	   test	   one	  would	   apply	   in	   a	  
GWAS.	   An	   excess	   of	   rare	   variants	   in	   the	  HLA-­‐complex	   on	   chr6	  was	   observed,	  
with	   significant	   p	   values	   ranging	   from	   10-­‐4	   and	   10-­‐7,	   as	   illustrated	   in	   the	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Manhattan	   plot	   (Figure	   3.10).	   No	   other	   SNP	   reached	   p=10-­‐7	   or	   higher.	   A	  
synonymous	   SNP	   in	   NDUFV2	   on	   chr18	   reached	   p=1.26-­‐6	   (MAF	   0.0187);	  
mutations	  in	  this	  gene	  are	  associated	  with	  Parkinson’s	  disease	  (Hattori,	  Yoshino	  
et	  al.	  1998)	  and	  bipolar	  disorder	  (Washizuka,	  Kakiuchi	  et	  al.	  2003;	  Doyle,	  Dahl	  et	  
al.	   2011)	  highlighting	   that	   the	   signal	   is	   likely	   to	  be	  associated	  with	  one	  of	   the	  
neurological	   diseases	   in	   the	   control	   exomes	   rather	   than	   CD.	   While	   the	   test	  
accounted	  for	  target	  capture	  efficiency	  and	  only	  calls	  with	  comparable	  call	  rates	  
were	   used,	   there	   are	   still	   evident	   pitfalls	   using	   different	   capture	   platforms	  
(Agilent	   Sure	   Select	   for	   controls	   compared	   to	   Roche	   NimbleGen	   for	   coeliacs)	  
and	   likely	   false	   positives	   were	   evident	   (see	   quantile-­‐quantilte	   (Q-­‐Q)	   plot	   in	  
Figure	  3.11).	  	  	  
	  
Figure	  3.10:	  Manhattan	  plot	  of	  single-­‐SNP	  tests	  comparing	  the	  case	  data	  (n	  =	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Figure	   3.11:	   Q-­‐Q	   plot	   of	   single-­‐SNP	   tests	   comparing	   case	   data	   (n=41)	   with	  





An	   aggregate	   test	   for	   rare	   variants	   in	   a	   complex	   trait,	   using	   a	   minor	   allele	  
frequency	   based	   on	   1000G,	   offers	   a	   genome	   wide	   approach	   that	   limits	  
problems	  that	  can	  be	  associated	  with	  SNP	  filtering:	  within-­‐gene	  heterogeneity	  
and	   reduced	   penetrance.	   This	   type	   of	   test	   compares	   the	   number	   of	   variants	  
within	   a	   gene	   to	   the	   genome-­‐wide	   distribution	   of	   rare	   variants	   in	   the	   same	  
functional	   category	   to	   derive	   a	   gene-­‐based	   Fisher	   exact	   P-­‐value	   (two-­‐tailed)	  
(Stitziel,	  Kiezun	  et	  al.	  2011;	  Kiezun,	  Garimella	  et	  al.	  2012).	  The	  test	  aggregates	  
variants	  into	  discrete	  features	  (a	  natural	  grouping	  unit	   in	  the	  exome	  is	  a	  gene)	  
to	  obtain	  greater	  statistical	  power.	  This	   is	  achieved	  by	  reducing	  multiple	  tests,	  
as	   the	   number	   of	   genes	   containing	   aggregated	   rare	   variants	   is	   tested	   rather	  
than	  one	  test	  per	  rare	  variant,	  and	  combining	  allele	  frequencies	  of	  aggregated	  
variants	   to	   achieve	   a	   higher	   overall	   allele	   frequency	   compared	   to	   small	  
individual	  rare	  variant	  allele	  frequencies.	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Three	  tests	  were	  performed	  comparing	  SNP	  calls	  in	  cases	  and	  controls	  based	  on	  
a	  genome-­‐wide	  distribution	  of	   rare	  alleles.	  A	  single-­‐SNP	  P-­‐value	   from	  multiple	  
variants	   in	   a	   gene	   was	   combined	   and	   derived	   from	   a	   two-­‐tailed	   Fisher	   exact	  
test,	   allowing	   the	   same	   inferences	   as	   one	   would	   make	   in	   a	   genome	   wide	  
association	   test.	   Related	   exome-­‐sequenced	   individuals	   were	   removed	   to	  
eliminate	   bias,	   and	   the	   remaining	   41	   exomes	   were	   compared	   to	   222	  
neurological	   control	   exomes;	   only	   variants	   with	   a	  MAF	   <0.5%	   in	   1000G	   2011	  
reference	   dataset	   were	   observed.	   Genes	   with	   rare	   variants	   in	   all	   deleterious	  
functional	   categories	   are	   shown	   in	   Table	   3.5.	   Table	   3.6	   lists	   genes	  harbouring	  
loss	  of	  function	  variants	  only.	  Table	  3.7	  lists	  genes	  with	  loss	  of	  function	  variants	  
in	  immune	  genes.	  	  
	  
Table	  3.5:	  Top	  5	  most	  significant	  genes	  for	  the	  aggregate	  test	  rare	  variants	  (LoF,	  
non-­‐synonymous	  and	  splice	  site)	  between	  cases	  and	  controls	  	  
	  
Gene	  
Number	  of	  rare	  alleles	  in	  
controls	  
(n	  =	  222)	  
Number	  of	  rare	  alleles	  in	  
cases	  
(n	  =	  41*)	   Fisher	  p	  
PER2	   6	   9	   0.00057	  
PLEKHA6	   0	   4	   0.00097	  
FLG	   5	   7	   0.0026	  
SLC3A1	   2	   5	   0.0029	  
WDR59	   2	   5	   0.0029	  
	  
*Total	   number	   of	   cases	   after	   removing	   additional	   exomes	   within	   each	   family.	   Rare	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Table	   3.6:	   Top	   3	   most	   significant	   genes	   for	   the	   aggregate	   test	   for	   rare	   LoF	  
variants	  only	  between	  cases	  and	  controls	  	  
	  
Gene	  
Number	  of	  rare	  alleles	  in	  
controls	  
(n	  =	  222)	  
Number	  of	  rare	  alleles	  in	  
cases	  
(n	  =	  41*)	  
Fisher	  
p	  
ITGAE	   0	   2	   0.027	  
TEX14	   0	   2	   0.027	  
CUBN	   2	   3	   0.043	  
	  
*Total	   number	   of	   cases	   after	   removing	   additional	   exomes	   within	   each	   family.	   Rare	  
allele	  is	  defined	  by	  a	  frequency	  less	  than	  0.5%	  in	  the	  1,000	  genomes	  data	  (n	  =	  1092).	  	  
	  
Table	   3.7:	   Top	   15	   most	   significant	   genes	   for	   the	   aggregate	   test	   for	   rare	   LoF	  
variants	  in	  immune	  genes	  between	  cases	  and	  controls	  	  	  
	  
Gene	  
Number	  of	  rare	  alleles	  in	  
controls	  
(n	  =	  222)	  
Number	  of	  rare	  alleles	  
in	  cases	  
(n	  =	  41*)	   Fisher	  p	  
CD1C	   0	   3	   0.005	  
CERK	   0	   3	   0.005	  
CRLF3	   0	   3	   0.005	  
DDR1	   2	   4	   0.010	  
HLA-­‐DOA	   4	   5	   0.012	  
ZFYVE16	   4	   5	   0.012	  
IKZF3	   1	   3	   0.016	  
RPS6KA2	   1	   3	   0.016	  
CDH17	   3	   4	   0.020	  
LPP	   5	   5	   0.020	  
CD180	   0	   2	   0.022	  
CTGF	   0	   2	   0.022	  
DNM1L	   0	   2	   0.022	  
EB13	   0	   2	   0.022	  
IFNW1	   0	   2	   0.022	  
	  
*Total	   number	   of	   cases	   after	   removing	   additional	   exomes	   within	   each	   family.	   Rare	  
allele	  is	  defined	  by	  a	  frequency	  less	  than	  0.5%	  in	  the	  1,000	  genomes	  data	  (n	  =	  1092).	  	  
The	   results	   in	   tables	  3.6	  and	  3.7	  are	  based	  on	  multiple	   testing	   corrections	  hence	   the	  
observed	   differences	   in	  P	   values;	   the	   test	   in	   table	   3.7	   contained	   a	   lower	   number	   of	  
genes	  than	  the	  test	  in	  table	  3.6,	  so	  the	  penalty	  for	  multiple	  testing	  was	  reduced.	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Genes	   in	   table	   3.5	   did	   not	   appear	   to	   have	   any	   potential	   function	   for	   CD	  
susceptibility,	  or	  any	  other	  overlapping	  disease	  where	  one	  can	  deduce	  a	  shared	  
function.	  For	  example,	  an	  excess	  of	  rare	  variants	  in	  cases	  and	  controls	  in	  PER2	  is	  
possibly	  owing	  to	  its	  function	  as	  a	  circadian	  pacemaker	  in	  the	  mammalian	  brain	  
involved	  in	  behavioral	  and	  metabolic	  factors,	  rather	  than	  being	  enriched	  for	  CD	  
risk	  variants;	  mutations	  in	  SLC3A1	  are	  associated	  with	  cystinuria,	  an	  autosomal	  
recessive	  disease	  characterized	  by	  kidney	  stones	  (Pras,	  Raben	  et	  al.	  1995);	  FLG,	  
a	   gene	   that	  encodes	   the	   filaggrin	  protein	   that	   forms	  a	   component	  of	   the	   skin	  
barrier,	   has	   strongly	   associated	   LoF	   variants	   in	   atopic	   eczema	   and	   ichthyosis	  
vulgaris	   (Sandilands,	   Terron-­‐Kwiatkowski	   et	   al.	   2007)	   but	   no	   association	   has	  
been	  implicated	  in	  InBD	  susceptibility	  	  (Van	  Limbergen,	  Russell	  et	  al.	  2009).	  	  
Based	   on	   protein	   function,	   ITGAE	   and	   CUBN	  were	   suggestive	   candidates	   for	  
further	   screening.	   ITGAE,	   also	   known	   as	   CD103,	   encodes	   an	   alpha	   integrin	  
involved	  in	  tissue	  specific	  retention	  of	  T	  lymphocytes	  at	  the	  basolateral	  surface	  
of	   intestinal	   epithelial	   cells	   and	   is	   a	   possible	   accessory	   function	   for	   the	  
activation	  of	  epithelial	  cells	  (Cepek,	  Parker	  et	  al.	  1993;	  Sheridan	  and	  Lefrancois	  
2011).	   Two	   confirmed	   novel	   stop	   gain	   (nonsense)	   SNVs	   in	   ITGAE	   c.2962G>T	  
(p.Glu988X)	  (identified	  in	  SAL-­‐12553-­‐6	  from	  FAM014)	  and	  c.314T>A	  (p.Leu105X)	  
(identified	  in	  Neu7058-­‐39198	  from	  Neu7058),	  were	  not	  present	  in	  222	  controls.	  
Both	  SNPs	  were	  tested	  for	  segregation	  in	  all	  affected	  and	  unaffected	  individuals	  
of	   FAM014	   and	   Neu7058.	   The	   c.314T>A	   substitution	   was	   present	   in	   four	  
individuals	  in	  Neu7058,	  three	  of	  which	  were	  non-­‐disease	  cases.	  Only	  one	  other	  
unaffected	   individual	   carried	   the	   c.2962G>T	   substitution	   in	   FAM014.	   Neither	  
mutation	  segregated	  with	  disease	  in	  two	  families.	  
CUBN	   (cubilin)	   is	   located	  on	  chromosome	  10p21.1	  and	  is	  expressed	  within	  the	  
epithelium	   of	   the	   intestine	   where	   it	   acts	   as	   a	   receptor	   for	   intrinsic	   factor-­‐
vitamin	   B	   (12)	   complexes	   (Fodinger,	   Wagner	   et	   al.	   2001).	   Missense	   and	  
insertion	   mutations	   in	   this	   gene	   have	   been	   associated	   with	   megalobastic	  
anaemia	   in	   Finnish	   families	   (Aminoff,	   Carter	   et	   al.	   1999),	   a	   rare	   autosomal	  
recessive	   condition	   characterized	   by	   selective	   intestinal	   vitamin	   B12	  
malabsorption.	   It	   is	   not	   known	   whether	   the	   three	   individuals	   bearing	   the	  
nonsense	  mutation	   in	  this	  gene	  have	  megaloblastic	  anaemia;	   it	   is	  common	  for	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CD	  patients	   to	   have	   low	  B12	   and	   folate	   levels,	   causing	   pernicious	   anaemia.	   A	  
recent	   meta-­‐analysis	   to	   identify	   risk	   variants	   for	   albuminuria	   for	   early	  
prevention	   of	   chronic	   kidney	   disease	   located	   a	   risk	   variant	   in	   CUBN	   to	   be	  
associated	  with	  albuminuria	  level	  in	  individuals	  with	  diabetes	  (Boger,	  Chen	  et	  al.	  
2011).	   Three	   novel	   stop	   gain	   (or	   nonsense)	   mutations	   in	   CUBN	   (RefSeq	  
accession	   number	   NM_001081)	   were	   observed	   in	   three	   separate	   individuals:	  
c.4459C>T	  (p.Arg1487X),	  c.5428C>T	  (p.Arg1810X)	  and	  c.6359G>A	  (p.Trp2120X).	  
All	   substitutions	   are	   possibly	   damaging,	   predicted	   by	   PolyPhen	   and	   GAIIx	  
sequence	  pile-­‐up	  data	  indicated	  real	  heterozygotes	  with	  a	  high	  read	  depth	  (173,	  
44	  and	  53	  respectively),	  confirmed	  by	  Sanger	  sequencing.	  	  
Overall,	  candidate	  genes	  harbouring	  true	  (as	  confirmed	  by	  Sanger	  sequencing)	  
rare	   variants,	   i)	   shared	  by	   related	  exomes,	   ii)	   that	   showed	  a	  higher	  burden	   in	  
cases	   than	   controls,	   and	   iii)	   that	   segregated	   in	   familial	   disease	   cases,	   were	  
selected	   for	   resequencing	   based	   on	   interesting	   immune	   function,	   size	   and	  
number	  of	  exons.	  	  
	  
3.6	  Chapter	  discussion	  	  
	  
Strategies	  to	  discover	  rare	  major	  impact	  variants	  in	  common	  disease	  have	  been	  
widely	   discussed	   (Cirulli	   and	   Goldstein	   2010;	   Eichler,	   Flint	   et	   al.	   2010)	   and	  
exome-­‐sequencing	  based	  studies	  are	  a	  popular	  approach	  to	  test	  for	  association	  
of	   rare	   coding	   variants	   with	   complex	   phenotypes.	   The	   empirical	   successes	   of	  
candidate	  gene	  resequencing	   (Ji,	  Foo	  et	  al.	  2008;	   Johansen,	  Wang	  et	  al.	  2010)	  
and	  Mendelian	   studies	   suggest	   a	   large	  portion	  of	   disease-­‐associated	   variation	  
lie	   within	   coding	   exons	   (Cooper,	   Ball	   et	   al.	   1998;	   Botstein	   and	   Risch	   2003;	  
Glazov,	  Zankl	  et	  al.	  2011).	  	  Based	  on	  this,	  it	  was	  likely	  that	  many	  rare	  mutations	  
in	   a	   gene(s)	   were	   to	   be	   located	   that	   could	   contribute	   to	   missing	   disease	  
heritability.	  	  
The	  75	  coeliac	  sample	  dataset	  contained	  an	  abundance	  of	  rare	  coding	  variants	  
(~33,000)	  and	  sequencing	  additional	  samples	  would	  probably	  continue	  to	  reveal	  
additional	   rare	  variants.	  Keizun	  et	  al.	  discovered	   that	  as	   sample	   size	   increases	  
the	   number	   of	   observed	   variants	   increases	   (an	   average	   of	   40	   times	   more	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nonsense	   variants	   in	   300	   samples	   than	   in	   a	   single	   sample	   alone)	   owing	   to	  
purifying	   selection	   and	   recent	   population	   expansion	   (Kiezun,	   Garimella	   et	   al.	  
2012).	   Large	   characterized	   families	   are	   therefore	   as	   important	   in	   exome	  
sequencing	   as	   in	   positional	   cloning	   or	   linkage	   methods,	   not	   only	   for	   variant	  
enrichment	   but	   to	   filter	   potential	   risk	   variants.	   Protection	   from	   confounding	  
factors	   owing	   to	   population	   stratification	   and	   allelic	   heterogeneity	   is	   another	  
advantage	  of	   family	   designs.	  DNA-­‐enrichment	  methods	   and	  massively	   parallel	  
high	   throughput	   sequencing	   promise	   high	   quality	   data	   of	   captured	   protein-­‐
coding	   variants	   -­‐	   of	   these	   functionally	   important	   variants,	   any	   two	   shared	  
between	  related	  individuals	  are	  likely	  to	  be	  causal	  if	  the	  variant	  segregates	  with	  
disease.	   If	   a	   rare	   variant	   of	   large	   effect	   was	   to	   be	   functionally	   defective	   in	   a	  
family,	  LoF,	  splice	  site	  and	  nonsyonymous	  mutations	  are	  a	  clear	  starting	  point	  
for	   analysis.	   This	   approach	   was	   adopted	   to	   search	   for	   a	   Mendelian	   or	   near	  
Mendelian	  form	  of	  CD.	  The	  second	  approach	  was	  to	   implement	  a	  case-­‐control	  
method	  by	  performing	   single-­‐SNP	   tests	   and	   rare	   variant	   gene-­‐burden	   tests	   to	  
search	  for	  mutations	  in	  genes	  reaching	  significance.	  The	  focus	  on	  immune	  genes	  
extended	  from	  GWAS	  and	  fine	  mapping	  results	  in	  CD.	  The	  latest	  fine	  mapping	  of	  
current	   coeliac	   loci	   identified	   13	   new	   coeliac	   risk	   loci	   at	   genome-­‐wide	  
significance	   (Trynka	   et	   al.	   2011),	   bringing	   the	   total	   to	   40	   (including	   the	   HLA).	  
Over	  90%	  of	  associated	  loci	  are	  represented	  in	  known	  immune	  system	  genes	  so	  
it	   was	   hypothesised	   that	   any	   rare	   variants	   of	   large	   effect	   would	   compromise	  
immunological	  function.	  	  
Specificity	   of	   variant	   identification	   was	   assessed	   based	   on	   concordance	   rates	  
with	  genotyping	  data	  and	  the	  percentage	  of	  Sanger	  sequencing	  false	  positives.	  
Here,	  a	  false	  positive	   is	  defined	  as	  the	  appearance	  of	  an	  allele	  at	  a	  sequenced	  
locus	  in	  the	  NGS	  data	  that	  is	  not	  observed	  in	  the	  Sanger	  sequencing	  data.	  High	  
specificity	   of	   variants	   in	   the	   sequencing	   dataset	   was	   observed	   by	   >99%	  
correlation	  with	  a	  GWAS	  common	  SNP	  HapMap	  control.	  Overall,	  37	  SNPs	  were	  
Sanger	  sequenced	  across	  all	  exome	  individuals.	  Three	  of	  the	  37	  were	  complete	  
false	  positives	  in	  the	  NGS	  data,	  resulting	  in	  an	  8.1%	  false	  positive	  rate.	  Four	  out	  
of	  37	  SNPs	  were	  false	  positive	  in	  only	  one	  of	  the	  two	  related	  exomes,	  possibly	  
due	  to	   low	  coverage	  at	   that	  variant	  site	   for	   the	  second	   individual	   leading	   to	  a	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sequencing	   error.	   Sequencing	   error	   decreased	  with	   better	   variant	   annotation	  
software;	  there	  were	  three	  complete	  false	  positives	  with	  SeattleSeq	  annotation	  
compared	   to	   zero	   with	   Annovar	   annotation.	   Furthermore,	   the	   top	   400	   novel	  
exome	  SNPs	  on	  the	   Immunochip	  array	   (discussed	  further	   in	  Chapter	  4)	  have	  a	  
false	   positive	   rate	   of	   25%;	   this	   error	   estimate	   comprises	   not	   only	   sequencing	  
miscalls,	   but	   clustering	   miscalls	   and	   any	   assay	   fails.	   Despite	   stringent	   quality	  
control	   error	   can	   still	   be	  present	   in	   sequencing	  data	   and	  unfortunately	   this	   is	  
the	   case	   when	   stratifying	   variants	   on	   the	   basis	   of	   putative	   functional	  
consequences;	  the	  class	  of	  variation	  that	  is	  annotated	  to	  be	  most	  deleterious	  is	  
also	  more	  heavily	  enriched	  for	  errors	  (MacArthur	  and	  Tyler-­‐Smith	  2010).	  Having	  
an	  up-­‐to-­‐date	  reference	  dataset,	  such	  as	  the	  1000	  Genomes,	  helps	  identify	  true	  
LoF	  variants.	  	  
The	   first	   large-­‐scale	  exome	   resequencing	   study	  was	  by	   Li	   et	   al.	  who	   found	  an	  
excess	  of	   low	  frequency	  rare	  mutations	   in	  200	  exomes	  (Li,	  Vinckenbosch	  et	  al.	  
2010).	   This	   data	   was	   not	   used	   as	   a	   permanent	   filter	   in	   the	   coeliac	   dataset	  
because	   of	   early	   technology	   and	   limited	   coverage.	   Overall,	   all	   75	   sequenced	  
coeliac	  exomes	  passed	  quality	  control	  with	  >13,000	  SNP	  calls	  at	  an	  average	  read	  
depth	  of	  50x	  per	  exome,	  compared	  to	  12x	   in	  the	  Li	  et	  al.	  dataset.	  One	  lane	  of	  
76bp	   paired	   end	   data	   (v4	   chemistry,	   GAIIx)	   typically	   provided	   ~21	  million	   on	  
target	   non-­‐duplicate	   reads.	   The	   in-­‐solution	   DNA	   capture	   method	   proved	  
markedly	   superior	   to	   array	   based	   capture	   and	   was	   optimized	   to	   decrease	  
duplicate	  reads	  (reduction	  of	  PCR	  cycles)	  and	  increase	  data	  coverage	  for	  variant	  
detection	   (no	   multiplexing).	   Yet,	   across	   all	   75	   exomes,	   an	   average	   80.4%	   of	  
post-­‐capture	   non-­‐duplicate	   on	   target	   reads	   was	   obtained	   (Appendix	   I-­‐C),	  
meaning	   20%,	   or	   4-­‐8	  Mb	   (1000	   –	   2000	   genes),	   of	   the	   target	   region	   was	   not	  
covered	  with	   sufficient	   read	  depth	   for	   variant	  detection.	  As	   far	  as	   sequencing	  
goes,	  these	  un-­‐captured	  regions	  will	  not	  be	  observed	  in	  the	  dataset.	  However,	  
even	  within	  the	  set	  of	  called	  variants,	   there	   is	  also	  an	   issue	  of	  whether	  a	   true	  
heterozygote	   in	   captured	   regions	   is	   in	   fact	   a	   heterozygote	   variant.	   The	   same	  
number	  of	  reads	  per	  allele	  is	  required	  to	  call	  an	  heterozygote	  but	  if	  alleles	  are	  
captured	   at	   different	   rates	   in	   the	   library	   processing	   step,	   then	   a	   sequencing	  
miscall	   is	   possible.	   Sanger	   sequencing	   validation	   is	   therefore	   a	   necessity	  with	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sequencing	  methods	  to	  validate	  true	  calls.	  Regional	  variability	  is	  also	  a	  concern	  
across	   different	   target	   capture	  methods	   for	   exome	   sequencing.	   Some	   regions	  
can	   have	   greater	   technical	   artefacts	   due	   to	   overlapping	   probes,	   or	   may	   be	  
under-­‐covered	   to	   high	   GC	   content	   or	   segmental	   duplications	   preventing	  
accurate	   alignment	   to	   the	   reference	   sequence	   (Hedges,	   Guettouche	   et	   al.	  
2011).	  There	  is	  also	  a	  problem	  of	  variable	  uniformity	  in	  NGS	  platforms.	  A	  mean	  
coverage	   does	   not	   mean	   that	   each	   base	   was	   read	   the	   reported	   number	   of	  
times;	  some	  are	  read	  only	  occasionally	  whilst	  others	  are	  oversampled.	  Further	  
sequencing	  will	   increase	   the	  number	  of	  unrepresented	   reads,	  but	  array-­‐based	  
genotyping	  to	  utilize	  maximum	  variant	  calling	  is	  also	  an	  option.	  	  
The	   key	   challenge	   for	   disease	   gene	   discovery	   using	   exome	   sequencing	   is	   the	  
huge	  number	  of	  apparently	  private	  mutations	  present	  by	  chance	   in	  any	  single	  
genome,	   making	   it	   difficult	   to	   decide	   which	   variant	   is	   causal,	   even	   if	   only	  
nonsynonymous,	   splice	   site	   and	   indel	   mutations	   are	   considered.	   This	   early	  
observation	   was	   highlighted	   in	   the	   phase	   two	   dataset,	   where	   thousands	   of	  
protein	  coding	  mutations	  per	  individual	  were	  identified	  e.g.	  16,044	  exonic	  SNPs	  
were	   observed	   in	   sample	   CAP200010,	   of	   which	   6,600	   were	   missense	   or	  
nonsense	  and	  15,855	  exonic	  SNPs	  were	  observed	  in	  CAP152916,	  of	  which	  6,759	  
were	  missense	  or	  nonsense.	  This	  posed	  a	  ‘needle	  in	  a	  haystack’	  problem.	  Having	  
the	   Immunochip	   case	   control	   dataset	   helped	   familial	   analysis	   to	   validate	  
candidate	   mutations.	   Two	   rare	   SNPs	   in	  MADD	   (MAP-­‐kinase	   activating	   death	  
domain,	   T	   cell	   expressed)	   and	   IL12RB2	   (interleukin	   12	   receptor)	   were	   on	   the	  
Immunochip	   assay,	   but	   did	   not	   reach	   significance	   at	   P<10-­‐5.	   This	   result	  
expressed	  the	  need	  for	  high	  quality	  control	  exome	  data,	  which	  came	  at	  a	  later	  
date	   (222	   neurological	   disease	   control	   exomes).	   Differences	   in	   in-­‐solution	  
capture	   methods	   used	   in	   this	   study	   have	   been	   evaluated	   in	   a	   prior	   study	  
(Agilent	   Sure	   Select	   for	   222	   control	   samples	   and	  Roche	  NimbleGen	   for	   75	   CD	  
exome	   samples);	   more	   high	   quality	   reads	   aligned	   to	   target	   regions	   with	  
NimbleGen’s	   capture	   probes	   (Sulonen,	   Ellonen	   et	   al.	   2011).	   These	   differences	  
may	  have	  had	  slight	   impact	  on	  the	  results	  for	  the	  single	  SNP	  and	  gene	  burden	  
tests.	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Although	   the	   familial	   design	   was	   adopted	   in	   order	   to	   filter	   potential	   risk	  
variants,	  segregation	  tests	  were	  either	  inconclusive	  due	  to	  small	  sample	  size	  or	  
failed	   to	   segregate	   directly	   in	   CD	   cases;	   the	   reference	   wild	   type	   alleles	   were	  
always	  present	  in	  affected	  cases.	  One	  positive	  segregation	  test	  was	  in	  the	  BRK	  
family;	   all	   CD	   cases	   in	   BRK	   carried	   the	   nonsense	   c.184C>T	   substitution	   in	  
TNFRSF21.	  Additional	  CD	  GWAS-­‐associations	  genes	  from	  the	  same	  super-­‐family	  
(TNFRSF18	   and	   TNFRSF14)	   highlighted	   TNFRSF21	   as	   a	   candidate	   for	  
resequencing.	   Surprisingly,	   for	   the	   single-­‐SNP	   test,	   the	   HLA	   region	   on	  
chromosome	  6	   showed	   strong	   significance,	   even	  with	   a	   small	   sample	   size	   (44	  
cases),	   but	   no	   other	   significant	   variant	  was	   established.	  Here	   the	   sample	   size	  
resulted	   in	   lack	  of	  power,	  and	   limited	  the	  extrapolation	  of	  any	  true	  result;	  the	  
most	   significant	   hits	   were	   probably	   sequencing	   artefact.	   For	   example,	   one	  
would	   need	   200	   cases	   (and	   200	   controls)	   to	   give	   0.2%	   power	   for	   a	   0.2%	  
frequency	  SNP	  to	  be	  detected	  at	  10-­‐8	  (Purcell,	  Cherny	  et	  al.	  2003).	  
The	   overall	   aim	   of	   analysis	   from	   sections	   3.5.3.1	   and	   3.5.3.2	   was	   to	   identify	  
candidate	  genes	  for	  targeted	  resequencing	  to	  assess	  if	  there	  were	  a	  significant	  
burden	   of	   rare	   variants	   in	   captured	   genes	   from	   enriched	   disease	   samples	  
(Chapter	   5).	   Cost	   and	   amplicon	   design	   considerations	   had	   to	   be	   taken	   into	  
account	  for	  the	  follow-­‐up	  study,	  so	  genes	  were	  selected	  based	  on	  likely	  function	  
in	  CD	  susceptibility,	  size	  of	  coding	  region	  and	  number	  of	  overall	  PCR	  amplicon	  
targets.	  Despite	  there	  being	  rare	  novel	  nonsense	  variants	  CUBN	  in	  coeliac	  cases,	  
these	   variants	   also	   occur	   in	   controls.	   With	   67	   exons	   and	   3,623	   amino	   acids,	  
CUBN	  has	  a	  relatively	  large	  coding	  sequencing,	  so	  majority	  of	  the	  population	  will	  
have	  at	   least	  one	  rare	  (defined	  as	  a	  mean	  allele	  frequency	  <0.5%)	  missense	  or	  
truncating	  variant	  at	  this	  locus.	  Even	  in	  all	  75	  exome	  cases,	  there	  are	  an	  excess	  
of	  LoF	  variants	   in	  CUBN	   (494),	  compared	  to	  11	   in	  CRLF3,	  a	  much	  smaller	  gene	  
with	  8	   exons	   and	  442	  amino	  acids.	  NGS	  of	   the	  entire	   coding	   regions	  of	   these	  
genes	  has	   the	  power	   to	  define	  which	   variants	   are	  pathogenic,	   however	  when	  
relying	  on	   an	  economy	  of	   scale,	   for	   a	   similar	   cost	   as	   sequencing	   CUBN	   alone,	  
five	  genes	  of	  ~2,200bp	  in	  coding	  length	  can	  be	  sequenced,	  therefore	  CUBN	  was	  
not	  selected	  for	  resequencing.	  All	  other	  candidate	  genes	  based	  on	  case	  control	  
rare	  allele	  tests	  and	  whether	  shared	  with	  another	  exome	  are	  listed	  in	  Table	  3.8.	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Table	   3.8:	   Candidate	   genes	   from	   exome	   sequencing	   analyses	   selected	   for	  
targeted	  gene	  resequencing	  
	  
Gene	   Analysis	  type	   cDNA	   size	  
(bp)	  







CD1C	   Case	  control	   1,435	   6	   Yes	   Yes	  
CERK	   Case	  control	   4,450	   13	   Yes	   Yes	  
CRLF3	   Case	  control	   2,917	   8	   Yes	   Yes	  
IKZF3	   Case	  control	   9,667	   8	   Yes	   Yes	  
CD180	   Case	  control/shared	  	   2,726	   3	   Yes	   Yes	  
EBI3	   Case	  control	   1,128	   5	   Yes	   Yes	  
IFNW1	   Case	  control	   1,514	   1	   Yes	   Yes	  
RAF1	   Shared	   3,300	   17	   Yes	   Yes	  
TNFRSF10A	   Shared	   1,357	   5	   Yes	   Yes	  
MAP4K2	   Shared	   2,955	   32	   Yes	   Yes	  
C1QBP	   Shared	   1,169	   6	   Yes	   Yes	  
TNFRSF13B	   Shared	   1,357	   5	   Yes	   Yes	  
TRAF4	   Shared	   2,921	   7	   Yes	   Yes	  
IL12RB1	   Shared	   2,100	   17	   Yes	   Yes	  
HAS1	   Shared	   2,087	   5	   Yes	   Yes	  
TNFRSF21	   Segregation	   3,595	   6	   Yes	   Yes	  
	  	  
3.7	  Chapter	  Conclusions	  
	  
The	  points	  below	  conclude	  the	  findings	  from	  the	  research	  in	  this	  chapter:	  
1. Many	   rare	   and	   low	   frequency	   (between	   0.09%	   and	   5%	   allele	  
frequencies)	  SNVs	  were	  found	  in	  75	  coeliac	  exomes.	  	  	  
2. No	   conclusive	   variants	   were	   found	   to	   be	   segregating	   with	   disease	   in	  
large	   (>2	   generation)	   multiply	   affected	   coeliac	   families,	   where	   two	   or	  
three	  exomes	  were	  sequenced	  per	  family.	  	  
3. Different	   analytical	   strategies	   were	   applied	   to	   locate	   genes	   with	  
potential	  CD	  association,	  within	  families	  and	  across	  the	  entire	  75-­‐disease	  
case	  dataset.	  	  
4. CUBN	   stood	   out	   as	   a	   clear	   candidate	   given	   its	   role	   as	   a	   vitamin	   B12	  
receptor	   and	   positive	   Sanger	   sequence	   validation,	   but	   was	   too	   large	  
(11,949bp)	  for	  resequencing.	  Another	  PhD	  student	  may	  study	  the	  role	  of	  
this	  gene	  in	  CD.	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5. 16	  candidate	  genes	  were	  sequenced	  in	  2,304	  cases	  and	  2,304	  controls	  in	  
a	  follow-­‐up	  study.	  This	  experiment	  is	  outlined	  in	  Chapter	  5	  of	  the	  thesis.
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4.1	  Introduction	  
	  
The	  Immunochip	  array	  was	  designed	  by	  a	  cohort	  of	  researchers,	  initiated	  by	  the	  
WTCCC,	  involved	  in	  autoimmune	  genetic	  studies	  with	  a	  main	  focus	  of	  dissecting	  
rare	  and	  common	  genetic	  variation	  at	  immune	  regions	  in	  autoimmune	  disease.	  
The	  custom	  Illumina	  Infinium	  HD	  array	  became	  commercially	  available	  in	  2010	  
to	  Immunochip	  consortium	  researchers	  and	  contained	  196,524	  polymorphisms	  
(718	  small	  indels	  and	  195,806	  SNPs)	  across	  186	  disease	  susceptibility	  loci	  in	  nine	  
autoimmune	  diseases	   (Greco,	  Corazza	  et	  al.	  1998;	  Murray,	  Moore	  et	  al.	  2007;	  
Cortes	   and	   Brown	   2011).	   Various	   laboratories	   contributed	   data	   from	   GWAS	  
significant	  (P<5	  x	  10-­‐8)	  regions	  and	  any	  fine	  mapping/resequencing	  regions	  -­‐	  the	  
entire	   SNP	   content	   was	   not	   genome	   wide	   but	   SNPs	   from	   several	   auto	   and	  
chronic	   immune	  mediated	  disease	  loci.	  This	  allowed	  deep	  replication	  of	  GWAS	  
data	   covering	   strong	   candidate	   genes	   to	   dissect	   true	   risk	   signals	   from	   top-­‐
ranked	  associations	  and	  greater	  refinement	  of	  disease-­‐associated	  variants	  that	  
was	   not	   possible	   on	   the	   Illumina	   Hap550	   or	   Omni2.5	   chips.	   Along	   with	  
established	   disease	   loci,	   all	   known	   dbSNP	   and	   1000G	   (2010	   release)	   variants	  
within	   0.1cM	   (HapMap3	   CEU)	   recombination	   blocks	   around	   each	   GWAS	   lead	  
marker	  on	  the	  chip	  enabled	  fine	  mapping	  of	  loci	  for	  rare	  and	  common	  variants	  
(Polychronakos	  2011).	  A	  collection	  of	  high	  density	  mapping	  studies	  have	  been	  
successfully	  published,	  using	  the	  standard	  single	  disease	  case	  control	  approach	  
(Cooper,	  Simmonds	  et	  al.	  2012;	  Eyre,	  Bowes	  et	  al.	  2012;	  Liu,	  Almarri	  et	  al.	  2012)	  
and	  meta	  analysis	  with	  previous	  GWAS	  data	  and	  imputation	  (Eyre,	  Bowes	  et	  al.	  
2012;	  Jostins,	  Ripke	  et	  al.	  2012;	  Juran,	  Hirschfield	  et	  al.	  2012;	  Tsoi,	  Spain	  et	  al.	  
2012).	  	  
All	   CD	   GWAS-­‐associated	   loci	   plus	   a	   subset	   of	   target	   captured	   exonic	   SNPs	  
selected	  from	  the	  exome	  sequencing	  dataset	  in	  Chapter	  3	  were	  contributed	  by	  
David	  van	  Heel	   (member	  of	   the	   Immunochip	  consortium)	   for	   the	   Immunochip	  
assay.	  The	  CD	  Immunochip	  fine	  mapping	  study	  published	  in	  2011	  implicated	  56	  
non-­‐HLA	   SNPs	   in	   40	   independent	   loci	   to	   be	   associated	   with	   CD	   disease	   risk,	  
meeting	   the	   strict	   criteria	   of	   a	   nominal	   P	   value	   <5	   x	   10-­‐8,	   set	   for	   large-­‐scale	  
GWAS	  and	  fine	  mapping	  studies	  (Trynka,	  Hunt	  et	  al.	  2011).	  This	  entire	  chapter	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details	  three	  sets	  of	  analysis	  using	  SNP	  markers	  from	  the	  Immunochip	  array:	   i)	  
linkage	   analysis	   in	   coeliac	   pedigrees	   using	   the	   entire	   Immunochip	  marker	   set	  
(discussed	  in	  next	  sections),	  ii)	  case	  control	  association	  analysis	  of	  the	  subset	  of	  
target	   captured	   exonic	   SNPs	   selected	   from	   the	   exome	   sequencing	   dataset	   in	  
Chapter	   3,	   iii)	   genetic	   load	   scoring	   of	   current	   57	   (including	   the	   highest	  
associated	   SNP	   at	   HLA-­‐DQ2.5)	   coeliac	   associated	   SNPs	   in	   coeliac	   individuals	  
from	  multiply	  affected	  families	  compared	  to	  population	  controls.	  	  
	  
4.1.1	  Principles	  of	  genetic	  linkage	  	  
	  
The	  process	  of	  recombination	  is	  the	  objective	  behind	  linkage	  inference	  in	  family	  
studies.	   During	   meiosis,	   crossing	   over	   occurring	   between	   two	   non-­‐sister	  
chromatids	   is	   given	   the	   term	   recombination.	   The	   resultant	   homologous	  
chromosomes	  will	   have	   new	   combinations,	   which	   in	   turn	   give	   rise	   to	   genetic	  
variation.	  The	  amount	  of	  crossing	  over	  that	  can	  take	  place	  is	  dependent	  on	  the	  
distance	   between	   two	   genes	   along	   the	   chromosome.	   Crossover	   and	   non-­‐
crossover	  events	  occur	  at	  equal	  frequency	  if	  two	  genes	  are	  far	  apart;	  this	  is	  the	  
opposite	  of	  genes	  that	  are	  closer	  together,	  which	  undergo	  less	  recombination.	  If	  
two	  loci	  are	  linked,	  the	  probability	  that	  that	  they	  are	  passed	  down	  together	  as	  a	  
haplotype	  depends	  upon	  the	  probability	  of	   recombination	  during	  meiosis,	  and	  
this	   probability	   is	   translated	   into	   a	   recombination	   frequency,	  θ,	   to	   determine	  
allele	   segregation	   in	   a	   disease	   trait.	   For	   example,	   in	   figure	   5.1,	   if	   D	   is	   an	  
unknown	  disease	  gene	  and	  C	   is	  an	  observed	  marker	   locus,	  and	   if	  C	  and	  D	  are	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Figure	  4.1:	  Linkage	  and	  disease	  genes	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A	  θ	   of	   50%	   specifies	   unlinked	   loci	   distantly	   located	   on	   the	   same	   chromosome	   or	   on	  
separate	  chromosomes,	  a	  consequence	  of	  independent	  assortment.	  A	  θ	  less	  than	  50%	  
means	  loci	  are	  linked	  with	  a	  small	  physical	  distance	  between	  them.	  	  
	  
4.1.2	  Linkage	  models	  in	  complex	  disease	  	  
	  
With	  genetically	  complex	  traits,	  there	  is	  unclear	  evidence	  of	  a	  single	  locus	  effect	  
with	  a	  specific	  mode	  of	   inheritance,	  such	  that	  the	  unreliability	  of	  conventional	  
linkage	  analysis	  requires	  distinct,	  model	  free	  strategies	  to	  be	  created	  (Curtis	  and	  
Sham	   1995).	   For	   a	   dichotomous	   trait	   genetic	   complexity	   is	   causative	   of	  
heterogeneity,	   involvement	   of	   multiple	   genetic	   loci	   and	   environmental	  
exposures,	  so	  requires	  a	  method	  where	  the	  precise	  mechanism	  of	  disease	  can	  
remain	  unknown.	  Affected	  sibling	  pair	  methods	  were	  modelled	  based	  on	   this,	  
followed	   by	   likelihood-­‐based	   methods	   in	   which	   the	   observed	   data	   is	   a	  
probability	  of	  θ	  of	   two	   loci	  by	  way	  of	   reporting	  a	   logarithm	   (base	  10)	  of	  odds	  
(LOD)	   score.	   	   The	   LOD	   score	   method	   was	   first	   defined	   in	   parametric	   models	  
where	   allele	   frequencies,	   penetrances	   and	   inter-­‐marker	   genetic	   distances	   (for	  
multipoint	   analyses)	  were	   required	   (Kruglyak,	   Daly	   et	   al.	   1996).	   This	  model	   is	  
successful	   where	   a	   clear	   inheritance	   pattern	   is	   observed,	   for	   example,	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is	  used	  for	  disorders	  of	  unclear	  inheritance	  and	  variable	  penetrance.	  It	  assumes	  
that	  linked	  loci	  shared	  by	  affected	  relative	  pairs	  share	  more	  alleles	  identical	  by	  
descent	   (IBD)	  at	   the	  marker	   locus	   than	  expected	  by	  chance	  only	   (Risch	  1990).	  
The	  test	  looks	  for	  chromosomal	  segments	  shared	  between	  affected	  individuals	  
by	  distinguishing	  IBD	  alleles	  from	  identical	  by	  state	  (IBS)	  alleles.	  Alleles	  IBS	  may	  
look	   identical	   but	   their	   common	   ancestor	   cannot	   be	   demonstrated,	   whereas	  
IBD	   alleles	   can	   be	   (Ott	   and	   Bhat	   1999).	   Only	   genotypic	   information	   from	   the	  
affected	   individuals	   is	   used	   for	   analysis,	   following	   the	   assumption	   that	   the	  
affected	   phenotype	   is	   more	   likely	   to	   be	   associated	   with	   the	   presence	   of	   the	  
disease	  allele.	  Unaffected	  individuals	  are	  used	  to	  provide	  genotypic	  information	  
on	   any	   un-­‐typed	   parents.	   Pedigree	   relationships,	   allele	   frequencies	   and	  
genotypes	  of	  all	  individuals	  are	  needed	  for	  NPL.	  	  
The	  linkage	  experiment	  in	  this	  chapter	  differs	  to	  other	  combined	  exome/whole	  
genome	   sequencing	   and	   linkage	   studies	   in	   monogenic	   disease.	   For	  
monogenic/Mendelian	  diseases,	  researchers	  have	  combined	  exome	  sequencing	  
in	  pedigrees	  where	  positive	  linkage	  has	  been	  identified	  to	  find	  the	  causal	  gene	  
(Louis-­‐Dit-­‐Picard,	   Barc	   et	   al.	   2012),	   and	   this	   has	   been	   successful	   for	   many	  
autosomal	  dominant	  (Johnson,	  Mandrioli	  et	  al.	  2010;	  Wang,	  Yang	  et	  al.	  2010),	  
recessive	  (Bilguvar,	  Ozturk	  et	  al.	  2010)	  and	  quantitative	  traits	  (Bowden,	  An	  et	  al.	  
2010).	   Linkage	   has	   also	   been	   used	   in	   complex	   traits.	   Recently,	   rare	  missense	  
mutations	   in	   CARD14	   have	   been	   implicated	   in	   psoriasis,	   using	   a	   variety	   of	  
strategies,	   some	   similar	   to	   ones	   taken	   in	   this	   study.	   Linkage	  was	   identified	   in	  
PSORS2	   chromosomal	   region,	   containing	   CARD14.	   Target	   capture	   and	  
sequencing	   then	   identified	   gain-­‐of-­‐function	   mutations	   in	   CARD14	   segregating	  
with	  disease	  (Bertin,	  Wang	  et	  al.	  2001;	  Jordan,	  Cao	  et	  al.	  2012).	  For	  a	  complete	  
mutation	   profile	   of	   the	   gene,	   exon	   4	   of	   CARD14	   (where	  most	   clustering	   rare	  
variants	   were	   located)	   was	   sequenced	   in	   1,856	   cases	   and	   882	   controls	   of	  
European	   ancestry	   and	   the	   entire	   case	   (6,000)	   control	   (4,000)	   cohort	   was	  
genotyped	  to	  establish	  allele	  frequencies	  of	  all	  rare	  CARD14	  variants.	  This	  study	  
was	   successful	   in	   finding	  a	  potential	   causal	   gene	   through	   linkage,	   establishing	  
that	   mutations	   in	   the	   gene	   also	   occurred	   outside	   of	   families	   with	   a	   genetic	  
predisposition	  and	  that	  harbouring	  rare	  variants	  are	  likely	  to	  confer	  a	  high	  risk	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for	   the	  phenotype	   (Jordan,	  Cao	  et	   al.	   2012).	   The	   study	   is	   a	   successful	  one	   for	  
complex	   disease	   and	   mirrors	   a	   monogenic	   disease	   finding	   in	   that	   one	   gene	  
(others	  genes	  also	  contribute	  to	  psoriasis	  susceptibility)	  containing	  rare	  variants	  
are	   possibly	   detrimental	   to	   disease	   risk.	   Furthermore,	   monogenic	   forms	   of	  
complex	   disease,	   such	   as	   in	   cutaneous	   lupus	   erythematosus,	   where	   an	  
autosomal	   dominant	   inheritance	   pattern	   was	   described	   by	   findings	   from	   a	  
genome-­‐wide	   linkage	   search	   in	   a	   large	   kindred	   (Lee-­‐Kirsch,	   Gong	   et	   al.	   2006)	  
provides	  further	  evidence	  of	  how	  linkage	  can	  identify	  a	  single	  gene	  responsible	  
for	  disease	  susceptibility.	  	  
In	   this	   chapter,	   linkage	  has	  been	  performed	   in	   large	  multigenerational	   coeliac	  
pedigrees	  using	  a	  set	  of	  common	  and	  rare	  SNP	  markers	  from	  the	  Immunochip	  
array.	   In	   order	   the	   link	   this	   information	   with	   the	   exome	   dataset	   of	   75	   CD	  
subjects,	  genomic	  regions	  under	  the	  linkage	  peaks	  were	  then	  inspected	  for	  rare	  
exome	   variants	   from	   the	   exome	   sequencing	   dataset	   (data	   from	   Chapter	   3,	  
phase	  two),	  in	  the	  hope	  of	  finding	  segregating	  variants	  in	  one	  or	  more	  genes	  to	  
take	  forward	  for	  targeted	  resequencing.	  	  
	  
4.2	  Aims	  and	  hypotheses	  
	  
Specific	  aims	  and	  hypothesis	  for	  three	  analyses	  are	  outlined	  below:	  
	  
i) Linkage	   analysis	   –	   the	   aim	   is	   to	   perform	   NPL	   analysis	   on	  multiply	  
affected	  families	  using	  196,524	  Immunochip	  SNP	  markers,	  to	  infer	  if	  
a	  rare	  coding	  disease	  risk	  variant	  is	  shared	  by	  affected	  individuals	  in	  
the	   same	   pedigree	   under	   a	   linkage	   peak.	   The	   linkage	   information	  
here	  provides	  knowledge	  of	  shared	  chromosomal	  regions,	  which	  can	  
be	   linked	   to	  exome	   sequencing	  data	   to	   search	   for	   rare	   segregating	  
variants	   carrying	   a	   disease	   risk.	   The	   hypothesis	   is	   if	   common	   SNPs	  
are	   segregating	  more	   than	   expected	   by	   chance	   then	   there	   will	   be	  
some	  rare	  functional	  variants	  under	  that	  peak	  also;	  the	  rare	  variant	  
will	  be	  IBD	  in	  affected	  individuals.	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ii) Case	   control	   association	   analysis	   -­‐	   the	   aim	   of	   having	   exome	   SNP	  
content	   on	   the	   Immunochip	   is	   to	   observe	   whether	   any	   rare	   (MAF	  
<0.5%	  as	  defined	  by	  Immunochip)	  or	  low	  frequency	  (MAF	  1%	  -­‐	  0.5%)	  
mutations	  captured	  from	  60	  coeliac	  exomes	  are	  associated	  with	  CD	  
in	   a	   large	   case	   control	   dataset.	   Not	   only	   does	   a	   large	   sample	   size	  
increase	  power	  for	  finding	  such	  mutations,	  it	  offers	  a	  strategy	  that	  is	  
cost	  effective	  -­‐	  it	  is	  far	  more	  affordable	  to	  genotype	  a	  large	  number	  
of	   samples	   than	   it	   is	   to	  exome	  capture	  and	  sequence	  each	  sample.	  
The	   hypothesis	   is	   that	   rare	   mutations	   in	   immunological	   relevant	  
exonic	  regions	  predispose	  to	  CD	  risk.	  	  
iii) Determining	  genetic	  load	  of	  coeliac	  associated	  risk	  loci	  -­‐	  the	  aim	  is	  
to	   compute	   a	   combined	   gene	   dose	   score	   of	   58	   current	   associated	  
coeliac	   loci	   in	   coeliac	   individuals	   and	   controls	   to	   determine	   if	  
affected	   individuals	   in	   families	   carry	   a	   higher	   proportion	   of	  GWAS-­‐
risk	   loci	   compared	   to	   healthy	   individuals	   in	   the	   same	   families	   and	  
unrelated	   population	   cases	   and	   controls.	   The	   hypothesis	   is	   that	  
affected	   individuals	   from	   coeliac	   families,	   where	   CD	   is	   highly	  
clustered	  due	  to	  a	  genetic	  predisposition,	  carry	  more	  CD	  associated	  
risk	  loci	  than	  controls.	  	  
	  
4.3	  Sample	  selection	  
	  
66	   coeliac	   cases	   and	   119	   related	   controls	   from	   12	   large	   multiply	   affected	  
pedigrees	  were	  selected	  for	  linkage	  analysis	  (Table	  4.1;	  see	  Figure	  1,	  Appendix	  I-­‐
A	  for	  pedigree	  illustrations).	  Pedigrees	  DA,	  BRK,	  BRE,	  HMN,	  BD,	  BR,	  BUT,	  H	  and	  
SDY	   were	   obtained	   from	   Professor	   Paul	   Ciclitira.	   These	   pedigrees	   have	   been	  
previously	  used	   for	   family-­‐based	   linkage	   studies	   in	  CD	   (Brett,	   Yiannakou	  et	   al.	  
1999;	  King,	  Yiannakou	  et	  al.	  2000;	  King,	  Fraser	  et	  al.	  2001;	  King,	  Moodie	  et	  al.	  
2002;	  King,	  Moodie	  et	  al.	  2003).	  	  
For	   exome	   SNP	   case-­‐control	   association	   analysis,	   the	   sample	   set	   consisted	   of	  
7,728	   coeliac	   cases,	   8,274	   controls	   of	   European	   (UK)	   ancestry,	   with	   an	  
additional	  112	  UK	  cases	   from	  coeliac	  pedigrees	  and	  129	   related	  controls	  used	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for	  genetic	   load	  analysis	   (Table	  1,	  Appendix	   I-­‐A).	  The	  UK	  control	  set	  contained	  
5,430	  UK	  1958	  Birth	  Cohort	  participants	  and	  2,844	  UK	  Blood	  Services-­‐Common	  
Controls.	   7,728	   affected	   coeliac	   individuals	   were	   diagnosed	   according	   to	  
standard	   clinical	   criteria	   including	  Marsh	   Stage	   III	   small	   intestinal	   biopsy	   and	  
compatible	  serology.	  Detailed	  case	  diagnoses	  are	  outlined	  in	  Trynka	  et	  al,	  online	  
methods	   (Trynka,	   Hunt	   et	   al.	   2011).	   112	   coeliacs	   from	   pedigrees	   were	   all	  
diagnosed	  according	  to	  the	  revised	  ESPGHAN	  criteria	  (ESPGHAN	  1990)	  .	  	  
	  















DA	   4/9	   4/4	   9/9	   2	  
BRK	   6/23	   6/6	   17/23	   2	  
BRE	   6/19	   6/6	   17/19	   1	  
HMN	   5/15	   5/5	   9/15	   1	  
BD	   6/10	   2/6	   4/10	   1	  
BR	   4/22	   3/4	   14/22	   1	  
BUT	   7/23	   6/7	   17/23	   1	  
H	   4/8	   4/4	   5/8	   1	  
SDY	   13/21	   10/13	   21/21	   3	  
FAM008	   8/6	   7/8	   2/6	   1	  
FAM063	   8/7	   7/8	   0/7	   1	  
FAM014	   6/22	   6/6	   4/22	   2	  
Total	   77/192	   66/77	   119/185	   17	  
	  
	  
4.4	  Experimental	  design	  and	  laboratory	  method	  
	  
All	   samples	   were	   genotyped	   on	   the	   Infinium	   HD	   Immunochip	   custom	   array	  
designed	   by	   Illumina.	   Genotyping	   was	   performed	   at	   Barts	   and	   the	   London	  
Genome	  Centre	  and	  arrays	  were	  scanned	  on	  the	  Illumina	  iScan	  at	  the	  Institute	  
of	  Child	  Health,	  University	  College	  London.	  NCBI	  build	  36	   (hg18)	  mapping	  was	  
used.	   Chapter	   2,	   section	   2.6	   details	   genotyping	   methods,	   as	   per	   Illumina’s	  
protocols.	  	  
Non-­‐parametric	   linkage	   analysis	   was	   performed	   using	   all	   Immunochip	   SNP	  
markers.	   Rare	   variants	   (0.5%	   frequency	   based	   on	   1000G)	   from	   the	   exome	  
	   126	  
sequencing	  dataset	  were	  extracted	   from	  regions	  under	   linkage	  peaks	   (p<0.01)	  
in	  all	  families.	  	  
Exome	   SNPs	  were	   selected	   for	   the	   Immunochip	   final	   design	   from	  both	   phase	  
and	   two	   exome	   sequencing	   experiments:	   1,526	   exome	   SNPs	   from	   60	   young	  
onset	   coeliac	   case	   samples	   captured	   by	   NimbleGen™	   exome	   microarray	   and	  
sequenced	   with	   Illumina	   GAIIx	   (76bp	   paired	   end	   multiplex	   sequencing)	   and	  
1,336	   SNPs	   highlighting	   interesting	   immune	   genes	   from	   four	   high	   coverage	  
exome	   resequenced	   samples	   (multiply	   affected	   (>4)	   individuals	   per	   family),	  
captured	  by	  NimbleGen™	  in-­‐solution	  capture	  and	  sequenced	  with	  Illumina	  GAIIx	  
76bp	  paired	  end	  sequencing.	  Chosen	  exome	  variants	  were	  missense	  mutations	  
in	   immune	   genes	   and	   all	   nonsense	   and	   frameshift	   mutations	   with	   an	   allele	  
frequency	   difference	   with	   1000G	   2010	   release	   CEU	   (Northern	   European	  
ancestry)	   data.	   The	   final	   exome	   SNP	   Immunochip	   dataset	   consisted	   of	   2,862	  
variants	  for	  genotyping.	  	  
From	  the	  most	  current	  coeliac	  fine	  mapping	  results,	  all	  SNPs	  reaching	  a	  p=10-­‐8	  
were	   extracted	   from	   the	   final	   immunochip	   dataset,	   totaling	   58	   variants	  
including	   the	   HLA	   high-­‐risk	   variant	   rs2187668.	   This	   dataset	   was	   used	   to	   test	  
genetic	  load	  of	  disease	  associated	  risk	  variants	  in	  coeliac	  individuals.	  	  
	  
4.5	  Results:	  Linkage	  analysis	  with	  Immunochip	  SNP	  markers	  
	  
	   4.5.1	  Sample	  and	  data	  quality	  control	  
	  
All	   analysis	   was	   performed	   with	   PLINK	   v1.07	   (Purcell,	   Neale	   et	   al.	   2007).	  
Polymorphic	   SNPs	   were	   selected	   by	   performing	   a	   Mendelian	   check	   and	  
removing	  individuals	  with	  an	  excess	  of	  mismatches	  i.e.	  those	  SNPs	  not	  inherited	  
by	   father	   or	   mother	   due	   to	   genotyping	   errors	   or	   erroneous	   assignment	   of	  
relative	  status	  in	  the	  pedigrees.	  Prior	  to	  this,	  all	  X-­‐linked	  and	  CNV	  tagging	  SNPs	  
were	   removed	   from	   the	   dataset.	   LD	   can	   inflate	   multipoint	   linkage	   analysis	  
results	   so	   LD	  pruning	  was	  performed	  on	   founders	  only	   to	   remove	  any	  bias.	  A	  
Hardy	  Weinberg	  equilibrium	  filter	  (HWE)	  of	  0.001	  and	  MAF	  of	  0.2	  was	  applied	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and	  SNPs	  were	  pruned	  using	  an	   r2	   threshold	  of	  0.2,	   leaving	  3,700	  markers	   for	  
linkage	  analysis.	  	  
One	   individual	   each	   from	   SDY	   and	   BRK	   family	   was	   removed	   due	   to	   excess	  
Mendelian	   errors.	   Clustering	   was	   performed	   based	   on	   IBS	   linkage	   in	   all	  
individuals	   to	   determine	   if	   familial	   samples	   clustered	   with	   control	   HapMap3	  
samples.	   All	   family	   samples	  were	  merged	  with	  HapMap3	   CEPH,	   CHB,	   JPT	   and	  
YRU	   samples	   and	   pairwise	   identical-­‐by-­‐sharing	   was	   calculated	   resulting	   in	  
overlapping	  clusters	  with	  HapMap3	  CEU	  samples.	  There	  was	  one	  major	  outlier	  
in	  the	  BRE	  family	  indicating	  mixed	  ethnicity.	  
	  
4.5.2	  Non-­‐parametric	  linkage	  analysis	  
	  
Subjects	   were	   classified	   as	   affected,	   unaffected	   or	   unknown	   affection	   status	  
according	   to	   pedigree	   records	   obtained	   by	   Professor	   Paul	   Ciclitira,	   Dr	   Susan	  
Neuhausen	  and	  us.	  Multipoint	  NPL	  analysis	  was	  performed	  with	  Merlin	  linkage	  
analysis	  software	  (Abecasis,	  Cherny	  et	  al.	  2002)	  based	  on	  the	  Kong	  and	  Cox	  LOD	  
score	  statistic	  comparing	  alleles	  shared	  IBD	  for	  all	  affected	  individuals	  (Kong	  and	  
Cox	   1997).	   To	   prove	   the	   hypothesis	   that	   rare	   variants	   with	   large	   effect	   size	  
result	   in	   large	   increases	   in	   allele	   sharing	   in	   families	   compared	   to	   common	  
variants	  of	  small	  effect	  size,	  an	  exponential	  model	  was	  selected.	  Under	  the	  NPL	  
null	  hypothesis	  that	  a	  locus	  is	  not	  linked	  to	  a	  susceptibility	  gene,	  the	  statistical	  
behaviour	  of	   the	  number	  of	   IBD	  alleles	  depends	  on	   their	   relationship	   to	   each	  
other,	  as	  determined	  by	  pedigree	  structure,	  and	  not	  on	  their	  disease	  status.	  For	  
a	   linked	   locus	   to	   contain	   a	   disease-­‐susceptibility	   gene	   there	   is	   an	   expected	  
increase	  in	  the	  number	  of	  IBD	  alleles	  among	  affected	  individuals,	  relative	  to	  null	  
expectation.	  The	  NPL	  statistic,	  or	  P	  value,	  reflects	  IBD	  alleles	  shared	  evaluating	  
non-­‐random	   segregation	   at	   chromosomal	   locations,	   which	   is	   reported	   here.	  
Furthermore	   the	   LOD	   scores	   reported	   here,	   proposed	   by	   Kong	   and	   Cox,	   is	  
maximized	   on	   a	   single	   parameter	  δ	   in	   the	   numerator	   based	   on	   the	   observed	  
genotypes,	   representing	   the	   degree	   of	   allele	   sharing	   amongst	   affected	  
individuals.	  Under	  the	  null,	  δ	  =	  0	  and	  the	  alternative	  δ	  >	  0	  corresponds	  to	  a	  high	  
degree	  of	  allele	  sharing	  (Nyholt	  2000).	  The	  score	  makes	  confidence	  comparisons	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amongst	   loci	   asymptotically	  and	   is	  an	  extension	  of	   the	  NPL	   statistic	   (Kruglyak,	  
Daly	  et	  al.	  1996).	  The	  LOD	  score	  differs	  in	  a	  parametric	  test	  because	  it	  is	  based	  
on	   the	   likelihoods	   of	   obtaining	   linkage	   given	   a	   set	   of	   assumptions	   in	   the	  
underlying	  model.	  	  
Because	   the	   interpretation	  of	   linkage	   results	   should	  be	  performed	   in	   terms	  of	  
the	  appropriate	  significance	  threshold	  on	  the	  pedigrees	  studied	  rather	  than	  the	  
observed	   statistics,	   maximum	   P	   values	   corresponding	   to	   the	   power	   of	   core	  
pedigrees	   to	   detect	   linkage	   was	   measured	   by	   running	   in-­‐silico	   simulations	  
assuming	  no	  locus	  heterogeneity.	  According	  to	  these	  simulations,	  BRE,	  BD,	  SDY,	  
FAM008,	   FAM063	  and	  FAM014	  showed	  sufficient	  power	   to	  produce	   linkage	  P	  
values	  of	  0.0001	  or	  more,	  determined	  by	  their	  maximum	  linkage	  P	  scores.	  A	  P	  of	  
0.0001	   is	   equivalent	   to	   a	   linkage	   LOD	   score	   of	   3.	   Table	   4.2	   shows	  maximum	  
linkage	  P	  values	  and	  size	  of	  linkage	  regions	  at	  P	  <	  0.01	  Mb.	  All	  linkage	  graphs	  are	  
in	  Appendix	  II.	  	  
	  
Table	  4.2:	  Summary	  of	  non-­‐parametric	  linkage	  results	  	  
	  
Family	  name	   Maximum	  
linkage	  p	  
Max	  observed	  
linkage	  p	  	  
Size	  of	  linkage	  
region	  at	  p	  <	  
0.01	  (Mb)	  





DA	   0.004	   0.005	   25.47	   6	  
BRK	   0.0013	   0.0011	   40.08	   3	  
BRE	   0.0004	   0.0004	   23.76	   1	  
HMN	   0.005	   0.005	   71.63	   3	  
BD	   0.0005	   0.05	   0	   0	  
BR	   0.002	   0.004	   46.04	   0	  
BUT	   0.0013	   0.003	   34.34	   0	  
SDY	   0.00002	   0.03	   0	   0	  
FAM008	   0.00001	   0.0002	   29.01	   0	  
FAM063	   0.0002	   0.0008	   52.42	   2	  
FAM014	   0.0002	   0.005	   26.98	   3	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Of	  the	  six	   families	   that	  had	  power	  of	  producing	  a	   linkage	  P	  value	  of	  10-­‐4,	  only	  
three	   had	   reached	   maximum	   observed	   linkage	   P	   values	   of	   10-­‐4	   across	   all	  
chromosomes:	   BRE,	   FAM008	   and	   FAM063.	   For	   the	   3700	  markers	   genotyped,	  
there	   was	   no	   evidence	   of	   linkage	   (P<0.01)	   between	   the	   marker	   SNPs	   or	   any	  
disease	  locus	  on	  any	  chromosome	  for	  families	  BD,	  SDY	  and	  H.	  	  	  
The	  highest	  maximum	  multipoint	  NPL	  LOD	  score	  was	  observed	  in	  BRE	  (NPL	  LOD	  
2.40)	   at	   chromosomal	   position	   5q33.3.	   The	   5q	   region	   has	   previously	   been	  
implicated	   in	   110	   Italian	   sib	   pairs	   and	   an	   independent	   set	   of	   Italian	   coeliac	  
families	  (Greco,	  Corazza	  et	  al.	  1998;	  Greco,	  Babron	  et	  al.	  2001),	  but	  no	  strength	  
of	  evidence	  was	  replicated	  in	  Finnish	  families	  (Liu,	  Juo	  et	  al.	  2002).	  However	  a	  
meta	  analysis	  of	  multiple	  European	  CD	  data	  established	  5q31-­‐33	  (CELIAC	  2)	  as	  a	  
significant	   linkage	   region	   (Babron,	   Nilsson	   et	   al.	   2003)	   highlighting	   increased	  
power	  effects	  when	  using	  meta	  datasets.	  A	  multipoint	  NPL	   LOD	   score	  of	  1.55	  
was	   observed	   for	   BUT	   at	   5q35.3,	   but	   no	   other	   families	   provided	   evidence	   of	  
linkage	  around	  this	  region.	  	  
BRK,	  BRE	  and	  FAM0063	  were	  the	  only	  families	  where	  LODs	  of	  >2	  were	  observed	  
at	  chromosomes	  2,	  4,	  5,	  6,	  7,	  9,	  11	  and	  19.	  The	  maximum	  observed	   linkage	  P	  
values	  for	  these	  families	  were	  0.001,	  0.0004	  and	  0.0008,	  respectively.	  For	  BRE,	  
the	  most	   significant	   LOD	  of	  2.41,	  outside	   the	  HLA,	  was	   to	  19p13.3;	   linkage	   to	  
19p13.1	  has	  previously	  been	  implicated	  in	  a	  Dutch	  sib-­‐pair	  family	  (Van	  Belzen,	  
Meijer	  et	  al.	  2003).	  Significant	  linkage	  on	  chromosome	  11p11	  was	  identified	  in	  
50	  UK	   coeliac	   families	   but	   here	   linkage	   in	   BRK	   and	   FAM063	  was	   identified	   at	  
11p15.5	   (King,	   Fraser	   et	   al.	   2001).	   Lower	   multipoint	   NPL	   LOD	   scores	   in	   the	  
CELIAC1	  locus	  on	  chromosome	  6p21.32,	  containing	  HLA	  class	  II	  molecules,	  were	  
observed	   in	   four	  out	  of	   the	  12	   families:	  2.5,	  1.2	  and	  1.71	  and	  1.5	   in	  BRE,	  BUT	  
and	  FAM008	  and	  HMN	  respectively.	  	  
Families	  with	  a	  low	  HLA	  risk	  were	  prioritised	  as	  potentially	  harbouring	  rare	  non-­‐
HLA	  high-­‐risk	  disease	  mutations.	  Figure	  4.2	   illustrates	   the	  number	  of	  different	  
HLA	  genotypes	   in	  familial	  cases	  and	  controls.	  46%	  of	  affected	   individuals	  were	  
HLA-­‐DQ2.5	   homozygote	   or	   heterozygote,	   and	   100%	   had	   at	   least	   one	   copy	   of	  
either	  DQ2.5	  or	  DQ8.	  No	  low	  risk	  HLA	  genotypes	  were	  observed	  in	  coeliac	  cases.	  
Overall	   74.5%	   (70/94)	   of	   unaffected	   individuals	   carried	   either	   HLA-­‐DQ2.5	   or	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HLA-­‐DQ8	   homozygous	   or	   heterozygous	   genotypes,	   which	   is	   larger	   than	   the	  
overall	   population	   (30%	   of	   general	   population	   carry	   DQ2.5/DQ8	   molecules).	  
Furthermore,	  of	  the	  74.5%	  DQ2.5/DQ8	  genotypes	  from	  unaffected	   individuals,	  
18.6%	  were	  from	  individuals	  who	  married	  into	  the	  family	  (13/70).	  	  
This	   information	   was	   of	   use	   to	   note	   why	   no	   linkage	   in	   the	   HLA	   region	   was	  
observed	   in	   8/12	   pedigrees.	   Firstly,	   it	   is	   important	   to	   understand	   what	   is	  
required	   for	   a	   family	   to	   be	   informative	   for	   linkage.	   For	   any	   linkage	   to	   be	  
observed,	  alleles	  have	  to	  be	  transmitted	  IBD	  on	  the	  shared	  chromosome	  in	  an	  
NPL	  model.	  Figure	  4.3	  illustrates	  the	  difference	  between	  alleles	  shared	  IBD	  and	  
IBS.	  In	  this	  scenario,	  when	  both	  siblings	  have	  a	  genotype	  of	  1,4,	  both	  type	  1	  and	  
type	  4	  alleles	  are	  IBD	  and	  IBS.	  When	  the	  second	  sibling	  has	  a	  genotype	  of	  2,1,	  
no	   IBD	   is	  present	  because	  one	   type	  1	  allele	   is	   inherited	   from	   the	  mother	  and	  
one	  is	  inherited	  from	  the	  father,	  so	  the	  ancestral	  source	  cannot	  be	  determined.	  	  
	  
Figure	   4.2:	   Graph	   of	   number	   of	   different	   HLA	   genotypes	   in	   affected	   and	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Figure	  4.3:	  Alleles	  shared	  IBD	  and	  IBS	  in	  sibling	  pairs	  when	  allele	  sharing	  differs	  
in	  second	  sibling,	  assuming	  the	  marker	  is	  unlinked	  to	  the	  disease	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Alleles	  shared	  IBD:	  1	  and	  4	   	   	  	  	  	  	  	  Allele	  shared	  IBD:	  no	  IBD	  present	  
Alleles	  shared	  IBS:	  1	  and	  4	   	   	  	  	  	  	  	  Allele	  shared	  IBS:	  1	   	  
	  
Adapted	   from	   Teare	   &	   Barrett	   (Teare	   and	   Barrett	   2005).	   First	   number	   is	   paternally	  
inherited	  allele;	  second	  number	  is	  maternally	  inherited	  allele.	  No	  inbreeding	  is	  allowed	  
for	  this	  situation	  to	  hold	  true.	  
	  
This	  example	  was	  extrapolated	  in	  all	  linkage	  pedigrees	  to	  concur	  why	  they	  were	  
not	   informative	   for	   linkage,	   using	   the	   HLA	   class	   II	   allele	   genotypes.	   As	   an	  
example,	   SDY	   family	   is	   illustrated	   in	   figure	   4.4	   and	   all	   HLA	   genotypes	   for	   11	  
remaining	   families	   are	   illustrated	   on	   the	   pedigrees	   in	   Figure	   1,	   Appendix	   I-­‐A.	  	  
For	   SDY	   a	   proportion	   of	   unaffected	   individuals	   also	   carry	   the	   DQ2.5	   risk	  
haplotype	   so	   it	   is	   hard	   to	   infer	   where	   the	   coeliac	   risk	   allele	   comes	   from.	   An	  
unaffected	   subject	   SDY9	   carries	   the	   DQ2.5	   allele,	   shared	   with	   5	   affected	  
members	   of	   the	   family.	   SDY10,	   the	   unaffected	   husband	   of	   SDY9,	   carries	   two	  
copies	  of	  the	  DQ2.5	  risk	  allele.	  Their	  offspring	  SDY29	  and	  SDY30	  both	  carry	  one	  
copy	   of	   the	   DQ2.5	   allele,	   which	   they	   have	   inherited	   from	   their	   unaffected	  
father.	   So	   the	  pedigree	  cannot	  be	  counted	  as	   informative	  because,	  given	   that	  
SDY10	   is	  homozygous	   for	  DQ2.5	  and	  SDY30	  and	  SDY29	  carry	  only	  one	  copy	  of	  
the	  allele,	  they	  can	  only	  have	  inherited	  them	  by	  this	  route.	  They	  both	  carry	  DQ8	  
on	   the	   other	   chromosome,	   inherited	   from	   the	   affected	  mother.	   The	   same	   is	  
true	  for	  SDY100	  and	  SDY20;	  since	  they	  are	  both	  homozygous	  for	  DQ2.5,	  one	  has	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to	  have	  been	  transmitted	  from	  the	  unaffected	  mother.	  This	  observation	  proves	  
transmission	  of	  risk	  alleles	   IBS	  rather	  than	  IBD,	  and	  hence	  why	  no	   linkage	  was	  
observed	  at	   the	  HLA	  region.	  Brett	  et	  al.	   (1999)	  also	  reported	  the	  same	  results	  
for	  family	  SDY,	  BRK	  AND	  H	  for	  HLA	  linkage	  (Brett,	  Yiannakou	  et	  al.	  1999).	  	  
	  




Red	  parental	  genotypes	  inferred	  from	  offspring	  genotypes.	  ‘X’	  denotes	  other	  genotype.	  
Third	  generation	  affected	  siblings	  all	  acquired	  DQ2.5	  risk	  allele	  from	  their	  father,	  SDY1.	  
Fourth	   generation	   transmissions	   are	   mostly	   IBS:	   DQ2.5	   alleles	   for	   SDY100,	   SDY17,	  
SDY20	  and	  SDY21	  cannot	  come	  from	  the	  same	  haplotype	  as	  the	  father,	  due	  to	  offspring	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4.5.3	  Analysis	  of	  exome	  variants	  in	  linkage	  peaks	  	  
	  
To	  search	  for	  rare	  coding	  variants	  in	  linkage	  regions	  with	  a	  P>0.01,	  the	  following	  
filters	  were	  applied	  to	  individual	  exomes	  from	  linkage	  families:	  i)	  MAF	  <0.5%,	  ii)	  
only	   LoF	   variants,	   iii)	   regions	   without	   duplications.	   In	   total	   18	   rare	  
nonsynonymous	   variants	   from	   individual	   familial	   exome	   sequencing	   datasets	  
were	  identified	  in	  linkage	  regions,	  summarised	  in	  table	  4.3.	  No	  rare	  indels	  were	  
observed	  under	  linkage	  peaks.	  To	  test	  whether	  the	  identified	  SNPs	  were	  present	  
on	  the	  same	  haplotype	  in	  all	  affected	  members	  of	  the	  linkage	  pedigree,	  all	  SNPs	  
were	  Sanger	  sequenced	  in	  every	  affected	  member	  of	  the	  family.	  Ten	  out	  of	  18	  
SNPs	   were	   validated	   in	   all	   affected	   individuals	   from	   five	   pedigrees,	   so	   were	  
present	   on	   the	   same	   ancestral	   haplotype.	   The	   10	   genes	   harbouring	   these	  
validated	   SNPs	  were	   selected	   for	   candidate	   gene	   resequencing,	   together	  with	  
17	  genes	  from	  Chapter	  3.	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Table	  4.3:	  Non-­‐synonymous	  SNPs	  located	  in	  linkage	  regions	  (p	  <	  0.01)	  
	  






BRK	   FAM179A	   nsSNP	   2:29259543	   c.2555T>C	   -­‐	   rs72788155/
missense	  
2/6	  
BRK	   NLRC4	   nsSNP	   2:32474767	   c.2166T>G	   Probably	  
damaging	  
-­‐	   6/6	  
FAM063	   EPAS1	   nsSNP	   2:46607609	   c.1798G>A	   Possibly	  
damaging	  
-­‐	   7/7	  
FAM063	   STON1	   nsSNP	   2:48809609	   c.1837C>G	   Probably	  
damaging	  
-­‐	   2/7	  





FAM014	   IQGAP2	   nsSNP	   5:75969341	   c.3136G>T	   -­‐	   -­‐	   1/6	  
FAM014	   DMGDH	   nsSNP	   5:78293933	   c.2573A>C	   Probably	  
damaging	  
-­‐	   4/6	  
HMN	   KIF13A	   nsSNP	   6:17826085	   c.1700A>C	   -­‐	   -­‐	   5/5	  





HMN	   GRM4	   nsSNP	   6:34101193	   c.81G>A	   Benign	   -­‐	   5/5	  
HMN	   TULP1	   nsSNP	   6:35471412	   c.1247G>A	   Probably	  
damaging	  
-­‐	   5/5	  





DA	   ABCA9	   nsSNP	   17:67039672	   c.758C>T	   Possibly	  
damaging	  
-­‐	   4/4	  
DA	   KCNJ16	   nsSNP	   17:68129412	   c.1184A>G	   Benign	   -­‐	   4/4	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DA	   SDK2	   nsSNP	   17:71431712	   c.1072C>T	   -­‐	   -­‐	   1/4	  	  
FAM014	   MALT1	   nsSNP	   18:56402558	   c.1567G>A	   Probably	  
damaging	  
-­‐	   6/6	  
DA	   ACOT8	   nsSNP	   20:44470575	   c.862C>T	   Probably	  
damaging	  
-­‐	   4/4	  
DA	   EYA2	   nsSNP	   20:45808514	   c.1267C>T	   Possibly	  
damaging	  
-­‐	   1/4	  	  
	  
Chromosome	  positions	  correspond	  to	  the	  same	  linkage	  regions	  in	  each	  family	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4.6	  Results:	  Exome	  SNP	  case	  control	  association	  	  
	  
A	   Fisher’s	   exact	   test	   was	   conducted	   to	   generate	   a	   P	   value	   of	   significance	  
comparing	   exome	   SNPs	   between	   7,728	   UK	   coeliac	   cases	   and	   8,274	   controls.	  
Prior	   to	   any	   analysis,	   very	   low	   call	   rate	   variants	   were	   removed.	   Illumina	  
GenomeStudio	   GenTrain2.0	   algorithm	   was	   used	   to	   cluster	   all	   samples,	   and	  
clusters	   were	   manually	   re-­‐adjusted	   or	   excluded	   for	   variants	   with	   low	   quality	  
statistics	  (call	  rate	  <99.5%,	   low	  GenCall	  score,	  and	  high-­‐intensity	  no-­‐calls).	  This	  
left	  1,932	  out	  of	  2,862	  variants	  passing	  quality	  control	  for	  the	  final	  association	  
dataset.	   The	   7,728	   coeliac	   case	   and	   8,274	   control	   dataset	   had	   previously	  
undergone	   quality	   control	   steps	   including	   exclusion	   for	   call	   rate	   <99.5%,	  
incompatible	   gender,	   duplicates,	   first	   or	   second	   degree	   relatives	   and	   ethnic	  
outliers	   (identified	  by	  multi-­‐dimensional	   scaling	  plots	  of	   samples	  merged	  with	  
HapMap3	  data)	  (Trynka,	  Hunt	  et	  al.	  2011).	  	  
In	  the	  final	  association	  analysis,	  SNPs	  with	  MAF	  >5%	  and	  known	  HLA	  SNPs	  were	  
removed,	   leaving	   seven	  SNPs	   from	   five	   loci	   that	   showed	  association	  at	   P<10-­‐5	  
(Table	  4.4).	  Odds	   ratios	   ranged	   from	  0.848	   to	  1.583	   for	  all	   seven	  associations.	  
Five	  SNPs	  (P<10-­‐5	  -­‐	  P<10-­‐7)	  did	  not	  reside	  in	  any	  genes	  exhibiting	  good	  functional	  
candidacy	  for	  CD.	  SNP	  imm_15_77018533	  is	  in	  a	  non-­‐coding	  region	  of	  SCAPER;	  
this	   gene	   is	   only	   expressed	   in	   the	  pancreas.	   Two	   SNPs	  on	   the	  X	   chromosome	  
(vh_X_5821532	   and	   vh_x_5831768)	   in	   NLGN4X,	   belonging	   to	   a	   family	   of	  
neuronal	   cell	   surface	   proteins,	   and	   imm_3_46561626	   in	   LLRC2	   also	   does	   not	  
have	  any	  type	  of	  immune	  mediated	  disease	  function.	  SNP	  rs1800562	  in	  the	  HFE	  
gene	   is	   just	   outside	   of	   the	   HLA	   region	   on	   6p22.2,	   similar	   to	   two	   associations	  
reaching	  P<5	  x	  10-­‐8:	  vh_6_24672519	  (P=2	  x	  10-­‐14	  OR	  =	  1.6)	  and	  vh_6_24684610	  
(P=1.8x10-­‐13	   OR	   =	   1.5)	   (Figure	   4.5).	   A	   conditional	   logistic	   regression	   was	  
performed	  on	  these	  SNPs	  to	  test	  for	  independent	  associations.	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Table	  4.4:	  Fisher	  Exact	  test	  results	  for	  rare	  exome	  SNPs	  in	  coeliac	  UK	  dataset	  at	  p	  <	  0.01	  	  
	  
Chr	   SNP	   Position	   Allele	  1	   F_A*	   F_U**	   Allele	  2	   P	  value	   OR	  
1	   imm_1_159289698	   159289698	   C	   0.007246	   0.004774	   T	   0.004532	   1.522	  
2	   imm_2_62081517	   62081517	   T	   0.02206	   0.01777	   C	   0.006349	   1.247	  
2	   vh_2_233605747	   233605747	   A	   0.003947	   0.006164	   G	   0.005832	   0.6389	  
3	   imm_3_46561626	   46561626	   C	   0.09181	   0.07638	   T	   6.79E-­‐07	   1.222	  
4	   imm_4_103165415	   103165415	   A	   0.06515	   0.05584	   G	   0.0005054	   1.178	  
6	   vh_6_24672519	   24672519	   G	   0.04497	   0.02889	   A	   2.04E-­‐14	   1.583	  
6	   vh_6_24684610	   24684610	   T	   0.04587	   0.03015	   C	   1.82E-­‐13	   1.546	  
6	   rs1800562	   26201120	   A	   0.06308	   0.07766	   G	   3.58E-­‐07	   0.7996	  
6	   imm_6_83723885	   83723885	   G	   0.01928	   0.02387	   A	   0.005005	   0.804	  
6	   vh_6_84164919	   84164919	   A	   0.01928	   0.02532	   T	   0.0002803	   0.7567	  
7	   imm_7_22737681	   22737681	   T	   0.0187	   0.02302	   C	   0.007012	   0.8085	  
8	   vh_8_38184403	   38184403	   G	   0.004076	   0.006406	   C	   0.004221	   0.6348	  
9	   imm_9_35368401	   35368401	   T	   0.01579	   0.01994	   C	   0.00538	   0.7883	  
10	   imm_10_101995610	   101995610	   T	   0.01766	   0.01402	   C	   0.00922	   1.265	  
10	   imm_10_112714563	   112714563	   T	   0.01792	   0.02266	   C	   0.002957	   0.787	  
11	   vh_11_56267736	   56267736	   G	   0.08534	   0.09439	   A	   0.004886	   0.8951	  
11	   imm_11_66374366	   66374366	   A	   0.01792	   0.01384	   G	   0.003545	   1.3	  
11	   imm_11_127837472	   127837472	   A	   0.01754	   0.0223	   G	   0.002383	   0.7827	  
15	   imm_15_77018533	   77018533	   C	   0.1455	   0.1302	   T	   7.41E-­‐05	   1.137	  
19	   vh_19_7114065	   7114065	   A	   0.07078	   0.07856	   G	   0.008376	   0.8935	  
23	   imm_X_140860	   140860	   T	   0.2325	   0.2158	   C	   0.002175	   1.101	  
23	   imm_X_219362	   219362	   A	   0.1469	   0.1328	   G	   0.001624	   1.124	  
23	   imm_X_1388421	   1388421	   T	   0.05593	   0.04828	   G	   0.006455	   1.168	  
23	   imm_X_1427404	   1427404	   C	   0.09083	   0.07947	   A	   0.001425	   1.157	  
23	   imm_X_1457644	   1457644	   C	   0.1618	   0.149	   G	   0.006401	   1.103	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23	   vh_X_5821532	   5821532	   A	   0.1402	   0.1613	   G	   2.87E-­‐05	   0.848	  
23	   vh_X_5831786	   5831786	   A	   0.1068	   0.0892	   G	   3.03E-­‐06	   1.221	  
	  
SNPs	  in	  HLA	  region	  were	  removed	  *Minor	  allele	  frequency	  in	  cases	  **	  Minor	  allele	  frequency	  in	  controls	  (as	  reported	  in	  PLINK	  v1.07)	  
OR	  =	  odds	  ratio
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Figure	  4.5:	  Q-­‐Q	  plot	  of	  Fisher	  Exact	  test	  P	  values	  
	  
	  
SNPs	  with	  MAF	   >5%	   in	   known	   disease	   loci	  were	   removed.	   Two	   SNPs	   deviating	   from	  
expected	   p	   values	   are	   vh_6_24672519	   (P=2	   x	   10-­‐14	   OR	   =	   1.6)	   and	   vh_6_24684610	  
(P=1.8x10-­‐13	  OR	  =	  1.5).	  	  
	  
4.6.1	  Conditional	  logistic	  regression	  
	  
In	  the	  UK	  only	  dataset,	  the	  r2	  and	  D’	  values	  for	  vh_6_24672519	  were	  0.013	  and	  
0.400,	  and	   for	  vh_6_24684610	   the	  values	  were	  0.013	  and	  0.413,	   respectively,	  
suggesting	  independent	  effects	  of	  both	  SNPs	  on	  chromosome	  6.	  Due	  to	  high	  LD	  
in	  the	  HLA	  region	  on	  chromosome	  6	  (close	  to	  where	  both	  SNPs	  are	  located),	  a	  
conditional	   logistic	   regression	  was	   performed	   to	   test	   for	   independent	   effects.	  
The	   regression	   analysis	   result	   showed	   that	   the	   HLA-­‐DQ2.5	   SNP	   rs2187668,	  
which	  has	  the	  largest	  effect	  in	  CD,	  accounts	  for	  all	  significance,	  so	  neither	  SNP	  is	  
independently	  associated	  with	  CD	  risk	  (Table	  4.5).	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Table	   4.5:	   Results	   for	   conditional	   logistic	   regression	   for	   two	   associated	   SNPs,	  
vh_6_24672519	  and	  vh_6_24684610	  
	  
HLA	  SNP	   r2	   D’	   Associated	  SNP	   OR	   P	  value	  
rs2395182	   0.001	   0.350	   vh_6_24672519	   1.527	   1.29E-­‐11	  
	   0.001	   0.390	   vh_6_24684610	   1.484	   1.42E-­‐10	  
rs2187668	   0.011	   0.404	   vh_6_24672519	   0.9352	   0.3758	  
	   0.011	   0.387	   vh_6_24684610	   0.9248	   0.2942	  
rs7775228	   0.002	   0.600	   vh_6_24672519	   1.64	   1.46E-­‐15	  
	   0.002	   0.548	   vh_6_24684610	   1.597	   1.55E-­‐14	  
rs4713586	   0.000	   0.617	   vh_6_24672519	   1.585	   1.01E-­‐13	  
	   0.000	   0.579	   vh_6_24684610	   1.55	   6.58E-­‐13	  
rs7454108	   0.000	   0.178	   vh_6_24672519	   1.581	   1.52E-­‐13	  
	   0.000	   0.148	   vh_6_24684610	   1.546	   9.24E-­‐13	  
	  
OR	  =	  odds	  ratio.	  r2	  and	  D’	  are	  measures	  of	  LD;	  complete	  and	  perfect	  LD	  is	  when	  D’	  =	  1	  
and	   r2	   =	   1	   i.e.	   two	   SNPs	   are	   co-­‐inherited	   100%	   of	   the	   time,	   respective	   of	   allele	  
frequencies,	   e.g.	   r2	   will	   only	   be	   1	   if	   there	   are	   2/4	   possible	   haplotypes	   but	   allele	  
frequencies	  are	  the	  same.	  	  
	  
4.7	  Results:	  Current	  coeliac	  associated	  loci	  contribution	  in	  coeliac	  individuals	  	  
	  
57	   independent	  non-­‐HLA	  SNPs	  associated	  with	  CD	   risk	  were	   subjected	   to	  SNP	  
score	  analysis	  using	  a	  SNP	  scoring	  algorithm	   in	  PLINK	   (v1.07).	   	  The	  score	   itself	  
was	  calculated	  based	  on	  the	  logarithm	  of	  allelic	  odds	  ratios	  to	  identify	  whether	  
certain	  individuals	  contained	  more	  of	  a	  set	  of	  associated	  variants.	  This	  provided	  
a	  quantitative	  measure	  of	   genetic	   load	   in	   coeliac	   cases	   compared	   to	   controls.	  	  
The	   analysis	   compared	   all	   UK	   coeliacs	   (7,728),	   all	   UK	   controls	   (8,274),	   all	  
coeliacs	  from	  large	  pedigrees	  (112)	  and	  pedigree	  related	  controls	  (129).	  Further	  
analysis	   compared	   SNP	   scores	   between	   groups	   of	   cases	   stratified	   against	   the	  
number	  of	  affected	  coeliacs	  per	  family.	  This	  analysis	  used	  UK	  coeliac	  cases	  for	  
which	   family	   information	   was	   available	   plus	   the	   112	   coeliacs	   from	   large	  
pedigrees.	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Box	  and	  whisker	  plots	  were	  produced	  in	  R	  (version	  2.13)	  illustrating	  SNP	  scores	  
for	  57	  coeliac	  associated	   loci	  and	  58	  coeliac	  associated	   loci	   including	   the	  HLA-­‐
DQ2.5	  SNP	  rs2187668	  (Figure	  4.6).	  A	  Wilcoxon	  rank	  test	  between	  all	  cases	  and	  
controls,	   assuming	   the	   data	   are	   independent	   and	   come	   from	   the	   same	  
population,	   highlighted	   a	   significant	   difference	   in	   SNP	   score	   across	   all	   loci	  
(Wilcoxon	   p<2	   x	   10-­‐16).	   The	   SNP	   score	  was	  much	   closer	   to	   the	  median	   for	   all	  
groups	  without	  rs2167668,	  but	  the	  P	  value	  remained	  the	  same	  (Wilcoxon	  p<2	  x	  
10-­‐16).	  A	  modest	  positive	  correlation	  in	  box	  plot	  medians	  between	  the	  number	  
of	  coeliac	  individuals	  per	  family	  and	  SNP	  score	  was	  observed,	  more	  so	  with	  the	  
inclusion	  of	   rs2187668	   (Figure	  4.7).	  A	   significant	  Kruskal-­‐Wallis	   test	  P	   value	  of	  
1.507-­‐11	   confirmed	   this	   observation. Here, a	   non-­‐parametric	   test	   assumes	  
independent	   groups,	   hence	  was	   chosen	   over	   a	   parametric	   test	   i.e.	   an	   Anova.	  
Analysis	  with	  57	  SNPs	  only	  reduces	  the	  Kruskal-­‐Wallis	  p	  value	  to	  3.03-­‐05	  and	  SNP	  
scores	   have	   a	   larger	   distribution	   around	   the	   median.	   Interestingly,	   the	   SNP	  
score	   for	   HLA-­‐DQ2.5	   SNP	   rs2187668	   on	   its	   own	   is	   increased	   when	   there	   are	  
more	  than	  four	  affected	  individuals	  in	  a	  family	  (Figure	  4.8).	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Figure	   4.6:	   SNP	   score	   for	   57	   coeliac	   risk	   loci,	   with	   and	   without	   HLA	   SNP	  
rs2187668	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Figure	  4.7:	  SNP	  score	  for	  57	  (58	  with	  HLA	  SNP	  rs2187668)	  coeliac	  risk	  loci	  
stratified	  against	  number	  of	  affected	  individuals	  per	  family	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Figure	  4.8:	  SNP	  score	  for	  HLA	  DQ2.5	  rs2187668	  alone	  vs.	  number	  of	  affected	  




4.8	  Chapter	  Discussion	  	  
	  
The	   content	   in	   this	   chapter	   used	  3,700	  post	   quality	   control	  markers	   from	   the	  
Immunochip	  dataset	   to	   compute	  NPL	   linkage	  analysis	   in	   12	   coeliac	  pedigrees,	  
1932	  post	  quality	  control	  exonic	  SNPs	  for	  a	  case	  control	  association	  test	  and	  58	  
coeliac	  associated	  SNPs	  for	  gene	  dose	  analysis.	  	  
The	   hopeful	   outcome	   of	   any	   case	   control	   association	   study	   is	   to	   find	   highly	  
associated	   SNPs	   in	   disease	   cases	   when	   compared	   to	   matched	   controls.	   The	  
decision	  to	  put	  exonic	  SNPs	  on	  the	  Immunochip	  array	  was	  to	  give	  early	  insight	  
of	  any	  rare	  causal	  mutations	  by	  testing	  them	  in	  thousands	  of	  cases	  and	  controls.	  
A	   normal	   GWAS	   array	   has	   polymorphic	   SNPs	   spanning	   the	   entire	   genome;	  
Immunochip	   contained	   custom	   content	   of	   which	   contained	   1,932	   SNPs	   (post	  
quality	   control)	   from	   very	   early	   exome	   data	   (aligned	   to	   reference	   human	  
genome	   build	   36)	   out	   of	   196,524	   variant	   markers	   (passing	   quality	   control	   at	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Illumina).	   A	   Fisher	   exact	   test	  was	   applied	   to	   search	   all	   loci,	   with	   exonic	   SNPs	  
PGWAS	  between	  p<10
-­‐5	  and	  p<10-­‐8,	  for	  genes	  with	  good	  functional	  candidacy	  for	  
CD.	  No	  exome	  SNPs	  with	  roles	   in	  CD,	  or	  any	  overlapping	  autoimmune	  disease	  
(Chapter	   1,	   Table	   1.1)	   reached	   significance	   between	   p<10-­‐5	   and	   p<10-­‐8	   in	   the	  
Immunochip	   dataset	   in	   7,728	   coeliac	   cases	   and	   8,274	   UK	   controls.	   	   The	   top	  
SNPs,	   vh_6_24672519	  and	  vh_6_24684610	  mapped	   to	  a	  non-­‐coding	   region	  of	  
ACOT13	   on	   chromosome	   6p22.3,	   just	   outside	   the	   MHC.	   Conditional	   logistic	  
regression	  confirmed	  non-­‐independent	  effects	  of	  both	  SNPs	  from	  the	  strongest	  
HLA	   DQ2.5	   SNP,	   rs2187668.	   Significantly,	   these	   SNPs	   were	   chosen	   from	   very	  
early	   pilot	   data;	   some	  early	   analysis	   flagging	   139	   exome	   SNPs	   present	   on	   the	  
Immunochip	   found	   43%	   to	   be	   false	   positive,	   and	   approximately	   a	   third	   of	  
possible	   risk	   variants	  were	   not	   genotyped	   after	   stringent	   quality	   control.	   It	   is	  
fair	  to	  conclude	  that	  due	  to	  this	  high	  false	  positive	  rate	  no	  real	  association	  was	  
found	   in	   the	   exome	   dataset.	   In	   spite	   of	   no	   significant	   association	   result,	   the	  
Immunochip	   dataset	   proved	   invaluable	   in	   confirming	   coeliac	   pedigree	  
relationships.	  Pedigree	  structures	  were	  confirmed	  by	  applying	  PLINK	  segmental	  
sharing	  methods.	  A	  simple	  pairwise	  IBD	  estimation	  using	  SNP	  by	  SNP	  identity	  by	  
state	  sharing	  has	  a	  sensitivity	  to	  detect	  only	  down	  to	  1st	  cousin	  relationships	  (pi-­‐
hat=12.5%	   sharing,	   3	   meioses	   separation)	   but	   PLINK	   segmental	   sharing	   can	  
identify	   individuals	   separated	   by	   6	   meioses	   or	   more.	   	   This	   validated	  
relationships	  and	  those	  with	  disconcordant	  pi-­‐hat	  values	  according	  to	  pedigree	  
structure	  were	  removed.	  	  
Combining	  linkage	  analysis	  with	  exome	  sequencing	  data	  was	  a	  strategy	  chosen	  
to	  pinpoint	  causal	  functional	  variants	  in	  regions	  where	  excess	  allele	  sharing	  was	  
evident;	   model	   free	   linkage	   was	   applied	   to	   identify	   IBD	   alleles	   and	   any	  
ambiguous	   evidence	   of	   linkage	   containing	   false	   positive	   loci	   was	   excluded	   as	  
only	  variants	  under	  the	  linkage	  peak	  were	  analysed.	  Linkage	  analysis	  in	  families	  
needs	  to	  be	  highly	  powered	  in	  order	  for	  significant	  LOD	  scores	  to	  be	  produced	  
and	  this	  was	  addressed	  by	  using	  multigenerational	  families	   instead	  of	  sib-­‐pairs	  
due	   to	   evidence	  of	   the	   latter	   being	  underpowered	   in	   previous	   coeliac	   studies	  
(Clot,	   Fulchignoni-­‐Lataud	   et	   al.	   1999;	   Greco,	   Babron	   et	   al.	   2001).	   One	   would	  
expect	   that	   the	   disease	   trait	   would	   have	   direct	   correspondence	   with	   the	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underlying	  alleles	  for	  the	  genotyped	  SNPs,	  as	  they	  were	  chosen	  from	  immuno-­‐
biologically	  relevant	  loci,	  and	  if	  disease	  risk	  were	  due	  to	  a	  rare	  variant	  then	  one	  
would	  expect	  to	  see	  that	  affected	  individuals	  would	  tend	  to	  inherit	  the	  rare	  risk	  
alleles	  from	  the	  same	  ancestral	  source.	  Ng	  et	  al.	  importantly	  pointed	  out	  in	  one	  
of	   the	   earliest	   exome	   sequencing	   studies	   that	   the	   large	   number	   of	   private	  
mutations	  in	  a	  single	  exome	  is	  a	  caveat	  when	  trying	  to	  identify	  causal	  variant(s).	  
They	   applied	   intersection	   filtering	   in	   individual	   exomes	   with	   a	   monogenic	  
disorder,	   Freeman	   Sheldon	   Syndrome,	   to	   identify	   a	   single	   gene,	   MYH3,	  
containing	   variants	   in	   multiple	   cases	   (Ng,	   Turner	   et	   al.	   2009).	   Their	   most	  
important	  finding	  was	  rare	  causal	  nonsynonymous	  variants	  were	  shared	  on	  the	  
same	   haplotype	   amongst	   affected	   individuals,	   proving	   that	   an	   exome	  
sequencing	  study	  can	  serve	  as	  a	  genome	  wide	  scan.	  The	   linkage	  method	  here	  
was	  to	  identify	  those	  shared	  haplotypes	  possibly	  harbouring	  exome	  variants.	  
The	   distribution	   of	   HLA	   genotypes	   in	   CD	   cases	   and	   controls	   made	   the	  
grandparental	   origins	   of	   alleles	   unclear,	   hence	   evidence	   of	   linkage	   was	   only	  
observed	   in	   three	   families.	   For	   the	   majority	   of	   pedigrees,	   coeliac-­‐associated	  
common	   HLA	   alleles,	   required	   for	   the	   HLA-­‐DQ2.5	   and	   DQ8	   genotypes,	   from	  
members	   marrying	   into	   the	   family	   resulted	   in	   uninformative	   pedigrees	   for	  
linkage,	  by	  way	  of	  being	  IBS	  rather	  than	  IBD.	  So,	  although	  the	  power	  issue	  can	  
be	   explained	   in	   terms	   of	   HLA	   linkage,	   it	   did	   not	   deter	   from	   using	   the	   same	  
pedigrees	  for	  the	  purpose	  of	  the	  aims	  in	  this	  chapter.	  Furthermore,	  replication	  
of	  HLA	   linkage	  has	  been	  unsuccessful	   in	  other	  coeliac	   linkage	  studies	  due	  to	  a	  
lack	   of	   distinction	   between	   alleles	   IBD	   and	   IBS,	   low	   marker	   density	   and	   no	  
differences	   in	   inheritance	  patterns	  between	  affected	  and	  unaffected	  members	  
(Eller,	  Vardi	  et	  al.	  2006;	  Vidal,	  Borg	  et	  al.	  2009).	   In	   support	  of	   the	  LOD	  scores	  
obtained	   here,	   previous	   linkage	   studies	   using	   families	   provided	   by	   Professor	  
Paul	  Ciclitira	  reported	  maximum	  LOD	  scores	  of	  1.9	  at	  10q23.1	  and	  16q23.3	  and	  
1.5	   at	   11p11	   (King,	   Yiannakou	   et	   al.	   2000),	   which	   increased	   to	   2.6	   when	   an	  
additional	   34	   families	   were	   included,	   using	   microsatellite	   markers,	   which	  
remain	  highly	   informative	  measures	  of	  associating	   linkage	  with	  disease	  due	  to	  
their	   greater	   allelic	   and	  haplotype	  diversity.	  Nowadays,	   a	   SNP	  based	   scan	   is	   a	  
more	  practical	  approach,	  but	  here	  linkage	  was	  attempted	  across	  a	  set	  of	  GWAS-­‐
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risk	   associated	  markers	   and	  essentially	   the	  186	   loci	   on	   the	   Immunochip	   array	  
did	  not	  offer	  full	  coverage	  of	  the	  genome.	  Given	  that,	  suggestive	  linkage	  (P=10-­‐
4)	  was	  detected	  in	  BRE,	  BRK	  and	  FAM0063	  at,	  or	  close	  to,	  previously	  implicated	  
non-­‐HLA	   CD	   linkage	   regions	   5q33.3,	   19p31.1	   and	   11p11,	   respectively.	  
Importantly,	  the	  linkage	  method	  applied	  here	  was	  another	  strategy	  to	  decrease	  
the	   abundance	   of	   variants	   in	   the	   exome	   sequencing	   data,	   however	   having	  
larger,	  extensive	   families	  and	  more	  exomes	   to	   search	   in	  would	  have	  provided	  
the	  power	  required	  for	  a	  more	  definitive	  result.	  A	  recent	  study	  by	  David	  Kelsell	  
(personal	   communication	   at	   the	   Blizard	   Institute)	   identified	   that	   55%	   of	   44	  
exomes	   from	   affected	   atopic	   eczema	   families	   have	  mutations	   in	   FLG,	   a	   gene	  
largely	   associated	   with	   this	   phenotype.	   This	   result	   was	   obtained	   by	   whole	  
exome	  sequencing	  of	  all	  members	  of	   the	  pedigrees,	   and	  a	  highly	   significant	  P	  
value,	  comparing	  FLG	  mutations	   in	  cases	  and	  controls	   (6	  x	  10-­‐11),	  supports	  the	  
advantage	  of	  an	  extensive	  exome	  dataset.	  	  	  
Excess	   HLA	   risk	   allele	   types	   identified	   in	   pedigrees	   was	   supported	   by	   genetic	  
load	  analysis	   in	  affected	   individuals.	  An	   increase	   in	   SNP	   scores	  was	  evident	   in	  
familial	  cases	  compared	  to	  all	  population	  controls,	  especially	  as	  the	  number	  of	  
affected	   individuals	   per	   family	   increased.	  However,	   the	  HLA-­‐DQ2.5	   rs2167668	  
SNP	  was	  probably	  the	  driving	  force	  of	  this	  increase,	  with	  the	  remaining	  57	  non-­‐
HLA	  loci	  having	  low	  additive	  scores	  overall,	  as	  highlighted	  when	  HLA-­‐DQ2.5	  was	  
analysed	  alone.	  This	  substantiates	  known	  gene	  dosage	  effects	  of	  HLA	  alleles	  in	  
CD	   individuals	   (Murray,	  Moore	  et	  al.	  2007)	  particularly	  the	  DQ2.5	  gene,	  which	  
has	   the	   largest	   odds	   ratio	   (OR=8)	   compared	   to	   57	   GWAS	   risk	   loci	   (highest	   to	  
lowest	  OR’s	  =	  1.70-­‐0.71).	  	  	  
Key	  to	  the	  aim	  of	  applying	  linkage	  was	  to	  recognize	  that	  only	  a	  few	  families	  in	  a	  
sample	  contribute	  significantly	  to	  a	  linkage	  signal,	  so	  a	  search	  for	  mutations	  can	  
be	  targeted	  to	  a	  small	  number	  of	  families.	  With	  that	   in	  mind,	  the	  analysis	  was	  
successful	   in	   identifying	   shared	   chromosomal	   regions,	   and	   to	   complete	   the	  
candidate	  gene	  list,	  exome	  variants	  under	  linkage	  peaks	  reaching	  LOD	  scores	  >1	  
were	   assessed.	   The	   SNVs	   in	   candidate	   have	   shown	   to	   be	   inherited	   IBD	   in	   all	  
affected	  members	  of	  the	  pedigrees	  by	  the	   linkage	  test	  and	  are	  present	  on	  the	  
same	   haplotype,	   as	   confirmed	   by	   Sanger	   sequencing.	   Gene	   selection	   for	  
	   148	  
targeted	   resequencing	   was	   based	   on,	   in	   order	   of	   priority,	   validation	   in	   all	  
affected	  individuals,	  cDNA	  size	  and	  known	  immune	  function	  	  (Table	  4.6).	  
	  
Table	   4.6:	   Candidate	   genes	   from	   linkage	   analysis	   selected	   for	   targeted	   gene	  
resequencing	  
	  
Gene	   cDNA	   size	  
(bp)	  
No.	   of	  
exons	  
Known	  immune?	   Validated	   true	  
positive	  in	  all	  cases?	  
NLRC4	   3,581	   10	   No	   Yes	  
EPAS1	   5,160	   16	   Yes	   Yes	  
ARHGAP25	   2,979	   11	   No	   Yes	  
GRM4	   3,879	   10	   No	   Yes	  
TULP1	   2,162	   15	   Yes	   Yes	  
KCNJ16	   4,002	   5	   No	   Yes	  
MALT1	   8,789	   17	   Yes	   Yes	  
ACOT8	   1,168	   6	   No	   Yes	  
	  
	  
4.9	  Chapter	  Conclusions	  
	  
The	  points	  below	  conclude	  the	  findings	  from	  the	  research	  in	  this	  chapter:	  
1. Linkage	   peaks	   with	   LOD	   scores	   >1	   were	   observed	   across	   12	   coeliac	  
pedigrees	  using	  NPL	  analysis.	  	  
2. No	   significant	   associations	  were	   found	  with	   1,932	   post	   quality	   filtered	  
exonic	   SNPs	   selected	   from	   the	   exome	   sequencing	   dataset	   (phase	   one	  
and	  two).	  
3. Excess	  HLA	  risk	  allele	  types	  were	  identified	  in	  12	  coeliac	  pedigrees	  and	  in	  
individuals	  where	  >4	  individuals	  in	  the	  family	  has	  the	  disease.	  	  
4. Eight	  genes	   from	  the	   linkage	  analysis,	  with	  variants	   shown	  to	  occur	  on	  
the	   same	  haplotype	   in	   the	   tested	   family,	   have	  been	   taken	   forward	   for	  
candidate	  gene	  resequencing	  (Chapter	  5).	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5.1	  Introduction	  
	  
The	  content	  in	  this	  chapter	  describes	  simultaneous	  amplicon	  sequencing-­‐based	  
variant	  discovery	  and	  genotyping	  for	  coding	  exons	  in	  24	  exome-­‐candidate	  genes	  
in	   2,304	   UK	   coeliac	   cases	   and	   2,304	  matching	   controls.	   This	   final	   project	   is	   a	  
follow-­‐up	  study	  of	  candidate	  genes	  chosen	  from	  shared	  exome	  variant	  analysis	  
in	   familial	   exomes	   (Chapter	   3),	   variant	   segregation	   analysis	   from	  
multigenerational	   families	   (Chapter	   3),	   an	   aggregate	   gene-­‐based	   test	   for	   rare	  
variants	  (Chapter	  3)	  and	  non-­‐parametric	  linkage	  analysis	  (Chapter	  4).	  	  
Recent	   large-­‐scale	   human	   sequencing	   studies	   have	   revealed	   an	   abundance	   of	  
rare	  variants	  (defined	  as	  MAF	  <0.5%)	  that	  are	  geographically	  localized	  and	  likely	  
to	   have	   deleterious	   functional	   consequences	   compared	   to	   their	   common	  
counterparts.	   A	   recent	   study	   resequenced	   202	   genes	   in	   14,002	   people	   and	  
found	  95%	  of	   coding	   variants	   to	  be	   rare	  of	  which	  74%	  were	  observed	   in	  only	  
one	   or	   two	   people	   (Nelson,	   Wegmann	   et	   al.	   2012).	   This	   study	   and	   others	  
showing	  similar	  results	  across	  ~15,000	  genes	  demonstrate	  that	  most	  rare	  allelic	  
mutations	   of	   any	   given	   sample	   will	   be	   unique	   and	   only	   detectable	   by	   direct	  
resequencing	  of	  the	  sample	  (Tennessen,	  Bigham	  et	  al.	  2012;	  Fu,	  O'Connor	  et	  al.	  
2013).	  Importantly,	  these	  latter	  studies	  have	  also	  discovered	  that	  excess	  of	  rare	  
variants	  is	  due	  to	  recent	  population	  growth	  and	  large	  samples	  sizes	  are	  required	  
in	  order	  to	  associate	  them	  with	  a	  complex	  phenotype,	  supporting	  findings	  from	  
population	  genetic	  studies	  (Cargill,	  Altshuler	  et	  al.	  1999;	  Williamson,	  Hernandez	  
et	  al.	  2005).	  	  
In	   order	   to	   discover	   rare	   variants	   contributing	   to	   disease	   and	   test	   them	   for	  
association	   with	   phenotype	   the	   overall	   proposed	   method	   has	   been	   to	  
resequence	   a	   small	   initial	   sample	   size	   and	   then	   genotype	   the	   discovered	  
variants	  in	  a	  larger	  sample	  set	  (Nejentsev,	  Walker	  et	  al.	  2009;	  Momozawa,	  Mni	  
et	  al.	  2011;	  Rivas,	  Beaudoin	  et	  al.	  2011).	  Nejentsev	  et	  al	  and	  Momozawa	  et	  al	  
only	   located	   low	   frequency	   (MAF	   0.5-­‐5%)	   coding	   mutations	   in	   IFIH1	   (MAF	   in	  
controls	   0.67-­‐2.22%)	   and	   IL23R	   respectively,	   where	   the	   small	   sequencing	  
sample	  size	  failed	  to	  determine	  a	  large	  fraction	  of	  the	  rare	  variants	  present.	  The	  
best	   example	   describes	   a	   mutational	   analysis	   of	   CARD15/NOD2	   mutations	   in	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453	   Crohn’s	   disease	   patients	  where	   3/67	   rare	   associated	   variants	  were	  more	  
frequent	   in	  cases,	  but	  exhibited	  an	  allele	  frequency	  of	  >0.05	  (Lesage,	  Zouali	  et	  
al.	   2002).	   A	   pooled	   sequencing	   study	   in	   RA	   targeted	   25	   GWAS	   associated	  
candidate	   genes	   based	   on	   gene	   relationships	   across	   implicated	   loci	   (GRAIL)	  
pathway	   analysis	   for	   exon	   resequencing	   but	   highlighted	   only	   relatively	   weak	  
associations	   in	   IL2RA	   and	   IL2RB	   (missense	  variant	  burden	  signal	  of	  association	  
p=0.007	  and	  p=0.018,	  respectively)	  (Jordan,	  Cao	  et	  al.	  2012;	  Diogo,	  Kurreeman	  
et	  al.	  2013).	  A	  study	  in	  idiopathic	  generalized	  epilepsy,	  using	  similar	  methods	  to	  
ones	  described	  in	  this	  thesis,	  failed	  to	  identify	  any	  rare	  risk	  disease	  associations	  
after	   genotyping	  3,897	   candidate	   variants	   (878	   cases,	   1,803	   controls)	   from	  an	  
exome	   sequencing	   dataset	   of	   119	   subjects	   with	   two	   forms	   of	   the	   disease,	  
indicating	  the	  lack	  of	  statistical	  power	  in	  the	  genotyped	  dataset	  to	  detect	  a	  true	  
association.	  The	   study	  highlighted	   that	   the	  variants	  were	   sufficiently	   rare	   that	  
each	   one	   only	   accounted	   for	   a	   small	   fraction	   of	   individuals	   and	   sequencing	  
might	  have	  provided	  a	  better	  resolution	  of	  these	  variants	  (Heinzen,	  Depondt	  et	  
al.	  2012).	  Collectively,	  these	  studies	  have	  shown	  that	  investigating	  risk	  alleles	  in	  
protein-­‐coding	   regions	   in	   associated	   loci	   can	   identify	   genes	   of	   biological	  
relevance	  in	  complex	  traits,	  but	  testing	  the	  entire	  rare	  variant	  content	  in	  a	  large	  
case	   control	   sample	   set	   is	   necessary	   to	   implicate	   large	   risk	   effects.	   For	   this	  
project,	  gene	  sequencing	  was	  chosen	  in	  place	  of	  genotyping	  the	  variants	  found	  
in	   them	   to	   allow	   assessment	   of	   the	   full	   exon	   sequences	   rather	   than	   just	  
information	  on	  sites	  over	  the	  exons,	  limiting	  areas	  for	  rare	  variant	  searching.	  In	  
addition,	   if	   there	   is	   a	   high	   false	   positive	   rate	   in	   exome	   target	   capture,	  
genotyping	   exonic	   SNPs	  will	   not	   be	   anymore	   informative	   and	   hence	   less	   cost	  
effective.	   Performing	   highly	  multiplexed	   sequencing	   of	   high	   quality	   and	   deep	  
coverage	  will	  enable	  direct	  genotyping	  in	  a	  case-­‐control	  sample	  set.	  	  
Many	   statistical	   methods	   have	   been	   proposed	   to	   detect	   rare	   variant	  
associations	   in	   common	   diseases.	   The	   analysis	   of	   rare	   variants	   is	   complicated	  
due	  to	  the	  fact	  that	  the	  power	  to	  detect	  a	  single	  rare	  SNV	  is	  dependent	  on	  its	  
MAF.	  To	  overcome	  the	  issue	  of	  power	  in	  a	  scenario	  where	  tens	  of	  thousands	  of	  
individuals	   cannot	   be	   sequenced,	   new	   methods	   have	   been	   developed	   that	  
aggregate	  rare	  variants	  across	  a	   target	   region	  and	   incorporate,	   for	  example,	   if	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the	   variant	   is	   a	   risk	   or	   protective	   variant	   and	   it’s	   function	   and	   effect	   on	   the	  
translated	   protein.	  Madsen	   and	   Browning	   proposed	  weighting	   variants	   based	  
on	  their	  estimated	  frequencies	  in	  controls,	  where	  variants	  with	  a	  low	  frequency	  
are	  given	  a	  higher	  weight	  compared	  to	  higher	  frequency	  variants	  (Madsen	  and	  
Browning	   2009).	   This	   differs	   from	   Li	   and	   Leal’s	   method	   based	   on	   testing	  
whether	   the	   rare	   variants	   present	   in	   cases	   are	   proportionately	   different	  
compared	  to	  controls	  (Li	  and	  Leal	  2008).	  Price	  et	  al	  extended	  the	  Madsen	  and	  
Browning	   method	   by	   including	   the	   functional	   effect	   of	   the	   variant	   in	   the	  
weighting	  scheme	  (Price,	  Kryukov	  et	  al.	  2010).	  The	  common	  factor	  to	  all	  these	  
tests,	  and	  others,	  is	  to	  group	  variants	  in	  a	  gene	  or	  candidate	  region	  and	  perform	  
a	  gene-­‐based	   test,	   instead	  of	  one	   test	  per	  variant	  per	  gene	   (Li	  and	  Leal	  2008;	  
Madsen	  and	  Browning	  2009;	  Bhatia,	  Bansal	  et	  al.	  2010;	  Han	  and	  Pan	  2010;	  King,	  
Rathouz	  et	  al.	  2010;	  Liu	  and	  Leal	  2010;	  Price,	  Kryukov	  et	  al.	  2010;	   Ionita-­‐Laza,	  
Buxbaum	  et	  al.	  2011;	  Neale,	  Rivas	  et	  al.	  2011).	  The	  main	  advantages	  of	   these	  
approaches	  are	  that	  statistical	  power	  is	  increased	  by:	  a)	  the	  burden	  of	  multiple	  
testing	  is	  reduced	  as	  the	  number	  of	  regions	  containing	  aggregated	  SNVs	  is	  much	  
lower	   than	  the	  number	  of	  overall	  SNVs;	  b)	   the	  combined	  allele	   frequencies	  of	  
aggregated	   SNVs	   are	   higher	   than	   the	   individual	   allele	   frequency	   of	   each	   rare	  
SNV.	  Gene-­‐based	  tests	  based	  on	  these	  developments	  have	  been	  applied	  in	  the	  
dataset	  described	  in	  the	  next	  sections.	  	  
	  
5.2	  Aim	  and	  hypothesis	  
	  
The	  aim	  of	  the	  final	  follow-­‐up	  study	  in	  this	  chapter	  is	  to	  determine	  if	  there	  are	  
any	  rare	  (MAF	  <0.5%)	  functional	  variants	  in	  the	  coding	  regions	  of	  24	  candidate	  
genes	   in	   coeliac	   cases	  or	   controls.	   These	   variants	  may	  be	  either	  protective	  or	  
have	  a	  pathogenic	  risk	  to	  disease	  and	  will	  be	  found	  through	  PCR	  of	  target	  genes	  
and	   highly	   multiplexed	   sequencing.	   All	   exons	   in	   candidate	   genes	   will	   be	  
resequenced	  in	  a	  large	  sample	  size	  to	  elucidate	  the	  complete	  rare	  fraction	  of	  all	  
coding	   regions.	   By	   treating	   sequence	   data	   like	   genotype	   data,	   single	   variant	  
association	  and	  gene	  burden	  tests	  will	  be	  performed	  on	  all	  coding	  variants.	  The	  
hypothesis	   is	   that	   rare	   variants	  might	   exist	   in	   candidate	   genes	   selected	   from	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exome	  sequencing	  of	  multiply	  affected	  families	  (using	  a	  combination	  of	  linkage,	  
shared	   variants	   analysis	   between	   multiple	   related	   subjects	   and	   gene	   burden	  
tests	  for	  multiple	  potentially	  causal	  variants)	  that	  account	  for	  familial	  clustering	  
in	   coeliac	   disease.	   The	   missing	   heritability	   for	   disease	   might	   lie	   in	   the	   rare	  
coding	  mutation	   region	  of	   the	  allelic	   spectrum	   in	   candidate	  genes,	   supporting	  
the	  CDRV	  hypothesis	  (Pritchard	  2001;	  Bodmer	  and	  Bonilla	  2008).	  	  
	  
5.3	  Pilot	  study	  
	  
A	   pilot	   study	   was	   carried	   out	   using	   multiplex	   PCR	   technology	   designed	   by	  
Fluidigm	   in	   order	   to	   test	   whether	   their	   multiplex	   amplicon	   tagging	   method	  
could	  be	  implemented	  into	  a	  project	  containing	  large	  sample	  sizes.	  The	  exons	  of	  
48	  genes	   from	  coeliac	   Immunochip	   significant	   regions	  were	   sequenced	   in	  384	  
coeliac	  samples.	  The	  main	  aims	  of	  the	  pilot	  study	  were:	  to	  assess	  sequence	  data	  
quality	  by	  testing	  the	  concordance	  rate	  of	  sequenced	  SNPs	  against	  Immunochip	  
genotyped	  SNPs;	   to	  determine	  what	  sequencing	  read	  pair	   length	  provided	  the	  
best	   data	   quality;	   to	   test	   coverage	   of	   reads	   and	   barcode	   evenness	   across	  
samples;	  to	  assess	  read	  length	  distribution	  of	  aligned	  reads;	  to	  assess	  clonality	  
of	  reads.	  	  
	  
5.3.1	   Fluidigm	   48.48	   Access	   Array 	   Intergrated	   Fluidic	   Circuit	  
technology	  	  
	  
Fluidigm	   48.48	   Access	   Array	   Intergrated	   Fluidic	   Circuit	   (IFC)	   technology	  
incorporates	  PCR	  into	  sample	  preparation	  for	  up	  to	  480	  target	  regions	  and	  384	  
individual	   barcodes.	   One	   Access	   Array	   can	   multiplex	   PCR	   480	   primer	   sets	  
(equating	  to	  480	  regions	  of	  interest)	  in	  48	  samples.	  The	  PCR	  takes	  place	  in	  the	  
centre	   of	   the	   microfluidic	   array,	   incorporating	   all	   target	   regions	   plus	   48	  
barcodes	   for	   each	   sample.	   Once	   the	   PCR	   products	   are	   harvested	   from	   eight	  
separate	   arrays,	   they	   are	   pooled	   to	   create	   one	   high	   throughput-­‐sequencing	  
library	   containing	   480	   amplicons	   from	   384	   individuals.	   Each	   sample	   in	   the	  
library	  contains	  flow-­‐cell	  sequences	  and	  a	  barcode	  sequence	  on	  the	  5’	  end	  that	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can	  be	  read	  using	  the	  standard	  Illumina	  indexing	  protocol	  (Figure	  5.1).	  The	  clear	  
advantage	  of	  this	  technology	  is	  that	  it	  allows	  multiple	  regions	  of	  interest	  to	  be	  
multiplexed	   in	   one	   PCR	   reaction	   with	   several	   samples,	   whilst	   allowing	   high	  
sequencing	  coverage	  necessary	  for	  rare	  variant	  analysis.	  	  
	  
	  
Figure	  5.1:	   Primer	   set	   up	   for	   Fluidigm	  multiplex	   amplicon	   tagging	   for	   Illumina	  
high	  throughput	  sequencing	  
	  
	  
Key:	  FC	  	  -­‐	  Illumina	  flow-­‐cell	  primers;	  BC	  –	  Fluidigm	  barcodes;	  CS	  –	  adapter	  sequences;	  
RS	  –	  region	  specific	  primers	  with	  CS	  adapter	  sequences	  at	  5’	  end	  
	  
	  
	   5.3.2	  Pilot	  study	  Method	  
	  
The	   coordinates	   for	   48	   exonic	   regions	   chosen	   from	   Immunochip	   loci	   were	  
submitted	  to	  Fluidigm	  for	  a	  custom	  assay	  design	  and	  validation.	  Once	  received,	  
primers	   and	   384	   coeliac	   samples	   were	   sent	   to	   Fluidigm’s	   Research	   and	  
Development	   site	   in	   Paris,	   France	   for	   processing	   on	   the	   Access	   Array	   IFC	  
machines.	  The	  48-­‐plex	  library	  was	  sequenced	  on	  the	  Illumina	  GAIIx	  at	  two	  sites	  
in	  the	  UK:	  six	  140bp,	  10bp	  index,	  bidirectional	  single	  end	  runs	  were	  sequenced	  
at	   Barts	   and	   the	   London	   Genome	   Centre	   and	   one	   100bp,	   10bp	   index,	  
bidirectional	   single	   end	   run	   was	   sequenced	   at	   Cancer	   Research	   UK	   (CRUK),	  
Cambridge.	   Bidirectional	   sequencing	  was	   selected	   as	   it	   allowed	   sequencing	  of	  
the	  5’	  and	  3’	  ends	   in	  one	  read,	  cutting	  the	  cost	  of	  a	  paired-­‐end	  read	   (the	  384	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barcodes	   in	   this	   pilot	   study	  were	   attached	   via	   the	   initial	   amplicon	  PCR,	   and	   a	  
second	  PCR	  step	  was	  performed	  to	  attach	  the	  bidirectional	  primers).	  The	  140bp	  
library	  was	  run	  on	  6	  lanes,	  each	  lane	  a	  different	  concentration	  of	  library:	  1pM,	  
3pM,	   6pM,	   9pM,	   12pM	   and	   16pM.	   Data	   was	   aligned	   to	   hg19/build37	   of	   an	  
indexed	  human	  genome	  using	  Novoalign	  and	  output	  in	  SAM	  format.	  SNP	  calling	  
was	   performed	   in	   SamTools	   v0.1.18.	  GATK	   v2.1-­‐9	   and	   SamTools	   v0.1.18	  were	  
used	  for	  depth	  of	  coverage	  analysis	  and	  variant	  calling.	  	  
	  
	   5.3.3	  Pilot	  study	  Results	  
	  
From	  the	  Barts	  140bp	  dataset,	  lane	  5	  (12pM	  concentration	  library)	  was	  optimal	  
for	  the	  number	  of	  aligned	  mapped	  reads,	  coverage	  and	  evenness	  of	  reads.	  For	  
this	  lane,	  76.7%	  of	  reads	  were	  over	  80bp	  (33,068,066	  total	  reads).	  For	  the	  CRUK	  
100bp	   run,	   95.8%	   of	   reads	   were	   over	   80bp	   (34,162,646	   total	   reads).	   Quality	  
score	   distributions	   were	   generated	   using	   FastQC	   v0.10.0	   software	  
(www.bioinformatics.babraham.ac.uk/projects/fastqc).	   The	   Phred	   score	   for	  
Barts	   lanes	   1-­‐6	   was	   between	   22	   and	   26,	   however	   there	   was	   a	   much	   wider	  
distribution	  compared	  to	  the	  CRUK	  100bp	  sequencing	  data	  (Appendix	  III,	  Figure	  
1).	  Overall,	  barcode	  evenness	  across	  384	  samples	  was	  excellent.	  Nine	  of	  the	  384	  
barcodes	   had	   a	   <50%	   median	   number	   of	   reads,	   and	   this	   included	   4	   water	  
samples	   (Figure	   5.2).	   The	  median	   number	   of	   reads	   per	   barcode	   for	   375	   post	  
quality	  control	  samples	  was	  90,021.	  A	  higher	  total	  number	  of	  aligned	  trimmed	  
reads	  was	  observed	  in	  the	  100bp	  sequencing	  dataset	  (Figure	  5.3).	  	  
There	  were	  44	  SNPs	  with	   Immunochip	  genotypes	  and	  339	  of	  367	  samples	  had	  
Immunochip	   genotype	   data.	   There	   were	   14,851	   calls	   made	   in	   both	   the	  
Immunochip	  array	  and	  Fluidigm	  sequencing	  data,	  and	  14,796	  of	  these	  calls	  were	  
concordant	   in	   both	   datasets,	   resulting	   in	   a	   concordance	   rare	   of	   99.6%.	   This	  
included	  one	  sample	  mix	  up	  (17	  discordance	  calls)	  and	  2	  poor	  SNPs	  (10	  and	  27	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Figure	  5.2:	  Total	  reads	  for	  384	  sample	  barcodes	  
	  
	  
100bp,	  10bp	  index,	  sequencing	  data	  was	  used	  to	  produce	  this	  graph	  	  
	  
	  
Figure	  5.3:	  Total	  aligned	  trimmed	  reads	  	  
	  
	  
Concentratiosn	   ranging	   from	   1pM	   to	   16pM	   correspond	   to	   different	   library	  
concentrations	   on	   one	   lane	   of	   the	   140bp,	   10bp	   index,	   sequencing	   run.	   CRUK	  
corresponds	  to	  the	  100bp,	  10bp	  index,	  sequencing	  run.	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5.3.3.1	  Read	  depth	  analysis	  	  	  
	   	   	  
It	  was	   important	  to	  establish	  depth	  and	  evenness	  of	  coverage	  per	  amplicon	   in	  
order	  to	  assess	  if	  sequences	  at	  ends	  of	  reads	  were	  less	  reliable	  than	  the	  rest	  of	  
the	   sequence.	   To	   computationally	   approach	   this	   question,	   a	   graph	   depicting	  
amplicon	  coverage	  per	  sample	  was	  generated;	  lane	  5	  of	  the	  Barts	  data	  (140bp	  
reads)	  was	  used	   to	  compare	   to	   the	  CRUK	  data	   (100bp	   reads).	   SamTools	  has	  a	  
tool	  to	  generate	  pileup	  data	  from	  aligned	  bam	  files	  and	  the	  read	  bases	  at	  each	  
position	  were	  extracted	  from	  each	  sample	  to	  produce	  graphs	  for	  each	  amplicon;	  
figure	  5.4	  illustrates	  an	  example	  of	  typical	  coverage	  for	  one	  amplicon	  in	  CUBN.	  
140bp	  reads	  produced	   increased	  coverage	  where	  primers	  overlapped,	  but	   the	  
100bp	  read	  was	  slightly	   short	   to	   fully	   sequence	   the	  196bp	  amplicon,	  however	  
there	  was	  less	  error	  at	  the	  ends	  of	  reads.	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Figure	  5.4:	  Depth	  of	  coverage	  per	  sample	  for	  CUBN	  196bp	  amplicon	  
	  
A	   	   	   	   	   	   	   	   	   B	   	  	  
	  
140bp	  single	  end	  bidirectional	  reads	  (A)	  and	  100bp	  single-­‐end	  bidirectional	  reads	  (A)	  from	  384	  samples.	  Immunochip	  SNP	  highlighted	  in	  red.	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5.3.3.2	  Clonality	  	  
	  
One	  concern	  with	  PCR	  based	  library	  preparation	  methods	  is	  clonal	  or	  duplicate	  
reads.	   These	   are	  multiple	   reads	  with	   the	   same	  orientation,	   start	   position	   and	  
read	   length,	   and	   arise	   from	   PCR	   amplification	   Although	   PCR	   amplification	  
increases	  the	  number	  of	  available	  molecules	  for	  sequencing,	  random	  errors	  can	  
be	   introduced	   due	   to	   changes	   in	   the	   number	   and	   representation	   of	   template	  
molecules.	   To	   recap,	   the	   exome	   sequencing	   data	   of	   pooled	   individuals	   had	   a	  
high	  proportion	  of	   clonal	   reads	  e.g.	  69.2%	   in	  pool	  1,	  mainly	  attributed	   to	  a	  2-­‐
step	   PCR	   (before	   and	   after	   hybridization,	   18	   and	   20	   cycles,	   respectively).	   This	  
resulted	   in	   a	   large	   proportion	   of	   reads	   being	   discarded.	   It	   was	   therefore	  
necessary	  to	  try	  and	  measure	  clonality	  in	  this	  pilot	  dataset,	  given	  the	  large	  scale	  
multiplexing	  and	  2-­‐step	  PCR	  (one	  to	  amplify	  the	  region	  specific	  amplicons	  and	  a	  
second	  to	  add	  the	  bidirectional	  primers).	  	  
A	  previously	  described	  method	  using	  degenerate	  bases	  as	  a	  molecular	  counter	  
to	   estimate	   the	   number	   of	   template	   molecules	   in	   the	   amplified	   variant	   was	  
applied	   here	   (Casbon,	   Osborne	   et	   al.	   2011).	   The	   degenerate	   base,	   N,	   can	  
incorporate	  an	  A,	  C,	  G	  or	  T.	  An	  amplified	  sequence	  displaying	  a	  mixture	  of	  bases	  
at	   these	   ‘N’	   reads	   indicates	   multiple	   variants	   have	   been	   sequenced	   and	  
therefore	   amplified.	   The	   authors	   ligated	   ‘N’	   bases	   onto	   fragments,	   however	  
they	  can	  also	  be	  introduced	  via	  PCR,	  which	  was	  the	  method	  used	  here.	  	  
Three	  degenerate	  base	  tags	  (NNN)	  were	  added	  onto	  the	  target	  specific	  primers.	  
A	  graph	  was	  produced	  by	  Vincent	  Plagnol	   to	  assess	  clonality.	  For	  each	  aligned	  
bam	  file,	   reads	  were	  extracted	   from	  a	  given	  position	  and	   the	  counts	  of	   ‘NNN’	  
base	  tags	  was	  measured	  based	  on	   if	   they	  occurred	  more	  than	  three	  times	  the	  
expected	   number	   (Figure	   5.5).	   Out	   of	   384	   samples,	   only	   three	   samples	  
exceeded	  the	  maximum	  “3-­‐fold”	  threshold	   in	  the	  100bp	  dataset,	  compared	  to	  
46	   samples	   in	   the	  140bp	  dataset.	  These	   results	   indicate	   that	   clonality	   is	  not	  a	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Figure	  5.5:	  Number	  of	  reads	  for	  position	  2526658	  for	  one	  sample	  
	  
	  
The	  number	  of	  counts	  is	  evenly	  distributed	  across	  the	  barcodes;	  the	  maximum	  
degenerate	  base	  count	  is	  11	  
	  
	   5.3.4	  Pilot	  Study	  Conclusions	  
	  
The	   outcomes	   from	   the	   pilot	   study	   proved	   helpful	   for	   assessing	   data	   quality	  
using	   Fluidigm’s	  Access	  Array	   IFC	   technology	   and	  high	   throughput	   sequencing	  
on	  an	  Illumina	  platform.	  Overall,	  the	  data	  produced	  was	  at	  optimal	  coverage	  for	  
variant	  calling	  and	  issues	  with	  clonality	  were	  bypassed	  with	  this	  technology,	  so	  
the	  degenerate	  base	  tags	  were	  not	  added	  to	  the	  primers	   for	   the	  main	  project	  
described	  later.	  It	  was	  evident	  that	  longer	  read	  lengths	  to	  sequence	  150-­‐200bp	  
amplicons	   on	   the	   GAIIx	   did	   not	   provide	   great	   read	   quality	   at	   the	   3’	   end.	  
Surprisingly,	   cluster	  density	   seemed	   to	  make	  no	  difference	   to	   the	  3’	   base	   call	  
quality.	   In	  addition,	  more	   reads	  over	  80bp	   (95.8%)	   in	   the	  100bp	  dataset	  were	  
observed	  compared	  to	  reads	  over	  100bp	   in	  the	  140bp	  dataset	   (52.9%	  for	   lane	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reads.	   The	   following	   conclusions	   can	  be	  made	   from	   this	   study:	   a)	   100bp	   read	  
length	  is	  optimal	  for	  multi-­‐sample	  sequencing;	  b)	  degenerate	  base	  tags	  are	  not	  
required	  as	  numbers	  of	  duplicate	   reads	  do	  not	  account	   for	  a	   large	  amount	  of	  
the	  sequencing	  data;	  c)	  the	  array	  technology	  works	  well	  for	  large-­‐scale	  amplicon	  
PCR	   of	   >384	   barcodes;	   d)	   Fluidigm’s	   barcodes	   work	   well	   and	   at	   the	   time	   of	  
completing	   this	   pilot	   they	   had	   designed	   an	   extra	   1,152	   barcodes	   for	   use,	  
totaling	   1,536	   barcodes	   for	   multiplexing	   into	   one	   sequencing	   library,	  
incorporated	  via	  a	  second	  PCR	  step.	  The	  bidirectional	  sequencing	  protocol	  was	  
not	  yet	  optimized	  for	  use	  with	  the	  Illumina	  HiSeq	  2000,	  which	  was	  the	  platform	  
of	   choice	   for	   the	   main	   study.	   Instead,	   paired-­‐end	   reads	   were	   performed,	  
eliminating	  the	  PCR	  step	  required	  to	  attach	  bidirectional	  primers.	  	  
	  
5.4	  Power	  Considerations	  
	  
A	  power	  calculation	  was	  performed	  to	  ascertain	  how	  many	  samples	  would	  be	  
required	  to	  locate	  a	  variant	  with	  OR’s	  (or	  relative	  risks)	  between	  2	  and	  3.5	  using	  
an	   online	   genetic	   power	   calculator	   (Purcell,	   Cherny	   et	   al.	   2003).	   Statistically,	  
1000	  cases	  and	  controls	  would	  give	  almost	  100%	  power	  to	  detect	  associations	  
at	  a	  false	  positive	  rate	  of	  α=0.05	  for	  an	  allele	  frequency	  of	  0.5%	  and	  OR	  of	  3.5	  in	  
a	  multiplicative	  model	  (Figure	  5.6).	  Here,	  the	  risk	  allele	  frequency	  has	  been	  kept	  
constant	   at	   0.5%.	   Another	   calculation	   was	   based	   on	   an	   OR	   of	   a	   known	   rare	  
variant	  in	  NOD2,	  G9068R	  (G>A).	  This	  marker	  has	  a	  genotype	  relative	  risk	  of	  3.05	  
and	  a	  risk	  allele	  frequency	  of	  0.12%	  in	  controls.	  The	  allelic	  OR’s	  and	  population	  
frequency	  of	  the	  minor	  allele,	  A,	  were	  calculated	  based	  on	  Hardy	  Weinberg,	  and	  
equated	   to	   1.	   The	   risk	   relative	   to	   the	   general	   population	   for	   individuals	   with	  
genotypes	   GG,	   AG	   and	   AA	   for	   the	   rare	   marker	   was	   8.86,	   2.9	   and	   0.95,	  
respectively.	   These	   numbers	   were	   used	   to	   calculate	   genetic	   power	   based	   on	  
2,304	  disease	  samples	  and	  2,304	  controls.	  With	  a	  risk	  allele	  frequency	  of	  0.5%	  
and	   genotype	   relative	   risks	   based	  on	  G9068R,	   2,304	   cases	   and	  2,304	   controls	  
gives	   85%	  power	   to	   reach	   a	  p	   value	  of	   0.001.	   Based	  on	   this,	   an	  overall	   4,608	  
case-­‐control	  sample	  size	  would	  be	  sufficient	  to	  find	  a	  high	  relative	  risk	  variant	  in	  
CD,	  with	  a	  MAF	  of	  0.5%.	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The	  effect	  of	  sample	  size	  on	  power	  for	  variants	  conferring	  relative	  risks	  between	  2	  and	  
3.5.	   Assumptions:	   multiplicative	   model,	   disease	   prevalence	   1%,	   high	   risk	   allele	  
frequency	   0.5%,	   case:control	   ratio	   1:1.	   RR	   =	   Relative	   Risk.	   First	   dashed	   line	   indicates	  
power	   for	   500	   cases	   and	   500	   controls.	   Second	  dashed	   line	   indicates	   power	   for	   1000	  
cases	  and	  1000	  controls.	  
	  
5.5	  Experimental	  design	  and	  sample	  set	  	  
	  
Fluidigm	   designed	   PCR	   primers	   for	   all	   RefSeq	   exons	   of	   24	   candidate	   genes	  
totaling	  506	  amplicons	  containing	  exonic	  sequences	  (Table	  5.1).	  Amplicons	  were	  
selected	  to	  be	  150-­‐200bp	  in	  size.	  The	  design	  covered	  all	  exons,	  excluding	  any	  5’	  
or	   3’	   un-­‐translated	   regions.	   21	   out	   of	   the	   24	   target	   genes	   had	   100%	   total	  
coverage	   of	   all	   exon	   amplicons.	   There	   was	   minor	   primer	   design	   dropout	   at	  
MALT1,	  MAP4K2	  and	  IL12RB1,	  however	  they	  still	  had	  a	  total	  coverage	  of	  98.8%,	  
99.3%	  and	  97.99%,	  respectively.	  The	  total	  length	  of	  (overlapping)	  amplicons	  was	  
96,581bp,	   68,494bp	   with	   primers	   removed	   (and	   overlapping)	   and	   55,807bp	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unique	  (non	  overlapping	  and	  primers	  removed).	  One	  Fluidigm	  Access	  Array	  was	  
intended	  to	  multiplex	  PCR	  48	  samples	  with	  506	  primer	  pairs	  (11-­‐plex	  assay	  per	  
well).	   The	   sample	   set	   consisted	   of	   2,304	   coeliac	   samples	   and	   2,304	  matching	  
population	   controls,	   including	   negative	   (water)	   controls.	   Samples	   discordant	  
with	  Immunochip	  genotypes	  and/or	  with	  known	  gender	  or	  genotype	  mismatch	  
issues	  from	  previous	  GWAS	  were	  excluded	  (Trynka,	  Hunt	  et	  al.	  2011).	  Samples	  
with	  known	  duplicates	  or	  relatedness	  (as	  distant	  first	  cousins)	  were	  excluded.	  	  
	  
Table	  5.1:	  Candidate	  genes	  for	  targeted	  amplicon	  resequencing	  
	  
Gene	   Analysis	  selected	  from	   cDNA	  size*	   Exons*	  
ACOT8	   Linkage	   1,168bp	   6	  
ARHGAP25	   Linkage	   2,979bp	   11	  
C1QBP	   Shared	  in	  familial	  exomes	   1,169bp	   6	  
CD180	   Case	  Control/Shared	   2,726bp	   3	  
CD1C	   Case	  Control	   1,435bp	   6	  
CERK	   Case	  Control	   4,450bp	  	   13	  
CRLF3	   Case	  Control	   2,917bp	  	   8	  
EBI3	   Case	  Control	   1,128bp	   5	  
EPAS1	   Linkage	   5,160bp	   16	  
GRM4	   Linkage	   3,879bp	   10	  
HAS1	   Shared	  in	  familial	  exomes	   2,087bp	   5	  
IFNW1	   Case	  Control	   1,514bp	   1	  
IKZF3	   Case	  Control	   9,667bp	  	   8	  
IL12RB1	   Shared	  in	  familial	  exomes	   2,100bp	   17	  
KCNJ16	   Linkage	   4,002bp	   5	  
MALT1	   Linkage	   8,789bp	   17	  
MAP4K2	   Shared	  in	  familial	  exomes	   2,955bp	   32	  
NLRC4	   Linkage	   3,581bp	   10	  
RAF1	   Shared	  in	  familial	  exomes	   3,300bp	   17	  
TNFRSF10A	   Shared	  in	  familial	  exomes	   2,714bp	   10	  
TNFRSF13B	   Shared	  in	  familial	  exomes	   1,357bp	   5	  
TNFRSF21	   Segregation	   3,595bp	   6	  
TRAF4	   Shared	  in	  familial	  exomes	   2,921bp	   7	  
TULP1	   Linkage	   2,162bp	   15	  
	  
*Information	  taken	  from	  Ensemble	  genome	  Browser,	  release	  71	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   5.5.1	  Laboratory	  method	  
	  
Chapter	  2,	  section	  2.7	  details	   the	  methods	  used	  for	  Fluidigm	  amplicon	  PCR.	   In	  
brief,	   50ng	   genomic	  DNA	  was	   PCR	   amplified	   in	   a	  multiplexed	   Fluidigm	  Access	  
Array	  microfluidics	  system.	  One	  microfluidic	  array	  was	  used	  for	  multiplexed	  PCR	  
of	  48	  samples	  (loaded	  on	  the	  left-­‐hand	  side	  of	  the	  array).	  PCR	  primers	  for	  506	  
PCR	   reactions	   were	   pooled	   up	   to	   11-­‐plex	   per	   well	   in	   48	   primer	   pools,	   which	  
were	   loaded	   on	   the	   right-­‐hand	   side	   of	   the	   array.	   Individual	   per	   sample	   per	  
primer	   pool	   PCR	   reactions	   took	   place	   in	   35nl	   reaction	   chambers,	   which	   took	  
place	   in	  the	  microfludics	  chamber	   in	  the	  centre	  of	   the	  array.	  After	  a	  two-­‐hour	  
amplification	   and	   harvest	   of	   products,	   PCR	   amplicons	   from	   a	   sample	   were	  
pooled	   and	   barcoded	   with	   one	   of	   1,536	   unique	   10bp	   sequences	   (Fluidigm	  
unidirectional	   sequencing	   protocol).	   An	   equal	   number	   of	   cases	   and	   controls	  
were	   combined	   to	   create	   one	   1,536	  multiplex	   library	   (1µl	   per	   sample).	   Three	  
libraries	   were	   generated	   in	   total.	   Libraries	   were	   initially	   sequenced	   on	   an	  
Illumina	  MiSeq	  for	  quality	  control	  of	  individual	  barcodes	  and	  to	  optimise	  loading	  
concentrations	   and	   cluster	   density	   targets	   for	   Illumina	   HiSeq	   sequencing.	  
Libraries	  were	  then	  sequenced	  one	  per	  lane	  using	  101bp	  paired-­‐end	  reads	  and	  a	  
10bp	   index	   read	   on	   the	   Illumina	   HiSeq	   2000	   at	   NIHR	   GSTFT/KCL	   Biomedical	  
Research	   Centre	   at	   Guy’s	   Hospital.	   Individual	   samples	  were	   demultiplexed	   by	  
Ilumina	  CASAVA	  software,	  allowing	  zero	  mismatches	  per	  10bp	  barcode.	  	  
Sanger	  dideoxy	  sequencing	  was	  performed	  as	   in	  Chapter	  3,	  section	  3.5.2.1.	  All	  
samples	   with	   rare	   variant	   allele	   genotypes,	   and	   a	   control	   sample,	   were	  
sequenced	  for	  27	  sites	  selected.	  	  
	  
	   5.5.2	  In	  silico	  methods	  and	  quality	  control	  steps	  
	  
Chapter	  2,	  section	  2.9.2	  contains	  detailed	  bioinformatic	  steps	  performed	  on	  the	  
4,608-­‐sample	   dataset.	   In	   brief,	   data	   analysis	   processes	   from	   9,216	   fastq	   files	  
included:	  1)	  PCR	  amplicon	  trimming	  using	  a	  modified	  version	  of	  Btrim	  software	  
(Kong	   2011),	   2)	   read	  mapping	  with	   Novoalign	   to	   hg19/build37	   of	   an	   indexed	  
reference	   genome,	   3)	   local	   realignment	   around	   known	   (1000G)	   and	   sample	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level	  novel	   indels,	  4)	  base	  quality	  score	   recalibration,	  5)	  SNP	  and	   indel	  calling,	  
and	  6)	  variant	  annotation.	  Steps	  3	  to	  6	  were	  performed	  using	  GATK	  2.4-­‐7.	  The	  
variants	   used	   were	   restricted	   to	   sites	   that	   passed	   standard	   GATK	   filters	   to	  
eliminate	  SNPs	  with	  strand	  bias,	   low	  quality	  of	  read	  depth,	  homopolymer	  runs	  
and	  SNPs	  near	   indels.	  Variants	  with	  an	  average	  depth	  >20	  and	  a	  quality	   score	  
>80	   were	   required.	   SamTools	   v0.1.18	   was	   also	   used	   to	   process	   data.	   SNP	  
genotypes	  were	  called	  at	  all	  68,494	  bases	  of	  amplicon	  sequence.	  Non-­‐reference	  
genotype	   sites	   were	   identified	   across	   all	   samples	   and	   VCF	   files	   containing	  
polymorphic	  variant	  sites	  and	  samples	  were	  combined	  and	  loaded	  into	  a	  project	  
for	   use	   with	   PLINK/SEQ	   v0.09	   software.	   Annotation	   in	   PLINK/SEQ	   was	  
performed	  with	   GENCODE	   V14	   gene	   definitions	   (Howald,	   Tanzer	   et	   al.	   2012).	  
Coding	  variants	  were	  identified	  as	  present	  in	  coding	  regions,	  and	  rare	  functional	  
variants	  were	  identified	  based	  on	  nonsense,	  splice,	  esplice	  (splice	  site	  in	  the	  first	  
or	  last	  two	  intronic	  bases),	  frameshift	  indel,	  codon	  indel	  (3n	  indel),	  readthrough,	  
and	   start	   lost	   predictions.	   PLINK/SEQ	   v0.09	   was	   used	   to	   perform	   all	   single	  
variant	   and	   gene-­‐based	   association	   analyses	   and	   for	   determination	   of	   TiTv	  
statistics.	  	  
Quality	  control	  steps	  of	  the	  combined	  SNP	  and	  indel	  VCF	  file	  in	  the	  PLINK/SEQ	  
project	   included	   the	   removal	   of:	   water	   samples	   (negative	   controls),	   samples	  
with	  low	  call	  rates	  across	  all	  SNVs,	  SNVs	  with	  low	  call	  rates	  across	  all	  samples.	  
The	   initial	   PLINK/SEQ	  project	   contained	  2,292	  polymorphic	   variants	   and	  4,608	  
samples.	  A	  SNP	  and	  indel	  call	  rate	  of	  97.7%	  and	  individual	  genotyping	  call	  rate	  
of	   97%	   (across	   all	   SNPs	   and	   indels)	   was	   applied	   (thresholds	   determined	   by	  
inspection	  of	   call	   rate	  plots	   in	  Appendix	   III,	   figures	   3	   and	  4).	  All	   heterozygous	  
calls	  were	  required	  to	  have	  an	  allele	  balance	  between	  25%	  and	  75%,	  calculated	  
by	   the	   division	   of	   alternate	   allele	   depth	   over	   total	   allele	   depth	   for	   a	   site	  
(Appendix	   III,	   Figure	  5).	   The	  mean	  allele	  balance	  at	  all	  heterozygous	   sites	  was	  
0.49±0.12.	   The	  mean	  ±	   two	   standard	  deviations	  was	  24%	  and	  73%,	   similar	   to	  
the	   25%-­‐75%	   allele	   balance	   used	   here	   and	   in	   Hunt	   et	   al	   (Hunt,	   Mistry	   et	   al.	  
2013)	  (Appendix	  IV),	  and	  the	  same	  number	  of	  variants	  was	  removed	  when	  both	  
filters	   were	   applied	   (52).	   Another	   recent	   study	   used	   variants	   with	   an	   allelic	  
balance	  between	  30%	  and	  70%	  (Lim,	  Raychaudhuri	  et	  al.	  2013);	  this	  would	  have	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removed	   91	   variants	   from	   the	   dataset,	   however	   the	   called	   variants	   had	   a	  
genotyping	   rate	   of	   >99%	  with	   25%	   -­‐75%	   filters	   so	   these	   limits	  were	   kept.	   GC	  
content	  can	  explain	  why	  low	  depth	  was	  observed	  at	  some,	  but	  not	  all,	  sites.	  For	  
example,	  a	  cluster	  of	  sites	  with	  low	  heterozygote	  allele	  depths	  in	  one	  amplicon	  
of	  EPAS1	  and	  three	  amplicons	  of	  HAS1	  contained	  69%,	  73%,	  67%	  and	  70%	  GC	  
content,	  respectively	  (Appendix	  III,	  Figure	  5).	  	  
	  
5.6	  Results	  	  
	  
On	   the	   basis	   of	   MiSeq	   50bp	   single-­‐end	   sequencing	   results	   for	   library	   quality	  
control,	  three	  libraries	  contained	  excellent	  barcode	  coverage	  across	  1,536	  10bp	  
sequences,	   with	   99.6%	   of	   the	   1,536	   barcodes	   producing	   pass-­‐filter	   read	  
numbers.	  These	  were	  between	  0.013%	  and	  0.13%	  of	  total	  pass	  filter	  reads	  per	  
lane.	  Most	   failing	   barcodes	  were	  water	   (negative	   control)	   samples.	   For	   three	  
HiSeq	   101bp,	   10bp	   index,	   paired-­‐end	   sequenced	   libraries,	   >93%	   reads	   passed	  
filter	   with	   on	   target	   cluster	   densities	   between	   640	   -­‐775	   k/mm2	   (Appendix	   III	  
Table	   1	   and	   Figure	   2).	   Amplicon	   evenness	   was	   good	   with	   many	   genotypes	  
requiring	  down-­‐sampling	  of	  250	  bases	  per	  site	  per	  sample	  (Appendix	  III,	  Figure	  
6).	   A	   filter	   of	   >20	   mean	   depth	   per	   sample	   was	   applied	   to	   call	   a	   variant.	  
Amplicons	  were	   visually	   inspected	   on	  UCSC	   tracks,	   and	   those	  with	   <20	  mean	  
coverage	  were	   removed.	   3.47%	  of	   55,807	   unique	   bases	   had	   <20	  mean	   depth	  
per	  sample	  and	  were	  all	  accounted	  for	  by	  18	  amplicons	  that	  failed	  PCR.	  13	  out	  
of	  the	  18	  failed	  amplicons	  had	  high	  GC	  content	  (between	  63	  and	  89%).	  	  
The	  high	  coverage	  data	  enabled	  stringent	  filtering	  on	  call	  rate	  per	  sample,	  per	  
variant	   site	   and	   on	   allelic	   balance,	   as	   described	   in	   section	   5.5.3.	   After	   quality	  
control	  and	  removal	  of	  excess	  related	  individuals,	  ethnic	  outliers	  and	  duplicates,	  
the	   final	   dataset	   comprised	   4,478	   phenotyped	   individuals	   (disease	   cases	   and	  
controls).	   1,335	   unique	   variants	   with	   a	   genotype	   call	   rate	   of	   99.98%	   were	  
discovered.	  The	  genotyping	  call	   rate	   included	  reference	  homozygote	  and	  non-­‐
reference	   genotypes.	   Of	   these,	   1,200	   variants	   were	   rare	   (MAF	   in	   2,230	   post	  
quality	   control	   controls,	   <0.5%).	   502	   variants	   were	   observed	   in	   published	  
datasets	  (dbSNP137	  containing	  all	  1000G	  pilot	  data	  plus	  phase	  1	   low	  coverage	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sites	   and	   National	   Heart,	   Lung	   and	   Blood	   Institute	   (NHLBI)	   exome	   data	   from	  
6,503	  samples)	  and	  833	  variant	  sites	  were	  novel.	  99.98%	  of	  all	  sample	  genotype	  
calls	  had	  a	  read	  depth	  >40	  and	  97.4%	  had	  a	  read	  depth	  >100.	  	  
The	   number	   of	   coding	   variants	   per	   gene	   was	   assessed	   and	   limited	   to	  
heterozygous	   variants	   only.	   Here,	   a	   coding	   variant	   is	   defined	   as	   one	   that	   is	  
present	   in	   the	   coding	   region;	   therefore,	   silent	   variants	   have	   been	   included	   in	  
the	  count	  (Table	  5.2).	  Of	  the	  1,335	  variants,	  939	  were	  in	  protein-­‐coding	  regions	  
of	  24	  genes	  and	  of	  these	  91.7%	  were	  rare	  (MAF	  in	  2,230	  controls,	  <0.5%).	  60%	  
of	   all	   coding	   variants	  were	  novel	  when	   compared	  with	  published	  datasets	   (as	  
above).	  No	  common	  or	  low	  frequency	  variants	  were	  seen	  at	  novel	  sites	  (mean	  
MAF	   0.00139%).	   Overall,	   60	   rare	   LoF	   variants	   (nonsense,	   codon	   indel,	  
frameshift,	  and	  splice	  site;	  based	  on	  GENCODE	  v14	  annotation)	  were	  identified	  
across	  20	  genes;	  four	  genes	  harboured	  no	  such	  variants.	  
Data	   quality	   was	   confirmed	   by	   a	   number	   of	   steps.	   One	   control	   sample	   was	  
genotyped	  42	   times	   (on	  different	   48-­‐sample	  microfluidic	   chips);	   the	   genotype	  
call	  error-­‐rate	  was	  two	  non-­‐consensus	  genotype	  calls	  of	  1,335	  called	  genotypes	  
(0.0018%).	   A	   quality	   control	   step	   measuring	   TiTv	   ratios	   for	   expected	   human	  
mutation	  types	  was	  2.99	  (3.18	  singletons)	  for	  coding-­‐region	  variants,	  2.86	  (3.13	  
for	  singletons)	  for	  rare	  variants,	  and	  2.69	  (2.90	  for	  singletons)	  for	  novel	  variants.	  
For	   novel	   coding-­‐region	   variants	   the	   TiTv	   ratio	  was	   2.78	   (2.89	   for	   singletons).	  
Sanger	  sequencing	  validation	  analysis	  was	  performed	  on	  all	  nonsense	  (17)	  and	  
frameshift	   (11)	   variants.	   There	   was	   one	   variant	   that	   failed	   PCR	   and	   one	  
frameshift	   indel	   and	   one	   nonsense	   variant	   that	   were	   false	   positive	   (false-­‐
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Table	  5.2:	  Number	  of	  coding,	  rare	  and	  loss	  of	  function	  variants	  across	  24	  
candidate	  genes	  
	  
Gene	  	   Number	  of	  
variants	  in	  
coding	  regions	  
Number	  of	  rare	  
(MAF<0.5)	  in	  
coding	  regions*	  
Number	  of	  rare	  
(<0.5)	  and	  LoF**	  
ACOT8	   29	   27	   5	  
ARHGAP25	   40	   34	   2	  
C1QBP	   9	   8	   2	  
CD180	   48	   43	   4	  
CD1C	   28	   26	   3	  
CERK	   54	   48	   4	  
CRLF3	   23	   20	   2	  
EBI3	   28	   25	   2	  
EPAS1	   59	   55	   3	  
GRM4	   69	   65	   0	  
HAS1	   61	   56	   1	  
IFNW1	   17	   16	   0	  
IKZF3	   29	   27	   1	  
IL12RB1	   60	   52	   4	  
KCNJ16	   36	   35	   3	  
MALT1	   21	   20	   3	  
MAP4K2	   34	   33	   2	  
NLRC4	   64	   61	   3	  
RAF1	   27	   26	   2	  
TNFRSF10A	   46	   42	   5	  
TNFRSF13B	   42	   34	   4	  
TNFRSF21	   39	   38	   0	  
TRAF4	   30	   28	   0	  
TULP1	   46	   42	   5	  
	  
*	  MAF	  as	  defined	  in	  controls.	  **Loss	  of	  function	  excludes	  synonymous	  and	  silent	  
variants.	  	  
	  
5.6.1	  Association	  and	  gene-­‐burden	  tests	  
	  
A	  first	  attempt	  to	  identify	  any	  low	  frequency	  or	  rare	  variants	  of	  larger	  effect	  was	  
performed	   for	   each	   coding-­‐region	   variant	   in	   a	   Fisher	   exact	   single-­‐variant	  
association	  analysis.	  135	  variants	  common	   in	  controls	  were	  removed	  from	  the	  
test	   (>0.5%	  MAF).	   A	   significant	   P	   value	  of	   6	   x	   10-­‐5	  was	   chosen	   to	   account	   for	  
multiple	   testing	   on	   939	   rare	   coding	   variants.	  No	   single	   SNP	   associations	  were	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observed	  (the	  highest	  P	  value	  was	  0.012).	  Gene	  based	  tests	  were	  subsequently	  
performed	  in	  PLINK/SEQ	  on	  all	  coding	  variants	  across	  24	  genes.	  A	  gene	  based	  C-­‐
alpha	   test	   allowed	   for	   both	   risk	   and	   protective	   effects	   for	   rare	   functional	  
variants.	  A	  sequence	  kernal	  association	   test	   (SKAT;	  a	  variance-­‐component	   test	  
that	  aggregates	   individual	  score	  statistics	  by	  assigning	  weights	  for	  each	  SNP	  to	  
perform	  (Wu,	  Lee	  et	  al.	  2011))	  and	  tests	  to	  identify	  excess	  rare	  variants	  seen	  in	  
cases,	  collectively	  (Burden	  test)	  and	  uniquely	  (Uniq	  test),	  were	  also	  performed.	  
Rare	   functional	   variants	   included	   in	   the	   tests	  were	   defined	   as	   <0.5%	   in	   2,230	  
controls	   and	   predicted	   nonsense,	   frameshift,	   codon	   indel	   and	   splice	   site	  
annotation.	  Here,	  a	  Bonferroni	  P	  value	  of	  <1	  x	  10-­‐3	  was	  selected	  based	  on	  the	  
number	  of	  transcripts	  tested,	  and	  not	  the	  number	  of	  genes,	  as	  some	  genes	  had	  
multiple	  transcripts.	  No	  significant	  P	  values	  were	  observed	  in	  any	  test	  for	  novel	  
or	  known	  variants.	  Table	  5.3	  shows	  genes	  with	  top	  five	  P	  values	  across	  all	  gene-­‐
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Table	   5.3:	   Top	   five	  P	   values	   for	  multiple	   rare	   variant	   gene-­‐based	   tests	   across	   all	   protein-­‐coding	   variants	   (novel	   and	   known)	   in	   24	  
candidate	  genes	  
	  
Gene	   Transcript	   Rare	  variant	  test	   Number	  of	  variants	  in	  test	   Test	  statistic	  p	  value	  
CERK	   NM_022766	   C-­‐Alpha	   48	   0.022	  
ARHGAP25	   NM_001007231	   C-­‐Alpha	   34	   0.118	  
HAS1	   NM_001523	   C-­‐Alpha	   56	   0.119	  
IL12RB1	   NM_005535	   C-­‐Alpha	   52	   0.229	  
TNFRSF13B	   NM_012452	   C-­‐Alpha	   34	   0.275	  
CERK	   NM_022766	   SKAT	   48	   0.002	  
ARHGAP25	   NM_001007231	   SKAT	   34	   0.096	  
HAS1	   NM_001523	   SKAT	   56	   0.126	  
IL12RB1	   NM_005535	   SKAT	   52	   0.188	  
CD1C	   NM_001765	   SKAT	   27	   0.263	  
EPAS1	   NM_001430	   UNIQ	   55	   0.004	  
CD1C	   NM_001765	   UNIQ	   27	   0.044	  
HAS1	   NM_001523	   UNIQ	   56	   0.092	  
IFNW1	   NM_002177	   UNIQ	   16	   0.140	  
RAF1	   NM_002880	   UNIQ	   26	   0.229	  
EPAS1	   NM_001430	   Burden	   55	   0.007	  
ARHGAP25	   NM_001007231	   Burden	   34	   0.167	  
TNFRSF21	   NM_014452	   Burden	   38	   0.234	  
CD1C	   NM_001765	   Burden	   27	   0.240	  
TNFRSF10A	   NM_003844	   Burden	   42	   0.262	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5.7	  Chapter	  Discussion	  	  
	  
The	   follow	   up	   study	   in	   this	   chapter	   has	   attempted	   to	   identify	   rare	   protein-­‐
coding	  mutations	  in	  24	  candidate	  genes	  selected	  from	  exome	  sequencing	  data	  
of	   75	   coeliac	   individuals	   from	   55	   multiple	   affected	   families.	   Candidate	   genes	  
were	   chosen	   based	   on	   if	   they	   harboured	   any	   rare	   variants	   shared	   in	   familial	  
exomess	   (with	   the	   assumption	   that	   closely	   related	   affected	   individuals	   share	  
rare	   risk	   variants),	   if	   they	   were	   in	   linkage	   peaks	   or	   if	   more	   variants	   were	  
observed	   in	   cases	   compared	   to	   controls	   in	   any	   particular	   gene	   (gene	   burden	  
test).	  The	  study	  was	  intended	  to	  prove	  or	  disprove	  the	  working	  hypothesis	  that	  
rare	  mutations	  of	  large	  effect	  size	  in	  CD	  may	  account	  for	  the	  missing	  heritability	  
of	  disease,	  and	  these	  variants	  can	  be	  found	  through	  NGS	  of	  candidate	  genes.	  	  
The	  investigation	  of	  the	  role	  of	  rare	  variants	  in	  complex	  traits	  (Gibson	  2011)	  has	  
led	   to	   many	   studies	   determining	   their	   distribution	   across	   the	   genome,	   their	  
phenotypic	  affects	  and	  how	  to	  apply	  statistical	  aggregate	  tests	  to	  quantify	  their	  
presence	   in	  a	  disease	  population	  (Asimit	  and	  Zeggini	  2010;	  Liu	  and	  Leal	  2012).	  
The	  relevance	  of	  rare	  variants	  has	  been	  widely	  demonstrated,	  for	  example,	  in	  a	  
quantitative	   trait	  where	  many	  rare	  nonsynonymous	  SNPs	  unique	  to	   the	  obese	  
population	  have	  been	  discovered	  (Ahituv,	  Kavaslar	  et	  al.	  2007),	  and	  in	  complex	  
phenotypes	   such	   as	   autism	   and	   Parkinson’s	   disease,	   where	   rare	   structural	  
variants	  play	  a	  significant	  role	   (Stankiewicz	  and	  Lupski	  2010).	  One	  of	   the	  main	  
purposes	   of	   elucidating	   the	   role	   of	   rare	   variants	   in	   functional	   regions	   of	   the	  
genome	  is	  to	  pinpoint	  a	  specific	  gene(s)	  in	  which	  the	  presence	  of	  variants	  with	  a	  
low	  MAF	   in	   the	   general	   population	   is	   attributable	   to	   disease	   risk	   in	   a	   disease	  
cohort.	  One	  key	  concern	  is	  having	  the	  statistical	  power	  to	  detect	  these	  variants,	  
which	   have	   an	   overall	   low	   population	   frequency	   but	   are	   in	   abundance	   in	   the	  
human	  population,	  due	  to	  recent	  population	  expansion	  (Coventry,	  Bull-­‐Otterson	  
et	   al.	   2010).	   The	  1000	  Genomes	  project	   found	   that	   for	   rare	   variant	   testing	   to	  
pinpoint	  disease	  associations,	  there	  is	  a	  significant	  reduction	  of	  power	  due	  to	  a	  
large	  number	  of	  variable	  sites	  and	  a	   lack	  of	  sharing	  of	   these	  variants	  amongst	  
diverge	  populations.	  So	  in	  essence,	  variants	  with	  any	  functional	  impact	  are	  rare	  
and	  have	  a	  higher	  population	  divergence	  (Gravel,	  Henn	  et	  al.	  2011).	  However,	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with	  enough	  statistical	  power,	  testing	  genes	  rather	  than	  multiple	  alleles	  as	  units	  
for	  an	  association	  test	  can	  identify	  meaningful	  associations	  (Kryukov,	  Shpunt	  et	  
al.	  2009).	  The	  experiment	  here	  was	  successful	  in	  that	  many	  rare	  mutations	  were	  
found	  (91.7%	  of	  all	  coding	  SNVs	  were	  rare)	  and	  the	  proportion	  of	  novel	  and	  rare	  
variants	   were	   similar	   to	   those	   found	   in	   other	   published	   datasets	   (Nelson,	  
Wegmann	  et	  al.	  2012;	  Tennessen,	  Bigham	  et	  al.	  2012).	  The	  data	  also	  reflects	  the	  
operation	   of	   purifying	   selection	   as	   all	   nonsynonymous	   substitutions	   were	  
skewed	  toward	  a	  low	  MAF	  (0.09%),	  similar	  to	  other	  findings	  (Cargill,	  Altshuler	  et	  
al.	  1999;	  Kryukov,	  Pennacchio	  et	  al.	  2007;	  Zhu,	  Ge	  et	  al.	  2011).	  	  
The	  Fluidigm	  multiplex	  PCR	  method	  used	  in	  this	  study	  was	  excellent	  in	  providing	  
the	  coverage	  required	  to	  confidently	  call	  a	  variant.	  Overall,	   the	  1,536	  barcode	  
pooling	   provided	   even	   coverage	   across	   all	   samples	   and	   amplicons,	   with	   only	  
3.5%	  of	   amplicons	   failing	  PCR,	  mainly	  due	   to	  GC	   rich	   content.	   The	  2-­‐step	  PCR	  
(target	   specific	   amplification	   followed	   by	   barcode	   PCR)	   did	   not	   introduce	  
clonality	   into	   the	   dataset,	   possibly	   due	   to	   the	   CoT	   PCR	  method	   employed	   by	  
Fluidigm	   to	   normalize	   PCR	   reactions	   (Mathieu-­‐Daude,	   Welsh	   et	   al.	   1996).	   By	  
applying	  CoT	  PCR	  with	  such	  a	  large	  number	  of	  amplicons	  in	  small	  PCR	  reactions,	  
under-­‐performing	   amplicons	   have	   a	   method	   to	   catch	   up	   with	   those	   that	   are	  
better	   performing.	   Compared	   to	   error-­‐prone	   low	   coverage	   sequencing	  where	  
genotype	   calls	   cannot	   be	   confidently	   made	   (Navon,	   Sul	   et	   al.	   2013),	   highly	  
multiplexed	  PCR	  amplicon	  sequencing	  proved	  to	  be	  an	  efficient	  method	  to	  gain	  
the	   depth	   needed	   at	   multiple	   variant	   sites	   in	   a	   large	   case	   control	   cohort.	  
Miscalling	  errors	   can	  be	  prevalent	   in	   sequencing	  data	  at	   individual	  genotypes,	  
especially	  when	   attempting	   to	   discriminate	   rare	   variants,	  which	   can	   easily	   be	  
perturbed	   due	   to	   their	   low	   MAFs.	   In	   addition,	   particular	   NGS	   errors	   are	  
systematic	  according	   to	   the	  platform	  used,	   for	   instance	  A>T	  miscalls	  are	  most	  
common	  in	  Illumina	  data	  (Bravo	  and	  Irizarry	  2010),	  and	  the	  quality	  of	  reads	  are	  
significantly	   lower	   in	   later	   cycles,	   possibly	   caused	   by	   incomplete	   extension	   of	  
the	  template	  (Metzker	  2010;	  Nakamura,	  Oshima	  et	  al.	  2011).	  The	  Illumina	  GAIIx	  
100bp	   data	   from	   the	   pilot	   study	   resulted	   in	   less	   error	   at	   the	   ends	   of	   reads	  
compared	   to	   140bp	   data,	   so	   101bp	   paired	   end	   (10bp	   index)	   sequencing	   runs	  
were	   chosen	   for	   the	  main	   study.	   The	   final	   dataset	   here	   contained	  only	  minor	  
	   173	  
miscalls	  (7.4%	  false-­‐positive	  rate)	  and	  all	  Sanger	  validated	  SNVs	  and	  indels	  had	  
the	   same	   alleles	   in	   Sanger-­‐sequencing	   assays	   as	   in	   the	   high	   throughput	  
sequencing	  data.	  One	  SNV	  annotated	  as	  a	  frameshift	  indel,	  was	  in	  fact	  validated	  
as	  a	  triallelic	  SNP.	  Firstly,	  the	  fact	  the	  SNP	  was	  reported	  as	  a	  triallelic	  variant	  and	  
not	   a	   bi-­‐allelic	   SNP	   shows	   improvement	   in	   the	   calling	  methods	   now	   available	  
(i.e.	  GATK).	  This	  is	  also	  true	  for	  the	  other	  triallelic	  SNVs	  (34	  in	  total)	  observed	  in	  
the	   data.	   It	   is	   not	   uncommon	   to	   see	   three	   nucleotides	   at	   one	   site,	   and	  
mutational	  mechanisms	  have	  been	  proposed	  that	  could	  potentially	  generate	  an	  
excess	  of	  triallelic	  sites.	  One	  explanation	  could	  be	  due	  to	  an	  elevated	  mutation	  
rate	  at	  a	  CpG	  site	  of	  at	  least	  two	  pathways	  (e.g.	  C-­‐T	  or	  C-­‐A)	  and	  CpG	  sites	  have	  
shown	   to	   be	   elevated	   in	   exons	   compared	   to	   overall	   occurrence	   in	   the	  whole	  
genome	  (Saxonov,	  Berg	  et	  al.	  2006).	  However,	  one	  study	  proposed	  that	  instead	  
of	   triallelic	   SNPs	   occurring	   at	   particular	   sites,	   they	   can	   incur	   during	  
recombination	  within	  the	  same	  individual	  (Hodgkinson	  and	  Eyre-­‐Walker	  2010).	  
Overall,	  the	  consequence	  of	  not	  detecting	  the	  unknown	  allele	  of	  a	  triallelic	  SNP	  
can	   be	   serious	   when	   the	   unknown	   allele	   carries	   a	   disease	   risk	   (Huebner,	  
Petermann	  et	  al.	  2007).	  Apart	   from	  Sanger	  validation,	  other	  data	  quality	  steps	  
were	   necessary;	   assessment	   of	   pass	   filter	   reads	   from	  water	   negative	   controls	  
and	  calculation	  of	  error	  rate	  of	  one	  positive	  control	  sequenced	  multiple	  times,	  
but	  PCR	  amplified	  on	  different	  multiplex	  arrays.	  Combined	  data	  quality	  results	  
highlighted	  the	  high	  specificity	  and	  sensitivity	  of	  the	  dataset	  enabling	  confident	  
genotype	  calls	  at	  variant	  sites	  across	  the	  sample	  set.	  	  
It	   was	   noted	   that	   with	   4,478	   (post	   quality	   control)	   sample	   set,	   single-­‐variant	  
association	  mapping	  of	  all	  coding	  rare	  variants	  was	  low	  powered	  for	  the	  number	  
of	  variants	  in	  the	  test	  and	  their	  associated	  low	  MAFs	  resulted	  in	  the	  test	  being	  
numerically	  unstable	   to	  analyze	  each	  variant	   independently	   (Bansal,	   Libiger	  et	  
al.	   2010;	   Morris	   and	   Zeggini	   2010).	   Therefore	   gene-­‐based	   tests,	   in	   which	  
multiple	   rare	   variants	   in	   the	   gene	   region	   are	   jointly	   analyzed	   to	   aggregate	   all	  
signals,	   were	   performed	   to	   better	   detect	   the	   combined	   effects	   of	   multiple	  
variants,	   given	   the	   evidence	   that	  multiple	   rare	   variants	   can	   have	   a	   collective	  
effect	  on	  disease	  risk	  (Cohen,	  Kiss	  et	  al.	  2004;	  Fearnhead,	  Wilding	  et	  al.	  2004).	  
These	  tests	  also	  reduced	  the	  effects	  of	  multiple	  testing,	  as	  the	  test	  was	  based	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on	   each	   gene	   transcript	   rather	   than	   each	   individual	   variant.	   Given	   that	   no	  
significant	   associations	   were	   identified,	   one	   fair	   conclusion	   is	   that	   the	   4,478	  
sample	   dataset	   lacked	   statistical	   power	   to	   achieve	   a	   significant	   rare	   variant	  
association	  at	  a	  candidate	  gene.	  For	  the	  gene	  with	  the	  highest	  P	  values	  (P=0.004	  
in	  a	  uniq	  case-­‐control	  allele	  test	  and	  P=0.007	  in	  a	  burden	  test),	  EPAS1,	  a	  larger	  
sample	  size	  may	  possibly	  have	  pushed	  the	  P	  value	  to	  a	  significant	  association	  at	  
P<1	   x	   10-­‐3,	   indicating	   that	   there	   is	   a	   significant	   excess	   of	   alleles	   in	   cases	  
compared	   to	   controls.	   Even	  when	   correcting	   for	   the	   number	   of	   genes,	   rather	  
than	   the	  number	  of	   transcripts	   tested	   (as	   some	   transcripts	   for	   the	   same	  gene	  
had	  the	  same	  number	  of	  variants),	  no	  significant	  associations	  were	  present	  at	  
P<1	  x	  10-­‐3.	  	  
A	  major	  difficulty	  with	  complex	  disease	   is	  selecting	  genomic	   locations	  to	  focus	  
on,	   compared	   to,	   for	   example,	   an	   X-­‐linked	   disease	   where	   all	   X-­‐chromosome	  
genes	  can	  be	  easily	  resequenced	  (Tarpey,	  Smith	  et	  al.	  2009).	  In	  this	  study,	  it	  was	  
necessary	   to	  balance	   the	  cost	  of	   resequencing	  with	   the	  number	  of	  genes	   that	  
might	   carry	   a	   rare	   risk	   variant.	   The	   candidate	   list	   was	   developed	   through	  
multiple	  strategies	  using	  exome	  capture	  data,	  where	  not	  all	  the	  exome	  will	  have	  
been	  captured.	  Given	  that	  only	  a	  small	  fraction	  of	  the	  genome	  was	  interrogated	  
(amplicons	   only	   cover	   small	   parts	   of	   the	   chromosomes),	   all	   samples	   were	  
directly	   sequenced	   so	   the	   sample	   set	  was	  utilized	   in	   the	  best	  way	  possible	   to	  
search	   for	   rare	   variants	   in	   investigative	   regions.	   The	   intention	   was	   that	  
sequencing	  could	  lead	  to	  identification	  of	  enough	  rare	  variants,	  in	  one	  or	  more	  
genes,	   that	   could	   explain	   a	   substantial	   proportion	   of	   the	  missing	   heritability.	  
However,	   even	   if	   a	   single	   gene	  with	   a	   large	   effect	   size	   in	   CD	  had	  been	   found	  
through	  the	  chosen	  analytical	  strategies,	  the	  therapeutic	  advantage	  would	  have	  
carried	   a	   larger	   pay	   off.	   For	   example,	   BRCA1/2	   mutations	   do	   not	   necessarily	  
explain	   much	   heritability	   of	   breast	   cancer,	   but	   there	   is	   diagnostic	   value	   for	  
treatment	  (Couch,	  Wang	  et	  al.	  2013).	  	  
On	   the	  basis	  of	   the	   results,	   there	   is	   lack	  of	   support	   to	  prove	   the	   rare	  variant-­‐
common	   disease	   hypothesis	   in	   subjects	   where	   there	   is	   familial	   clustering	   of	  
disease.	   These	   findings	   support	   a	   recent	   resequencing	   study	   of	   25	  GWAS	   risk	  
genes	   from	   six	   autoimmune	   diseases	   in	   42,000	   subjects	   that	   concluded	   rare	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coding	   mutations	   play	   a	   negligible	   role	   in	   the	   autoimmune	   diseases	   under	  
investigation	   (Hunt,	  Mistry	   et	   al.	   2013).	   The	   role	   of	   rare	   variants	   in	   common	  
disease	  is	  further	  discussed	  in	  Chapter	  6:	  Discussion.	  	  
	  
5.8	  Chapter	  Conclusions	  
	  
The	  points	  below	  conclude	  the	  findings	  from	  the	  research	  in	  this	  chapter:	  
1. Fluidigm	   Access	   Array	   multiplex	   PCR	   technology	   was	   excellent	   in	  
providing	   the	   necessary	   coverage	   required	   for	   highly	   multiplexed	  
amplicon	  sequencing.	  	  
2. The	   high	   quality	   dataset	   was	   acquired	   by	   applying	   high	   individual	   call	  
rates	  and	  SNV	  genotyping	  call	  rates,	  along	  with	  other	  data	  quality	  filters.	  	  
3. Many	  rare	  variants	  in	  4,478	  post	  quality	  control	  samples	  were	  observed	  
in	  protein	  coding	  regions	  of	  24	  candidate	  genes,	  of	  which	  60	  SNVs	  were	  
rare	  (MAF	  <0.5%)	  and	  LoF,	  according	  to	  GENCODE	  v14	  annotation.	  	  
4. Various	  gene-­‐based	  methods	  to	  test	  the	  effects	  of	  multiple	  rare	  variants	  
per	  gene	  were	  performed,	  but	  no	  significant	  associations	  were	  observed	  
in	  any	  candidate	  gene.	  	  
5. For	  EPAS1	   (P=0.004	   in	   a	   uniq	   case-­‐control	   allele	   test	   and	  P=0.007	   in	   a	  
burden	   test)	   testing	   the	   variants	   a	   larger	   sample	   size	   is	   required	   to	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6.1	  Research	  background	  and	  summary	  of	  findings	  	  
	  
The	   spectrum	   of	   genetic	   variation	   in	   human	   diseases	   ranges	   from	   common	  
variants	  of	  combined	  weak	  effects	  to	  rare	  variants	  with	  modest	  to	  strong	  effects	  
on	   the	  disease	  phenotype.	  Rare,	  high-­‐risk,	  monogenic	  variants	  have	  classically	  
been	  determined	  through	   linkage	  and	  positional	  cloning	  analysis	   in	  Mendelian	  
pattern	  diseases	  (Kerem,	  Rommens	  et	  al.	  1989;	  Riordan,	  Rommens	  et	  al.	  1989),	  
and	   more	   recently	   exome	   sequencing,	   whereas	   a	   large	   fraction	   of	   common	  
variants	   have	   been	   investigated	   by	   GWAS	   in	   common	   complex	   diseases	  
(Hirschhorn,	   Lohmueller	   et	   al.	   2002),	  made	  possible	   by	   the	   completion	  of	   the	  
HapMap	   project	   (Consortium	   2003;	   Thorisson,	   Smith	   et	   al.	   2005).	   The	   CDCV	  
hypothesis	   was	   rooted	   in	   descriptions	   of	   the	   allelic	   spectrum	   of	   disease,	  
outlining	   the	   totality	   of	   variations	   contributing	   to	   disease:	   low	   penetrance	  
(disease	   is	   expressed	   in	   a	   minority	   of	   individuals	   with	   the	   phenotype),	   high	  
penetrance,	   common	   and	   rare	   variations	   (Reich	   and	   Lander	   2001).	   Since	  
variants	   of	   relatively	   low	   penetrance	   but	   with	   common	   population	   allele	  
frequencies	   (that	  are	  shared	  between	  multiple	   individuals)	  have	  not	  explained	  
much	  of	  the	  heritability	  of	  disease	  risk	  (due	  to	  genetic	  effects),	  focus	  has	  been	  
shifted	   toward	   locating	  multiple	   rare	  variants	  with	  high	  penetrance	   that	  could	  
explain	   the	   majority	   of	   genetic	   susceptibility	   to	   common	   disease	   (the	   CDRV	  
hypothesis)	   (Schork,	   Murray	   et	   al.	   2009).	   Studies	   have	   firmly	   proposed	   that	  
amino-­‐acid	   altering	   (nonsynonymous)	   mutations	   generally	   have	   a	   rare	  
population	   frequency	   compared	   to	   silent	   substitutions	   (Cargill,	  Altshuler	   et	   al.	  
1999),	  due	  to	  negative	  selection	  acting	  upon	  deleterious	  mutations	  preventing	  
them	   from	   reaching	   high	   allele	   frequencies,	   producing	   an	   excess	   of	   rare	  
variation	   (Fay,	  Wyckoff	   et	   al.	   2001;	  Bustamante,	   Fledel-­‐Alon	  et	   al.	   2005).	   This	  
excess	   has	   also	   been	   attributed	   to	   recent	   population	   expansion	   (Williamson,	  
Hernandez	   et	   al.	   2005)	   with	   one	   study	   predicting	   30-­‐42%	   of	   nonsynonymous	  
(amino	  acid	  altering)	  mutations	  are	  moderately	  deleterious	  after	  accounting	  for	  
demographic	  effects	  in	  African	  and	  European	  populations	  (Boyko,	  Williamson	  et	  
al.	  2008).	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A	   major	   advance	   in	   the	   field	   of	   genetics	   in	   the	   last	   five	   years	   has	   been	   the	  
creation	   of	   technology	   that	   allowed	   capture	   and	   sequencing	   of	   the	   entire	  
protein-­‐coding	   region	   of	   the	   genome	   by	   companies	   such	   as	   NimbleGen	   and	  
Agilent.	   Since	   the	   technology	   for	   exome	   sequencing	   became	   available,	  
researchers	   were	   able	   to	   carry	   out	   hypothesis-­‐free	   studies	   using	   sequenced	  
variants	   in	   the	   exome,	   similar	   to	   GWAS	   studies	   using	   genotyped	   markers.	  
Filtering	   approaches	   and	   investigating	   novel	   variants	   in	   genes	   common	   to	  
disease	   individuals	   led	   to	   many	   studies	   publishing	   findings,	   some	   of	   which	  
enabled	  a	  genetic	  diagnosis	   in	   rare	  Mendelian	   traits	   (Hoischen,	   van	  Bon	  et	  al.	  
2010;	  Krawitz,	  Schweiger	  et	  al.	  2010;	  Pierce,	  Walsh	  et	  al.	  2010;	  Wang,	  Yang	  et	  
al.	  2010).	  Exome	  studies	  in	  mental	  disorders,	  such	  as	  autism,	  schizophrenia	  and	  
mental	   retardation,	   have	   also	   located	   rare	   CNVs	   in	   gene	   risk	   pathways	  
(Stefansson,	  Rujescu	  et	  al.	  2008;	  Helbig,	  Mefford	  et	  al.	  2009;	  Pinto,	  Pagnamenta	  
et	  al.	  2010),	  and	  in	  combined	  consanguinity	  and	  homozygosity	  mapping	  studies	  
(Caliskan,	  Chong	  et	  al.	  2011).	  The	  success	  of	  these	  studies	  are	  also	  owed	  to	  the	  
expansion	  of	  sequencing	  technologies	  for	  deeper	  resolution	  of	  novel	  and	  known	  
genetic	  variants	   (Shendure	  and	   Ji	  2008;	  Metzker	  2010;	  Nekrutenko	  and	  Taylor	  
2012),	   where	   the	   1000G	   project	   has	   been	   at	   the	   forefront	   of	   uncovering	  
variation	   of	   at	   least	   1%	   frequency	   in	   major	   population	   groups	   (Abecasis,	  
Altshuler	  et	  al.	  2010;	  Abecasis,	  Auton	  et	  al.	  2012).	  	  
The	   primary	   aim	   of	   the	   research	   in	   this	   thesis	   was	   to	   locate	   rare	   variants	  
predisposing	   to	  CD	   risk,	   through	   target	   capture	  of	   protein	   coding	   regions	   and	  
high	  throughput	  sequencing,	  with	  evidence	  of	  positive	  findings	  from	  candidate	  
gene	   studies	   in	   other	   genetic	   diseases	   (Yeo,	   Farooqi	   et	   al.	   1998;	   Kotowski,	  
Pertsemlidis	  et	  al.	  2006;	  Raychaudhuri,	  Iartchouk	  et	  al.	  2011).	  To	  recap,	  whole-­‐
exome	   sequencing	   (Chapter	   3)	  was	   selected	   as	   a	  method	   to	   identify	   any	   rare	  
(<5%	   MAF)	   mutations	   that	   might	   directly	   affect	   gene/protein	   function	   in	   CD	  
individuals	   selected	   from	  55	  multiply	  affected	   (>2	  affected	  per	   family)	  disease	  
families.	  A	  family-­‐based	  sample	  set	  was	  used	  to	  detect	  a	  Mendelian	  pattern	  of	  
inheritance	   in	   an	   otherwise	   complex	   genetically	   heterogenous	   disease	  
(Cardenas-­‐Roldan,	  Rojas-­‐Villarraga	  et	  al.	  2013).	  Because	  of	  the	  highly	  heritable	  
nature	   of	   CD	   (Nistico,	   Fagnani	   et	   al.	   2006),	   if	   there	   were	   a	   high	   risk	   variant	  
	   179	  
causing	   severe	   phenotypes	   it	   should	   be	   present	   in	   families.	   Any	   highly	  
penetrant	  rare	  mutations	  found	  might	  explain	  the	  ~60%	  of	  missing	  heritability	  
in	  CD,	  if	  associated	  with	  disease	  in	  a	  large	  case	  control	  sample	  set.	  	  
Early	  on,	   it	  was	   recognized	  that	   the	  main	  caveat	   to	   the	  experiment	  was	  many	  
thousands	  of	  candidate	  variants	  (average	  15,601	  protein	  coding	  mutations	  per	  
sample)	   were	   identified,	   creating	   a	   challenge	   in	   locating	   true	   disease	   causing	  
mutations.	   The	   intention	   was	   to	   apply	   various	   strategies	   to	   the	   dataset	  
generated	   from	   a	   newly	   released	   capture	   method	   (NimbleGen	   in-­‐solution	  
exome	   capture,	   released	   in	   2010)	   requiring	   new	   strategic	   applications,	   from	  
segregation	  analysis	  to	  gene-­‐based	  tests.	  No	  conclusive	  variants	  were	  found	  to	  
be	   segregating	   with	   disease	   in	   >2	   generation	   families	   with	   >2	   affected	  
individuals.	  Gene-­‐based	  analysis	   identified	  CUBN	  as	  a	  potential	  candidate	  with	  
three	   different	   mutations	   in	   three	   unrelated	   individuals,	   indicating	   rare	  
mutations	   in	   this	   gene	   may	   carry	   a	   disease	   risk.	   This	   gene	   might	   be	   taken	  
forward	  as	  a	   future	  experiment	  since	   it	  was	  too	   large	  to	  resequence	  here	   in	  a	  
Fluidigm	   multiplex	   assay.	   Other	   candidate	   genes	   that	   carried	   more	   or	   less	  
variants	   then	  expected	   in	   cases	   compared	   to	   controls	   (identified	  by	  a	   Fisher’s	  
exact	   test)	  were	   selected	   for	   resequencing.	  Another	   strategy	   to	   locate	   shared	  
chromosomal	   regions	  with	   potential	   rare	   variants	   in	   coeliac	   families	  was	   NPL	  
linkage	  analysis.	  Significant	  linkage	  (LOD	  >3)	  was	  not	  observed	  in	  12	  pedigrees,	  
however	   many	   peaks	   with	   LODs	   of	   >1	   were	   present.	   Since	   these	   peaks	  
highlighted	  shared	  chromosomal	  regions,	  exome	  variants	  under	  the	  peaks	  were	  
assessed	   and	   Sanger	   sequenced	   in	   the	   entire	   family	   to	   confirm	   the	   variant’s	  
presence	   on	   a	   shared	   haplotype.	   Eight	   genes	   were	   taken	   forward	   for	  
resequencing.	   Interestingly,	   a	   finding	   that	   is	   also	   conclusive	   across	   all	   coeliac	  
studies,	   was	   the	   presence	   of	   common	  HLA	   risk	   allele	   types	   segregating	   in	   12	  
linkage	   pedigrees,	   some	  of	  which	   came	   from	  persons	  married	   into	   the	   family	  
and	  therefore	  not	  ancestral.	  	  
To	   study	   further	   rare	   variation	   in	   candidate	   genes	   (n	   =	   24),	   gene-­‐based	   tests	  
were	  performed	  on	  the	  candidate	  gene	  sequenced	  dataset	   in	  2,304	  cases	  and	  
2,304	  controls.	  Many	  missense	  and	  silent	  mutations	  were	  observed	  in	  exons	  of	  
genes,	  and	  only	  a	  handful	  of	  LoF	  mutations.	  91.7%	  of	  coding	  variants	  were	  rare,	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similar	   to	   findings	   in	   a	   recent	   rare	   variant	   autoimmune	   disease	   study	   (Hunt,	  
Mistry	  et	  al.	  2013).	  No	  mutations	  were	  significantly	  associated	  with	  disease	  risk	  
or	  protection,	  however	  a	   larger	  case	  control	   sample	  set	   is	   required	  to	   test	   for	  
any	   significant	   association	   in	  EPAS1	   (P=0.004	   in	   a	  uniq	   case-­‐control	   allele	   test	  
and	  P=0.007	   in	  a	  burden	   test).	  EPAS1	   (also	  known	  as	  HIF2A)	   is	  a	   transcription	  
factor	  expressed	  in	  endothelial	  cells	  and	  produces	  the	  hypoxia-­‐inducible	  factor	  
2-­‐alpha	  protein,	  which	  plays	  a	   role	   in	   the	  body’s	  adaption	  of	  changing	  oxygen	  
levels.	   A	   gain	   of	   function	   mutation	   in	   EPAS1	   has	   been	   implicated	   in	   familial	  
erythrocytosis	   (Percy,	   Furlow	   et	   al.	   2008).	   In	   a	   study	   testing	   the	   effects	   of	  
hypoxia-­‐inducible	  factors	  1	  and	  2	  (HIF1	  and	  HIF2)	  in	  diabetic	  mice,	  the	  authors	  
found	  that	  glucose	  activates	  HIF1	  and	  HIF2	   in	  rat	  beta	  cells	  and	  both	   isoforms	  
are	  activated	  in	  islets	  suggesting	  hyperglycaemia	  could	  induce	  pancreatic	  beta-­‐
cell	  hypoxia	  (Bensellam,	  Duvillie	  et	  al.	  2012).	  Since	  many	  risk	  loci	  are	  common	  to	  
both	   T1D	   and	   CD,	   EPAS1	   may	   also	   play	   a	   role	   in	   CD	   pathogenesis.	   Further	  
studies	   of	   the	   possible	   function	   of	   this	   gene	   in	   coeliac	   patients	   must	   first	  
confirm	  any	  significant	  association	  followed	  by	  a	  sequencing	  replication	  study	  of	  
the	   entire	   exonic	   region	   in	   more	   samples.	   Even	   a	   meta-­‐analysis	   combining	  
known	  T1D	  and	  CD	  GWAS	  and	  fine	  mapping	  genotypes	  with	  imputation	  of	  rare	  
variants	  from	  sequenced	  variants	  in	  this	  study	  could	  highlight	  an	  association	  in	  
EPAS1	  using	  a	  large	  case	  control	  sample	  size,	  as	  observed	  in	  other	  autoimmune	  
diseases	  (Zhang,	  Yan	  et	  al.	  2013;	  Zheng,	  Yin	  et	  al.	  2013).	  
A	   recent	   study	   applied	   imputation	   of	   rare	  whole	   genome	   sequenced	   variants	  
into	   >95,000	   Icelandic	   genotyped	   individuals	   and	   found	   that	   a	   rare	   nonsense	  
mutation	  in	  LGR4	  associated	  with	  low	  bone	  mineral	  density	  in	  osteoporosis	  also	  
had	   an	   increased	   risk	   in	   squamous	   cell	   carcinoma	   and	   biliary	   tract	   cancer	  
(Styrkarsdottir,	   Thorleifsson	   et	   al.	   2013).	   This	   study	   does	   highlight	   some	   key	  
points:	   imputation	   from	   rare	   variants	   into	   tagged	   SNPs	   is	   not	   completely	  
accurate,	   but	   the	   authors	   did	   apply	   familial	   imputation	   by	   way	   of	   increasing	  
accuracy	  as	  one	  would	  expect	   related	   individuals	   to	  have	   the	  same	  genotypes	  
(they	  used	  familial	  sequenced	  variants	  to	   impute	   into	  un-­‐genotyped	  relatives);	  
the	  study	  covered	  all	  genes	  genome-­‐wide	  compared	  to	  24	  candidate	  genes	  used	  
here	   and	   yet	   only	   discovered	   one	   rare	   (0.1%)	   mutation,	   and	   loss	   of	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heterozygosity	  was	  only	  assessed	  in	  four	  biliary	  tract	  cancer	  variant	  carriers,	  so	  
more	   functional	   work	   is	   required	   to	   completely	   assess	   phenotypic	   effect	   in	  
carriers.	   Since	   high	   effect	   rare	   variants	   are	   known	   in	   these	   cancer	   types,	   one	  
would	  expect	  rare	  variant	  detection	  in	  such	  a	  big	  sample	  size,	  which	  may	  not	  be	  
the	   case	   for	   a	   common	   disease,	   as	   observed	   for	   rare	   variants	   in	   SIAE	   where	  
there	  was	  a	   lack	  of	  association	  across	  multiple	  common	  autoimmune	  diseases	  
(Hunt,	  Smyth	  et	  al.	  2012).	  	  
	  
6.2	  Effects	  of	  sample	  and	  experimental	  design	  	  
	  
Choosing	   the	  correct	   sample	  set	   for	  exome	  sequencing	   is	  a	  key	  component	   in	  
the	  experimental	  design.	  It	  is	  unfeasible	  for	  researchers	  to	  sequence	  the	  tens	  of	  
thousands	   of	   individuals	   required	   for	   rare	   variant	   detection	   because	   they	   are	  
present	  at	   such	   low	   frequencies.	   To	  maintain	  adequate	   costs	  and	  balance	   the	  
potential	  of	  finding	  a	  result,	  the	  75-­‐sample	  set	  here	  was	  a	  combination	  of	  first	  
and	   second-­‐degree	   relatives	   from	   coeliac	   families.	   This	   is	   akin	   to	   selecting	  
extreme	  phenotype	   samples	   for	   a	   quantitative	   trait	   (Li,	   Lewinger	   et	   al.	   2011),	  
and	   since	   pedigrees	   had	   a	   history	   of	   disease	   in	   at	   least	   two	   generations,	   the	  
potential	  of	  finding	  a	  variant	  segregating	  in	  a	  Mendelian	  fashion	  was	  felt	  to	  be	  
high.	  In	  addition,	  a	  previous	  study	  showed	  that	  relatives	  of	  coeliacs	  have	  a	  high	  
risk	   of	   carrying	   silent	   CD,	   so	   using	   family	   samples	   can	   enrich	   for	   any	   disease	  
causing	  mutations	  (Petaros,	  Martelossi	  et	  al.	  2002).	  	  
Given	   these	   assumptions,	   in	   a	   family	   design	   for	   rare	   variant	   detection,	   the	  
question	  that	  should	  be	  addressed	  is	  under	  what	  circumstance	  are	  rare	  variants	  
with	   a	   disease	   risk	   expected	   to	   segregate	   in	   familial	   disease	   cases.	   A	   recent	  
study	   found	   that	   as	   λs	   (defined	   as	   the	   ratio	   of	   disease	   manifestation	   if	   one	  
sibling	   is	   affected,	   compared	   with	   prevalence	   of	   disease	   in	   the	   population)	  
increased,	  the	  probability	  of	  co-­‐segregation	  of	  the	  rare	  variant	  declined	  (Helbig,	  
Hodge	  et	  al.	  2013).	  The	  authors	  used	  the	  presence	  of	  the	  15q13.3	  microdeletion	  
in	  probands	  with	  idiopathic	  generalized	  epilepsy	  as	  an	  example	  and	  noted	  that	  
for	  a	  variant	  with	  an	  OR	  of	  5,	  the	  probability	  that	  an	  affected	  relative	  carrying	  
the	  variant	  was	  58%	  when	  the	  λs	  was	  50,	  compared	  to	  82%	  when	  the	  λs	  was	  2.	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However,	   for	   moderate	   ORs	   (between	   1	   -­‐	   1.3),	   λs	   had	   little	   effect	   on	   the	  
probability.	  Another	  study	  similarly	  highlighted	  that	  for	  a	  complex	  disease	  with	  
a	  high	  λs	  sequencing	  unrelated	  individuals	  was	  preferable,	  but	  for	  diseases	  with	  
small	  λs	  sequencing	  an	  affected	  individual	  with	  an	  affected	  close	  relative	  can	  be	  
a	   powerful	   strategy	   for	   the	   identification	   of	   rare	   variants,	   based	   on	   a	  model	  
using	  2,000	  affected	  individuals	  (Ionita-­‐Laza	  and	  Ottman	  2011).	  The	  λs	  of	  10	  for	  
CD	  might	  not	  have	  an	  effect	  on	  the	  probability	  of	  an	  affected	  relative	  carrying	  a	  
rare	   risk	  variant,	  according	   to	   the	  probability	   theory	  employed	   in	  Helbig	  et	  al.	  
The	   strategy	   of	   sequencing	   one	   or	   two	   affected	   relatives	   per	   family	   (with	   an	  
affected	  close	  relative)	  in	  this	  study	  was	  moderately	  powerful,	  according	  to	  the	  
model	  outlined	  in	  Ionita-­‐Laza	  et	  al,	  however	  a	  sample	  size	  of	  >75	  was	  probably	  
required	   to	   detect	   those	   shared	   variants,	   albeit	   at	   a	   cost	   of	   an	   increased	  
number	   of	   variants	   to	   filter	   through.	   On	   the	   other	   hand,	   if	   the	   funding	   was	  
available,	  it	  might	  have	  been	  advantageous	  to	  sequence	  every	  affected	  member	  
of	   the	   family	   to	   increase	   power.	   Exome	   sequencing	   data	   in	   consanguineous	  
eczema	   families	  has	   located	  multiple	   variants	   in	   a	   single	   known	  disease	  gene,	  
FLG,	  observed	   in	  different	  affected	   individuals.	  No	  single	  variant	  was	  common	  
to	   all	   affected	   cases	   revealing	   that	   rare	   variants	   are	   unique	   to	   the	   individual	  
(David	  Kelsell,	  personal	  communication).	   If	  one	  gene	  was	  causal	   to	  CD	  risk,	  all	  
affected	   individuals	   would	   have	   to	   be	   sequenced	   in	   order	   to	   locate	   all	   risk	  
variants	  in	  the	  gene	  clustering	  in	  the	  family.	  	  
The	   control	   sample	   set	   is	   just	   as	   important	   as	   the	   case	   sample	   set.	   Recent	  
experiments	   testing	   the	  outcome	  of	   a	   combination	  of	   rare	   variant	   tests	   using	  
three	   different	   control	   datasets	   with	   three	   family	   structures	   (trios,	   enriched	  
trios,	  where	   only	   one	   sibling	   is	   tested,	   and	  ASP)	   showed	   that	   using	   unrelated	  
controls	  gave	  better	  power	   than	  using	  controls	   from	   family	  data	   (Preston	  and	  
Dudbridge	  2013	  in	  press).	  No	  related	  control	  samples	  were	  exome	  sequenced	  in	  
this	   study,	   but	   200	   unrelated	   exome	   controls	   from	   neurodegenerative	  
phenotypes	   from	   the	   UK	   were	   used.	   Small	   differences	   in	   ancestry	   between	  
cases	  and	  controls	  can	  still	  incur	  false	  positive	  results	  since	  rare	  variants	  have	  a	  
restricted	  geographic	  distribution	  (Mathieson	  and	  McVean	  2012),	  but	  given	  that	  
similar	  false	  positive	  rates	  were	  observed	  in	  the	  initial	  discovery	  exome	  dataset	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as	   in	   the	   candidate	   gene	   resequencing	   dataset	   (8.1%	   and	   7.4%,	   respectively),	  
which	   had	   a	   matching	   population	   control	   dataset	   of	   2,304	   individuals,	   the	  
unrelated	  independent	  control	  set	  for	  the	  exome	  sequencing	  experiment	  was	  a	  
good	  choice.	  	  
Linkage	   analysis	   in	   this	   thesis	   was	   performed	   to	   locate	   shared	   chromosomal	  
regions	   in	   coeliac	   families	   in	  which	   segregating	   rare	   variants	  might	   be	   found.	  
Several	   factors	   affect	   the	   power	   of	   a	   linkage	   test	   to	   produce	   a	   result:	  
polymorphism	   of	   the	   marker,	   mode	   of	   inheritance	   of	   the	   disease	   and	  
recombination	  distance	  between	  the	  disease	  locus	  and	  marker,	  all	  of	  which	  may	  
have	  been	  factors	   in	   the	  analysis	  here.	  Using	  a	  multiplicative	   linkage	  model,	   it	  
has	  been	   shown	   that	  diseases	  with	  a	   large	  λs	   often	   indicate	  genotype	   specific	  
effects	  that	  are	  not	  well	  detected	  by	  linkage	  methods	  and	  multiple	  loci	  having	  a	  
combined	   effect	   must	   be	   taken	   into	   account	   (Rybicki	   and	   Elston	   2000).	   The	  
authors	  also	  highlighted	  that	  IBD	  distribution	  amongst	  distant	  relationships	  (i.e.	  
uncle-­‐nephew)	   is	   dependent	   on	   marker	   allele	   frequencies,	   so	   although	   it	   is	  
beneficial	  to	  use	  these	  relationship	  types,	  for	  a	  rare	  marker	  allele	  there	  could	  be	  
a	   lack	   of	   IBD.	   The	   linkage	   study	   here	   used	   markers	   with	   MAF	   <0.2,	   so	   IBD	  
sharing	   may	   not	   have	   been	   significant	   amongst	   the	   more	   distantly	   related	  
individuals	   in	   the	   pedigree.	   There	   is	   also	   the	   issue	   of	   multiple	   phenocopies,	  
defined	   here	   as	   the	   disease	   being	   acquired	   by	   different	   means,	   i.e.	   different	  
underlying	   markers	   in	   affected	   individuals	   compared	   to	   other	   cases	   in	   a	  
pedigree.	  In	  one	  study,	  phenocopy	  impact	  has	  been	  shown	  to	  have	  a	  significant	  
effect	  when	  epistatic	  effects	  were	  included	  in	  a	  simulated	  disease	  model	  (Lescai	  
and	  Franceschi	  2010).	  Correcting	  for	  these	  interaction	  effects	  may	  significantly	  
improve	  the	  linkage	  LOD	  score	  (Sung	  and	  Wijsman	  2007).	  	  
	  
6.3	  Progression	  in	  exome	  studies	  	  
	  
This	   work	   in	   this	   thesis	   was	   one	   of	   the	   earliest	   projects	   aiming	   to	   seek	   rare	  
variants	  in	  the	  exome,	  and	  since	  then	  many	  changes	  have	  occurred	  surrounding	  
exome	  sequencing.	  At	   the	   time	  of	  project	   commencement	   (2009),	   the	   cost	  of	  
sequencing	   one	   exome	   was	   approximately	   £1,200,	   using	   NimbleGen	   exome	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capture	  and	  Illumina	  sequencing.	  Companies	  such	  as	  23andMe	  are	  now	  offering	  
prices	  of	  $999	  per	  exome,	  so	  the	  cost	  is	  not	  significantly	  different	  when	  taking	  
library	  preparation	  costs	  into	  account.	  However,	  as	  the	  cost	  of	  NGS	  decreases,	  it	  
is	   cost-­‐effective	   to	   sequence	   multiple	   exomes,	   especially	   in	   a	   collaborative	  
effort.	  The	  effectiveness	  of	  exome	  sequencing	  has	  initiated	  large	  collaborations	  
employing	  the	  method	  for	  the	  discovery	  of	  novel	  genes	  contributing	  to	  disease	  
phenotypes.	   The	   NHLBI	   Exome	   Sequencing	   Project	   is	   a	   combination	   of	   heart,	  
lung	   and	   blood	   disorders	   from	   large,	   well-­‐characterized	   populations	   in	   the	  
United	  States	  with	  the	  aim	  of	  finding	  novel	  disease	  mechanisms.	  A	  plethora	  of	  
studies	  have	  already	  been	  published	  (Regalado,	  Guo	  et	  al.	  2011;	  Boileau,	  Guo	  et	  
al.	   2012;	   Emond,	   Louie	   et	   al.	   2012;	   Krumm,	   Sudmant	   et	   al.	   2012;	   Norton,	  
Robertson	  et	  al.	  2012;	  Tennessen,	  Bigham	  et	  al.	  2012).	  Some	  studies	  evaluated	  
all	  the	  rare	  coding	  variation	  in	  relation	  to	  functional	  impact,	  with	  similar	  findings	  
to	   other	   coding	   variation	   studies	   (Norton,	   Robertson	   et	   al.	   2012;	   Tennessen,	  
Bigham	   et	   al.	   2012),	   and	   one	   study	   used	   the	   data	   to	   detect	   CNV	   variation	  
showing	   high	   correlation	   with	   whole-­‐genome	   data	   when	   using	   exome-­‐based	  
genotyping	   to	   detect	   copy	   number	   polymorphisms	   (Krumm,	   Sudmant	   et	   al.	  
2012).	  	  
Similar	   efforts	   are	   established	   in	   the	   UK	   to	   detect	   new	   discoveries	   in	   a	   large	  
European	  cohort.	  The	  UK10K	  initiative	  aims	  to	  sequence	  6,000	  exomes	  with	  an	  
average	   72x	   sequencing	   depth	   and	   4,000	  whole-­‐genomes	  with	   an	   average	   6x	  
depth.	   Where	   the	   1000G	   sequenced	   individuals	   from	   distinct	   geographic	  
populations,	   the	   UK10K	   aims	   to	   provide	   a	   deeper	   resolution	   in	   a	   European	  
cohort.	  The	  6x	   low	  pass	   sequencing	  coverage	  has	  a	   resolution	   to	  detect	  more	  
variants	  than	  the	  4x	  depth	  used	  by	  1000G	  and	  in	  a	  larger	  sample	  size.	  Another	  
difference	   lies	   in	   the	   main	   aim	   of	   the	   UK10K	   project,	   which	   is	   to	   link	  
phenotype/genotype	   relationships	  by	  using	  deeply	  phenotyped	   samples	   (from	  
Twins	   UK	   and	   Avon	   Longitudinal	   Study	   of	   Parents	   and	   Children	   repositories)	  
allowing	  a	  genetic	  comparison	  of	  shared	  traits.	  	  
These	   initiatives	   highlight	   a	   major	   advance	   in	   the	   field;	   to	   find	   and	   confirm	  
disease	  causal	  mutations	  by	  sequencing	  thousands	  of	  individuals	  across	  multiple	  
related	   diseases	   in	   order	   to	   gain	   statistical	   power	   required	   for	   accurate	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sequence-­‐based	  genotyping.	  The	  UK10K	  dataset	  provides	  a	  great	  control	  sample	  
resource	   for	   ongoing	   smaller	   sequencing	   studies,	   something	   that	   was	   not	  
available	   in	  2009.	  The	   resource	  has	  also	  enabled	   imputation	  of	   low	   frequency	  
(MAF	   <0.1%)	   variants	   into	   current	  GWAS	   data	   to	   increase	   power,	   and	  will	   be	  
downloaded	   onto	   reference	   databases	   (e.g.	   dbSNP,	   RefSeq)	   providing	   deeper	  
annotation	  of	  the	  genome.	  Along	  with	  the	  efforts	  from	  ENCODE,	  where	  features	  
of	  genes	  have	  been	  significantly	  enhanced	  with	  high	  accuracy	  (Harrow,	  Frankish	  
et	  al.	  2012),	  these	  data	  will	  really	  benefit	  future	  studies	  aiming	  to	  locate	  genetic	  
causal	  variants.	  	  
	  
6.4	  Where	  does	  ‘missing	  heritability’	  of	  disease	  lie?	  
	  
The	  main	  question	  the	  research	  in	  this	  thesis	  attempted	  to	  answer	  was:	  do	  rare	  
variants	   carrying	   a	   high	   disease	   risk	   account	   for	   the	   missing	   heritability	   of	  
disease?	   In	   light	   of	   recent	   findings	   in	   42,000	   subjects	   across	   six	   autoimmune	  
diseases	   that	   found	   no	   rare	   variants	   at	   GWAS	   risk	   loci,	   showing	   the	   lack	   of	  
support	   for	   synthetic	   and	   rare	   associations	   of	   large	   effect	   (Hunt,	  Mistry	   et	   al.	  
2013),	   similar	   conclusions	   can	   be	   made	   here.	   Although	   different	   approaches	  
were	   taken	   (resequencing	   of	   GWAS	   risk	   loci	   and	   resequencing	   of	   candidate	  
genes	   from	   an	   exome	   sequencing	   dataset),	   the	   aims	   of	   both	   studies	   were	  
relatively	  similar	  and	  based	  on	  the	  CDRV	  hypothesis.	  If	  missing	  heritability	  does	  
not	  lie	  in	  the	  rare	  allele	  mutational	  spectrum	  of	  disease,	  it	  disproves	  the	  CDRV	  
hypothesis	   and	   other	   explanations	   should	   be	   sought.	   Proposals	   include	  
epistasis,	   structural	  variants,	  parent-­‐of-­‐origin	  effects	   (Goriely	  and	  Wilkie	  2010)	  
and	  inherited	  epigenetic	  factors	  (Eichler,	  Flint	  et	  al.	  2010).	  	  
To	  really	  know	  how	  much	  of	  the	  missing	  heritability	  to	  search	  for,	  it	  is	  useful	  to	  
know	  how	  much	   is	   exactly	  missing	   and	  how	  much	   is	   unknown.	  Many	   reviews	  
discuss	   flaws	   in	  estimates	  of	  heritability	   (Visscher,	  Hill	  et	  al.	  2008;	  Tenesa	  and	  
Haley	   2013),	   particularly	   unaccounted	   for	   gene-­‐gene	   and	   gene-­‐environment	  
interactions.	  Narrow	  sense	  heritability	   is	  more	  useful	   in	  predicting	  disease	  risk	  
as	   it	   calculates	   the	   average	   disease	   risk	   passed	   on	   to	   offspring,	   but	   it	   only	  
predicts	   contribution	   when	   there	   is	   no	   interaction	   between	   loci.	   Zuk	   et	   al	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discuss	   ‘phantom	   heritability’	   in	   their	   study,	   a	   phenomenon	   that	   can	  
overestimate	   the	   proportion	   of	   phenotypic	   variation	   explained	   by	   additive	  
effects	   of	   all	   variants	   inferred	   from	   population	   data	   by	   not	   including	   genetic	  
interaction	   data,	   and	   assuming	   it	   is	   additive	   (Zuk,	   Hechter	   et	   al.	   2012).	   An	  
additive	  effect	   is	  defined	  as	  the	  risk	  allele	  acting	   in	  an	   independent	  and	   linear	  
manner,	  with	  each	   independent	  allele	  having	  a	   cumulative	  effect.	  This	   in	   turn	  
underestimates	   the	   overall	   heritability	   of	   a	   trait,	   initially	   predicted	   from	  
pedigree-­‐based	   studies.	   For	   example,	   the	   71	   GWAS-­‐risk	   loci	   contributing	   to	  
Crohn’s	   disease	   susceptibility	   only	   explains	   23.2%	   of	   heritability	   (Franke,	  
McGovern	  et	  al.	  2010).	  This	   could	  possibly	  be	  explained	  by	   the	  use	  of	   tagging	  
SNPs	   that	   can	   underestimate	   true	   risk	   from	   the	   causal	   allele,	   or	   by	   not	  
accounting	   for	  multiple	   loci	   interactions.	  Epistasis	   is	   known	   to	  be	  of	  biological	  
importance	   (Phillips	   2008)	   and	   refers	   to	   interacting	   pairs	   of	   loci,	   where	   the	  
phenotype	  of	  one	  locus	  is	  explained	  by	  the	  genotype	  at	  another	  (Carlborg	  and	  
Haley	   2004),	   and	   directly	   negates	   any	   additive	   allele	   effects.	   Estimation	   of	  
epistatic	   effects	   can	   be	   incorporated	   into	   estimations	   of	   heritability,	   but	   will	  
probably	   require	   extremely	   large	   sample	   sizes	   due	   to	   small	   individual	  
interaction	  effects	  (Zuk,	  Hechter	  et	  al.	  2012).	  	  
Additional	   undetected	   common	   variations	   of	   weak	   effects	   might	   account	   for	  
missing	  heritability,	  as	  has	  been	  suggested	  by	  a	   study	   in	  yeast	   strains	   (Bloom,	  
Ehrenreich	  et	  al.	  2013).	  The	  authors	  attempted	  to	  explain	  differences	  between	  
broad	   sense	   (phenotypic	   variation	  due	   to	  heritable	   factors)	   and	  narrow	   sense	  
(phenotypic	  variation	  due	  to	  additive	  genetic	  factors)	  heritability	  by	  identifying	  
the	   presence	   of	   two-­‐locus	   interactions,	   however	   only	   small	   effects	   were	  
detected.	  The	  findings	  suggest	   that	  missing	  narrow	  sense	  heritability	   is	  due	  to	  
multiple	  weak	  effect	  loci,	  consistent	  with	  a	  study	  in	  human	  height,	  and	  any	  loci	  
interactions	  only	  account	  for	  a	  small	  contribution	  (Yang,	  Benyamin	  et	  al.	  2010).	  
Statistical	   models	   have	   also	   been	   developed	   that	   take	   into	   account	   the	  
contribution	   of	   SNPs	   just	   under	   the	   significance	   threshold	   for	   disease	  
association,	   such	   as	   polygenic	   analysis	   which	   aggregates	   SNPs	   and	   tests	   their	  
collective	   effect	   on	  phenotype	   (Purcell,	  Wray	   et	   al.	   2009).	   Another	   study	   also	  
applied	   a	   polygenic	   model	   to	   a	   simulated	   GWAS	   dataset	   and	   Bayesian	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computation	   and	   supported	   the	   ‘common	   causal	   variant	   weak	   effect	   size’	  
contribution	   to	   heritability	   (Stahl,	   Wegmann	   et	   al.	   2012).	   These	   studies	  
collectively	  suggest	  that	  many	  low	  penetrant	  variants	  are	  yet	  to	  be	  discovered	  
(Park,	  Wacholder	  et	  al.	  2010).	  	  
	  	  
6.5	  Research	  update	  and	  concluding	  remarks	  	  	  
	  
For	   rare-­‐variant	   analysis	   in	   complex	   disease,	   new	   algorithms	   are	   consistently	  
being	  developed.	  Only	   recently,	  a	  new	  method	  by	  Daniel	  MacArthur	  has	  been	  
developed	   to	   process	   simultaneously	   a	   high	   number	   of	   exomes,	   resulting	   in	  
cleaner	   data	   outputs	   and	   the	   discovery	   of	   new	   causal	   variants.	   Importantly,	  
robust	   case	   control	   comparisons	   can	   be	   made	   (Vincent	   Plagnol,	   personal	  
communication).	   Vincent	   Plagnol	   applied	   this	   algorithm	   to	   the	   75-­‐diseae	   case	  
exome	   dataset,	   confirming	   many	   of	   the	   variants	   found	   using	   the	   calling	  
algorithm	  applied	   in	  this	  thesis	   (SamTools),	  but	  some	  variants	  were	  missing	  or	  
annotated	   differently.	   For	   example,	   one	   variant	   in	   C4BPA	   that	   was	   a	   false	  
positive	  was	  not	  present	  in	  the	  new	  data,	  proving	  a	  cleaner	  output	  with	  the	  new	  
algorithm,	   and	   a	   nonsynonymous	   variant	   in	   C1QPB	   was	   annotated	   as	   a	  
synonymous	  SNP.	  Three	  nonsynonymous	  SNPs	  in	  TRAF4,	  ACOT8	  and	  TNFRSF21,	  
respectively,	  were	  not	  present	   in	  the	  new	  dataset	  possibly	  because	  a	  different	  
target	   region	   was	   used.	   So	   although	   the	   new	   algorithm	   has	   not	   drastically	  
changed	   the	   results,	   the	   lack	   of	   nonsynonymous	   SNPs	   in	   TRAF4,	   ACOT8	   and	  
TNFRSF21	   might	   have	   prevented	   them	   being	   chosen	   for	   resequencing,	   if	   the	  
new	  calling	  method	  was	  applied	  at	   the	   time	  of	  analysis.	   Interestingly,	  none	  of	  
these	  genes	  resulted	  in	  a	  gene-­‐based	  test	  P	  value	  of	  <0.01.	  As	  this	  experiment	  
was	  done	  many	  years	  ago,	  and	  significant	  improvements	  in	  statistical	  methods	  
and	  experimental	  designs	  have	  been	  proposed,	  it	  might	  have	  been	  beneficial	  to	  
exome	   sequence	   all	   affected	   individuals	   from	   coeliac	   pedigrees	   to	   locate	   the	  
complete	   rare	   mutational	   spectrum	   of	   all	   affected	   individuals	   with	   a	   familial	  
aggregation	  of	  disease.	  	  
In	  conclusion,	  the	  research	  shown	  in	  this	  thesis	  has	  provided	  extensive	  evidence	  
about	  the	  contribution	  of	  rare	  variation	  in	  familial	  coeliac	  cases.	  The	  strategy	  of	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sequencing	  multiply	  affected	   families,	  and	  deep	   follow	  up	  of	  candidate	  genes,	  
has	  not	  identified	  new	  disease	  risk	  mutations.	  It	  could	  be	  that	  a	  subset	  of	  rare	  
disease	  causing	  variants	  are	  only	  specific	  to	  one	  family	  and	  therefore	  will	  not	  be	  
observed	  at	  the	  disease	  population	  level.	  Evidence	  from	  the	  BRK	  family,	  where	  
all	   disease	   cases	   carry	   the	   novel	   C>T	   SNP	   in	   TNFRSF21,	   points	   towards	   this	  
scenario.	   On	   the	   other	   hand,	   perhaps	   undetected	   common	   variants	   of	   weak	  
effects	   (and	   other	   factors,	   e.g.	   environmental)	   may	   account	   for	   familial	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This	  research	  in	  this	  thesis	  has	  attempted	  to	  target	  rare	  variation	  predisposing	  
to	  CD.	  The	  current	  dataset	  leads	  to	  the	  conclusion	  that	  rare	  variation	  does	  not	  
lead	   to	  disease	   risk	   in	   this	   family-­‐based	  cohort,	  but	   future	  work	  based	  on	   the	  
results	   here	   may	   possibly	   lead	   to	   a	   different	   outcome.	   Below	   is	   a	   list	   of	  
proposals	  for	  a	  future	  PhD	  student:	  
• Test	  EPAS1	   in	  a	  larger	  case-­‐control	  sample	  size:	  since	  the	  P	  value	  in	  the	  
4,608-­‐sample	   dataset	   was	   0.007	   it	   may	   worth	   testing	   this	   gene	   in	   a	  
larger	  sample	  size	  for	  any	  significant	  rare	  variant	  disease	  associations.	  A	  
custom	   Taqman	   genotyping	   assay	   containing	   all	   EPAS1	   coding	   SNPs	   is	  
the	  simplest	  experiment	  that	  will	  quickly	  answer	  this	  question.	  	  	  
• Resequence	   CUBN:	   this	   gene	   was	   too	   large	   to	   incorporate	   into	   the	  
Fluidigm	   targeted	   resequencing	   assay.	   For	   this,	   a	   single-­‐gene	  
resequencing	   experiment	   in	   a	   medium	   case-­‐control	   sample	   to	   begin	  
with,	   (approximately	  500	  cases	  and	  controls)	  will	   test	  whether	   there	   is	  
an	   excess	   of	   rare	   variation	   in	   coeliac	   cases	   compared	   to	   controls.	  
Fluidigm	   resequencing	   technology	   can	   still	   be	  used	  here,	  but	  a	  48-­‐plex	  
assay	  would	  suffice.	  	  
If	  one	  was	  to	  continue	  the	  search	  for	  rare	  variation	  in	  CD	  using	  familial	  samples	  
to	  enrich	  for	  disease	  mutations	  and	  to	  account	  for	  familial	  clustering	  of	  disease,	  
another	   design	   would	   be	   to	   exome	   sequence	   every	   affected	   individual	   from	  
many	  coeliac	  pedigrees	  and	  compare	  to	  a	  matching	  population	  control	  dataset	  
e.g.	  the	  UK10K	  exome	  dataset.	  This	  would	  provide	  a	  highly	  annotated	  dataset	  of	  
every	  coding	  mutation	  in	  all	  sequenced	  individuals,	  however	  it	  may	  also	  lead	  to	  
some	   data	   being	   discarded	   due	   to	   the	   sharing	   of	   chromosomal	   regions	   in	  
families.	  Additionally,	  up	   to	   thousands	  of	  samples	  may	  be	  required	  to	  achieve	  
the	   statistical	   power	   required	   in	   a	   complex	   disease,	   but	   in	   terms	   of	   sample	  
design,	  many	  different	  approaches	  can	  be	  applied	  to	  achieve	  the	  best	  statistical	  
result.	   It	  has	  been	  shown	  that	  exome	  sequencing	   trios	  and	   then	  performing	  a	  
family-­‐based	  association	  test	  may	  be	  particularly	  useful	  for	  rare	  variants,	  since	  
the	   sample	   set	   would	   be	   robust	   to	   population	   stratification	   and	   Mendelian	  
errors	   can	   be	   checked	   to	   reduce	   the	   false	   positive	   rate	   (De,	   Yip	   et	   al.	   2013).	  
Furthermore,	  there	  is	  evidence	  of	  increased	  sensitivity	  to	  find	  lower	  effect	  sizes	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with	  the	  use	  of	  an	  enriched	  trio	   (one	  sibling	   from	  an	  ASP)	   in	  gene-­‐based	  tests	  
(Preston	   and	  Dudbridge	   2013	   in	   press).	   Since	   the	   study	   here	   utilized	   a	   family	  
design	  and	  a	  case-­‐control	  design	  on	  candidate	  genes,	  it	  provides	  a	  clue	  that	  the	  
search	   for	   heritability	   may	   yield	   positive	   results	   if	   focused	   elsewhere.	   The	  
following	  section	  discusses	   future	  research	   in	   the	   field	  of	  genetics	   that	  can	  be	  
applied	  to	  CD,	  if	  one	  was	  to	  move	  away	  from	  attempting	  to	  locate	  rare	  disease	  
variation.	  	  
	  
7.1	  Further	  research	  in	  the	  field	  of	  coeliac	  disease	  genetics	  
	  
Immunochip	   findings	   in	   CD	   show	   that	   most	   of	   the	   association	   signals	   are	  
localized	  around	  transcription	  start	  sites	  and	  3’	  UTR	  regions	  (Trynka,	  Hunt	  et	  al.	  
2011).	  Additionally,	  ENCODE	  findings	  revealed	  that	  most	  disease	  variants	   lie	   in	  
regulatory	  regions	  and	  significant	  activity	  in	  these	  areas,	  including	  how	  much	  of	  
the	  protein	  is	  produced	  rather	  than	  any	  modification	  to	  its	  structure,	  prove	  that	  
there	   is	   much	  more	   occurring	   in	   non-­‐coding	   regions	   than	   previously	   thought	  
(Schaub,	  Boyle	  et	  al.	  2012).	  For	  further	  genetic	  studies	  in	  CD,	  it	  may	  be	  a	  good	  
idea	  to	  revisit	  findings	  from	  GWAS	  and	  fine	  mapping	  studies	  and	  attempt	  to	  link	  
variant	  signals,	  even	  those	  not	  reaching	  GWAS	  significance	  as	  these	  probably	  fit	  
under	   the	   umbrella	   of	   undetected	   loci,	   with	   a	   causal	   variant.	   Studies	   have	  
shown	   that	   SNPs	   associated	   with	   common	   traits	   are	   enriched	   for	   expression	  
quantitative	   trait	   loci	   (eQTL)	   (Lango	   Allen,	   Estrada	   et	   al.	   2010;	   Nica,	  
Montgomery	  et	  al.	  2010;	  Nicolae,	  Gamazon	  et	  al.	  2010),	  and	  even	  the	   last	  CD	  
GWAS	   study	   found	   significant	   eQTLs	   in	   20/38	   non-­‐HLA	   coeliac	   loci	   (Dubois,	  
Trynka	  et	  al.	  2010).	  The	  best	  example	  is	  the	  SORT1	  gene	  associated	  with	  plasma	  
LDL	  concentration,	  where	  the	  associated	  variant	  modifies	  a	  CEBPB	  transcription	  
factor	   binding	   site	   located	   in	   an	   enhancer,	   directly	   altering	   the	   expression	   of	  
SORT1	  (Musunuru,	  Rader	  et	  al.	  2010).	  Since	  common	  trait	  associated	  SNPs	  may	  
be	   acting	   by	   altering	   gene	   regulatory	   regions,	   assessing	   cell	   subtypes	   with	  
phenotypic	   associations	   might	   be	   able	   to	   identify	   true	   causal	   variations.	   The	  
ENCODE	  project	  revealed	  SNPs	  associated	  with	  a	  disease	  phenotype	  were	  also	  
associated	  with	  a	  specific	  cell	  type	  or	  transcription	  factor	  (Dunham,	  Kundaje	  et	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al.	   2012).	   A	   study	   by	   Trynka	   et	   al	   supports	   this	   finding	   in	   a	   study	   identifying	  
chromatin	   marks	   in	   cell	   types	   (Trynka,	   Sandor	   et	   al.	   2013).	   They	   show	   that	  
chromatin	  peaks	  overlap	  with	  SNPs	  associated	  with	  common	  traits,	  e.g.	  31	  SNPs	  
from	  RA	  regions	  overlap	  with	  chromatin	  marks	  in	  CD4+	  regulatory	  T	  cells.	  Their	  
findings	   highlight	   that	   cell	   type	   specific	   chromatin	   marks	   associated	   with	  
phenotype	   can	   identify	   causal	   cell	   types.	   Looking	   deeper	   into	   immune	   cell	  
subtypes	   in	   CD	   associated	   loci	   may	   therefore	   be	   the	   next	   step	   to	   further	  
elucidate	  specific	  causal	  pathways.	  	  
Methods	   for	   single-­‐cell	  analysis	   can	  be	  applied	   to	  enable	  deeper	   resolution	  of	  
cell	   types.	   Methods	   published	   in	   the	   past	   have	   employed	   whole-­‐genome	  
amplification	   (WGA)	   of	   single	   cells	   (Zhang,	   Cui	   et	   al.	   1992)	   and	   degenerate	  
oligonucleotide	   PCR-­‐based	   methods,	   but	   this	   technique	   generates	   short	  
products	  not	  useful	  for	  many	  applications	  (Telenius,	  Carter	  et	  al.	  1992).	  Multiple	  
displacement	  amplification	  using	  hexamer	  primers	  and	  Phi	  29	  DNA	  polymerase	  
generates	  much	  larger	  products	  (<10Kb)	  (Dean,	  Nelson	  et	  al.	  2001)	  and	  is	  used	  
for	  genotyping	  SNPs	  on	  Illumina	  chips,	  for	  example	  (Barker,	  Hansen	  et	  al.	  2004).	  
New	   methodologies	   are	   continuously	   being	   published	   to	   increase	   coverage	  
required	  for	  single	  cell	  sequencing.	  A	  recent	  study	  reported	  a	  new	  WGA	  method	  
named	  MALBAC,	   eliminating	   amplification	   bias	   associated	  with	   previous	  WGA	  
methods	   (Zong,	   Lu	   et	   al.	   2012).	   The	   authors	   designed	   primers	   to	   anneal	  
randomly	  to	  single-­‐cell	  DNA	  molecules,	  performed	  PCR	  with	  a	  DNA	  polymerase	  
with	   displacement	   activity	   to	   create	   semi-­‐amplicons,	   and	   then	   used	   these	   as	  
templates	  to	  produce	  full	  amplicons	  (Figure	  7.1).	  With	  this	  technique,	  they	  were	  
able	   to	   identify	   SNVs	   from	   MALBAC-­‐amplicons	   with	   no	   false	   positives	   and	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MALBAC	  =	  multiple	  annealing	  and	  looping-­‐based	  amplification	  cycles.	  Taken	  from	  Zong,	  
Lu	  et	  al.	  2012.	  	  
	  
Now,	   advances	   in	  NGS	   have	   enabled	   direct	   analysis	   of	   single	   cell	   genomes.	   A	  
recently	   published	   study	   applied	   single-­‐cell	   RNA	   sequencing	   in	   dendritic	   cells	  
from	   bone	   marrows	   of	   mice	   to	   investigate	   heterogeneity	   in	   the	   response	   of	  
these	  cells	  to	  lipopolysaccharide	  (Shalek,	  Satija	  et	  al.	  2013).	  The	  study	  revealed	  
interesting	   findings	   surrounding	   variation	   across	   single	   cells,	   such	   as	   bimodal	  
splicing	  patterns	  with	  one	  isoform	  having	  a	  distinct	  function,	  differential	  activity	  
in	   clusters	   of	   genes	   (i.e.	   in	   antiviral	   regulatory	   genes	   where	   co-­‐variation	   in	  
different	   cell	   transcripts	   helped	   to	   identify	   the	   antiviral	   cell	   circuit),	   and	  
variation	  in	  expression	  patterns	  reflecting	  different	  cell	  developmental	  states.	  If	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such	  variation	  is	  observed	  across	  immune	  cells,	  there	  is	  further	  scope	  in	  linking	  
disease	  genotypes	  to	  single-­‐cell	  phenotypes.	  	  
Commercial	  companies,	  such	  as	  Fluidigm,	  have	  also	  progressed	  onto	  single	  cell	  
genomics.	   Fluidigm’s	   intergrated	  microfluidics	   system	  has	   been	   developed	   for	  
preparation	   of	   hundreds	   of	   cDNA	   libraries	   from	   single-­‐cell	   samples	   for	  mRNA	  
sequencing,	   enabling	   single-­‐cell	   gene	   expression	   profiling.	   The	   technology	  
combines	  96	  cDNA	  library	  preparations	  in	  parallel	  on	  an	  array	  (Figure	  7.2).	  The	  
amplified	  cDNA	  samples	  are	   then	  subjected	   to	   library	  preparation	   for	   Illumina	  
sequencing.	  The	  method	  has	  shown	  to	  produce	  high	  quality	  sequencing	  libraries	  
by	   Fluidigm’s	   Research	   and	   Development	   group,	   and	   also	   confirmed	  
transcriptional	  heterogeneity	  within	  homogenous	  cell	  populations	   (Shug,	  Chen	  
et	  al.	  2013).	  Using	   this	   technology	   to	  assess	  single-­‐cell	  expression	   in	  CD	  might	  
detect	   whether	   there	   are	   specific	   variations	   within	   cells	   from	   CD	   associated	  
immune	  loci.	  	  
	  




The	  IFC	  array	  performs	  single–cell	  cDNA	  library	  preparations	  in	  tiny	  compartments.	  
Taken	  from	  (Shug,	  Chen	  et	  al.	  2013)	  
	  
To	  summarize,	  the	  points	  outlined	  at	  the	  start	  of	  this	  chapter	  can	  be	  undertaken	  
for	  further	  progression	  of	  locating	  rare	  variation	  in	  CD:	  EPAS1	  and	  CUBN	  might	  
hold	  key	  genetic	  variants	  predisposing	  to	  CD	  risk	  and	  are	  likely	  candidate	  genes	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Results 
Single-cell mRNA-Seq has emerged as a powerful tool for understanding 
complex biological phenomena at single-cell resolution. This technique has 
been applied to determine lineage in early development and organogenesis. 
However, single-cell mRNA-Seq is costly, laborious, limited to the analysis of 
small cell numbers (e.g. tens) and has uncontrolled amplification biases. We 
developed an integrated microfluidic system for routine preparation of 
hundreds of full-length cDNA single-cell samples in parallel, which streamlines 
the mRNA workflow from cell isolation to cDNA generation and enables gene 
expression profiling of each individual cell through next-generation 
sequencing. Incorporation of internal synthetic RNA controls in the system 
allows us to better assess both systematic and experimental noise. mRNA-
Seq based whole transcriptome analysis of single cells reveals a broad 
spectrum of transcriptional heterogeneity within nominally homogeneous cell 
populations.  We observe significant gene expression differences between 
individual cells within the same cultured cell line, and even larger differences 
between cells from different cell lines (K562, BJ Fibroblast, HL-60 and 
keratinocytes).  Further, we have identified unique gene expression signatures 
for these different types of cells. 
  
Analysis of single-cell transcriptomes reveals gene expression states that define cellular subpopulations 
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C1TM Single-Cell Auto Prep System Overview 
The C1 Single-Cell Auto Prep System is an integrated microfluidic system 
for routine preparation of 96 full-length cDNA libraries in parallel. The 
system provides a unique and simplified workflow for single-cell mRNA-Seq 
through a microfluidic integrated fluidic circuit (IFC) and automatically 
performs cell isolation, wash, live/dead cell taining, cell lysis, reverse 
tran crip ion and ong-ra ge PCR amplification (Figure 1). Ninety-six 
individual amplified cDNA sample  are retrieved from the C1 IFC for single-
cell gene expression and for next-generation sequencing. Overall hands-on 
time from single cell to sequence ready libraries is 3-4 hours, with an 
overall runtime of <14 hours. 
Figure 1. A simplified workflow 
for The C1 Single-Cell mRNA-
Seq Application.  
 
a). Single-cell mRNA-Seq 
Workflow.  C1 Single-Cell 
Auto Prep System automates 
single-cell isolation, washing, 
staining, lysis, RT, and PCR 
to provide high quality cDNA 
for further analysis. All the cell 
handling steps are completed 
in a C1 IFC. The harvested 
cDNA is subject to 
tagmentation and library prep 
using Illumina® Nextera XT 
DNA Sample Preparation Kit 
and then sequencing on an 
Illumina sequencer. 
 
b). IFC Architecture 
 
c). Cell capture module. Each 
cell capture module can 
perform up to 5 reaction steps 
including cell capture, 
live/dead staining, wash, 
reverse transcription, and 
PCR amplification with active 
mixing between chambers. 
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C1 Single-Cell Auto Prep System 
i, C1 IFC iii, Image of C1 cell capture 
unit and a captured cell  
ii. IFC architecture 
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Methods and materials 
¾cDNA was generated using Clontech SMARTerTM Ultra Low RNA Kit (Clontech, PN 634935) and the Advantage 2 
PCR Kit within the C1 System. The harvested cDNA were tagmented by using Illumina Nextera XT DNA Sample 
Preparation Kit (Illumina, PN FC-131-1096) with some modifications. 
 
¾ERCC RNA Spike-In Control (Life Technologies, PN 4466740) was used as a model system  to assess the C1 Single-
Cell Auto Prep System reproducibility and dynamic range. The control mix was directly loaded into the C1 IFC at a total 
concentration of 1.4x 10^6 copies per reaction with a transcript concentration range of 0.19-4x105 copies per reaction. 
Harvest samples from the C1 IFC were evaluated by qPCR on the Fluidigm BioMark System, and were also prepared 
for sequencing for analysis on the Illumina MiSeq sequencer. 
 
¾mRNA-Seq for four types of cultured cell lines were performed on Fluidigm C1 Single-Cell Auto Prep System.  
 
¾Both ERCC and single-cell mRNA-Seq libraries were sequenced on Illumina MiSeq-V1. Single-cell samples were 
also sequenced at a higher depth on HiSeq 2000 sequencer. Tophat 2 and Cufflinks were used to align, assemble, and 
estimate ERCC RNA and single-cell mRNA abundance. 
Conclusions 
¾The C1 mRNA-Seq protocol generates full-length cDNA of high quality and enables simple, reproducible, 
cost-effective sequencing  library preparation from individual cells. 
 
¾ERCC RNA input abundance and sequence reads density correlate well. Cell inlet input at 1.55 copies of 
ERCC transcript is detectable by both qPCR (in 20 of 96 samples) and MiSeq sequencing  at low depth (in 
4 of 96 samples).  
 
¾The dynamic range of ERCC transcripts measured by qPCR on a 96.96 Dynamic Array IFC and MiSeq 
sequencer is consistent over 5 orders of magnitude. 
 
¾Coefficient of variation of the C1 system decreases as ERCC transcript input concentration is increased, 
as expected as reaction site sampling and increased read depth reduces noise. 
 
¾Incorporation of internal synthetic RNA controls in the C1 mRNA-Seq protocol allows better assessment 
of both systematic and experimental noise and monitoring of both the system and chemistry performance. 
 
¾Single-cell mRNA-Seq whole transcriptome analysis reveals a broad spectrum of transcriptional 
heterogeneity within nominally homogeneous cell populations. 
 
¾PCA analysis based on mid-coverage (~3 million reads per cell) mRNA-Seq data accurately classifies 60 
single cells into 4 cell  types (K562, BJ, Keratinocyte and HL60). 
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Size distribution of cDNA and library generated from individual cells  
High quality single-cell full length cDNA was generated from the C1 Single-Cell Auto Prep System. Average 
length of cDNA is about 2 kb with a size range of 300-10 kb measured by Bioanalyzer® 2100. cDNA yield varied 
with cell types and treatment and generally was 10-20 ng in total for the cultured cell lines tested at Fluidigm.  
Figure 2:  Size distribution of single-cell cDNA generated from the C1 Single-Cell Auto Prep System 
and single-cell mRNA-Seq libraries.  a). Bioanalyzer trace of cDNA product obtained from K562 cells (DNA 
high sensitivity chip). The red line corresponds to cDNA produced from a single K562 cell and the blue line 
corresponds to a reaction chamber with no cell captured. The 800 bp peak corresponds to synthetic RNA 
controls included in the mRNA-Seq workflow.  
b). Bioanalyzer trace of one library pool  generated from 96 individual cells by Nextera XT sample prep kit 
without size selection and two rounds of cleanup by solid-phase reverse immobilization (SPRI). 
Assessment of mRNA -Seq performance on the C1 Single-Cell Auto 
Prep System 
Performance of single-cell mRNA-Seq on the C1 Single-Cell Auto Prep System was evaluated using 
ERCC RNA Spike-In Control Mix 1. The ERCC control mix consists of 92 polyadenylated transcripts with 
a size range of 273-2,022 bases and six orders of magnitude range in concentration.  Analysis of ERCC 
libraries generated from the C1 Single-Cell Auto Prep System shows a linear response over the 
measured range of 0.77-4x105 copies/reaction. Expression levels between replicate reactions on the C1 
IFC show good correlation (R > 0.96) across the entire chip. Single copy RNA detection is demonstrated, 
although intermittently, likely due to sampling at the reaction site.  






















Figure 3. qPCR Heatmap of a 96.96 Dynamic Array IFC acquired on the Fluidigm BioMark System.  
Total input of ERCC RNA Spike-In Control Mix1 is 1.4x106/reaction. Ninety-two primer pairs were designed to 
target the corresponding transcripts, and 91 of 92 were qualified for qPCR testing. qPCR was performed on a 
Fluidigm 96.96 Dynamic Array IFC. Stochastic distribution of transcripts was observed when the input 
concentration was 50 copies/reaction or less on the C1 IFC. Transcripts at 1.55 copies/reaction were 
intermittently detected by qPCR on the 96.96 Dynamic Array IFC. 
Figure 4. Relationship of ERCC transcript input with sequencing RPKM values and mRNA-Seq variation. 
ERCC RNA Spike-In Control Mix 1 was applied to a C1 IFC at total transcript concentration of 1.4E+6 
copies/reaction and subjected to RT-PCR. The libraries were prepared from the harvest samples using Illumina 
Nextera XT DNA Sample Preparation Kit and sequenced on Illumina MiSeq.  Each data point represents a 
unique transcript.  
a). Correlation of RPKM values with transcript  input concentration.  The RPKM value for each transcript is 
the average of 96 harvest samples. 
b). Variation and positive rate of ERCC transcripts Seq. The coefficient of variation  represents each ERCC 
transcript variation across 96 samples. The positive rate of each ERCC transcript represents number of 















































































































































Figure 5. Accuracy of ERCC transcripts seq and C1 IFC uniformity. a). Ten of 96 pair-wise correlations (R) between 
individual cell inlets on a C1 IFC; b). Box plot of variation of 96 libraries pair-wise correlations (R) across a C1 IFC. 
Performance of single-cell mRNA -Seq protocol and heterogeneity of 
single-cell gene expression 
To demonstrate the system performance and utility for single-cell genomic research, we conducted single-cell 
mRNA-Seq whole transcriptome analysis for four types of cultured cell lines (K562, BJ Fibroblast, HL-60 and 
keratinocytes). The results showed >98% mapped reads within 2-fold of the average, >65% mapping rate to 
RefSeq, <2% mapping rate to rRNA and uniform coverage across transcripts with <4 kb length. The single-cell 
mRNA-Seq reveals a broad spectrum of transcriptional heterogeneity within nominally homogeneous cell 
populations of the same cell line in tissue culture, and even greater difference between different cell lines. 
























































Figure 6. Sequence read coverage and reproducibility of the single-cell mRNA-Seq workflow. Cultured 
K562 cells were applied to 4 C1 IFCs on 4 different days. Twenty four of  96 harvest samples from each IFC 
were sequenced on MiSeq-V1 with pair end reads (2x30 cycles), resulting in over 4x105 total reads per cell. 
Read coverage of 92/93 (>98%) live cells captured is within 2-fold of average. Libraries prepared from “no 
cell captured “and dead cells as determined by live/dead staining yielded very low read numbers.    
Figure 7. Mapping rate of single-cell mRNA-Seq. Cultured K562 cells were applied to 4 C1 IFCs on 4 
different days. Twenty-four of  96 harvest samples from each array were sequenced on MiSeq-V1 with pair 
end reads (2x30 cycles), resulting in over 4x105 total reads per cell. Empty capture sites (“no cell”) and 
dead cells are excluded from the plot. 
Figure 8. Examples of the transcript length-normalized coverage across all genes with >10 
RPKM.  A library of 3 individual K562 cells was sequenced on one lane of a HiSeq 2000 Sequencer, 
yielding >30 million reads per cell. The position 0 is the 5’-end of the transcripts and 100 is the extreme 
3’-end of the transcripts. 
Figure 9. Principal component analysis 
(PCA) of single-cell gene expression. 
Data were collected for four types of 
cultured cells (HL-60, K562, BJ Fibroblast 
and Keratinocyte; 15 individual cells per 
cell type). Genes with <10 RPKM are 
excluded.  A total of 12,163 genes were 
used for the PCA. 
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prove	   fruitful,	   then	   there	   is	   the	  possibility	   that	   thousands	  of	  more	   individuals	  
will	  require	  sequencing,	  which	  is	  costly,	  hence	  why	  collaborative	  initiatives	  such	  
as	  UK10K	  and	  NHLBI	  Exome	  Sequencing	  Project	  have	  been	  set	  up.	  If	  one	  wants	  
to	  move	  away	  from	  rare	  variant	  searching	  involving	  larger	  sample	  sizes,	  studies	  
involving	  single	  cell	  genomics,	  with	  an	  aim	  of	  focusing	  on	  gene	  expression	  and	  
specific	  gene	  interactions	  within	  cells	  and	  linking	  them	  with	  disease	  phenotype	  
can	  provide	  a	  closer	  look	  at	  the	  functional	  consequences	  of	  mutations	  in	  certain	  
cell	   types.	   This	   will	   develop	   a	   better	   understanding	   of	   genetic	   heterogeneity	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Appendix	  I	  -­‐	  A	  
Samples	  and	  Pedigree	  Information	  
	  
Coeliac	   individuals	   from	   affected	   coeliac	   families	   were	   selected	   for	   exome	  
sequencing.	   All	   available	   family	   samples	   (affected	   and	   unaffected)	   were	  
genotyped	  on	  the	  Illumina	  Immunochip	  Infinium	  array.	  	  
	  
Table	  1:	  Coeliac	  samples	  sequenced	  and	  coeliac	  samples	  and	  related	  controls	  
genotyped	  	  
	  












NEU4768	   14/79	   31604	  
34806	  
0	   American	  
NEU4801	   9/59	   33165	  
33210	  
40123	  
0	   American	  
NEU7017	   7/49	   36790	  
37456	  
38481	  
0	   American	  
NEU7058	   7/25	   39087	  
39198	  
0	   American	  
NEU4735	   7/23	   31580	  
35241	  
38794	  
0	   American	  
NAL108	   8/13	   5846	  
6133	  
0	   Swedish	  
DA	   5	   DA194	  
DA269	  
13	   British	  
BRK	   6	   BRK11	  
BRK4	  
23	   British	  
BRE	   6	   BRE	  3	   23	   British	  
HMN	   5	   HMN10	   14	   British	  
BD	   6	   BD125	   6	   British	  
BR	   4	   BR88	   17	   British	  
BUT	   7	   BUT36	   23	   British	  
B	   4	   -­‐	   11	   British	  
H	   3	   H74	   9	   British	  
FAM001	   4	   CAP152699	  
CAP152713	  
CAP200344	  
3	   British	  
FAM002	   4	   SAL-­‐12592-­‐9	  
SAL-­‐12706-­‐6	  
2	   British	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SDY	   13/31	   SDY11	  
SDY20	  
SDY101	  
31	   British	  
FAM004	   3	   SAL-­‐14125-­‐3	   1	   British	  
FAM005	   6	   SAL-­‐13730-­‐4	   1	   British	  
FAM006	   4	   SAL-­‐12575-­‐0	  
SAL-­‐13281-­‐5	  
2	   British	  
FAM007	   3	   CAP152916	  
CAP200010	  
2	   British	  
FAM008	   8	   SAL-­‐12583-­‐9	   9	   British	  
FAM009	   5	   SAL-­‐13577-­‐2	   4	   British	  
FAM010	   7	   SAL-­‐12598-­‐5	  
FAM010-­‐4	  
4	   British	  
FAM011	   4	   SAL-­‐13559-­‐1	   1	   British	  
FAM012	   4	   CAP152573	   1	   British	  
FAM013	   3	   SAL-­‐13472-­‐7	   0	   British	  
FAM014	   6	   SAL-­‐12553-­‐6	  
FAM014-­‐6	  
10	   British	  
FAM015	   3	   SAL-­‐13966-­‐5	   0	   British	  
FAM016	   3	   SAL-­‐14024-­‐1	   1	   British	  
FAM017	   3	   SAL-­‐13123-­‐0	   1	   British	  
FAM018	   4	   SAL-­‐14202-­‐9	   1	   British	  
FAM019	   4	   SAL-­‐13369-­‐2	   1	   British	  
FAM020	   5	   SAL-­‐12746-­‐0	   1	   British	  
FAM021	   5	   SAL-­‐12792-­‐1	   1	   British	  
FAM023	   5	   CAP152616	   1	   British	  
FAM024	   7	   CAP152677	   1	   British	  
FAM025	   5	   CAP152708	   1	   British	  
FAM026	   4	   CAP153119	   1	   British	  
FAM027	   3	   CAP152582	   1	   British	  
FAM028	   5	   CAP152646	   1	   British	  
FAM031	   2	   CAP152629	   1	   British	  
FAM033	   3	   CAP152730	   1	   British	  
FAM034	   3	   CAP152602	   1	   British	  
FAM035	   3	   CAP152726	   1	   British	  
FAM036	   2	   CAP152633	   1	   British	  
FAM037	   3	   CAP152825	   1	   British	  
FAM038	   3	   CAP153231	   1	   British	  
FAM039	   4	   CAP153113	   1	   British	  
FAM043	   3	   SAL-­‐12544-­‐6	   1	   British	  
FAM050	   ?	   SAL-­‐13357-­‐9	   1	   British	  
FAM062	   9	   CUK-­‐71848	   1	   British	  
FAM063	   7	   CUK-­‐41789	   7	   British	  
FAM065	   5	   SAL-­‐12847-­‐2	   1	   British	  
SPORADIC	   -­‐	   CAP152639	   1	   British	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Figure	  1:	  Pedigrees	  illustrating	  exome	  sequenced	  and	  genotyped	  samples	  
	  
Samples	   in	   black	   are	   ‘exome’	   and	   ‘genotype’;	   samples	   in	   blue	   are	   ‘genotype’	   only;	  
pedigrees	  for	  FAM001,	  FAM007	  and	  FAM010	  were	  unavailable.	  HLA	  genotypes	  shown	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Appendix	  I	  -­‐	  B	  
Preparation	  of	  Illumina	  library	  prior	  to	  solution	  capture	  (EZ	  Exome	  
System)	  with	  no	  pre	  hybridisation	  PCR	  
	  
This	  protocol	  uses	  Sigma	  made	  paired-­‐end	  PCR	  primers	  and	  library	  preparation	  
components	  from	  New	  England	  Biosciences	  for	  exome	  sequence	  capture	  library	  
preparaton	  and	  subsequent	  Illumina	  GAII	  paired-­‐end	  sequencing.	  PCR	  is	  carried	  




Company	   Product	  Number	   Concentration	  given	  
NEB	   	   	  
Klenow	  Enzyme	   M0210S	   5U/µl,	  200U	  per	  kit	  
Klenow	   Buffer	   (NEB	   buffer	  
II)	  
B7002S	   10x,	  6ml	  
Klenow	  fragment	  3-­‐5exo	   M0212L	   5U/µl,	  1000U	  per	  kit	  
T4	   DNA	   Ligase	   buffer	   with	  
10mMATP	  
B0202S	   10x	  (use	  neat),	  6ml	  	  	  
T4	  DNA	  Polymerase	   M0203L	   3U/µl,	  750U	  
DNA	  ligase	  and	  buffer	  kit	   M2200L	   2000U/µl	   (ligase);	   150	  
reactions	  
dNTP	  mix	   N0447S	   10mM,	  800µl	  
T4	  PNK	   M0201L	   10,000U/ml,	  2500U	  per	  kit	  
Phusion®	   High-­‐Fidelity	   PCR	  
Master	  Mix	  with	  HF	  Buffer	  	  
F-­‐531L	   500	  PCR	  reactions	  worth	  
Amersham	  	   	   	  
dATP	   28-­‐4065-­‐01	   100mM,	   25µMol	   pack,	   use	  
at	  1mM	  
Invitrogen	   	   	  
SYBR	  Green	  I	  dye	   S-­‐7563	   10,000X,	  need	  at	  1X	  
Human	  Cot-­‐1	  DNA	  	   15279011	   1	   mg/ml	   in	   10	   mM	   Tris-­‐
HCl	  (pH	  7.4),	  1	  mM	  EDTA)	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Beckman	  Coulter	   	   	  
AMPure	  XP	  beads	  -­‐	  5ml	   A63880	   5ml	  
Agencourt	  SPRIStand™	  	   A29182	   Magnetic	  6-­‐tube	  Stand	  
Qiagen	   	   	  
QIAquick	   PCR	   Purification	  
Kit	  
28106	   250	  clean	  ups	  
QIAquick	  MinElute	  PCR	  
Purification	  Kit	  
28005	   50	  clean	  ups	  
Sigma	   	   	  
Trizma	  hydrochloride	   T2913-­‐1L	   1M	  
Sodium	  Chloride	  Solution	   71386	   5M	  




1. SeqCap	  EZ	  Exome	  Library	  4	  capture	  kit	  or	  48	  capture	  kit	  	  
Upon	  arrival,	  aliquot	  and	  store	  the	  SeqCap	  EZ	  Exome	  Library	  	  
a. If	  frozen,	  thaw	  the	  Exome	  Library	  on	  ice	  
b. Vortex	  the	  Exome	  library	  for	  3	  seconds	  
c. Centrifuge	   the	   tube	   of	   the	   Exome	   Library	   at	   10,000	   x	   g	   for	   1	  
minute	  	  
d. Aliquot	   the	   Exome	   Library	   into	   100ng	   single-­‐use	   aliquots	   (4.5	  
µl/aliquot)	  in	  0.2ml	  PCR	  tubes	  and	  store	  at	  -­‐20	  °C	  until	  use.	  	  
	  
Note:	   The	   Exome	   Library	   should	   not	   undergo	   multiple	   freeze/thaw	   cycles.	   To	  
avoid	   this,	   it	   is	   recommended	   that	   the	   library	   is	   aliquoted	   into	   single-­‐use	  
volumes	  to	  prevent	  damage	  from	  successive	  freeze/thaw	  cycles	  	  
	  
Primers	  and	  Adapters	  
Order	   PCR	   primers	   below	   from	   Sigma	   Aldrich;	   HPLC	   grade	   and	   dry,	   and	  
resuspend	   in	   water	   at	   given	   volumes	   for	   100	   µM	   (stock).	   Dilute	   an	   aliquot	  
(working	  stock)	  of	  PCR	  primers	  to	  concentrations	  given	  below:	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Component	   Concentration	   Sequence	  
Homemade	  
PCR	  Primer	  PE	  
1.0	  
100	  µM	   5’-­‐	  AAT	  GAT	  ACG	  GCG	  ACC	  ACC	  GAG	  
ATC	  TAC	  ACT	  CTT	  TCC	  CTA	  CAC	  GAC	  
GCT	  CTT	  CCG	  ATC*	  T	  -­‐3’	  
Homemade	  
PCR	  Primer	  PE	  
2.0	  
100	  µM	   5’-­‐CAA	  GCA	  GAA	  GAC	  GGC	  ATA	  CGA	  
GAT	  CGG	  TCT	  CGG	  CAT	  TCC	  TGC	  TGA	  
ACC	  GCT	  CTT	  CCG	  ATC*	  T	  -­‐3’	  
Homemade	  
PE	  adapter	  1	  	  
15	  µM	   5’-­‐	  ACA	  CTC	  TTT	  CCC	  TAC	  ACG	  ACG	  
CTC	  TTC	  CGA	  TC*T-­‐3’	  
Homemade	  
PE	  adapter	  2	  
15	  µM	   5’-­‐[Phos]-­‐GAT	  CGG	  AAG	  AGC	  GGT	  TCA	  





1000	  µM	   5’-­‐	  AAT	  GAT	  ACG	  GCG	  ACC	  ACC	  GAG	  
ATC	  TAC	  ACT	  CTT	  TCC	  CTA	  CAC	  GAC	  
GCT	  CTT	  CCG	  ATC*	  T	  -­‐3’	  
PE	  Hyb	  
Enhancing	  
(PE-­‐HE)	  oligo	  	  
1000	  µM	   5’-­‐CAA	  GCA	  GAA	  GAC	  GGC	  ATA	  CGA	  
GAT	  CGG	  TCT	  CGG	  CAT	  TCC	  TGC	  TGA	  
ACC	  GCT	  CTT	  CCG	  ATC*	  T	  -­‐3’	  
*Phosphorothioate	  bond	  
	  
Adapter	  preparation	  upon	  arrival	  from	  Sigma:	  	  
Upon	  arrival	  from	  sigma	  Adapters	  must	  be	  made	  double	  stranded	  (i.e.	  annealed	  
together)	  so	  for	  first	  time	  use	  follow	  instructions	  below,	  subsequent	  uses	  of	  the	  
adaptors	  will	  not	  require	  this	  process	  to	  be	  carried	  out.	  
	  
1. Mix	  adaptor	  oligonucleotides	  together	  to	  a	  final	  concentration	  of	  15	  µM	  
each,	  in	  10	  mM	  Tris/10mM	  NaCl	  pH	  7.0.	  	  
2. Anneal	   adapter	   strands	   in	   a	   PCR	   machine	   programmed	   with	   the	  
following	  settings:	  
a. Ramp	  at	  0.5	  °C/sec	  to	  97.5	  °C	  
b. Hold	  at	  97.5	  °C	  for	  150	  sec	  
c. 97.5	  °C	  for	  2	  sec	  with	  a	  temperature	  drop	  of	  0.1	  C/cycle	  for	  775	  
cycles	  	  
	  
Note:	  Store	  stock	  and	  working	  aliquots	  of	  primers	  and	  adapters	  at	  -­‐20	  °C	  
	  
Fragment	  genomic	  DNA	  using	  a	  Covaris™	  	  
	  
Library	   preparation	   using	   the	   Illumina	   Paired-­‐End	   Sample	   Prep	   kit	   requires	   1-­‐
5µg	  of	  genomic	  DNA.	  Aim	  to	  fragment	  DNA	  into	  <1	  Kb	  sizes.	  
1. Aliquot	  5	  μg	  (by	  picogreen	  concentration;	  see	  Picogreening	  of	  DNA	  SOP)	  
of	  genomic	  DNA.	  	  
2. Make	  each	  5	  μg	  aliquot	  to	  a	  total	  volume	  of	  80	  μl	  with	  water.	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3. Mix	  and	  transfer	  each	  aliquot	  to	  a	  new	  Micro	  tube	  (6mm	  x	  16mm)	  AFA	  
fibre	  vial.	  	  
4. Seal	  the	  tubes	  using	  a	  Metal	  crimp	  8mm	  seal	  cap	  and	  crimping	  tube.	  	  
5. Optimise	  shear	  settings	  per	  Covaris	  instrument.	  	  
a. For	   the	   following	  settings,	   size	  distribution	  obtained	   is	  between	  
75bp	  and	  	   	   	   	   	  1000	  bp	  and	  the	  peak	  size	  distribution	  is	  between	  
200-­‐300bp:	  duty	  cycle	  10%,	  intensity	  5,	  cycle/bust	  200,	  time	  140s	  	  
6. Remove	  vials	  from	  the	  machine	  and	  open;	  on	  ice	  transfer	  into	  a	  fresh	  1.5	  
ml	  lo-­‐bind	  tube	  with	  a	  pipette.	  
7. Run	  1	  μl	  on	  Bioanalyzer	  7500	  chip	   for	   size	   confirmation;	  aim	   to	  obtain	  
250-­‐300bp	  peaks.	  	  
8. Clean	  up	  samples	  with	  Qiagen	  QIAquick	  PCR	  Purification	  kit;	  elute	  in	  30	  
μl	  of	  Buffer	  EB	  into	  new	  1.5ml	  lo-­‐bind	  tubes.	  	  
	  
Note:	  Maximum	  DNA	  input	  per	  Qiagen	  clean	  up	  column	  is	  10	  µg	  





1. Prepare	  end-­‐repair	  reaction	  mix	  (reaction	  mix	  volume	  given	  per	  sample	  
concentrations	  as	  supplied	  by	  NEB)	  
	  
 Fragmented	  DNA	  	   	   30	  μl	   	   	  
 Molecular	  grade	  Water	   	   	   46	  μl	   	   	  
 T4	  DNA	  ligase	  buffer	  	   	   	   10	  μl	   	   	  
 dNTP’s	  Mix	  	   	   	   	   	  	  4	  μl	   	   	  
 T4	  DNA	  Polymerase	   	   	   	  	  5	  μl	   	   	  
 Klenow	  enzyme	  	   	   	   	   	  	  1	  μl	   	   	  
 T4	  PNK	  	   	   	   	   	   	  	  5	  μl	   	   	  
	  	  	  	  	  	  Total	   	   	   	   	  	   100	  μl	   	   	  
2. Pipette	  70ul	  of	  Mastermix	   into	  each	  of	  4	   small	   PCR	   tubes;	   add	  30ul	  of	  
cleaned	  fragmented	  sample	  into	  each	  tube.	  Put	  cap	  on.	  Gently	  mix	  with	  
pipette.	  	  
3. Incubate	  in	  thermal	  cycler	  for	  30	  minutes	  @	  20oC	  
4. Follow	  the	  protocol	  in	  QIAquick	  PCR	  purification	  kit;	  elute	  each	  of	  the	  4	  
samples	  with	  	  	  32	  μl	  of	  Buffer	  EB	  into	  new	  1.5ml	  lo-­‐bind	  tubes.	  
	  
Note:	  When	  transferring	  DNA	  into	  PB	  buffer	  for	  first	  step	  of	  clean	  up,	  wash	  out	  
PCR	  tubes	  with	  PB	  buffer	  to	  ensure	  as	  much	  as	  possible	  goes	  into	  the	  clean	  up	  
	  
Add	  A	  to	  the	  3’	  end	  
	  
1. Prepare	   end-­‐repair	   reaction	   mix	   (in	   a	   1.5ml	   lo-­‐bind	   tube)	   -­‐	   *before	  
proceeding	  dilute	  dATP	   (5	  µl	   dATP	   into	  495	  µl	   EB	  as	  not	  used	  at	   stock	  
concentration)	  aliquot	  out	  and	  freeze.	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 End	  repaired	  DNA	  	   	   	   32	  μl	  
 NEB	  Buffer	  2	   	   	   	   	  	  5	  μl	   	   	  
 1mM	  dATP*	   	   	   	   10	  μl	   	   	  
 Klenow	  exo	   	   	   	   	  	  3	  μl	   	   	  
	  	  	  	  	  	  Total	   	   	   	   	   50	  μl	   	   	  
2. Pipette	  18ul	  of	  Mastermix	   into	  each	  of	  4	  small	  PCR	  tubes;	  add	  32ul	  of	  
cleaned	   end	   repaired	   DNA	   sample	   into	   each	   tube.	   Gently	   mix	   with	  
pipette	  Put	  cap	  on.	  
3. Incubate	  in	  thermal	  cycler	  for	  30	  minutes	  @	  37	  oC	  
4. Follow	  the	  protocol	  in	  Qiagen	  MinElute	  PCR	  purification	  kit;	  elute	  each	  
of	  the	  4	  samples	  with	  10	  μl	  of	  Buffer	  EB	  into	  new	  1.5ml	  lo-­‐bind	  tubes.	  
	  
Ligate	  Adaptors	  to	  DNA	  fragment	  	  
	  
• Take	   out	   AMPure™	   XP	   beads	   now	   and	   allow	   to	   reach	   room	  
temperature	  
This	   procedure	   uses	   a	   10:1	  molar	   ratio	   of	   adapter	   to	   DNA	   insert,	   based	   on	   a	  
starting	  quantity	  of	  5	  μg	  of	  DNA	  before	  fragmentation.	  	  
1. Prepare	  ligation	  reaction	  mix	  (reaction	  mix	  given	  per	  sample)	  
	  
 A	  tailed	  DNA	  from	  3	   	   	   	   10	  μl	  
 DNA	  ligase	  buffer	  	   	   	   	   25	  μl	   	   	  
 Homemade	  PE	  adapter	  1	  (15	  µM)	   	   	  	  5	  μl	   	   	  
 Homemade	  PE	  adapter	  2	  (15	  µM)	   	  5	  μl	   	   	   	  
 DNA	  ligase	  	   	   	   	  	   	   	  5	  μl	   	   	  
	  	  	  	  	  	  Total	   	   	   	   	   	   50	  μl	   	   	  	  	  	  
2. Pipette	  40ul	  of	  Mastermix	   into	  each	  of	  4	   small	   PCR	   tubes;	   add	  10ul	  of	  
cleaned	  ligated	  DNA	  sample	  into	  each	  tube.	  Gently	  mix	  with	  pipette.	  Put	  
cap	  on.	  
	  
3. 	  Incubate	  for	  15	  minutes	  in	  thermal	  cycler	  @	  20	  oC	  
Note:	   The	   following	   SPRI	   bead	   purification	   needs	   to	   be	   carried	   out	   straight	  
away.	  	  
	  
SPRI	  bead	  purification	  	  
Clean	   ligated	   sample	   with	   SPRI	   beads,	   eluting	   in	   water.	   This	   gets	   rid	   of	   DNA	  
<100bp	  and	  salt/	  enzymes/contaminants	  
	  
Materials	  required:	   	   AMPure™	  XP	  beads	  *NB	  6	  month	  shelf	  life	  
Agencourt	  SPRIStand™	  -­‐	  Magnetic	  6-­‐tube	  Stand	  	  
	   	   	   	   Pipettes	  and	  tips	  
1.5ml	   Eppendorf	   Lo-­‐Bind	   tubes,	   3	   for	   each	  	  	  	  
sample	  
	   	   	   	   Vortex	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   Heat	  Block	  @	  37°C	  
	   	   	   	   Molecular	  biology	  grade	  water	  
	   	   	   	   70%	  Ethanol	  
	   	   	   	   Centrifuge	  
	  
Before	  You	  Begin	  
• Allow	   beads	   to	   come	   to	   room	   temperature	   for	   at	   least	   30	   minutes.	  
Reagents	   need	   to	   be	   mixed	   well	   prior	   to	   use	   and	   should	   appear	  
homogeneous	  and	  consistent	  in	  colour.	  	  
• Make	  fresh	  70	  %	  ethanol:	  7	  ml	  100%	  ethanol	   in	  3	  ml	  molecular	  biology	  
grade	  water.	  	  
Purification	  procedure:	  
1. Take	   90	  µl	   of	   SPRI	   beads	   and	   add	   to	   50	  μl	   sample	   in	   a	   1.5	  ml	   Lo-­‐bind	  
tube.	  	  
2. Vortex	  and	  hold	  at	  room	  temperature	  for	  5	  minutes.	  
3. Place	  tube	  in	  the	  magnetic	  rack	  and	  leave	  for	  5	  minutes	  or	  until	  solution	  
is	  clear.	  
4. Carefully	   remove	   the	   clear	   solution	   from	   the	   tubes	  with	   a	   pipette	   and	  
discard.	  
5. Dispense	  700µl	  of	  70%	  ethanol	  into	  each	  tube	  while	  in	  the	  magnetic	  rack	  
taking	   care	   not	   to	   disturb	   the	   magnetic	   beads.	   Aspirate	   and	   discard	  
ethanol.	  
6. Repeat	  the	  ethanol	  wash	  once	  again	  (total	  of	  two	  washes).	  
7. Dry	  the	  samples	  on	  a	  heat	  block	  (keep	  the	  lid	  of	  the	  tube	  open)	  @	  37°C	  
for	  5	  minutes	  or	  until	  the	  residual	  ethanol	  has	  evaporated.	  Careful	  not	  to	  
over	  dry.	  
8. Add	  50	  µl	  of	  molecular	  biology	  grade	  water,	  vortex	  and	  incubate	  at	  room	  
temperature	  for	  2	  minutes.	  Spin	  down	  in	  centrifuge.	  	  
9. Place	   tubes	   into	   the	  magnetic	   rack	   and	   leave	   for	   2-­‐3	  minutes	   or	   until	  
sample	  is	  clear.	  
10. Carefully	  remove	  the	  water	  and	  retain	  in	  a	  new	  1.5	  ml	  Lo-­‐bind	  tube.	  
11. Repeat	  step	  8	  -­‐10	  once	  more,	  retaining	  the	  water	  in	  the	  same	  1.5	  ml	  lo-­‐
bind	  tube.	  Total	  volume	  of	  eluate	  should	  be	  100	  µl.	  
12. Centrifuge	  the	  eluate	  at	  13,000	  rpm	  for	  10	  minutes.	  
13. Transfer	   the	   sample	   to	   a	   new	   1.5	  ml	   Lo-­‐bind	   tube	   leaving	   behind	   any	  
precipitated	  beads.	  
14. Check	  size	  of	  resulting	  fragments	  using	  1	  µl	  of	  library	  using	  Agilent	  DNA	  
7500	   chip	  on	  Bioanalyzer	   2100.NB	  adaptors	  on	  DNA	  will	   add	  90~bp	   to	  
length	  of	  fragmented	  DNA	  	  
15. Quantify	  sample	  on	  Nanodrop	  in	  triplicate	  and	  take	  average	  –	  using	  this	  
concentration	  make	  1µg	  aliquots.	  Only	  one	  1µg	  aliquot	  will	   be	  needed	  
for	  the	  hybridisation,	  others	  can	  be	  frozen	  for	  future	  hybridizations.	  
Stop	   Point:	   cleaned	   samples	   can	   be	   frozen	   at	   -­‐20	   °C	   until	   exome	   library	  
hybridisation	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Exome	  Library	  Hybridization	  (skip	  to	  page	  15	  if	  not	  performing	  enrichment	  in	  
house)	  
	  
Step	  1.	  Prepare	  for	  hybridization	  	  
	  
1. Turn	   on	   a	   heat	   block	   to	   95°C	   and	   let	   it	   equilibrate	   to	   set	   the	  
temperature.	  
2. Remove	  the	  appropriate	  number	  of	  100ng	  probe	  pool	  aliquots	  from	  the	  
-­‐20	  °C	  freezer	  and	  allow	  them	  to	  thaw	  on	  ice.	  	  
	  
Step	  2.	  Prepare	  hybridization	  cocktail	  
1. Add	  100	  µl	  of	  1mg/ml	  Cot	  DNA	  and	  1	  µg	  of	  SPRI	  bead	  cleaned	  sample	  
library	  to	  a	  new	  1.5ml	  lo-­‐bind	  tube.	  
2. Add	   1	   µl	   of	   each	   1000	   µM	   PE-­‐HE1	   and	   PE-­‐HE2	   Oligo’s	   to	   the	   sample	  
library	  plus	  Cot	  DNA.	  
3. Close	  the	  tube’s	  lid	  and	  make	  a	  hole	  in	  the	  top	  of	  the	  tube’s	  cap	  with	  a	  
small	  needle	  
4. Dry	  sample	  in	  a	  SpeedVac	  on	  high	  heat	  (60	  °C)	  –	  careful	  not	  to	  over-­‐dry	  
as	  DNA	  will	  not	  resuspend	  thoroughly.	  
	  
Note:	   Denaturation	   of	   the	   DNA	  with	   high	   heat	   is	   not	   problematic	   after	   linker	  
ligation	   because	   the	   hybridization	   utilizes	   single-­‐stranded	   DNA.	   This	   step	  may	  
take	  30	  min	  or	  longer.	  
	  
5. To	  each	  dried-­‐down	  library/COT	  DNA	  sample	  add:	  
a. 7.5	  μl	  2x	  SC	  Hybridization	  Buffer	  (Nimblegen	  provided)	  
b. 3	  µl	  SC	  Hybridization	  Component	  A	  (Nimblegen	  provided)	  
6. Cover	  the	  hole	  on	  tube	  with	  laboratory	  tape.	  Vortex	  samples	  for	  10	  sec	  
and	  centrifuge	  at	  maximum	  speed	  for	  10	  seconds.	  
7. Place	  each	  sample	   in	  a	  95°C	  heat	  block	  for	  10	  minutes	  to	  denature	  the	  
DNA.	  
8. Centrifuge	   sample	   at	   maximum	   speed	   for	   10	   seconds	   at	   room	  
temperature.	  
9. Transfer	   the	   entire	   sample	   to	   the	   100ng	   (4.5	  µl	   aliquot)	   aliquot	   of	   the	  
Exome	  Library	  in	  a	  0.2ml	  PCR	  tube.	  
10. Vortex	  for	  3	  seconds	  and	  centrifuge	  at	  maximum	  speed	  for	  10	  seconds.	  
11. Incubate	  in	  a	  thermocycler	  (with	  heated	  lid	  turned	  on)	  at	  47	  °C	  for	  64-­‐72	  
hours.	  
	  
Exome	  Library	  Washing	  and	  Elution	  of	  Captures	  Samples	  	  
Monitor	  water	   bath	   temperature	  with	   a	   high	   quality	   reliable	   thermometer	   to	  
ensure	  that	  the	  water	  bath	  temperature	  is	  47oC.	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Step	  1.	  Prepare	  Sequence	  Capture	  Wash	  Buffers	  
1. Dilute	  10X	  SC	  Wash	  Buffers	  (I,	  II,	  and	  III)	  and	  2X	  Stringent	  Wash	  Buffer	  to	  1X	  
working	  solutions.	  





1X	   Stringent	   Wash	  
Buffer	  
10ml	   -­‐	   2X	   Stringent	   Wash	  
Buffer	  
10ml	   20ml	  
1X	  SC	  Wash	  Buffer	  I	   2ml	  –	  10X	  SC	  Wash	  Buffer	  I	   18ml	   20ml	  
1X	  SC	  Wash	  Buffer	  II	   1ml	  –	  10X	  SC	  Wash	  Buffer	  II	   9ml	   10ml	  
1X	  SC	  Wash	  Buffer	  III	   1ml	  –	  10X	  SC	  Wash	  Buffer	  III	   9ml	   10ml	  
	  
2. Pre-­‐heat	  the	  following	  SC	  Wash	  Buffers:	  
a. 20ml	  of	  Stringent	  Wash	  Buffer	  heated	  to	  47°C	  in	  a	  water	  bath	  
b. 5ml	  of	  SC	  Wash	  Buffer	  I	  heated	  to	  47°C	  in	  a	  water	  bath	  
	  
Step	  2.	  Prepare	  Streptavidin	  Dynabead	  Binding	  and	  Wash	  Buffer	  
1. Prepare	   the	   Streptavidin	   Dynabead	   Binding	   and	   Wash	   Buffer	   in	   either	   a	  
15ml	  or	  50ml	  conical	  tube,	  depending	  on	  the	  number	  of	  captures:	  
Component	   4	  Captures*	   48	  Captures	  
1M	  Trizma	  hydrochloride	   	   25	  µl	   	  	  	  	  	  	  245	  µl	  
0.5M	  EDTA	   	   5	  µl	   	  	  	  	  	  	  	  	  49	  µl	  
5M	  NaCl	   	  1,000	  µl	   	  	  9,800	  µl	  
PCR-­‐grade	  water	   	  1,470	  µl	   14.406	  µl	  
Total	   	   2.5ml	   	  	  	  	  	  25.5ml	  
*Volume	  adjusted	  for	  pipetting	  variance.	  	  
	  
2. Vortex	  for	  20	  seconds	  and	  label	  the	  tube	  appropriately.	  
3. Store	   the	   Streptavidin	   Dynabead	   Binding	   and	   Wash	   Buffer	   at	   room	  
temperature.	  Buffer	  can	  be	  stored	  for	  up	  to	  2	  months.	  	  
Step	  3.	  Prepare	  the	  Streptavidin	  Dynabeads	  
1. Allow	   the	   Streptavidin	   Dynabeads	   to	   warm	   to	   room	   temperature	   for	   30	  
minutes	  prior	  to	  use.	  
2. Mix	  the	  beads	  thoroughly	  by	  vortexing	  for	  1	  minute.	  
3. Aliquot	  100µl	  of	  beads	   for	  each	  capture	   into	  a	  single	  1.5ml	   tube	   (i.e.	   for	  1	  
capture	  use	  100µl	  beads	  and	  for	  4	  captures	  use	  400µl	  beads,	  etc.).	  Enough	  
beads	  for	  6	  captures	  can	  be	  prepared	  in	  a	  single	  tube.	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4. Place	   the	   tube	  on	  a	  magnet	   suitable	   to	  hold	  1.5ml	   tubes.	  When	   the	   liquid	  
becomes	   clear	   (approximately	   5	   minutes),	   remove	   and	   discard	   the	   liquid	  
being	  careful	  to	  leave	  all	  of	  the	  beads	  in	  the	  tube.	  
5. Add	  twice	  the	  initial	  volume	  of	  beads	  of	  Streptavidin	  Dynabead	  Binding	  and	  
Wash	  Buffer	   to	  each	   tube	   (i.e.	   for	  1	  capture	  use	  200µl	  of	  buffer	  and	   for	  4	  
captures	  use	  800µl	  buffer,	  etc.).	  
6. Remove	  the	  tube	  from	  the	  magnet	  and	  vortex	  for	  10	  seconds.	  
7. Place	  the	  tube	  back	  on	  the	  magnet	  to	  bind	  the	  beads.	  Once	  clear,	   remove	  
and	  discard	  the	  liquid.	  
8. Repeat	  Steps	  5	  -­‐	  7	  (for	  a	  total	  of	  2	  washes).	  
9. After	  removing	  the	  buffer	  following	  the	  second	  wash,	  resuspend	  the	  beads	  
in	  1x	  the	  original	  volume	  using	  the	  Streptavidin	  Dynabead	  Binding	  and	  Wash	  
Buffer	   (i.e.	   for	   1	   capture	   use	   100µl	   buffer	   and	   for	   4	   captures	   use	   400µl	  
buffer,	  etc.).	  
10. Aliquot	  100µl	  of	  resuspended	  beads	  into	  new	  0.2ml	  tubes.	  
11. Use	   the	   magnet	   to	   bind	   the	   beads.	   Remove	   and	   discard	   the	   liquid	   when	  
clear.	  
12. The	   Streptavidin	   Dynabeads	   are	   now	   ready	   to	   bind	   the	   captured	   DNA.	  
Proceed	  directly	  to	  the	  next	  step.	  
Step	  4.	  Bind	  DNA	  to	  the	  Streptavidin	  Dynabeads	  
1. Transfer	  the	  hybridization	  samples	  to	  the	  Streptavidin	  Dynabeads	  prepared	  
in	  Step	  3.	  	  
2. Mix	  thoroughly	  by	  pipetting	  up	  and	  down	  10	  times.	  
3. Bind	  the	  captured	  sample	  to	  the	  beads	  by	  placing	  the	  tubes	  containing	  the	  
beads	  and	  DNA	  in	  a	  thermocycler	  set	  to	  47°C	  for	  45	  minutes.	  
4. Mix	  the	  samples	  by	  vortexing	  for	  3	  seconds	  at	  15	  minute	  intervals	  to	  ensure	  
that	  the	  beads	  remain	  in	  suspension.	  
Step	  5.	  Wash	  the	  Streptavidin	  Dynabeads	  Plus	  Bound	  DNA	  
1. After	  the	  45	  minute	  incubation,	  transfer	  the	  entire	  mixture	  to	  a	  1.5ml	  tube.	  
2. Use	   the	   magnet	   to	   bind	   the	   beads.	   Remove	   and	   discard	   the	   liquid	   once	  
clear.	  
3. Add	  100µl	  of	  SC	  Wash	  Buffer	  I	  heated	  to	  47°C.	  
4. Mix	  by	  vortexing	  for	  10	  seconds.	  
5. Place	  the	  tubes	  on	  the	  magnet	  to	  bind	  the	  beads.	  Remove	  and	  discard	  the	  
liquid	  once	  clear.	  
6. Remove	  the	  tubes	  from	  the	  magnet	  and	  add	  200µl	  of	  Stringent	  Wash	  Buffer.	  
Pipette	  up	  and	  down	  10	  times	  to	  mix.	  
7. Incubate	  at	  47°C	  for	  5	  minutes.	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8. Repeat	  Steps	  5	  -­‐	  7	  for	  a	  total	  of	  2	  washes	  with	  Stringent	  Wash	  Buffer.	  
9. Place	  the	  tubes	  on	  the	  magnet	  to	  bind	  the	  beads.	  Remove	  and	  discard	  the	  
liquid	  once	  clear.	  
10. Add	  200µl	  of	  room	  temperature	  SC	  Wash	  Buffer	  I	  and	  mix	  by	  vortexing	  for	  2	  
minutes.	  
11. Place	  the	  tubes	  on	  the	  magnet	  to	  bind	  the	  beads.	  Remove	  and	  discard	  the	  
liquid	  once	  clear.	  
12. Add	  200µl	  of	  room	  temperature	  SC	  Wash	  Buffer	  II	  and	  mix	  by	  vortexing	  for	  1	  
minute.	  
13. Place	  the	  tubes	  on	  the	  magnet	  to	  bind	  the	  beads.	  Remove	  and	  discard	  the	  
liquid	  once	  clear.	  
14. Add	  200µl	  of	  room	  temperature	  SC	  Wash	  Buffer	  III	  and	  mix	  by	  vortexing	  for	  
30	  seconds.	  
15. Place	  the	  tubes	  on	  the	  magnet	  to	  bind	  the	  beads.	  Remove	  and	  discard	  the	  
liquid	  once	  clear.	  
16. Remove	  the	  tubes	  from	  the	  magnet	  and	  add	  50µl	  PCR-­‐grade	  water	  to	  each	  
tube	  of	  bead-­‐bound	  captured	  sample.	  
Stop	   Point:	   Store	   the	   beads	   plus	   captured	   samples	   at	   -­‐20	   C	   until	   ready	   to	  
proceed	  to	  Post	  Capture	  LM-­‐PCR	  
	  
Post	  capture	  LMPCR	  
	  
1. Prepare	   post	   capture	   LMPCR	   reaction	   mix,	   12	   reactions	   per	   eluate,	   2	  
reactions	  with	  SYBR	  green	   I	  dye,	  one	  negative	  control	  and	  one	  positive	  
control,	  both	  with	  SYBR	  green	  I	  dye.	  Prepare	  reactions	  in	  1.5	  ml	  lo-­‐bind	  
tubes.	  	  
2. SYBR	  green	  I	  given	  at	  10	  000	  X	  concentration;	  dilute	  1	  μl	  in	  799	  μl	  DMSO	  
(1:800)	  
 Eluate	   	   	  	   	   	   	   	   4	  μl	  
 2x	  Phusion	  Master	  Mix	   	   	   	   	  	  	  	  	  	  	  	  	  	  	  25	  μl	   	  
 PE	  primer	  1.0	  (25	  µM)	   	   	   	   	   1	  μl	   	  	  	  
 PE	  primer	  	  2.0	  (25	  µM)	   	   	   	   1	  μl	   	  	  	  
 SYBR	  green	  (diluted	  in	  DMSO	  1:800)	   	   	   1	  μl	   	  	  	  	  	  
 Molecular	  Grade	  water	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	   	  	  	  	  	  	  	  	  	  	  	  18μl	   	  
	  	  	  	  	  	  Total	   	   	   	   	   	   	  	  	  	  	  	  	  	  	  	  	  50	  μl	   	  
3. Aliquot	  46µl	  of	  Mastermix	  in	  10	  lo-­‐bind	  tubes	  (without	  SYBR	  green)	  and	  
45µl	  of	  Mastermix	  in	  2	  lo-­‐bind	  tubes	  (with	  SYBR	  green)	  plus	  the	  control	  
tubes.	  Add	  4µl	  of	  eluate	  per	  tube.	  Add	  1	  µl	  of	  SYBR	  green	  in	  each	  of	  the	  
2	  lo-­‐bind	  tubes	  and	  control	  tubes.	  	  	  
4. Run	   PCR	   on	   the	   Corbett	   Rotor-­‐gene	   RT-­‐PCR	   machine,	   using	   following	  
thermal	  cycling	  conditions:	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1. 98oC	  30s	  	  
2. 98oC	  10s	  
3. 65oC	  30s	  
4. 72oC	  30s	  –	  collect	  result	  at	  this	  step	  	  
	  
Terminate	  reaction	  just	  before	  amplification	  reaches	  plateau	  curve.	  	  
	  
5. Make	   two	   pools	   of	   5	   PCR	   reactions	   (those	  without	   SYBR	   green	   I);	   add	  
1,250	  μl	  Qiagen	  PBI	  buffer	  to	  each	  of	  the	  two	  pools.	  Follow	  the	  protocol	  
in	   QIAquick	   PCR	   purification	   kit,	   elute	   with	   50	   μl	   EB.	   Mix	   the	   two	  
resulting	  pools	  together,	  so	  100	  μl	  in	  total	  from	  10	  PCR	  reactions.	  	  
	  
Determine	  the	  post	  capture	  LMPCR	  concentration	  and	  size	  
1. Measure	  concentration	  of	  library	  by	  qPCR.	  	  
2. Run	  Agilent	  Bioanalyzer	  DNA7500	  chip	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Appendix	  I-­‐C	  
Summary	  Statistics	  for	  75	  coeliac	  exomes	  
	  
	  
Sample	   Mean	  coverage	   Number	  of	  SNPs	   Total	  reads	   Total	  unique	  reads	   %	  unique	  reads	   %	  reads	  on	  target	  
BD125	   49.9	   15314	   21806499	   17522198	   80.4	   85.8	  
BRK11	   38.7	   14792	   19488200	   13920438	   71.4	   83.3	  
BRK4	   38.0	   14319	   19383798	   13464140	   69.5	   83.2	  
BUT36	   74.3	   15748	   35961107	   27931526	   77.7	   84.6	  
CAP152573	   54.3	   15105	   22269704	   20809469	   93.4	   88.5	  
CAP152582	   51.4	   15352	   21261310	   19875402	   93.5	   87.2	  
CAP152602	   58.2	   15210	   25508789	   23768557	   93.2	   85.0	  
CAP152616	   65.7	   15019	   27373757	   24610549	   89.9	   88.4	  
CAP152629	   45.9	   14779	   19367470	   18213413	   94	   87.1	  
CAP152633	   55.9	   14913	   24654132	   22656262	   91.9	   85.4	  
CAP152639	   45.1	   12791	   20487543	   19492259	   95.1	   86.2	  
CAP152646	   60.6	   15061	   26787695	   25029622	   93.4	   85.1	  
CAP152658	   48.4	   16663	   20644436	   19199835	   93	   84.5	  
CAP152677	   107.1	   15326	   52997717	   42201911	   79.6	   87.5	  
CAP152699	   67.3	   15519	   28230050	   24629384	   87.2	   89.4	  
CAP152708	   71.4	   14840	   29951044	   28034390	   93.6	   88.2	  
CAP152713	   112.7	   15290	   53114021	   43554049	   82	   89.3	  
CAP152726	   54.9	   14888	   25088339	   23566243	   93.9	   82.4	  
CAP152730	   40.8	   15044	   16227946	   14934907	   92	   86.6	  
CAP152825	   61.1	   15345	   26223092	   24003151	   91.5	   86.9	  
CAP152916	   69.5	   15235	   30987209	   28714566	   92.7	   86.6	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CAP153113	   67.3	   15152	   30396359	   28247009	   92.9	   85.0	  
CAP153119	   65.0	   15192	   29112035	   25688348	   88.2	   87.0	  
CAP153231	   59.8	   15241	   26061548	   24223058	   92.9	   85.5	  
CAP200010	   60.2	   15371	   26001856	   23893175	   91.9	   86.6	  
CAP200344	   60.5	   15614	   26383621	   23538963	   89.2	   87.5	  
CUK-­‐41789	   63.1	   15259	   34913754	   28483442	   81.6	   75.0	  
CUK-­‐71848	   69.2	   15620	   35028306	   30299232	   86.5	   77.8	  
DA194	   44.8	   13676	   22960721	   15888421	   69.2	   84.5	  
DA269	   51.3	   14313	   22526005	   17645066	   78.3	   86.3	  
FAM010-­‐4	   48.7	   16638	   48765253	   35895980	   73.6	   47.3	  
FAM014-­‐6	   40.2	   16361	   43749347	   29222387	   66.8	   47.6	  
H74	   16.9	   16505	   9466873	   7583305	   80.1	   79.7	  
HMN10	   13.7	   14263	   8611430	   6271787	   72.8	   68.7	  
Naluai	   63.4	   15612	   25999072	   23174204	   89.1	   88.2	  
Naluai	   59.1	   15493	   24549860	   22278612	   90.7	   87.2	  
Neuhausen4735	   67.6	   15228	   26056990	   24589360	   94.4	   86.3	  
Neuhausen4735	   34.3	   14893	   19743950	   18813543	   95.3	   59.9	  
Neuhausen4735	   42.8	   16164	   35145165	   29530782	   84	   51.2	  
Neuhausen4768	   42.8	   15180	   25898998	   24320220	   93.9	   59.5	  
Neuhausen4768	   53.0	   15280	   20576500	   19278197	   93.7	   86.2	  
Neuhausen4801	   69.8	   15240	   28163868	   25607734	   90.9	   88.3	  
Neuhausen4801	   58.3	   15653	   24132862	   21050052	   87.2	   85.9	  
Neuhausen4801	   64.9	   15216	   26144218	   23136401	   88.5	   87.7	  
Neuhausen7017	   48.4	   15425	   21832717	   19595612	   89.8	   78.4	  
Neuhausen7017	   46.9	   15214	   17929953	   15887718	   88.6	   87.4	  
Neuhausen7017	   61.8	   15408	   24234228	   21989897	   90.7	   87.2	  
Neuhausen7058	   51.1	   15105	   19669432	   18508536	   94.1	   85.4	  
Neuhausen7058	   59.6	   15201	   22335030	   20901435	   93.6	   88.8	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SAL-­‐12544-­‐6	   66.4	   15250	   26369954	   25009023	   94.8	   87.0	  
SAL-­‐12553-­‐6	   92.0	   15160	   41779561	   35245721	   84.4	   90.6	  
SAL-­‐12575-­‐0	   22.2	   12770	   59120951	   15719553	   26.6	   51.5	  
SAL-­‐12583-­‐9	   72.9	   14038	   37348622	   31995783	   85.7	   85.6	  
SAL-­‐12592-­‐9	   41.8	   12884	   19913810	   17546341	   88.1	   85.2	  
SAL-­‐12598-­‐5	   59.7	   14655	   25179001	   23652659	   93.9	   84.6	  
SAL-­‐12706-­‐6	   58.6	   14921	   30653765	   28810630	   94	   73.3	  
SAL-­‐12746-­‐0	   40.4	   12460	   19672961	   17778083	   90.4	   80.2	  
SAL-­‐12792-­‐1	   66.5	   14611	   27731440	   25907859	   93.4	   83.9	  
SAL-­‐12847-­‐2	   52.6	   16087	   30728026	   28824424	   93.8	   63.3	  
SAL-­‐13093-­‐6	   102.7	   14018	   51141008	   38837379	   75.9	   89.8	  
SAL-­‐13123-­‐0	   37.9	   12103	   17947394	   16605739	   92.5	   85.4	  
SAL-­‐13281-­‐5	   84.0	   14795	   51658474	   42532697	   82.3	   75.0	  
SAL-­‐13357-­‐9	   28.8	   14310	   11087549	   10610810	   95.7	   87.6	  
SAL-­‐13359-­‐1	   36.4	   12811	   15527983	   14628854	   94.2	   90.3	  
SAL-­‐13369-­‐2	   35.0	   13038	   17239755	   14750871	   85.6	   85.1	  
SAL-­‐13472-­‐7	   33.1	   12302	   14658611	   13469866	   91.9	   86.8	  
SAL-­‐13477-­‐2	   63.6	   15078	   54726041	   41168886	   75.2	   61.4	  
SAL-­‐13730-­‐4	   38.3	   13337	   18527186	   17142783	   92.5	   77.9	  
SAL-­‐13966-­‐5	   34.9	   12223	   14623026	   13531857	   92.5	   87.5	  
SAL-­‐14024-­‐1	   33.8	   12631	   14677702	   13580414	   92.5	   87.2	  
SAL-­‐14125-­‐3	   38.7	   13100	   16706684	   15391261	   92.1	   91.1	  
SAL-­‐14202-­‐9	   40.2	   13101	   19139632	   16817288	   87.9	   83.4	  
SDY101	   47.7	   15437	   19426782	   17179335	   88.4	   89.4	  
SDY20	   60.9	   14931	   24104415	   21420247	   88.9	   87.9	  
Samples	  in	  grey	  highlight	  were	  sequenced	  twice	  due	  to	  initial	  poor	  capture	  and/or	  sequencing	  run	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Figure	  1:	  Quality	  score	  distribution	  for	  140bp	  and	  100bp	  sequencing	  runs	  	  
	  
	   A B 	  
	  
A:	  140bp,	  12pM	  lane;	  B:	  100bp	  lane.	  Generated	  by	  FastQC	  software.	  	  
	  
	  
Table	   1:	   MiSeq	   and	   HiSeq	   sequencing	   summaries	   for	   3	   x	   1536-­‐multiplexed	  
libraries	  of	  506	  PCR	  amplicon	  sequences;	  clusters	  passing	  filter	  and	  density	  
	  
	   Clusters	  PF	  %	   Cluster	  density	  k/mm2	  
	   Lib	  01	   Lib	  02	   Lib	  03	   Lib	  01	   Lib	  02	   Lib	  03	  
Concentration	   4pM	   4pM	   4pM	   6pM	   6pM	   5pM	  
Miseq*	   90.4	   89.8	   88.8	   702	   685	   989	  
HiSeq	  2000**	   93.8	   93.6	   95.4	   748	   775	   640	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Figure	  4:	  Individual	  genotyping	  call	  rate	  cut	  off	  in	  4,608	  samples	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Figure	  5:	  Alternate	  allele	  depth	  over	  total	  allele	  depth	  over	  all	  heterozygote	  
sites	  in	  coding	  regions	  of	  24	  genes	  	  
	  
	  	  	  	  
Figure	  6:	  Mean	  depth	  per	  sample	  
	  
	  
Depth	   data	  was	   produced	  with	   a	   random	  100	  of	   4,478	   post	   quality	   control	   samples.	  
GATK	   settings	   were	   minimum	   base	   call	   quality	   16,	   mapping	   quality	   >40	   and	   down-­‐
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Negligible impact of rare autoimmune-locus
coding-region variants on missing heritability
Karen A. Hunt1, Vanisha Mistry1, Nicholas A. Bockett1, Tariq Ahmad2, Maria Ban3, Jonathan N. Barker4, Jeffrey C. Barrett5,
Hannah Blackburn5, Oliver Brand6, Oliver Burren7, Francesca Capon4, Alastair Compston3, Stephen C. L. Gough6, Luke Jostins8,
YongKong9, JamesC. Lee10,Monkol Lek11, Daniel G.MacArthur11, JohnC.Mansfield12, ChristopherG.Mathew4, CharlesA.Mein13,
MuddassarMirza4, SarahNutland7, SunaOnengut-Gumuscu14, EfterpiPapouli4,MilesParkes10, StephenS.Rich14, StevenSawcer3,
Jack Satsangi15, Matthew J. Simmonds6, Richard C. Trembath16, Neil M. Walker7, Eva Wozniak13, John A. Todd7,
Michael A. Simpson4, Vincent Plagnol17 & David A. van Heel1
Genome-wide association studies (GWAS) have identified common
variants of modest-effect size at hundreds of loci for common auto-
immune diseases; however, a substantial fraction of heritability
remains unexplained, to which rare variants may contribute1,2. To
discover rare variants and test them for association with a pheno-
type, most studies re-sequence a small initial sample size and then
genotype the discovered variants in a larger sample set3–5. This
approach fails to analyse a large fraction of the rare variants present
in the entire sample set. Here we perform simultaneous amplicon-
sequencing-based variant discovery and genotyping for coding
exons of 25 GWAS risk genes in 41,911 UK residents of white
European origin, comprising 24,892 subjects with six autoimmune
disease phenotypes and 17,019 controls, and show that rare coding-
region variants at known loci have a negligible role in common
autoimmune disease susceptibility. These results do not support
the rare-variant synthetic genome-wide-association hypothesis6
(in which unobserved rare causal variants lead to association
detected at common tag variants). Many known autoimmune dis-
ease risk loci contain multiple, independently associated, common
and low-frequency variants, and so genes at these loci are a priori
stronger candidates for harbouring rare coding-region variants
than other genes. Our data indicate that the missing heritability
for common autoimmune diseases may not be attributable to the
rare coding-region variant portion of the allelic spectrum, but per-
haps, as others have proposed, may be a result of many common-
variant loci of weak effect7–10.
Recent large-scale human sequencing studies have revealed an
abundance of rare variants (which we define as minor allele frequency
(MAF), 0.5%) and shown that these are geographically localized and
are more likely to have deleterious functional consequences11,12. In the
largest sample size studied to date12, 202 genes in 14,002 people were
re-sequenced, and,95%of exonic variants identifiedwere found to be
rare, with 74% observed in only one or two subjects. More broadly,
across,15,000 genes, similar findings were observed in recent exome-
sequencing studies of 2,440 and 6,515 subjects13,14. Importantly, these
studies demonstrate that even if we had reference variation databases
fromamillion subjects,most of the rare-variant allelic spectrumof any
given sample set (for example, a case–control cohort) will be unique
and only identifiable by direct re-sequencing of the entire sample set.
There are only a handful of published examples of rare coding-region
variants associated with common autoimmune diseases (although
many examples in familial/Mendelian immune-mediated diseases).
Coding-region variants in IFIH1 associated with type 1 diabetes
(MAF in controls5 0.67–2.2%)3, TYK2 with multiple autoimmune
diseases15 and IL23R with inflammatory bowel disease5, for example,
are low frequency (which we define as MAF5 0.5–5%) rather than
particularly rare. In other examples, the existing evidence for asso-
ciation, and/or the effect sizes, are relatively weak (for example,
CARD14 and psoriasis16, IL2RA and IL2RB and rheumatoid arthritis17).
The association of rare coding-region variants ofNOD2 (also known as
CARD15) in Crohn’s disease probably provides the best example,
albeit three low-frequency variants comprise over 80% of all the dis-
ease-causingmutations18.Most of the studies also lose power (especially
for tests inwhichmultiple rare variants are pooled into a single analysis,
for example by gene) by initially sequencing only a small sample subset
rather than testing the entire rare-variant content of a large case–control
sample set. We sought to improve on these methods by performing
highly multiplexed sequencing of sufficiently high quality to enable
direct genotyping in the entirety of a large autoimmune disease case–
control collection.
We selected subjects from a single population—individuals of white
Northern-European ethnicity living in the UK (Methods)—to mini-
mize any effects of population stratification. We selected to re-
sequence all RefSeq exons for 25 genes from 20 GWAS-identified risk
loci showing overlap between six common autoimmune disease phe-
notypes (autoimmune thyroid disease, coeliac disease, Crohn’s disease,
psoriasis,multiple sclerosis and type 1 diabetes).All genes studiedwere
fromrisk loci for at least twophenotypes, all genes had known immune
system function, 18 out of 20 loci had either a single candidate immune
gene or all immune genes at a locus were selected (the remaining two
loci had partial transcripts of another immune gene within the 0.1 cen-
timorgan (cM) linkage disequilibrium block), and all genes and loci
were densely genotyped on the Illumina ImmunoChip (Supplemen-
tary Table 1)19. We attempted high-throughput sequencing of 52,224
samples (including positive and negative controls, and repeats). We
performed extensive quality control on both samples and variant calls
(Methods). The final data set comprised 41,911 phenotyped indivi-
duals (autoimmune disease cases and controls), with ImmunoChip
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array genotypes available for 32,806 of these individuals (Supplemen-
tary Table 2). We discovered 4,377 variant sites across all amplicons,
and the genotype call rate was 99.9989% (reference homozygote aswell
as non-reference genotypes) across 41,911 individuals. Of these, 2,990
variants were in protein-coding regions (including exon splice sites) of
the 25 genes (Table 1 and Supplementary Table 3); 97.1% of which are
rare (MAF in 17,019 controls,,0.5%); 73.6% are novel when compared
with current published data sets (dbSNP137, 1000 Genomes Project,
National Heart, Lung, and Blood Institute (NHLBI)) containing.6,000
individuals and 67.3% are novel compared to an unpublished data set
of 25,994 exome-sequenced individuals (D. G. MacArthur, personal
communication); and 68.9% were only seen in one (singleton) or two
(doubleton) individuals. These proportions of novel, and rare, variants
are similar to recent data from other large re-sequencing studies12.
Our very high coverage data (99.8% of 183.4million (site X sample)
genotype calls had a read depth of$40 and 96.6% had a read depth of
.100; Supplementary Fig. 1) enabled stringent data filtering on call
rate per sample, per variant site, and other criteria (Methods). To
confirm data quality, we performed further experiments and analyses
as follows: (1) we genotyped one control sample 296 times (on differ-
ent 48-sample microfluidic chips), and the genotype call error rate
was two non-consensus genotype calls of 1,295,581 called genotypes
(0.00015%); (2) 32,806 out of 41,911 subjects also had dense
ImmunoChip genotyping data at the 25 genes, and genotype concord-
ance at 91 variant sites genotyped on both platforms was 99.994%; (3)
transition/transversion (Ti/Tv) rates, a quality-control measure based
on expected human mutation types, were 2.434 at coding-region
variants (2.427 at singletons), 2.44 at rare (MAF, 0.5%) variants
(2.437 at singletons) and 2.275 at novel variants (2.273 at singletons)
(definitions in Table 1); (4) we selected all (35) nonsense single nuc-
leotide variants (SNVs) and all (39) frameshift insertions/deletions
(indels) in the ImmunoChip-genotyped samples for Sanger sequen-
cing: two variants failed assay/PCR (polymerase chain reaction) design
and there was one false-positive SNV and one false-positive indel
(overall false-positive rate5 2.8%). All 70 validated SNVs and indels
had the same alleles in high-throughput and Sanger-sequencing
Table 1 | Variant types in protein-coding regions of 25 genes in
41,911 phenotyped individuals
Variant type All variants Rare
(MAF,0.5%)*
Novel{
Nonsynonymous SNV 1,792 1,758 1,379
Splicing SNV 86 85 65
Stopgain SNV 47 47 42
Synonymous SNV 1,024 972 674
Frameshift indels 31 31 31
Nonframeshift indels 10 10 10
Total variants 2,990 2,903 2,201
Singleton 1,602 1,598 1,411
Doubleton 470 468 378
Numbers shown are after quality-control steps. Annotation performed with GENCODE V14 gene
definitions. Triallelic (n5124) and quadrallelic (n53) sites (combined SNVs and indels) are shown as
multiple separate variants with the appropriate annotation for each non-reference allele.
*MAF in 17,019 sequenced controls.
{Not seen in dbSNP137, or 1000 Genomes Project (April 2012 release), or NHLBI (data release
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Figure 1 | Association analyses of discovered rare functional variants in
autoimmune diseases. We define rare functional variants as MAF, 0.5% in
17,019 controls and predicted nonsynonymous, premature-stop or splice-site
annotation. Quantile–quantile plots compare observed versus expected test-
statistic distributions, with shading indicating 99% confidence intervals. Full
results are available in SupplementaryData. Each of six individual diseases, and
all autoimmune diseases combined, were tested as phenotypes. a, Gene-based
C-alpha test (25 genes by 7 phenotypes, n5 41,911 subjects) allowing for both
risk and protective effects for rare functional variants. Singleton variants pooled
into a single binomial count per phenotype. b, Gene-based burden tests (25
genes by 7 phenotypes, n5 41,911 subjects) comparing summed allele counts
for rare functional variants in cases versus controls with Fisher’s exact test.
c, Conditional gene-based burden test (25 genes by 6 phenotypes, n5 32,806
subjects): rare functional-variant allele counts are summed for each individual
per gene and introduced in a logistic regression, including ImmunoChip
covariates for multiple independent top (common) variant signals selected on
the basis of a stepwise regression (down to P. 1024). The psoriasis phenotype
was not tested as most samples do not have ImmunoChip data. d, Count of
case-unique rare alleles (UNIQ) tests (25 genes by 7 phenotypes, n5 41,911
subjects): compares the number of rare functional variants only observed in
cases with the distribution of this value upon random permutation (10,000
times) of the phenotypes. e, Count of control-unique rare alleles (UNIQ) tests:
same as d but for rare functional variants uniquely observed in controls.
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assays; (5) proportions of rare, and of known, variants were similar to
those found by other large sequencing studies, and we identified no
common or low-frequency novel variant sites.
We first attempted to identify any low-frequency or rare variants of
larger effect.We performed for each coding-region variant and each of
seven phenotypes (including all autoimmune disease cases combined)
a single-variant association analysis. Only previously reported loci
were observed with common variants (MAF. 5%), as expected. We
identified three low-frequency (MAF5 0.5–5%) and rare (MAF in
17,019 controls5,0.5%) exonic variants with single SNP association
P, 1024 (chosen as a partial Bonferronimultiple testing correction for
25 genes and 7 phenotypes, but not correcting for all variants per
gene) (Supplementary Table 4 and Supplementary Data). We next
analysed low-frequency and rare exonic variants, conditioning on
common-variant non-coding signals at each locus, and observed no
additional association signals (Supplementary Data). An association
between type 1 diabetes and the low-frequency UBASH3A SNP
rs17114930 was observed, but conditional regression analysis showed
this signal to be secondary to a stronger common-frequency variant/
haplotype previously identified by GWAS20. We identified novel low-
frequency (nearly ‘common’ as MAF in 17,019 controls 5 4.97%)
NCF2 coding-region variant associations with coeliac disease at two
SNPs (rs17849502, nonsynonymous; rs17849501, synonymous; in
almost complete linkage disequilibrium r25 0.992). Both variants
were present on the Illumina ImmunoChip, but just failed quality-
control criteria in our previous coeliac disease study owing to missing
data19. We replicated the UK findings in 4,313 coeliac cases and 3,954
controls (European samples, Methods; rs17849502 P5 4.463 1025
(Cochran–Mantel–Haenszel test), odds ratio 1.35 (95% CI5 1.17–
1.55)). Logistic regression analysis conditioning on rs17849502 in
the UK re-sequencing data set revealed no further single-variant coel-
iac disease association signals belowP, 1024.NCF2 is a component of
the neutrophil NADPH oxidase respiratory burst complex. Different
disease-causing mutations cause the recessive Mendelian phenotype
chronic granulomatous disease. The rs17849502/H389Q variant is
also associated with the autoimmune disease systemic lupus erythe-
matosus21. Functional studies have shown that the minor allele of
rs17849502/H389Q reduces the binding efficiency of NCF2 to the
guanine nucleotide-exchange factor VAV1 (ref. 21). These data now
implicate a disease mechanism of impaired neutrophil function in
coeliac disease, a condition previously thought to be of predominantly
B- and T-cell-mediated immunopathogenesis, and where neutrophils
may have a role in regulating adaptive immunity22.
We noted that even with ,7,000 cases and ,17,000 controls the
power to detect association signals using single-variant tests for variants
(MAF, 0.5%) of modest effect (for example, odds ratio, 3) is limited
(Supplementary Fig. 2) and therefore we performed gene-based pooled-
variant association tests to better detect the combined effect of multiple
variants. We defined coding-region variants as functional candidates if
the variants were rare (MAF in 17,019 controls5,0.5%) and predicted
to be of potential functional impact (nonsynonymous, premature stop,
splice-site altering; see Methods). We pooled variants (by gene) in ana-
lyses to detect different scenarios (Fig. 1 and Supplementary Data),
including the C-alpha test, which can detect a combination of risk and
protective variants; burden tests to detect either an excess of risk variants
in cases or protective variants in controls; a modified version of the
burden test using conditional regression and common-variant non-
coding signals at a locus as covariates; a test to detect an excess of rare
variants seen uniquely in cases (the case or control unique tests being
particularly suitable for the study of the large numbers of singleton and
doubleton variants we observe); and a test to detect an excess of rare
variants seen uniquely in controls. The distribution of association stat-
istics for all five pooled gene tests across each of the six or seven pheno-
types tested was consistent with the global null of no association.
On the basis of these results, in the largest (to the best of our know-
ledge) human disease sample sequencing study to date, we find little
support for a significant impact of rare coding-region variants in
known risk genes for the autoimmune disease phenotypes tested.
Our data provide little stimulus in support of large-scale whole-exome
sequencing projects in common autoimmune diseases. Using average
genetic-effect estimates from our data (Methods), over all loci and
phenotypes we have tested, we estimate that rare variants contribute
to less than 3% of the heritability explained by common variants at
these known risk loci23.
METHODS SUMMARY
Sequencing. DNA (corresponding to exonic sequence of 25 autoimmune disease
risk genes) was PCR-amplified in a multiplexed microfluidics assay (Fluidigm
Access Array). PCR amplicons from a sample were pooled, and barcoded with
one of 1,536 unique ten-base-pair sequences. Libraries of 1,536 samples were
sequenced on Illumina HiSeq instruments. Reads were aligned to the GRCh37
human reference and SNVs and small indels called. Samples and called variants
were extensively filtered on the basis of call rate andother criteria. Selected variants
were validated by Sanger dideoxy sequencing. Genotype data from Illumina
ImmunoChip array-based genotyping was merged with Fluidigm sequencing-
based genotypes.
Statistical analysis. Statistical analysiswas performed inR, andusing PLINK/SEQ
software.
Full Methods and any associated references are available in the online version of
the paper.
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METHODS
Gene selection.All genes studied (listed in Supplementary Table 3) were risk loci
for at least two phenotypes, had a known immune system function, were from loci
with only a single strong candidate immune gene (or all immune genes were
selected at four loci: IL18R1, IL18RAP; CTLA4, CD28, ICOS; IL2, IL21; PTPRK,
THEMIS), and all genes and loci were densely genotyped with all 1000 Genomes
pilot project variants on the Illumina ImmunoChip (for design of this chip, see
ref. 19). Additional criteria favouring locus selection were: known multiple inde-
pendent association signals, risk (not necessarily same variants/haplotype or signal
direction) for many autoimmune diseases, fine-mapping or other data strongly
suggesting a single candidate gene, and smaller complementary DNA size.
Samples. UK samples for the six component immune disease phenotypes have
been described in previous publications (which also contain full details of Ethics
Committee approvals)19,20,24-27, as have the three control populations19,28. Informed
consent was obtained from all subjects. Individuals with self-reported autoimmune
diseasewere excluded from theUKBlood Services—CommonControls andNIHR
CambridgeBiomedical ResearchCentreCambridgeBioResource controls. Samples
with self-stated non-white European ethnicity were excluded (later further con-
firmed by ImmunoChip-based principal component ethnicity analysis for 32,806
samples). Samples with gross discordance with ImmunoChip genotypes and/or
with known gender or genotype-mismatch issues from previous GWAS were
excluded. Samples with known duplicates or relatedness (as distant as first cousins)
were excluded, relatedness was later confirmed by ImmunoChip genome-wide
identity-by-state analysis and by analysis of multiple rare-variant sharing in
Fluidigm sequencing data. Additional independent European samples genotyped
for rs17849502 (4,313 coeliac cases and 3,954 controls) were previously described19.
Wet-lab. PCR primers were designed for all RefSeq exons of 26 genes, and ampli-
cons selected to be 150–200 base pairs (bp) in size. There was minor primer design
dropout at IL18R1, STAT4,THEMIS andZMIZ1, although.94%of exon sequence
was still covered at these genes. Variant calls at the gene YDJC later proved unre-
liable with highly biased allele depths at heterozygote sites, probably due to the very
high exon GC content (,70%), and this gene was not further analysed nor is it
discussed elsewhere in this study. The total length of (overlapping) amplicons was
95,927 bp; with primers removed (still overlapping) 72,612 bp; and with primers
removed and unique sequence 58,550bp. PCR amplification was performed using
50ng genomic DNA per sample on the 48 sample/plate Fluidigm microfluidic
Access Array system. PCR primers for 511 PCR reactions were pooled up to 12-
plexperwell in 48 pools. Individual per sample perpool PCRreactions took place in
,35-nl reaction chambers with,300DNAhaplocopies per reaction. All pools per
sample were combined. Each sample’s pool was then individually barcoded in a
second PCR reaction with one of 1,536 10-bp Fluidigm-designed unique barcodes
(Fluidigm unidirectional sequencing protocol).
Sequencing. Thirty-four libraries (each of 1,536 barcoded samples) were gener-
ated. Libraries were first sequenced on an IlluminaMiSeq for rapid quality control
of the barcoding step, and to optimize loading concentrations/cluster density.
Libraries were then sequenced one per lane using 101-bp paired-end reads and
an 11-bp index read (the last base of each read being only used for chemistry cycle
phasing purposes) on Illumina HiSeq sequencers. Lanes were repeated if target
cluster density or target clusters passing filter were not achieved. Individual sam-
ples were de-multiplexed by Illumina CASAVA software, allowing zero mis-
matches per 10-bp barcode. Sanger sequencing was performed on PCR
products using an ABI 3730xl DNA analyser and ABI big dye terminator 3.1 cycle
chemistry. We sequenced all samples with rare-variant allele genotypes, and a
control sample, for the 74 sites selected.
Bioinformatics. PCR primers were trimmed from the 59 end of individual reads
using a modified version of btrim29. Trimmed sequences were aligned to the
GRCh37 human reference genome using gapped quality-aware alignment, and
base call quality recalibration implemented inNovoalign V2.07.18 with settings ‘-t
100 -H -g 65 -x 7 -o FullNW’. Data were realigned against known (1000 Genomes
and Mills-Devine 2-hit) indels and per-sample called indels. SNPs were called
using GATK 1.6-5 and settings ‘–min_base_quality_score 15 -stand_call_conf
30–baq CALCULATE_AS_NECESSARY -glm SNP–baqGapOpenPenalty 65–
downsampling_type BY_SAMPLE–downsample_to_coverage 250’ and then hard
filtered using GATK settings ‘QUAL,80.0 DP,20 MQ,40.0 QD,2.0
MQRankSum,-12.5 HRun.59 (several other recommended best practice
GATK settings were not appropriate for PCR amplicon data), and around indels.
Small indels (up to 15-bp gaps from Novoalign) were called using GATK and
settings ‘–min_base_quality_score 15 -stand_call_conf 30–baq CALCULATE_
AS_NECESSARY -glm INDEL–baqGapOpenPenalty 65–downsampling_type
BY_SAMPLE–downsample_to_coverage 250’ and then hard filtered using
GATK settings ‘QUAL,80.0 DP,20 QD,2.0’ (several other recommended
best-practice GATK settings were not appropriate for PCR amplicon data). The
most important of these settings were likely to be calling genotypes asmissingwith
sequencing depth,20 high-quality bases and theminimumPhred 15 recalibrated
base call quality score to define high-quality bases. Both SAMtools and VCFtools
software were also used to process data. SNP genotypes (including non-reference
genotypes) were called at all 58,550 bases of amplicon sequence. Samples with
,57,600 SNP genotype calls (98.4%, a threshold determined by inspection of the
call rate plot) were removed and scheduled for repeat processing. Clusters of very
close non-reference genotypes in an individual sample were removed. Non-
reference genotype sites were then identified across all samples, and VCF-level
data reduced to variants at polymorphic sites (in one or more samples). A com-
bined VCF file of all polymorphic sites and samples was then loaded into PLINK/
SEQ v0.09. Multiple-step filtering based on call rate per sample and call rate per
variant site was applied, with final requirements.99.95% call rate per sample and
per variant site. Lower call rate samples at this stage were also scheduled for repeat
processing.We removed variants if the sumof heterozygote genotype allele depths
was ,25% or .75%. The final filtered data was then exported to a VCF file
containing all variants and samples for analysis in R. ImmunoChip data was
loaded into Illumina GenomeStudio software from .idat files, and all samples
called together in GenomeStudio using the cluster settings as previously
described19. Data were merged with HapMap Phase 3 genotypes, principal com-
ponent analysis performed, and the first two principal components used to val-
idate ethnicity (Supplementary Fig. 3).
Barcode and sequencing amplicon performance. Barcode evenness was excel-
lent, with typically 99.0%of the 1,536 barcodes producing pass-filter read numbers
that were between 0.033% and 0.13% of the total pass-filter reads per lane (0.065%
expected), withmost of the failing barcodes tagging knownwater-negative control
samples or (based on repeat amplification with a different barcode) due to poor
DNA quality. Amplicon evenness was good, and for many genotype calls we
were required to downsample data to 250 bases per site per sample
(Supplementary Fig. 1). However, 10 of 511 amplicons effectively failed PCR. In
a typical analysis of 100 high-quality samples, 2% of the 58,550 unique amplicon
bases had a minimummean read-depth of,20, nearly all accounted for by the 10
failing amplicons.
Variant annotation. Annotation of all variants was first performed using
ANNOVAR (Feb 2013) and the GENCODE V14 data set. Coding variants were
identified. Rare functional variants were identified based on stop, frameshift indel,
nonsynonymous (SNV or 3n indel) or splice predictions. We performed an addi-
tional layer of annotation for high confidence loss of functionmutations, using the
methods described in ref. 30. The Variant Effect Predictor (VEP v2.5) tool from
Ensembl was modified to produce custom annotation tags and additional loss of
function (LOF) annotations. The additional LOF annotation was applied to var-
iants which were annotated as STOP_GAINED, SPLICE_DONOR_VARIANT,
SPLICE_ACCEPTOR_VARIANT, and FRAME_SHIFT and flagged if any filters
failed. Filters included: LOF is the ancestral allele; exon is surrounded by non-
canonical splice site (that is not AG/GT); LOF removes less than 5% of remaining
protein; LOF is rescued by nearby start codon which results in less than 5% of
protein truncated; transcript only has one coding exon; splice-sitemutationwithin
intron smaller than 15 bp; splice site is non-canonical OR other splice site within
same intron is non-canonical; unable to determine exon/intron boundaries sur-
rounding variant. A LOF variant is predicted as high confidence if there is one
transcript that passes all filters, otherwise it is predicted as low confidence. We
noted that LOF mutations were seen in 21 out of 25 genes, all were heterozygous
genotypes, and mainly (87 out of 97) as singletons or doubletons in the 41,911
samples (Supplementary Table 3).
Statistical analysis.Most analysis was performed in R using custom code (avail-
able on request). For tests using permutations (C-alpha, UNIQ-cases and UNIQ-
controls in Fig. 1), we randomly permuted in R the case–control status 10,000
times. The unconditional burden test (Fig. 1b) used a Fisher’s exact text.
Conditional burden tests used the glm function in R, including selected
ImmunoChip common variants as covariates (selection based on a stepwise
regression analysis up to 1024). For the C-alpha statistic computation (Fig. 1a),
the expected proportion of rare alleles in the case–control cohorts was set to the
proportion of cases and controls. Figure 1 was generated using the fact that under
the null of no association22log(P) is distributed as chi-squared with 2 degrees of
freedom. PLINK/SEQ v0.09 (http://atgu.mgh.harvard.edu/plinkseq/index.shtml)
was used for Ti/Tv statistics, and to confirm findings of R analyses (not shown).
We used PLINK/SEQ for the genotype concordance analysis between Immuno-
Chip and Fluidigm-sequencing data. Discordant calls were observed at 169 of
2,985,255 (0.0056%) genotypes, occurring at 36 out of 91 polymorphic variant
sites present in both data sets. We inspected Illumina ImmunoChip R theta
intensity plots for the discordant genotypes, and observed 8 discordant genotypes
to be likely due to ImmunoChip data mis-clustering, and 11 discordant genotypes
tobedue toa third or fourthobserved allele in thehigh-throughput sequencingdata.
At the sites with third and fourth alleles, we note the ImmunoChip array assays can
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only call two alleles, therefore is not possible to determine whether these sequence
genotype calls are real or errors. R code used for analysis is available from V.P.
Estimation of average genetic effect contributed by rare variants. For each
combination of locus by disease, we combined all rare functional variants (frequency
, 0.5% in 1,000 Genomes/NHLBI data sets and nonsynonymous, LOF or splicing)
in a burden statistic X and computed the combined frequency of X in the sample.
Using a logistic regression model with the disease phenotype as outcome, we esti-
mated the odds ratio associated with the burden variable X. This knowledge of
frequency and odds ratio for the burden variable X enables the estimation of the
average genetic effect (AGE, as defined in ref. 23) version of the variance explained.
We thencompared this variance at each combinationof locus/genewith thevariance
explained by what we consider to be a typical common variant association (odds
ratio 1.2, MAF 20%, assuming a single common variant per locus). To deal with the
uncertainty inestimatedodds ratio andobtaina confidence interval for this value,we
randomly sampled the odds ratio from their estimated distribution for each pair of
disease/locus. Averaging over the 150 combinations of 6 diseases by 25 loci, we
estimate the ratio of heritability explained for all rare variants byall commonvariants
to have a mean value of 1.6%, with a confidence interval of (1.2–2.3%). It is pointed
out in ref. 23 that theAGEestimate canunderestimate the true explained varianceby
rare variants. Nevertheless, assuming that rare variants are generally all risk or all
protective at a given gene, their simulations also show that the underestimation is
limited, in the range of a 25% decrease. Taking this conservative estimate of the
under-estimation level, we find the upper bound of the 95% of the confidence
interval to be 3.05%.Hence, our data indicate that the aggregate contribution of rare
variants to the heritability (,0.5% MAF, and averaged over these loci/diseases) is
unlikely toexceedapproximately 3%of theheritability assigned to commonvariants.
We acknowledge that a much larger underestimation (and therefore a much larger
heritability explained for rare variants) is possible in thepresenceof a combinationof
high risk and highly protective rare variants at the same locus. Although we cannot
exclude such scenario, it is unlikely to be widespread. We also assumed in our
estimates that rare variants act additively at the log scale. Although this assumption
is standard, we cannot exclude that a combination of rare variants results in a much
stronger predictive outcome than rare variants individually, hence underestimating
the heritability associated with rare variants.
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Dense genotyping identifies and localizes multiple common and
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Abstract
We densely genotyped, using 1000 Genomes Project pilot CEU and additional re-sequencing
study variants, 183 reported immune-mediated disease non-HLA risk loci in 12,041 celiac disease
cases and 12,228 controls. We identified 13 new celiac disease risk loci at genome wide
significance, bringing the total number of known loci (including HLA) to 40. Multiple
independent association signals are found at over a third of these loci, attributable to a
combination of common, low frequency, and rare genetic variants. In comparison with previously
available data such as HapMap3, our dense genotyping in a large sample size provided increased
resolution of the pattern of linkage disequilibrium, and suggested localization of many signals to
finer scale regions. In particular, 29 of 54 fine-mapped signals appeared localized to specific
single genes - and in some instances to gene regulatory elements. We define a complex genetic
architecture of risk regions, and refine risk signals, providing a next step towards elucidating
causal disease mechanisms.
INTRODUCTION
Celiac disease is a common complex chronic immune-mediated disease with seroprevalence
of ~1%1,2 in individuals of white European origin. A T-cell mediated small intestinal
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immune response is generated against gliadin fragments from wheat, rye and barley cereal
proteins leading to villous atrophy. Its aetiology is poorly understood. Association with
HLA variants was first shown in 1972, and predisposing HLA-DQ2 and -DQ8 sub-types are
necessary but not sufficient to cause disease. Recent genome wide association studies
(GWAS) have identified a further 26 non-HLA risk loci3-6. Many of these loci are also
associated with other autoimmune or chronic immune-mediated diseases (albeit sometimes
different markers and effect directions7), with particular overlap observed between celiac
disease, type 1 diabetes8 and rheumatoid arthritis9.
Currently unanswered questions regarding the genetic predisposition to celiac disease, which
are also relevant for other immune-mediated diseases, include explaining the remaining
major fraction of heritability, including rare and additional common risk variants; and
identification of causal variants and causal genes (or at least more finely localizing the risk
signal). The Immunochip Consortium10 developed to explore these questions, taking
advantage of emerging comprehensive common, low frequency, and rare variation datasets,
and of a commercial offer of much lower per-sample custom genotyping costs for a very
large project comprised of related diseases.
The Immunochip, a custom Illumina Infinium HD array, was designed to densely genotype,
using 1000Genomes and any other available disease specific resequencing data, immune-
mediated disease loci identified by common variant GWAS. The 1000 Genomes Project
pilot CEU low-coverage whole genome sequencing dataset captures 95% of variants of
MAF=0.05, and although underpowered to comprehensively detect variants of rarer allele
frequency, still identifies 60% of variants of MAF=0.02, and 30% of variants of
MAF=0.0111. The Consortium selected 186 distinct loci containing markers meeting
genome wide significance criteria (P<5×10−8) from twelve such diseases (autoimmune
thyroid disease, ankylosing spondylitis, Crohn’s disease, celiac disease, IgA deficiency,
multiple sclerosis, primary biliary cirrhosis, psoriasis, rheumatoid arthritis, systemic lupus
erythematosus, type 1 diabetes and ulcerative colitis). All 1000 Genomes Project low-
coverage pilot CEU population sample variants11 (Sept 2009 release) within 0.1cM
(HapMap3 CEU) recombination blocks around each GWAS region lead marker were
submitted for array design. No filtering on correlated variants (linkage disequilibrium) was
applied. Further case and control regional resequencing data were submitted by several
groups (Online Methods, Supplementary Note), as well as a small proportion of
investigator-specific undisclosed content including intermediate-significance GWAS results.
Most GWAS have been performed using common SNPs (typical minor allele frequency
(MAF) >5%), further selected for low inter-marker correlation and/or even genomic spacing.
In contrast to GWAS, the Immunochip presents a comprehensive in-depth opportunity to
dissect the architecture of both rare and common genetic variation, at immuno-biologically
relevant genomic regions, in human diseases. Due to the presence in our final Immunochip
dataset of the majority of 1000 Genomes Project pilot CEU polymorphic genetic variants
(and additional resequencing at some loci), the true causal variants from many risk loci may
have been directly genotyped and analysed.
RESULTS
A total of 207,728 variants were submitted for Immunochip assay design and 196,524
passed manufacturing quality control at Illumina. After extensive and stringent data quality
control (Online Methods), we analysed a near-complete dataset (overall 0.008% missing
genotype calls) comprising 12,041 celiac disease cases and 12,228 controls (from 7
geographic regions, Table 1) and 139,553 polymorphic (defined here as ≥2 observed
genotype groups) markers. 634 biallelic SNPs were assayed in duplicate, at these we
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observed 189 of 15,384,884 (0.0012%) genotype calls to be discordant. Considering the
intended 207,728 variants submitted for design, and an observed ~9.1% non-polymorphic
rate in our post-quality control data, we estimate we have high quality genotype data on
~74% of the complete 1000 Genomes Project pilot CEU true polymorphic variant set at the
fine-mapped regions.
We observed that 36 of the 183 non-HLA immune-mediated disease loci selected for
Immunochip dense 1000Genomes-based genotyping achieved genome-wide significance
(P<5×10−8) for celiac disease in either the current study or our previous GWAS5 (summary
association statistics for all markers are available in T1DBase). All variants reaching
genome wide significance were common (MAF >5%). We also observed marked
enrichment for intermediate significance level celiac disease association signals (e.g.
rs6691768, NFIA locus, P= 5.3×10−8) at a proportion of the remaining 147 dense-genotyped
non-celiac autoimmune disease regions (Supplementary Figure 1). Variants from 3 dense-
genotyped regions selected on Immunochip for a non-immune-mediated trait (bipolar
disorder) showed no excess of association signals (Supplementary Figure 1).
We identified 13 new celiac risk loci (P<5×10−8, Figure 1, Table 2, Supplementary Figure
2), 10 of which were from immune-mediated disease loci selected for Immunochip dense
1000Genomes-based genotyping. Several of these new loci were reported at lesser
significance levels in our previous studies5,9, and almost all have been reported in at least
one other immune-mediated disease. These, with HLA, bring to 40 the total number of
reported (current and/or previous study5, which had an overlapping but slightly different
sample set) genome wide significant celiac disease loci. Most contain candidate genes of
immunological function, consistent with our previous findings at celiac disease loci3-5.
Effect sizes (odds ratios, inverting protective effects) for the most significant marker per
locus were median 1.155 (range 1.124 – 1.360) for the top signals from 26 non-HLA loci
measured using Illumina Hap300/Hap550-chip linkage disequilibrium-pruned tag SNPs in
our 2010 celiac disease GWAS5 and median 1.166 (range 1.087 – 1.408) for the
corresponding most significant marker (for the same signal) per locus in the current high
density fine-mapping Immunochip dataset (Wilcoxon test P=0.75, Supplementary Table 1).
Although we observe no difference in effect sizes between GWAS lead SNPs and
subsequent fine-mapped signals, we note that case resequencing in the current Immunochip
dataset is limited (see also Discussion).
In all, we report 57 independent coeliac disease association signals (Table 2) from 39
separate loci, of which 18 (32%) were not efficiently (r2>0.9, Supplementary Table 2)
tagged by our previous GWAS5 (Illumina Hap550, post quality control dataset) markers.
Multiple independent common and rare variant signals
In contrast to most GWAS chips, the Immunochip contains a substantial proportion of lower
MAF polymorphic variants. Of 139,553 variants in our 11,837 European-origin controls,
24,661 variants are low frequency (defined11 as MAF 5% to 0.5%) and a further
22,941variants are rare (MAF<0.5%). We investigated the possibility of multiple
independently associated variants (of all allele frequencies) at each locus, using stepwise
logistic regression conditioning on the most significant variant at the locus (Online Methods,
Supplementary Table 3). This analysis can be sensitive to genotype miscalling and missing
data12, hence our use of extremely rigorous quality control measures for the dataset and
manual inspection of genotype clusters for all reported markers.
We observed two or more independent signals at 13 of 36 high-density genotyped non-HLA
loci (Figure 2). Four of these loci each had three independent signals (STAT4, the
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chromosome 3 CCR region, IL12A, SOCS1/PRM1/PRM2, Table 2). Low frequency and/or
rare variant signals were seen at four separate loci (RGS1, CD28/CTLA4/ICOS, SOCS1/
PRM1/PRM2, PTPN2). Notably, the strongest effect (OR 1.70) was seen at the rare variant
imm_16_11281298 (SOCS1/PRM1/PRM2 locus) with genotype counts (AA/AG/GG) of
1/136/11904 (MAF 0.57%) in all celiac cases and 0/91/12136 (MAF 0.37%) in all controls
(detailed genotype count and allele frequency data for top signals by collection are shown in
Supplementary Table 4).
We next performed haplotype analysis on all loci with multiple independent signals, to
investigate whether the multiple signals were due to multiple causal effects or a single effect
best tagged by several variants. For all but one locus (PTPN2) the haplotype association
tests (not shown) were of similar significance to the single SNP association tests, suggesting
that for each signal we have genotyped either the causal variant, or markers very strongly
correlated with it. These findings contrast with those from a recent resequencing study13,
probably because of the much greater variant density of our study. However, at the PTPN2
locus, the imm_18_12833137(T) + ccc-18-12847758-G-A(G) haplotype was considerably
more associated (P=4.8×10−14, OR 0.84) than either SNP alone (imm_18_12833137
P=1.9×10−10; ccc-18-12847758-G-A P= 0.0008).
Interestingly at the SOCS1 locus, the third independent signal imm_16_11292457 shows
association only after conditioning on the two other signals (P=2.0×10−4) but not in the
single SNP non-conditioned association analysis (P=0.15). Further inspection revealed the
protective imm_16_11292457(A) allele to be correlated (in linkage disequilibrium) with the
risk (A) allele of the first signal imm_16_11268703, thus although there are indeed three
independent signals, the effect of the third signal is only revealed after conditioning on the
first. A similar statistical effect (Simpson’s paradox) was recently shown at a Parkinson’s
disease locus14.
Fine-mapping to localize causal signals
GWAS signals are typically reported within relatively large linkage disequilibrium blocks.
We tested whether our much denser genotyping strategy would allow finer-scale
localization, and the pinpointing of association signals. We found that markers strongly
correlated (r2>0.9) with the most significant independent variant clustered together, and
defined regions that are a median 12.5x smaller than the relevant HapMap3 CEU 0.1cM
linkage disequilibrium blocks (Table 2, Figure 2, Supplementary Figure 2). Localization was
highly successful for some regions (e.g. PTPRK, TAGAP), but not possible at others (e.g.
IL2-IL21). At many loci, the localized regions comprised only a handful of markers in close
physical proximity.
Considering the 36 high density genotyped loci, we have localized to a single gene 29 of the
total 54 independent non-HLA signals (Table 2, Supplementary Figure 2). We identified all
markers strongly correlated (r2>0.9) with the independent non-HLA variants reported in our
analyses (from Table 2), and on functional annotation (Supplementary Table 2) identified
only a handful of markers in exonic regions and of these only three are protein altering
variants (nsSNPs: imm_1_2516606 (MMEL1), imm_12_110368991 (SH2B3),
1kg_X_152937386 (IRAK1). In contrast, a number of signals appeared to be more finely
localized around the transcription start site of specific genes (which we defined as the first
exon, and 10kb 5ᓉ of the first exon), including signals at RUNX3, RGS1, ETS1, TAGAP,
ZFP36L1; and around the 3ᓉ UTR region (and 10kb 3ᓉ) including signals at IRF4, PTPRK
and ICOSLG.
Overlap between multiple independent signal regions was seen at some loci (Figure 2),
suggesting that causal variants might be functioning through a shared mechanism e.g. within
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a 2kb region of the PTPRK 3ᓉ UTR; within a 11kb region 5ᓉ of IL12A; or within a 28kb
region of TNFAIP3. In contrast, multiple independent signals were observed that spread
between the three immune genes of the CD28/CTLA4/ICOS region.
DISCUSSION
We show that fine mapping of GWAS regions using dense resequencing data, e.g. (as here)
from the 1000Genomes project, is feasible and generates substantial additional information
at many loci. We identify a complex architecture of multiple common and rare genetic risk
variants at around a third of the now 40 proven celiac disease loci. The design of our study
has allowed us to find many more such complex regions than the ~10% with multiple
signals seen in our previous study5 and a recent large GWAS for human height15. It seems
probable that if larger sample sizes than in the current study were to be tested, additional loci
might be shown to have a similarly rich multiple risk variant architecture. Multiple
independent risk signals for celiac disease have also long been known in the HLA region16.
Our success in celiac disease might be partly due to the extensive selective pressures for
haplotypic diversity that have taken place at immune gene loci17. Previous studies have
reported independently associated common and rare variants at individual loci for a handful
of phenotypes e.g. fetal haemoglobin13, sick sinus syndrome18, Crohn’s disease19,
hypertriglyceridemia20. To the best of our knowledge, ours is the first study to have
comprehensively surveyed the genetic architecture of all known risk loci for a trait.
In part, our identification of rare variants at risk regions relies on the prior discovery of a
genome-wide significant common variant association signal at each locus. This then permits
a per-locus rather than genome-wide multiple testing correction when searching for
additional independent association signals. Only particularly strong rare variant signals
would, on their own, generate significance levels reaching the genome-wide threshold
typically used in GWAS studies (P<5×10−8). Alternative methods, such as collapsing rare
variant signals across a gene or functional categories of genes have therefore been suggested
as approaches to the same problem21. Although a rare variant may have occurred on a recent
haplotypic background, and thus show linkage disequilibrium at substantially longer range
than common variants, we deliberately restricted our search to around the common variant
linkage disequilibrium blocks as to do otherwise would have incurred a considerably greater
penalty from multiple testing. Therefore, although our study provides considerable
encouragement for exome and whole genome sequencing efforts aimed at identifying rare
risk variants (not necessarily restricted to GWAS loci) in common complex diseases, it
further highlights the statistical challenges of establishing rare variant associations.
We used a dense genotyping strategy and stepwise conditional association analysis, but did
not identify any rare highly penetrant variants that might explain the genome-wide
significant common SNP signals at any of the 39 loci. Our study does have limitations in
this regard, particularly i) analysis restricted to 0.1cM linkage disequilibrium blocks; ii) the
limited control resequencing sample size of the 1000 Genomes Project pilot CEU dataset;
iii) the limited case resequencing sample size; and iv) case resequencing limited to three loci
for celiac disease, and selected loci for other immune diseases. We observed a weak trend
towards lower MAF (P=0.042, Wilcoxon test, Supplementary Table 1) for the best fine-
mapping SNP (Immunochip experiment) versus the lead SNP from our 2010 tag SNP
GWAS (measuring MAF in a subset of samples genotyped in both datasets). One signal
showed substantially higher MAF (>25% change) on fine-mapping, four signals showed
substantially lower MAF on fine mapping (Supplementary Table 1), yet all fine-mapping
variants corresponding to lead GWAS SNPs remained common (MAF>0.10). We suggest
that these changes in MAF upon fine-mapping of lead GWAS SNPs simply reflect more
precise measurement of common frequency risk haplotypes. Although we cannot exclude
Trynka et al. Page 6
Nat Genet. Author manuscript; available in PMC 2012 June 01.
 Europe PM
C Funders Author M
anuscripts
 Europe PM
C Funders Author M
anuscripts
the possibility that a single high-penetrance lower-frequency variant explains most of the
association signal at a locus, especially without more comprehensive case resequencing, we
find no evidence in support this possibility in the current fine-mapping experiment. Nor can
our stepwise selection procedure robustly refute the “synthetic association” hypothesis - in
particular that a combination of multiple rare variants jointly explains the association
signal22 - although similarly we have not observed so far evidence supporting this
possibility.
We established at genome wide significance 13 new loci for celiac disease, most of which
have been reported previously at lesser significance or for another immune-mediated
disease. The Illumina Hap550 chip (used in our 2010 GWAS) should have detected 10 of
the 13 new loci, and in total 39 of the 57 independent non-HLA signals that we report. A
current genotyping platform, the Illumina Omni2.5 chip would have detected 12 of the 13
new loci, and in total 50 of the 57 independent non-HLA signals that we report. Neither chip
would have provided the finer scale localization of the Immunochip. The thirteen new loci
contain many candidate genes of immunological function (P=0.0002 for enrichment of the
Gene Ontology term “immune system process”23), in line with expectations from our
previous studies. We also show evidence suggesting substantial additional signals at other
immune-mediated disease loci, which lie beneath the genome wide significance reporting
threshold applied to the current dataset. It is a point of debate whether such strict
(P<5×10−8) criteria should apply - a Bayesian analyst might apply a higher prior at a locus
already reported in another immune-mediated disease. Alternatively, an Immunochip-wide P
value with a Bonferroni correction for independent SNPs, as used recently for the
Cardiochip custom genotyping project24, of P<1.9 × 10−6 (Online Methods) would yield 16
additional celiac disease loci. These 16 loci also mostly contain immune system genes. An
analysis of these currently intermediate significance signals would gain substantial
additional power by a meta-analysis across the several hundred thousand samples from
multiple immune-mediated disease collections presently being run on Immunochip,
We found that our previous GWAS using tag SNPs gave very similar estimates of effect size
to our current fine-mapping experiment (Supplementary Table 1), in contrast to a simulation
study which suggested that GWAS markers often underestimate risk14. We have, however,
found substantial evidence for multiple additional signals at known loci and report many
new loci. In Europeans, the current 39 non-HLA loci now explain 13.7% of coeliac disease
genetic variance (HLA accounts for a further ~40%). We also show a long tail of likely
effects of weaker significance, which will explain substantial additional heritability.
Only one of the variants reported here was discovered by a disease-specific resequencing
study: ccc-18-12847758-G-A (rs62097857), a marker identified by the WTCCC group’s
resequencing of Crohn’s disease cases and controls (Supplementary Note) and also present
in the Watson genome. We submitted for Immunochip ~4,000 variants from high throughput
resequencing of pools of 80 celiac disease cases for extended genomic regions at three loci
(RGS1, IL12A, IL2- IL21, Supplementary Note). These did not contribute additional signals
over and above those obtained from the 1000 Genomes Project pilot CEU variants, although
did contribute to increase the numbers of variants correlated with each signal (i.e the set of
markers that likely contains the causal variant(s)) and more precisely define the bounds of
the signal localization. We note that larger scale case resequencing (e.g. many hundreds of
samples) would identify a rarer spectrum of variants than the current study, and has
previously been used with success at selected genes and phenotypes.
The possibility of performing fine-scale mapping of GWAS regions using e.g. 1000
Genomes Project data has been discussed as a natural follow-on strategy for such
studies25,26 and has been recently used to identify risk variants in APOL1 in African-
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Americans with renal disease27. Our current report is the first to test such a strategy on a
large scale in a complex disease. At multiple regions, we were able to refine the signal to a
handful of variants over a few kilobases or tens of kilobases, although some regions (e.g.
IL2-IL21) were resistant to this approach presumably due to particularly strong linkage
disequilibrium. Most GWAS publications report signals mapping to a “LD block” based on
HapMap recombination rates (sample size, 60 CEU families). In our data, where we have
both i) much denser genotyping than GWAS chips (mean 13.6x at celiac loci versus the
Illumina Hap550 chip) and ii) nearly 25,000 genotyped samples for the linkage
disequilibrium calculations, we are able to observe much finer scale recombination and more
precisely estimate of the bounds of no/minimal recombination intervals. Our findings are
similar in terms of genotyping density and the resulting fine-mapped region size and lack of
haplotype-specific effects to an earlier study of the IL2RA locus in type 1 diabetes26. At the
majority of regions a tight block of highly correlated variants was seen, rather than a gradual
decay of correlation (e.g. Figure 2 plots for IL12A, PTPRK). At many loci, we have now
defined a handful of likely candidates to be the causal variant(s) to be taken forward into
functional studies, although we may have missed candidate variants at some regions due to
the sample size of the 1000 Genomes Project pilot CEU dataset (60 individuals), their status
as controls, and our estimate that ~25% of these variants were excluded from our final
dataset. These might be assessed by imputation methods28, but our approach – particularly
with regards to the more sensitive conditional regression analysis - has been to prefer the
more accurate direct genotyping of all assayable variants. As and when much larger whole
genome resequencing based reference datasets become available (e.g. the main 1000
Genomes Project), these might be used to impute into our Immunochip dataset, including
substantially lower frequency variants29. We also investigated whether our use of multiple
ethnic subgroups within Europe (e.g. southern European Spanish versus northern European
UK) or the relatively small Indian collection contributed to fine mapping, and found that in
most cases, the same degree of localization was possible with just the UK collection alone
(data not shown).
Our data suggest that most common risk variants might function by influencing regulatory
regions, consistent with those previously reported in other immune-mediated diseases, and
complex traits in general11. The exception is the SH2B3 nsSNP imm_12_110368991
(rs3184504), reported in our 2008 celiac GWAS4, which even with the fine-mapping of 938
polymorphic variants from the SH2B3 region remains the strongest signal at this locus thus
suggesting it may be the causal variant. The same variant has been associated with other
immune diseases, and a functional immune phenotype5. Interestingly, we observed a
common ~980bp intergenic deletion between IL2 and IL21 (DGV40686, accurately
genotyped by Infinium assay with control MAF 7.3%) correlated with the second
independent signal at this region, although we have no evidence to suggest causality.
Our fine-scale localization approach has identified likely causal genes at many loci, and at
eight genes signals localized around the 5ᓉ or 3ᓉ regulatory regions. For example, at the
THEMIS/PTPRK locus, two independently associated sets of variants cluster in the 3ᓉ UTR
of the PTPRK gene (one, imm_6_128332892/rs3190930 in a predicted binding site for
miRNA hsa-miR-1910). PTPRK, a TGF-beta target gene, is involved in CD4+ T cell
development and a deletion mutation causes T helper deficiency in the LEC rat strain30. The
signal at TAGAP lies within a 4kb region immediately 5ᓉ of the transcription start site,
presumably containing promoter elements. At ETS1, the signal comprises 6 variants
overlapping the promoter and 1st exon of the T cell expressed isoform NM_001162422.1,
and one of the variants (imm_11_127897147/rs61907765) has predicted regulatory potential
and overlaps multiple transcription factor binding sites (UCSC GenomeBrowser ChipSeq
and ESPERR tracks, Supplementary Table 2). Similarly interesting variants are observed in
regulatory regions of RUNX3 (imm_1_25165788/rs11249212), and RGS1
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(imm_1_190807644/rs1313292, imm_1_190811418/rs2984920) (Supplementary Table 2).
Such an approach to identify the functional potential of risk variants was recently successful
used to define a causal systemic lupus erythematosus TNFAIP3 variant31. Although we have
localized signals at many loci, and recent research suggests the likely causal gene is often
located near the most strongly associated variant15, only more detailed functional studies
(e.g. transcription factor binding assays31 and transcriptional activity assays of constructs
with individual single nucleotide alterations at risk SNPs32), will prove precisely which gene
variants might be causal.
We conclude that dense fine mapping of regions identified through GWAS studies can
uncover a complex genetic architecture of independent common and rare variants, and often
successfully localize risk variant signals to a small set of SNPs to be taken forward into
functional assays. Denser fine mapping studies, utilising larger resequencing sample sizes
from both cases and controls over broader regions, might provide further resolution of
GWAS signals.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Manhattan plot of association statistics for known and novel celiac disease risk loci
Novel loci indicated in blue, loci with multiple signals indicated with grey highlight.
Significance threshold drawn at P=5×10−8.
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Figure 2. Loci with multiple independent signals
Non-conditioned P values shown for loci with multiple independent signals (from Table 2).
The most associated variant for a signal shown in bold colour, further variants in r2>0.90
(calculated from the 24,249 sample Immunochip dataset) shown in normal colour. First
signal coloured blue, second coloured red, third coloured green. Squares indicate markers
present in our previous celiac disease GWAS post quality control dataset (Illumina
Hap550)5.
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Table 1
Sample Collections
Population sample Celiac cases Controls
UK 7728 8274b
The Netherlands 1123 1147
Poland 505 533
Spain - CEGECa 545 308
Spain - Madrida 537 320
Italy - Rome, Milan, Naples 1374 1255
India - Punjab 229 391
Total 12041 12228
aThe two Spanish population samples were considered separately due to genotyping in different laboratories.
b5430 UK 1958 Birth Cohort participants, and 2844 UK Blood Services-Common Controls.
Each of the collections from the UK, Netherlands, Poland, Spain (Madrid) and Italy contained essentially the same sample set as our 2010 celiac
disease GWAS5, with now substantial additional samples from the UK and Netherlands and exclusion of amplified DNA samples from the Spanish
collections. The Indian collection has not previously been studied. Our 2010 GWAS contained several collections not studied here.
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Molecular Genetics of
Coeliac Disease
Vanisha Mistry, Blizard Institute, Queen Mary University of London, London, UK
David van Heel, Blizard Institute, Queen Mary University of London, London, UK
Coeliac disease (CD) is a common inflammatory disease of
the small intestine. It has a prevalence of 1% in the
population and is strongly heritable. Current germline
disease risk variants explain 50%of knownheritability,
the majority contributed by a strong human leukocyte
antigen (HLA)-DQ association. The role of HLA-DQ in the
immunology of CD is well understood, for example the
role of tissue transglutaminase and HLA-DQ in modifying
and binding immuno-dominant dietary cereal (gluten)
peptides. Genome-wide association studies have found39
loci with risk variants of more modest effect. The use of
high-throughput sequencing technologies to locate rare
variants of larger effect may aid in the complete reso-
lution of this complex trait, as well as in other auto-
immune diseases, which show considerable overlap in
immunological pathways.
Introduction
Coeliac disease (CD) (or gluten sensitive enteropathy) is a
common autoimmune disorder of the small intestine. An
immune response is generated by the presence of gluten –
storage proteins found in wheat, barley and rye – in gen-
etically susceptible individuals, triggering an inﬂammatory
response causing intestinal morphological changes.
AlthoughCD shares similarities in its symptomswith other
inﬂammatory bowel diseases, it is the ingestion of gluten
that elicits an abnormal immune response in susceptible
individuals. Its molecular basis can be described as a
quantitative polygenic trait as the outcome phenotype is
consequential of combinations of genes on multiple loci
having an eﬀect on each other. The identiﬁcation of the
human leukocyte antigen (HLA) DQ gene variants and
their role in CD has contributed to our understanding of
disease. Recent studies have implicated other disease loci
mostly located in immunological pathways.
Clinical Manifestations and
Pathophysiology
CD aﬀects the mucosa of the small intestine, leading to
presentation of symptoms such as malabsorption, mal-
nutrion, steatorrhea (diarrhoea caused by excess fat),
weight loss, abdominal pain and anaemia (Figure 1). The
mucosa of the small intestine is covered by villi: ﬁnger-like
projectionswith a large surface area for absorption. Its core
is an extension of the lamina propia and crypts (circular
intestinal cells) lie at the base. The dietary prolamins –
storage proteins in grain – trigger inﬂammation. One
gluten protein is gliadin; these peptides pass through the
epithelial barrier of the intestine into the lamina propria,
and deamidation occurs due to generation of auto-
antibodies to the enzyme tissue transglutaminase (TG2)
(Molberg et al., 1998; Figure 2). This increases peptide
aﬃnity to HLA class II molecules (HLA-DQ2 or HLA-
DQ8), generating CD4+ T-helper 1 cell (Th1) activation.
Intraepithelial lymphocytes (IELs) have the role of des-
troying epithelial cells in the mucosa via natural killer
receptors (NKRs) expressed on their surface. It is through
NKRs that IELs recognise MHC-1 molecules induced on
the surface of enterocytes by stress and inﬂammation.
Here, armed eﬀector IELs are activated to lymphokine-
activated killing cells, producing epithelial cell death in T
cell receptor – independent manner. CD is described as a
Th1-mediated disease, as it shows up-regulation of inter-
feron (IFN)-gproduction andT-bet levels in gut inﬁltrating
cells (Holtmann andNeurath, 2004). An increased number
of T cells are prevalent in individuals with CD; upon gluten
ingestion there is inﬁltration ofT cells in the lamina propria
followed by crypt hyperplasia and villous atrophy.
Epidemiology
Although gluten is one environmental factor (other factors
are likely but yet unidentiﬁed), there are multiple inherited
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family and twin studies. The sibling recurrence risk ratio is
between 10 and 30 for disease development, and one of a
dizygotic twin pair has a 70% chance of developing disease
(Greco et al., 2002). Approximately 1 in 100 individuals of
European descent and .4–.95% of individuals in USA
(Dube et al., 2005) have CD, but it is less common in Asia
and South America.
The dispersion of HLA-DQ variants coincides with
disease occurrence; HLA-DQ8 is most common in Latin
America and Northern Europe, whereas HLA-DQ2 is
most common inWestern Europe, North andWest Africa,
theMiddle East and Central Asia (Cummins and Roberts-
Thomson, 2009). High frequencies of HLA-DQ2 are pre-
sent in the Saharawi population of Algeria, where the
prevalence of disease is 5.6% (Catassi et al., 1999), con-
trasting to almost negligible prevalence in the Chinese/
Japanese population.
The ratio of diagnosed to undiagnosed disease is 1:7
(Heap and van Heel, 2009); testing for disease presence has
improved with more sensitive and speciﬁc serological
screenings. Testing for the presence of immunoglobulin A
(IgA) autoantibodies to endomysium is a speciﬁc marker
for the presence of CD (Dieterich et al., 1998). If positive,
conﬁrmation is necessary by biopsy of the small intestine.
TheMarsh classiﬁcation is used systematically for diagnosis
according to small bowel pathology. HLA typing can be
useful for exclusion in patients with equivocal histological
ﬁnding but has low speciﬁcity (Kaukinen et al., 2002).
Currently adhering to a gluten-free diet (GFD) leads to
disease remission and symptoms typically reduce within a
few weeks. There are subsets of patients who do not
respond toGFD (2–5%), mainly those diagnosed at age of
50 or above; this is known as refractory CD. The leading
cause of death for these patients is enteropathy-associated
T cell lymphoma (Al-toma et al., 2007).
Immunogenetics in CD
CD, similar to other autoimmune diseases, shows strong
association with major histocompatibility complex
(MHC)-associated genes, which play a role in the immune
system. Thesemolecules are encoded at chromosome 6p21;
MHCclass IImolecules are encoded at gene lociHLA-DQ,
HLA-DP and HLA-DR. See also: Major Histocompat-
ibility Complex: Disease Associations
Gliadin peptides enter intestinal
epithileum
Giladin is deamidated by TG2 into a
negatively charged protein
HLA DQ2/DQ8 present on surface
of APCs
Binding of HLA and gliadin leads to
expression of IFN and activation of
CD4+ T lymphocytes
Finger like projections of intestinal
villi are now blunt: villous atrophy
Clinical symptoms: malabsorption, malnutrition, weight loss, anaemia
Activated lymphocytes move from
crypt area to tips of villi: increased
intra-epithelial lymphocytes (IELs)
Crypts lengthen and become
enlarged: crypt hyperplasia
Figure 1 Flow diagram highlighting clinical manifestations of disease upon gluten ingestion.
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HLA association
The most common genetic background coeliac individuals
share is the presence of either HLA-DQ2 or HLA-DQ8
serotype present on theHLA-DQ abheterodimer (Figure3).
These molecules are expressed on antigen-presenting cells
(B cells, dendritic cells and macrophages). The early iden-
tiﬁed HLA-DQ2 serotype was found to be primarily
associated with disease (Tosi et al., 1983), which is medi-
ated through the DQ2.5 haplotype; the DQ2.2 haplotype
does not appear to predispose to disease (Sollid et al.,
1989). HLA-DQ2 is encoded by HLA-DQA105 allele
(alpha chain) and HLA-DQB102 allele (beta chain). The
two alleles are present in cis conformation on the DR3
haplotype. 90%of European patients carry theHLA-DQ2
heterodimer and the remaining carries either one DQ2
allele or HLA-DQ8 (Karell et al., 2003). HLA-DQ8 is
encoded by HLA-DQA103 (alpha chain) and HLA-
DQB10302 alleles (beta chain).
It is possible to generate a combination of DQ2.2 and
DQ2.5 haplotypes depending on parental genotype since
each haplotype is only present on one chromosome. If in cis
conformation, both alpha and beta chain are encoded on
the same chromosome rather than each parent supplying
one chain (trans conformation). One or two copies of
HLA-DQ2 give an intermediate or high risk for disease.
Monsuur et al. (2008) predicted HLA-associated risk fac-
tors using tagging SNPs. They showed increased risk
individuals were homozygous for the DQ2.5 haplotype or
possessed a single copy of DQ2.5 and one copy of DQ2.2,
DQ2.7 or DQ2.8 (Monsuur et al., 2008). This coincides
with previous ﬁndings by van Belzen et al. (2004) who
reported that being homozygote for DQ2.5 gives a 4–6
times increased risk of disease (van Belzen et al., 2004).
The presence of HLA class II genes is not the sole genetic
component for disease; HLA-DQ2 is expressed in 30% of
the European population (Sollid et al., 1989), with 2–5% of
gene carriers developingdisease.These early ﬁndings suggest
other genetic factors contribute to the manifestation of CD.
Finding Disease Genes
Todetermine absolute risk of disease, non-HLA risk alleles
in CD must be taken into account. The past decade has
been subject to a series of successful genetic studies all with












Deamidated peptide presented to T cells by APC via HLA-DQ2 or HLA-DQ8
Figure 2 Model of deamidated gluten peptide presentation by APC to T cells for subsequent loading onto HLA-DQ2 or HLA-DQ8 heterodimers. Gluten
peptides (or gliadin peptides, which is a gluten protein) pass through a fairly permeable epithelial layer of the small intestine in untreated coeliac disease.
Intestinal permeability is compromised by IELs producing more interferon thereby intensifying the immune reaction. Gliadin peptides react with
transglutaminase 2 (TG2) serum autoantobodies in the lamina propria. TG2 is the autoantigen of coeliac disease and plays a primary role of crosslinking and
deamidation of gliadin. Ingested gliadin is crosslinked by TG2 causing specific deamidation of glutamine into glutamic acid. After deamidation the gliadin
peptides can be presented more efficiently to gliadin reactive CD4 T cells by APCs via HLA-DQ2 or HLA-DQ8.
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complex disease. The completion of the Human Genome
Project in 2003 allowed signiﬁcant progress in family
linkage studies; geneticmarkers spanning the entire human
genome enabled extensive mapping eﬀorts resulting in the
discovery of many genes forMendelian diseases and traits.
Recently, the mapping of common and low frequency
variation (International HapMap Consortium, 1000
Genomes Project Consortium) has made it possible to
locate and map genes surrounding disease risk loci by
genome-wide association studies (GWAS).
Linkage disequilibrium
The concept of linkage disequilibrium (LD) is centralised
on the nonrandom association of alleles at diﬀerent loci. A
SNP occurs once every 100–300 bases in the genome.
Natural selection, or chance, caused the spread of common
SNPmutations that arose thousands of generations ago; a
second mutation occurring later but close to an earlier one
results in both alleles being transmitted to the same oﬀ-
spring in subsequent generations. It is this model that is
exploited in GWA studies. An increased risk of disease
caused by one SNP denotes direct association between that
SNP and disease in the population and indirect association
between several nearby SNPs, due to LD. Therefore it is
possible to identify association in the chromosomal region
without genotyping every SNP in the genome.
International HapMap Project and 1000
Genomes Project
The International HapMap Project commenced in 2003
with a focus to map all common genetic variation (greater
than 5%minor allele frequency) across several populations,
equating to 3.5 million SNPs. Approximately 90% of the
genetic variation in the Caucasian population has been
captured. A valuable outcome is the determination of LD
in four major populations, conﬁrming its usefulness as a
reference sample in GWA investigations.
The 1000Genomes Project (1000G)was set up in 2007 to
capture low frequency variants (1%) in the human genome
(http://www.1000genomes.org). The pilot phase included
low coverage sequencing of 179 individuals from four
populations, high coverage sequencing of two trios and
exon sequencing of nearly 700 individuals from seven
populations (Durbin et al., 2010). This public reference
catalogue of human genetic variation will aid in more
GWAS identifying previously missed associations and
provide a ﬁlter in Mendelian disease for exclusionary
purposes.
Genetic linkage studies
Family-based designs have been used in genetic studies
since Mendel’s laws of inheritance dominated the funda-
mental concepts of genetics. The independence of segre-
gation, as inferred by Mendel’s law of segregation, is not
always true: there are group of traits that are linked and the
genes controlling them tend to be inherited together by the
oﬀspring as a group, not independently. Heritable vari-
ation is reliant on the outcome of meiotic transmission and
linkage analysis is the inference of the outcome of meiosis.
The underlying principle is that if two individuals are
phenotypically similar that is carry disease, then a genetic
marker located near a disease susceptibility gene must also
be similar that is shared by both carriers. The factors
contributing to the linkage model, which will prove or

























Figure 3 HLA haplotype combinations in coeliac disease. White boxes denote ‘other’ haplotype. DQ2.5 cis is shown as a heterozygote; a DQ2.5 cis
homozygote will carry same alleles on both chromosomes. Majority of CD patients express HLA-DQ2.5 encoded either in cis on the DR3-DQ2 haplotype, or
in trans on the DR5-DQ7/DR7-DQ2 haplotype for heterozygous individuals. HLA-DQ2.2 confers low risk for CD if expressed solely. HLA-DQ8 is expressed in
DQ2-negative patients (Abadie et al., 2011). Adapted from Dubois and van Heel (2008).
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of the trait loci and the genetic distance between the disease
gene and marker being tested. See also: Genetic Linkage
Mapping
Genome-wide association studies
GWAS using SNP markers is a more powerful approach
for elucidating genetic determinants than family-based
linkage studies. It was developed in tandem with the
‘commondisease common variant’ hypothesis, recognising
that multiple genomic loci were likely to be involved in
susceptibility to common multifactorial traits due to vari-
ants being present at relatively high frequency with an
individually small magnitude of eﬀect. See also: Genome-
wide Association Studies: The Success, Failure and Future
Some studies have been follow-ups from linkage signals
or candidate gene studies to narrow down association to a
single haplotype, such as the regionnear theCTLA4 gene in
CD (Hunt et al., 2005). SNP markers across the whole
genome are tested for association with a disease in a large
cohort of disease cases compared with a similar or higher
number of controls. After performing correctional tests
common variants in correlation with disease are identiﬁed
depending on the risk allele frequency, its association
between marker genotyped and relative risk conferred by
genotype. Up to now associated variants have been found
mostly in noncoding regions by GWAS, so it is accepted
that common variant contribution to disease is more likely
to be of regulatory function rather than protein coding.
Known Genetic Structure of CD
As noted, the most signiﬁcant association to CD is with
HLA-DQ2. Possession of HLA-DQ2 serotypes is neces-
sary for aﬃnity to deamidated gliadin, yet 30% of the
Caucasian population also carry HLA-DQ2 without
developing disease. Despite its importance in disease
pathophysiology HLA contribution to disease is currently
estimated at approximately 40% (Dubois et al., 2010).
Regions identified through linkage analysis
Unlike Mendelian disease, complex disease has had less
success in ﬁnding causal variants through linkage. A large
number of non-HLA variants have been implicated in CD
yet show lack of signiﬁcant association in multiple popu-
lations. Linkage was found to various regions including 5q
(Percopo et al., 2003) and 19p (van Belzen et al., 2003); the
former was replicated in a meta analysis of multiple
populations (Babron et al., 2003). One region containing
CTLA4, ICOS and CD28 is involved in immune sup-
pression hence was highlighted as a valid candidate. Hap-
lotype analysis showed strong association in the Irish
population (Brophy et al., 2006) and variants in the 3’
region of CTLA4 were thought to inﬂuence responses in
type 1 diabetes (T1D) (King et al., 2000). In spite of
promising initial analysis, replication in genome-wide
scans was inconsistent for this region (King et al., 2003).
The power of family studies is decreased due to small
eﬀect sizes attributable to genetic variants present at high
frequency. An exception is NOD2 in Crohn’s disease
(Hugot et al., 2001) and HLA replication in CD due to
common encoding variants being of large eﬀect size, hence
having suﬃcient power. This explains that predisposition
to complex disease is not caused by just a handful of highly
penetrantmutations but amixture ofmultiple risk variants
with varying eﬀect size.
Susceptibility gene loci identified by GWAS
To date twoGWA studies in the UK have been carried out
in CD identifying non-HLA variants. In the ﬁrst study 778
coeliac cases and 1422 matched population controls using
310605 SNPs showed highest association on chromosome
4q27 harbouring the KIAA1109-TENR-IL2-IL21 LD
block (van Heel et al., 2007). Follow up studies found
associations inREL, TNFAIP3 (Trynka et al., 2009) and a
region encompassing CTLA4, ICOS and CD28 (Smyth
et al., 2008). The UK follow up replication study by Hunt
et al. (2008) identiﬁed a further seven regions meeting
genome-wide combined signiﬁcance (p=55 1027)
(Hunt et al., 2008). An additional association was found in
ITGA4 in aUS case control collection (Garner et al., 2009).
The second generation GWAS by Dubois et al. (2010)
recognised a further 13 genome-wide signiﬁcant regions,
most containing genes controlling immune responses. This
study estimated current non-HLA loci to account for 6%
of the total genetic variance of CD, whereas the rest is
dominated byHLAcontribution increasing the heritability
estimate to just under 50% (Dubois et al., 2010).
Associated CD loci
Current associated loci point to primary altering of the
immune system response in several immune-related path-
ways. Three main associated loci reported before and
replicated in the second GWAS (Dubois et al., 2010), are
brieﬂy discussed.
IL2/IL21 region
This region is the strongest non-HLA marker. It is con-
tained in the  700 kb LD block of the 4q27 chromosomal
region. Recently signiﬁcant associations between the SNP
rs6822844, located in the intergenic IL2/IL21 region, and
six autoimmune diseases have been reported (Maiti et al.,
2010) implicating it as a general autoimmune disease sus-
ceptibility locus.
IL2 is involved in stimulating T cell activation and pro-
liferation, but can also stimulate proliferation of natural
killer (NK) cells and immunoglobin production from B
cells. It maintains CD4 and CD25 Treg cells and destroys
self-reactive T cells via activation-induced cell death
(Fontenot et al., 2005).
IL21 acts on NK cells, CD4+ T cells and B lymphocytes
to induce and sustain antibody production after tissue
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damage (Sarra et al., 2011). This region has been shown to
induce messenger ribonucleic acid synthesis for genes
involved in activating innate immunity and Th1 response,
such as T-bet and IFN-gamma (Strengell et al., 2002).
There is evidence that IL21 is increased in untreated coeliac
mucosa (Caruso et al., 2007).
RSG1
RGS1 regulates activity in G-protein signalling and is
involved in B cell proliferation and activation. Interest-
ingly, it shows expression in IELs (Hunt et al., 2008), which
recogniseMHC-1molecules throughNK receptors in CD.
RGS1 also regulates chemokine receptor signalling and B
cell traﬃcking to lymph nodes in mice (Han et al., 2005).
Recently, Tran et al. (2010) illustrated how IFN-b can
induce the expression of RGS1 in peripheral blood cells of
MS patients, suggesting involvement in disease treatment
(Tran et al., 2010).
SH2B3
SH2B3 is an adapter protein with pleckstrin homology and
is involved in inhibiting T cell inactivation via Src hom-
ology 2 domains (Li et al., 2000). It mediates interaction
between T cell receptors and intracellular signalling path-
ways. It also inhibits the activation of nuclear factor on
activated T cells, which binds to deoxyribonucleic acid
regulating the expression of cytokines, including IL2.
SH2B3 has been implicated in having a protective role
against bacteria infection inCDas carriers of the risk allele,
rs3184504A, have strong activation of the NOD2 recog-
nition pathway (Zhernakova et al., 2010).
Overlap with other autoimmune disease
The numbers of autoimmune disease loci that overlap with
CD highlight shared immunological pathways, mainly
resulting in inactivation of T cells. Approximately 64% of
39 known CD loci are shared with at least one other
autoimmune disease (Gutierrez-Achury et al., 2011). The
main shared loci are with T1D, rheumatoid arthritis,
Crohn’s disease and ulcerative colitis (Table 1).
Finding causal variants
GWAS ﬁndings reveal associated variants that are mostly
common, havemodest to weak eﬀect sizes, and are credible
disease markers, however only explain a small percentage
of heritability. Subsequent to discovering a region har-
bouring a risk locus, all genetic variants in the locus require
detailed analysis to ﬁnd the causative variant and to
establish its quantitative contribution todisease. Followup
in vivo studies are necessary to investigate functional
pathways and deduce biological mechanisms of disease
susceptibility or resistance.
Pinpointing causal variants requires ﬁne mapping of the
associated regions(s), followed by targeted resequencing,
exome (exons of genes) orwhole genome sequencing. These
techniques are becoming common practice due to ongoing
advances in high-throughput sequencing technologies.
Attention is now being focused on low frequency (.5–5%
minor allele frequency) and rare variant (below .5%)
analysis, shown to contribute signiﬁcantly to genetic
architecture of disease (Durbin et al., 2010) coincidingwith
the ‘rare variant common disease’ hypothesis.
Fine mapping
Fine mapping is a necessary step after genotyping to reﬁne
associated region(s) to a causal variant(s) by analysing a
high density of genetic markers across the LD region. Fine
mapping in coeliac-associated regions are yet to be pub-
lished, however extensive mapping across the MHC region
for discovery of HLA-linked loci to T1D has been carried
out (Brown et al., 2009). Mapping around the 4Mb region
established HLA-B and HLA-A to be associated inde-
pendently of HLA class II genes in TID, a contrast to CD
where no other independent associations in theHLA region
have been found. Results from this study iterated the mul-
tilocus eﬀects due to classical HLA genes and extensive LD
spanning the entire region. The major susceptibility gene to
T1D was reﬁned to two independent groups of SNPs
encompassing IL2RA intron 1 and ‘5’ regions of IL2RA and
RBM17 after large-scale ﬁne mapping (Lowe et al., 2007).
Present research in SLE has localised the eﬀect of IL2/IL21
locus to two SNPs in high LD through ﬁne mapping of 45
tag SNPs in the region (Hughes et al., 2011). Furthermore,
genome-wide imputation from a reference panel (i.e. CEU
HapMap) can show much stronger associations; this has
been highlighted for the TAGAP risk locus in rheumatoid
arthritis (Plenge et al., 2010; Chen et al., 2011).
At present, custom-designed platforms are being used in
association studies of several chronic and autoimmune
disease loci (Immunochip) and cardiovascular disease, type
2 diabetes and obesity loci (Metabo-Chip) to ﬁne map-
associated variants to smaller regions and search for rare
variation to assist in closing the heritability gap.
Targeted resequencing, exome and whole genome
sequencing
It has been frequently proposed that rare mutations of
larger eﬀect size account for a substantial proportion of the
missingheritability in disease (Pritchard, 2001). Identifying
rare mutations altering protein function independent of
common SNPs is the hopeful outcome of targeted rese-
quencing in an associated candidate region. Momozawa
et al. (2011) identiﬁed low frequency coding variants from
63 GWAS-identiﬁed positional candidate genes by show-
ing protection against inﬂammatory bowel disease in
IL32R but found no rare variants predisposed to Crohn’s
disease (Momozawa et al., 2011). In contrast, four rare
variants in the IFIH1 gene were found to confer protection
against T1D by altering protein expression and structure
(Nejentsev et al., 2009).
Another approach is to sequence the exomes of disease
individuals to capture functional variation ( 30Mb)
predisposing to disease (Ng et al., 2008). Protein coding
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Table 1 39 non-HLA coeliac loci showing association with other autoimmune diseases
Associated
coeliac loci Reported genes
Overlapping autoimmune
diseasesd References
1q24.2c CD247 Rheumatoid arthritis Plenge et al. (2010)
1q24.3c FASLG, TNFSF18,
TNFSF4
Crohn’s disease Barrett et al. (2008)
1q32.1b Intergenic Ulcerative colitis, Type 1
diabetes, Crohn’s disease
Barrett et al. (2008); Barrett et al.
(2009); McGovern et al. (2010)
1q31.2a RGS1 Crohn’s disease Hunt et al. (2008); Parkes et al. (2007)




Barrett et al. (2009); Nair et al. (2009);
McGovern et al. (2010); Reveille et al.
(2010)
1p36.11b RUNX3 Psoriasis Nair et al. (2009)
1p36.23c PARK7, TNFRSF9 Ulcerative colitis, Crohn’s
disease
Franke et al. (2010); Anderson et al.
(2011)
1p36.32b TNFRSF14, MMEL1 Rheumatoid arthritis,
Ulcerative colitis




Crohn’s disease Hunt et al. (2008); Franke et al. (2010)
2p14b PLEK Rheumatoid arthritis Plenge et al. (2010)
2p16.1a REL, AHSA2 Ulcerative colitis, Crohn’s
disease, Psoriasis,
Rheumatoid arthritis
Trynka et al. (2009); Franke et al.
(2010); McGovern et al. (2010); Plenge
et al. (2010)
2q31.3a ITGA4, UBE2E3 Ankylosing spondylitis Garner et al. (2009); Reveille et al.
(2010)
2q33.2a CTLA4, ICOS, CD28 Type 1 diabetes,
Rheumatoid arthritis
Smyth et al. (2008); Barrett et al.
(2009); Plenge et al. (2010)
3q13.33b CD80, KTELC1 None
3p14.1c FRMD4B None




Hunt et al. (2008); Daly et al. (2008);
McGovern et al. (2010)
3p22.3b CCR4 None
3q25.33a IL12A, SCHIP1 Multiple sclerosis Hunt et al. (2008);De Jager et al. (2009)
3q26.2c Intergenic None
3q28a LPP None Hunt et al. (2008)
4q27a IL2, IL21, KIAA1109,
TENR, ADAD1
Ulcerative colitis, Type 1
diabetes, Rheumatoid
arthritis
van Heel et al. (2007); Barrett et al.
(2009); Plenge et al. (2010); Anderson
et al. (2011)
6q15b BACH2, MAP3K7 Type 1 diabetes, Crohn’s
disease
Barrett et al. (2009); Franke et al.
(2010)
6q22.33b PTPRK, THEMIS None
(Continued )
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genes constitute approximately 1% of the genome but
harbour 85% of mutations with large eﬀects on disease
traits and an excess of low frequency nonsynonymous
variants (Li et al., 2010). It is largely acknowledged that
mutations found in the exome are more rare as these
regions inﬂuence expression of proteins, leading to dele-
terious eﬀects, so are prevented from attaining a high fre-
quency by selection. Present discoveries have substantiated
these observations (Zhu et al., 2011). There has been a
dramatic surge in exome capture and massively parallel
sequencing in rare disease, which have historically been
constrained by small kindred sizes and locus heterogeneity.
Ng et al. (2009) published the ﬁrst proof of principle paper
(Ng et al., 2009).
The obvious setback to exome sequencing is information
on only the coding region of the genome is analysed. To
truly elucidate the relationship between disease phenotype
and their corresponding genetic basis, attentionought to be
focused on the entire genome. With ongoing decrease in
sequencing cost, this techniquemay be aﬀordable in a large
Table 1 Continued
Associated
coeliac loci Reported genes
Overlapping autoimmune
diseasesd References




Graham et al. (2008); Nair et al. (2009);
Trynka et al. (2009); Plenge et al.
(2010); Anderson et al. (2011)
6q25.3a TAGAP Crohn’s disease Hunt et al. (2008); Franke et al. (2010)
6p25.3c IRF4 None
7p14.1c ELMO1 None
8q24.21b Intergenic Multiple Sclerosis, Crohn’s
disease
Bahlo et al. (2009); Franke et al. (2010)
11q24.3b ETS1 Systemic lupus
erythematosus
Yang et al. (2010)
10q22.3b ZMIZ1 Multiple sclerosis, Crohn’s
disease, Early onset IBD
De Jager et al. (2009); Imielinski et al.
(2009); Franke et al. (2010)
12q24.12a SH2B3, ATXN2 Rheumatoid arthritis, Type
1 diabetes
Hunt et al. (2008); Barrett et al. (2009);
Plenge et al. (2010)
13q14.2c Intergenic None
14q24.1c ZFP36L1 Type 1 diabetes, Crohn’s
disease
Barrett et al. (2009); Franke et al.
(2010)
16p13.13b CIITA, SOCS1, CLEC16A Multiple sclerosis, Type 1
diabetes, Ulcerative colitis
Barrett et al. (2009); McGovern et al.
(2010); De Jager et al. (2009)
17q21.31c Intergenic None
18p11.21a PTPN2 Type 1 diabetes, Crohn’s
disease
Barrett et al. (2008); Barrett et al.
(2009)
21q22.3b ICOSLG Type 1 diabetes, Crohn’s
disease, Rheumatoid
arthritis, Ulcerative colitis
Barrett et al. (2008); Smyth et al.
(2008); Barrett et al. (2009); Plenge
et al. (2010); Anderson et al. (2011)
22q11.21c UBE2L3, YDJC Crohn’s disease, Systemic
lupus erythematosus
Franke et al. (2010); Yang et al. (2010)
Xp22.2c TLR7, TLR8 None
aLoci reported prior to Dubois et al. (2010).
bCoeliac loci with genome wide signiﬁcance at Pcombined55 1028.
cCoeliac loci with suggestive evidence at either 10264Pcombined45 1028 or PGWAS51024 and Pfollow2up5.01.
dAutoimmune diseases with overlapping loci according to the Catalogue of Published Genome-Wide Association Studies (http://www.geno-
me.gov/26525384); accessed on 31 March 2011.
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cohort of patients required for complex disease genetics.
See also: Next Generation Sequencing Technologies and
Their Applications
Concluding remarks
This review has discussed the genetics of CD, composed of
a strong HLA background and current associated loci
found through GWAS, and the next steps for casual vari-
ant discovery in genetics. With any complex disease, it is
important to appreciate types of variation in the human
genome and their eﬀects on each other. It is unlikely that
common and rare variants in only one gene are common to
all autoimmune diseases (Surolia et al., 2010), as it is evi-
dent multiple genes show interaction in multiple immune
pathways. Both rare and common variants are thought to
be attributable to disease onset, but gene–gene and gene–
environment interactions should be taken into account
when construing biological disease pathways. For com-
plete resolution of the CD, exome sequencing is the next
step for rare functional discovery, as well as deep rese-
quencing of associated genes in cases and controls. For
association-based studies, Immunochip and content
incorporated onto arrays from sequencing projects, such as
1000G and UK10K (www.uk10k.org), will drive a new
generation ofGWAS focusing on rare variation, supported
by functional studies on candidate genes of interest.
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